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Abstract 
Background: Metabolic disorders are common in Saudi Arabia. Adherence to a special 
diet is essential to prevent developmental disability in phenylketonuria (PKU). Our aim 
was to identify the risk factors for non-compliance with treatment of aminoacidopathies 
and poor outcome in PKU patients at King Faisal Specialist Hospital & Research Centre 
in Saudi Arabia. 
Methods: A qualitative study assessed nutritional knowledge, attitudes and practices 
through interviews (n=5) and focus groups (2) with health care providers, and interviews 
with patients with aminoacidopathies (6) and families (17). A quantitative study assessed 
40 PKU patients by anthropometric measurements, dietary records, phenylalanine blood 
levels, developmental assessments, and questionnaires with the patients and their 
mothers. The Vineland-II Adaptive Behaviour Scales were translated into Arabic and 
adapted to the Saudi culture to be used as the assessment tool to measure outcome. 
Regression analysis and independent t-tests were used to investigate relations. 
Results:  
Qualitative findings: Major themes identified: Lack of sufficient services, inadequate 
dietary knowledge, limited resources for families and dietitians, social and emotional 
attitudes towards diet, and compliance by the child and mother. 
Quantitative results:  
1- Factors contributing to low Vineland-II Adaptive Behaviour Composite score 
(ABCs):     a. Delayed diagnosis: Mean ABCs (±1SD) according to age at start of 
treatment (Significant difference p<0.0001): 
• Diagnosed ≤1 month: 92.2 (±11)  
• Diagnosed >1 month: 60.5 (±20.6) 
b. Disease severity: There was a significant difference (p=0.008) in the ABCs 
between patients with Mild PKU (diagnosis phenylalanine 600-1200µmol/l) 
and Classic PKU (diagnosis phenylalanine >1200µmol/l). 
2- Factors leading to inadequate blood phenylalanine control: Delayed diagnosis, poor 
compliance with dietary phenylalanine restriction, and inadequate intake of the prescribed 
supplement.  
Conclusion: Newborn screening for PKU has been very successful in improving 
outcome but this could be further enhanced by targeted improvements in the education 
and support of families and in the metabolic care services.  
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Glossary of terms  
 
Aminoacidopathies: Inborn errors of amino acid metabolism result in the build up of 
one or more amino acids in the blood and urine. 
 
Finger prick: A procedure in which a finger is pricked with a lancet to obtain a small 
quantity of capillary blood for testing. 
 
Formula: KFSH&RC use the Ross Metabolic Formula System products, Phenex-I for 
infants and toddlers and recently started Phenex-II for adults and children above 4 
years of age. These are phenylalanine free amino-acid mixtures in powder form. The 
families are trained to measure the prescribed amount of the powder and reconstitute 
it with water. 
 
Free foods: Foods so low in phenylalanine that they can be permitted without 
measurement, such as honey, jam, sugars, oils, vinegars, spices, apple juice, some 
types of candies and sweets, and some fruits and vegetables that contain less than 20–
25 mg of phenylalanine in 100g. 
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CHAPTER 1 
INTRODUCTION 
 
1. Introduction 
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Inborn errors of metabolism have not been a high priority in the health care system in 
Saudi Arabia in the past, even though collectively they are a significant public health 
problem in the country (Saadallah & Rashed, 2007). A newborn screening programme 
has recently begun in Saudi Arabia, it is gradually growing to cover all parts of the 
country (Al-Odaib et al., 2011). Many children receiving treatment currently were 
diagnosed in infancy through testing shortly after birth because of an affected sibling. 
Unfortunately many others were diagnosed late, after their illness had progressed to 
permanent neurological impairment (Ozand, 1998). Delayed diagnosis, the relatively 
short safety window of most of the metabolic disorders, combined with the 
tremendous lack of public awareness both play a part in delayed referrals to 
appropriate services, and lead to neurological damage in affected infants (Afifi & 
Abdul-Jabbar, 2007; Al-Gazali, Hamamy, & Al-Arrayad, 2006; and Nasserullah et al., 
2003). 
Nutritional management - the use of a diet with a reduced content of a specific amino 
acid or amino acids is the mainstay of treatment for phenylketonuria (PKU) and 
maple syrup urine disease (MSUD) and it is an important adjunct to drug treatment of 
tyrosinaemia type 1. However, research concerning nutrition for metabolic disorders 
in Saudi Arabia is scarce. Basic research to help classify the services, current care 
practices, nutritional management, and needs of the patients with metabolic disorders 
and their health care providers is essential, especially with the start of the newborn 
screening programme. This research will hopefully be a start to assessing these 
practices and services for patients with aminoacidopathies and their families, and 
identifying the risk factors associated with unsatisfactory dietary compliance for 
patients with PKU.  This research was carried out with the aim of informing targeted 
interventions for the benefit of the patients. 
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1.1 Overall aims of the study 
 To describe the current nutritional management of patients with 
aminoacidopathies in Saudi Arabia.  
 To identify the risk factors that lead the patients and their families to have 
inadequate control over the disorder.  
 To use the results of this research to inform appropriate intervention strategies 
and services for the patients and their families to help them improve 
compliance. 
1.2 Research question 
What are the risk factors associated with unsatisfactory nutritional management in a 
proportion of patients with aminoacidopathies in Saudi Arabia? 
1.3 Research objectives 
1. To assess the nutrition awareness of the patients with aminoacidopathies 
(phenylketonuria (PKU), maple syrup urine disease (MSUD), and 
tyrosinaemia type 1) and their families. 
2. To explore the attitudes and practices of the patients and their families with 
regard to the nutritional management of their disorders. 
3. To assess whether current services address the expressed and perceived needs 
of the patients and their families. 
4. To identify the risk factors and the barriers associated with noncompliance 
with the dietary requirements leading to inadequate metabolic control and high 
risk of poor outcome for patients with PKU.  
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1.4 Study design summary 
This research was a cross-sectional study of a group of patients with 
aminoacidopathies in Saudi Arabia. It was a 2-phase study design with a mixed 
method approach; using the sequential exploratory strategy as recommended by 
Creswell (2009) and Morgan (1998a). Phase 1 was an exploratory qualitative study, 
and Phase 2 was a quantitative assessment of the risk factors contributing to poor 
outcome for the patients with PKU at the King Faisal Specialist Hospital and 
Research Centre (KFSH&RC).  
Phase 1 
This phase comprised qualitative research that explored the current status of patients 
with aminoacidopathies and informed the second phase of the study.  
A. Interviews: Qualitative data was collected from open and semi-structured 
interviews: 
• Interviews and observations of key informants from the health care team  
• Focus groups and interviews with health care providers  
• Interviews with the patients 
• Interviews with the families of patients 
B. Observations: Observations were based on purposefully selected participants 
to examine: 
• Formula preparation by patients and carers  
• Dietitian counselling sessions 
• Doctor clinic sessions 
C. Market survey: A market survey was conducted to observe the availability 
and accessibility of the special low protein food products. 
D. Medical records review: The medical history, developmental assessments and 
past blood levels were reviewed for the participating patients.  
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Phase 2 
This phase was a quantitative cross sectional survey including: 
1. Nutritional assessment: For the patients 
- Anthropometric measures 
- Clinical measures: current morbidity data and blood levels 
- Diet analysis 
2. Questionnaires: For the patients and their families 
- Socio-economic status 
- Quality of life 
- Nutrition knowledge, attitudes and practices 
- Dietary compliance  
3. Medical records review: 
- Medical history 
- Past blood levels   
4. Development assessment: For the patients 
- Past developmental assessments from medical records 
- The Vineland-II Survey Interview Form (which involved 
translating and adapting the Vineland-II to Arabic). 
1.5 Anticipated outcomes 
 To establish an understanding of the current conditions in various aspects 
of care for patients with aminoacidopathies in Saudi Arabia. 
 To describe the perceptions of the patients and their families towards the 
services, treatment, education, and support they receive. 
 To increase awareness about the importance of compliance with dietary 
management as an essential part of treatment among the target group. 
25 
 To determine the risk factors and barriers leading to inadequate metabolic 
control for the patients.  
 To gain adequate evidence to inform the development of a targeted 
nutrition management programme to support patients with 
aminoacidopathies and their families, with a view to expanding the project 
to include all the patients with metabolic disorders in Saudi Arabia. 
1.6 Thesis overview 
Chapter 2 presents a review of the literature on MSUD and tyrosinaemia type 1 in 
general and PKU in particular. Background information about metabolic disorders in 
the Middle East is reviewed with a focus on Saudi Arabia. 
Chapter 3 describes in detail the methods used in this study. The data was collected in 
Riyadh, the capital of Saudi Arabia (Figure 1), at King Faisal Specialist Hospital and 
Research Centre (KFSH&RC). KFSH&RC is the main centre that patients with 
metabolic disorders are referred to from different parts of the country.  
Chapter 4 explains the rationale for using the Vineland-II scales in this study. It 
illustrates the translation and adaptation of the Vineland-II scales to Arabic, and the 
testing process of the instrument before using it with the patients in this study. 
The findings of Phase 1 of this study, which was a qualitative phase, are provided in 
Chapter 5. The interpretation and discussion of the key findings are presented in 
Chapter 6. Results of Phase 2, which was a quantitative study, are presented in 
Chapter 7. The main results are then discussed in view of the relevant literature in 
Chapter 8. Finally, Chapter 9 concludes with the recommendations arising from this 
research. The Appendices contain the consent form, Phase 1 interview forms, sample 
interview, the questionnaires for Phase 2, and the list of adjustments and adaptations 
to the Vineland-II when translated to Arabic. 
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Figure 1: Saudi Arabia. Adapted from (Worldofmaps.net, 2012). 
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CHAPTER 2 
LITERATURE REVIEW 
 
2. Literature Review 
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2.1 Overview of inborn errors of metabolism (IEM) 
Inborn errors of metabolism or metabolic disorder are caused by point defects in 
metabolism. The number of known disorders exceeds 500; they are rare individually, 
but combined account for a considerable proportion of suffering and illness (Clarke, 
2002). Accurate diagnosis is very important for the treatment and prevention of 
debilitating effects of the disorders (Saudubray, Sedel, & Walter, 2006).  
Clarke (2002) describes how metabolic disturbances, due to deficiency of some 
catalytic or transport proteins, cause the signs and symptoms of disease in patients 
with inborn errors of metabolism. In many disorders disease is caused by the 
accumulation of the substrate of an altered enzyme, in some other disorders 
accumulation of a normally minor metabolite, or deficiency of a product from a 
specific reaction are the primary causes of disease.  
Most inborn errors of metabolism are inherited, and the majority are inherited as 
single-gene defects, and transmitted in an autosomal recessive manner. Consanguinity 
increases the probability that the couple are both carriers of a recessive mutation and 
this increases the likelihood of having children affected with the disorder (Bittles, 
2001). Consanguineous marriages are high in small communities that are culturally or 
geographically isolated; this contributes to the high incidence of some disorders in 
specific ethnic groups (Al-Gazali et al., 2006; and Clarke, 2002). 
In metabolic disorders the onset of clinical symptoms varies from hours after birth to 
weeks, some disorders even have an onset later in childhood. Incorrect or delayed 
diagnosis is a common problem in the management of inborn errors of metabolism. 
Many of the disorders have non-specific signs and symptoms that could be easily 
attributed to sepsis or other common illnesses. Deterioration of a child without a 
known reason and without response to common forms of treatment (e.g. antibiotics) is 
an important indicator for the suspicion of a metabolic disorder (Saudubray, 
Desguerre, Sedel, & Charpentier, 2006). 
  
30 
2.2 Newborn screening for IEM 
Newborn screening (NBS) programmes are established in many countries to identify 
infants affected by specific diseases before the development of clinical signs and 
symptoms, thus allowing early medical intervention and treatment to prevent 
deterioration, disability, or even death. Management of many metabolic disorders 
developed through recognizing how the point defects in metabolism cause the disease, 
then attempting by metabolic manipulation, such as dietary, pharmacologic, or other, 
to neutralize or reverse these effects (Walter & Wraith, 2006). Unfortunately, in some 
disorders understanding of how the inborn error causes disease is still incomplete 
(Saudubray et al., 2006).  
Newborn screening has achieved a great deal over the past 40 years. Guthrie’s 
development of a simple screening test for PKU had led to the institution of the first 
PKU screening programme for newborns in the USA (Guthrie, 1961; Guthrie & Susi, 
1963; and Jones & Bennett, 2002). It started in the state of Massachusetts in 1962, 
other states and countries started introducing population screening throughout the 
sixties and seventies (Levy H.L., 2005; Levy P.A., 2010; and Marsden, Larson, & 
Levy, 2006). The UK adopted the Guthrie blood-spot screening process in 1969, and 
shifted from routine screening by many local health authorities to a national level for 
all newborns (Pollitt et al., 1997).  
Newborn screening for PKU has been proven as cost-effective over a decade ago, and 
has been considered as a fundamental public health programme (Dhondt, Farriaux, 
Sailly, & Lebrun, 1991; Hisashige, 1994; National Institutes of Health Consensus 
Development Panel, 2001; and Seymour et al., 1997). A review by Lord and 
colleagues established that in the UK screening for PKU by itself justifies the 
collection of blood samples from newborns (Lord et al., 1999). Screening for 
medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) and glutaric 
acidaemia type 1 (GA1) has been proven to be worthwhile as well (Marsden et al., 
2006; and Wilcken, 2012). It prevents death, disability and alleviates the financial 
burden of caring for disabled individuals by the community.  
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The screening technology has advanced tremendously by the introduction of the 
tandem mass spectrometry (MS/MS) for population screening in the early nineties. It 
allowed for rapid, reliable, and cost-effective detection of many disorders using a 
single sample (Chace, DiPerna, & Naylor, 1999; Chace & Naylor, 1999; and Levy 
P.A., 2010). The significant advancement in MS/MS technology made it an integral 
part of laboratories. The imperative interactions between laboratories and clinicians 
became easier, supporting the diagnosis and monitoring process of patients 
(Strathmann & Hoofnagle, 2011). Many countries started using the MS/MS in 
extending their newborn screening programmes to include more disorders, including 
Australia, China, Japan, New Zealand, South Korea, Taiwan, and several European 
countries (Bodamer, Hoffmann, & Lindner, 2007; Huang et al., 2011; Niu et al., 2010; 
Schulze et al., 2003; Shigematsu et al., 2002; and Yoon et al., 2003; Wilcken & 
Wiley, 2008; Wilcken et al., 2009; and Wilson et al., 2012). 
In the US, most of the states have had an extended screening programme since the 
introduction of MS/MS, but there has been considerable variability between states 
(Therrell & Adams, 2007). In an effort to unify newborn screening between the states 
the American College of Medical Genetics (ACMG) was commissioned by the 
Maternal and Child Health Bureau to establish uniform policies for newborn 
screening for all of the states (Watson et al., 2006). The expert panel of the ACMG 
recommended mandating screening for 29 core conditions, because there are effective 
treatments and good knowledge of these conditions. They also identified a secondary 
target of 25 conditions, as they are incidentally identified when screening for the main 
conditions or clinically significant but without an effective treatment. Nearly all the 
states have adopted the new panel of screening (Levy H.L., 2010). The efforts of the 
ACMG in collaborative improvement of policies related to newborn screening have 
led to improvements in communications between professionals. Consequently this has 
led to improving the management of patients with metabolic disorders (Berry, Lloyd-
Puryear, & Watson, 2010). 
Screening for less severe disorders is still disputed by some researchers (Baily & 
Murray, 2008; Moyer, Calonge, Teutsch, & Botkin, 2008; Pandor, Eastham, Beverley, 
Chilcott, & Paisley, 2004; and Pollitt, 2001). Therefore, not every country has 
expanded newborn screening to cover all the disorders that can be screened for. In 
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Germany they screen for 12 disorders, in the UK they screen for PKU and MCADD, 
while in France they only screen for PKU (Klein, 2011; Lindner et al., 2011; and 
Pollitt, 2009). Pandor and colleagues (2004), in their systematic review of newborn 
screening for the UK, concluded that there were no justifications for including 
disorders other than PKU and MCADD to the newborn screening programme in the 
UK, as only these two disorders meet the criteria for population screening. The main 
criteria for screening for a condition entail the availability of proper follow-up of 
positive results, confirmation of diagnoses, availability of treatment, continuous 
management, and good knowledge of the natural history of the disorders (Kaye & the 
Committee on Genetics, 2006; Klein, 2011; and Pandor et al., 2004). 
In contrast, Downing and Pollitt (2008) argue that the UK has lagged behind other 
countries in utilizing the MS/MS technology for expanding newborn screening. 
Especially that there are many disorders with successful treatments, and patients may 
suffer negative effects with delayed diagnosis (Pollitt, 2009). The main arguments in 
favour are the cost-effectiveness of early detection and treatment as a result of 
newborn screening, compared to diagnosis and treatment following presentation of 
symptoms, and the positive effects of screening on outcome for the patients. 
At the same time the extended newborn screening programmes of some countries are 
criticised of expanding too rapidly. Researchers have debated the benefit and cost 
effectiveness of expanding newborn screening to include as many detectable disorders 
as possible. Several of the disorders on some expanded newborn screening 
programmes are either lacking effective treatment, not needing treatment in infancy, 
the natural history of the condition is not understood, or long-term data is not 
available on follow-up of patients with mild disease or pre-symptomatic patients 
(Baily & Murray, 2008; Coman & Bhattacharya, 2012; and Dhondt, 2010). The 
ACMG has been criticised for recommending some disorders for newborn screening; 
disorders that did not meet the screening criteria, nor followed evidence based 
approach when selected (President's Council on Bioethics, 2008; and Moyer et al., 
2008). These researchers advocate the re-evaluation of the recommended disorders 
and the inclusion of some disorders into pilot studies rather than mandating screening 
for them, until more evidence is available. 
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The researchers argue that such rapid expansions of newborn screening programmes 
to include disorders with many uncertainties are placing unnecessary burdens on the 
families and the health care systems. Authorities could be spending on expanded 
newborn screening when it might be more beneficial to spend the money on other 
health programmes (Baily & Murray, 2008; Levy P.A., 2010; Moyer et al., 2008; and 
Pollitt, 2007). 
The families could also suffer from unnecessary stress and anxiety when faced with a 
diagnosis of an untreatable disorder, or a disorder with an uncertain outcome (Dhondt, 
2010; and Waisbren et al., 2003). In addition to the financial burden they would incur 
in pursuing treatment possibilities or unneeded treatments (Baily & Murray, 2008; 
Bennett et al., 2012; and Coman & Bhattacharya, 2012). Bailey and colleagues (2009) 
recommend providing psychological support to the families with the expansion of 
newborn screening to conditions that lack clear medical treatments. This is to help the 
families understand the conditions and to ensure follow-up. 
Newborn screening is a fundamental public health programme that is continuously 
evolving. Many researchers call for international cooperation to benefit from the 
different experiences in diagnosis, treatment, follow-up and management of these rare 
conditions (Berry et al., 2010; Dhondt, 2010; Klein, 2011; Pollitt, 2009; and Wilcken, 
2010), with the importance of focusing on saving lives, preventing disability, and 
improving quality of life (Grosse, 2005). 
An impressive and important worldwide collaboration is described by McHugh and 
colleagues (2011). Forty five countries have participated in validating and defining 
cut-off values for 64 metabolic disorders for newborn screening by tandem mass 
spectrometry (McHugh et al., 2011). This is significant because different countries 
have different cut-off ranges for the same disorder on screening (Burgard et al., 2011). 
This effort has been described as innovative in establishing evidence based cut-off 
values for newborn screening by MS/MS. These disorders are rare, therefore pooling 
samples and values from around the world has lead to refining the cut-off ranges for 
newborn screening, increasing the positive predictive values and reducing false-
positive tests (Howell, 2011).  
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Another achievement of this collaborative project is the development of a recognition 
software that produces interpretive tools for the conditions that are screened for by 
MS/MS. The tools work with raw data independently from cut-off values. They 
helped attain reduction in both false-negative and false-positive results (Marquardt et 
al., 2012). Such great achievements vastly improve newborn screening programmes 
and certainly have a positive impact on patients, emphasizing the importance of 
international collaborations.   
2.3 Inborn errors of metabolism and newborn screening in the 
Middle East 
A number of studies have looked at inborn errors of metabolism in the countries 
neighbouring Saudi Arabia. The incidence of PKU in Turkey is reported to be at 
1:5049 (Tunçbilek & Özgüç, 2007). They have a national child health programme for 
PKU screening. It started in 1986 and gradually increased to cover all urban areas of 
the country. It is run by the Ministry of Health in collaboration with three University 
Children’s Hospitals (Ozalp et al., 2001). Some of the problems they faced with their 
screening programme were inadequate sample collection, difficulty in reaching some 
detected cases, and compliance problems with dietary management. They recognise 
the need to provide support for the patients of metabolic disorders and their families, 
and recommend establishing country wide criteria for genetic counselling and patient 
support. In one effort to improve support Gökmen-Ozel and colleagues (2011) studied 
the effects of educating the caregivers of patients with PKU at their homes in Turkey. 
They found that continuous dietary education that incorporates home visits has had a 
positive effect on lowering the patients’ phenylalanine levels. 
Some hospitals are doing selective screening for a number of other metabolic 
disorders. They are finding high numbers of at risk babies to have metabolic 
disorders, but the numbers are not enough to extrapolate a country wide incidence 
(Tümer, Biberoglu, Hasanoglu, Ezgu, & Atalay, 2004; and Tunçbilek & Özgüç, 
2007). The high incidence of metabolic disorders in Turkey is attributed to the high 
number of consanguineous marriages, which was found to be in 72% of the families 
of patients (Tunçbilek & Özgüç, 2007). This rate is much higher than the Turkish 
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national rate of consanguineous marriages of 22%, the researchers report a declining 
trend in national consanguinity (Koc, 2008). 
There has been newborn screening for PKU in the Gaza strip since 1994, but this is 
only in the government clinics. Two-thirds of the newborns are delivered at the 
United Nations Relief and Works Agency for Palestine Refugees in the Near East 
(UNRWA) clinics and receive healthcare there, where no PKU screening tests are 
undertaken (Abu Shahla, Abed, & Abu Shahla, 2004). In the year 2000 only 35.5% of 
newborns were tested for PKU. The researchers note that PKU is a public health 
problem and the prevalence and incidence of PKU among the population is not 
known. This compelled them to carry out the first organized study about PKU in the 
Gaza strip. The overall prevalence of PKU was found to be 6.35/100,000 (1:15,700), 
with significant inter-regional differences among the different provinces and localities 
of the Gaza Strip. The highest incidence was in the rural areas at 28.3/100,000 
(1:3500), where 60% of the families were of first-cousin marriages. Their results 
showed that PKU patients have very poor monitoring and weak commitment to blood 
testing, with only 35.4 % of the patients monitoring their diets monthly. The 
researchers state the need to improve the Gaza PKU screening, follow-up, and 
monitoring programmes (Abu Shahla et al., 2004). 
Waterston (2004) commended the Gaza team for evaluating their PKU screening 
programme at such time of struggle when health services usually prioritise health 
relief rather than prevention. The author recommended the expansion of screening to 
the UNRWA clinics in the Gaza strip to include all newborns. There is a need there to 
promote awareness and education among families and health care providers about 
PKU and screening. In addition, there is a need for funding to train the staff and to 
provide treatment for the patients, if the programme to be successful.  
Newborn screening for PKU has started at the UNRWA clinics in the West Bank in 
2006, but not in Gaza (UNRWA, 2006). In 2010 the UNRWA started PKU screening 
in their clinics in Jordan in collaboration with the Jordanian Ministry of Health 
(UNRWA, 2010). At the same time Jordan were piloting a national PKU screening 
programme (Krotoski et al., 2009). 
36 
  
In Lebanon, they have had a private newborn screening programme since 1996 in two 
university centres (Daher, Beaini, Mahfouz, Cortas, & Younis, 2003; and Khneisser, 
Adib, Megarbane, & Lukacs, 2008). They screen for PKU, galactosemia, glucose-6-
phosphate dehydrogenase deficiency, and congenital hypothyroidism. Nearly 20% of 
newborns are screened through samples sent from affiliated hospitals around the 
country. In 2006, the newborn screening laboratory of the Saint Joseph University in 
Beirut decided to expand their screening programme to include more inborn errors of 
metabolism utilising the MS/MS technology. The expansion was in collaboration with 
the Metabolic Laboratory at the Hamburg University Medical Centre in Germany 
(HUMC). Initially they sent samples to the HUMC for screening. Then by early 2008 
they acquired the MS/MS equipment and trained their staff to carry the screening 
locally, with continued technical support from the HUMC (Khneisser et al., 2008). 
Karam et al (2011) declare that only 29% of PKU patients in Lebanon were identified 
through newborn screening. They stress the need for implementing a national 
newborn screening programme. There were plans to transfer the newborn screening 
responsibility to the Ministry of Health in Lebanon and to cover all newborns by 2011 
(Krotoski et al., 2009).  
Golbahar and colleagues did a selective screening study from 1996 to 2001, in the 
region of Shiraz, Iran, and found high incidence of PKU (1:3672), tyrosinaemia  
(1:10,651), and MSUD (1:21,303). They believe these high numbers are mostly 
attributed to the high rate of consanguineous marriages in the region (Golbahar, 
Karamizadeh, & Honardar, 2002). In a more recent study, Habib et al (2010) 
calculated the incidence of PKU in Iran to be at 1:6250. Ghiasvand et al (2009) found 
high prevalence of PKU among the mentally disabled population in Iran, they 
consider this to indicate high incidence of PKU among newborns in Iran. The authors 
believe that the high incidence is due to the high frequency of the PKU allele and the 
high rate of consanguineous marriages in Iran. They recommend nationwide 
screening for PKU rather than the current local screening programmes.  
First-cousin marriages among Iranians are reported to be around 27.9% in the general 
population (Saadat, Ansari-Lari, & Farhud, 2004). In a study involving 82 families of 
PKU patients in Iran, 46 families (56%) were of first-cousin marriages. This lead the 
37 
researchers to attribute 50% of the high incidence of PKU in their population to 
consanguinity (Koochmeshgi, Bagheri, & Hosseini-Mazinani, 2002). 
Several studies from Iran were concerned with carrier detection and mutation analysis 
of PKU in Iran (Hosseini-Mazinani, Koochmeshgi, Khazaee-Koohpar, Hosein-Pur-
Nobari, & Seifati, 2008; Vallian, Barahimi, & Moeini, 2003; and Zare-Karizi et al., 
2011). The researchers hoped to set up diagnostic tests for prenatal diagnosis and 
carrier detection of PKU among the Iranian population. Zare-Karizi and colleagues 
(2011) identified the PKU mutations for 124 patients in Iran. Four mutations were 
found to be most prevalent among the Iranian PKU patients.   
The United Arab Emirates (UAE) started PKU screening for newborns in 1995. In an 
evaluation study of the screening programme, from its start in 1995 to the end of 
2000, the incidence for classic PKU in the UAE was calculated to be 1:20,050. 
Coverage of the newborn screening in 2000 was at 65% of newborns only. The plan 
was to integrate the newborn screening programme with other health programmes to 
improve coverage (al-Hosani, Salah, Saade, Osman, & al-Zahid, 2003). The UAE 
Ministry of Heath is planning an expansion of their newborn screening programme to 
include up to 20 more disorders (Krotoski et al., 2009).  
Qatar started a newborn screening programme in 2003 in collaboration with the 
University Children’s Hospital in Heidelberg, Germany (UCH). Samples were sent 
from Qatar to Germany to be screened. In their evaluation of the programme after 
screening 25,214 newborns in two and a half years, the researchers calculate the 
incidence of metabolic disorders in Qatar to be considerably higher than in Germany. 
The identified patients during this period give an incidence of 1:1327 for metabolic 
disorders in Qatar, while in Germany the incidence is 1:2517, making the relative risk 
of having a metabolic disorder in Qatar double that in Germany (Lindner et al., 2007). 
The UCH provided valuable training and support for the staff in Qatar, as by 2009 it 
was planned that all newborn screening and diagnoses will be carried out locally in a 
newly equipped metabolic centre in Qatar (Krotoski et al., 2009; and Lindner et al., 
2007). 
Organised services for metabolic disorders were instigated in Oman in 1998, without 
the availability of newborn screening. Joshi and colleagues (2002) reviewed all the 
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patients diagnosed with metabolic disorders from the start of these services until the 
end of 2000. Their aim was to identify the prevalence of inborn errors of metabolism 
in Oman. They calculated the general incidence of metabolic disorders in Oman to be 
1:1555, and found that 76% of the patients had consanguineous parents. Currently 
Oman has newborn screening for a few blood genetic disorders and there are plans to 
expand it to cover some metabolic disorders (Joshi & Venugopalan, 2007; and 
Krotoski et al., 2009). Bahrain and Kuwait have newborn screening programmes for 
one or more disorders and are piloting screening programmes for additional metabolic 
disorders (Abdel-Hamid, Tisocki, Sharaf, & Ramadan, 2007; AlArrayed & AlHajeri, 
2012; Krotoski et al., 2009; and Padilla, Krotoski, & Therrell, Jr., 2010) 
Research on inborn errors of metabolism in the region surrounding Saudi Arabia is 
lacking current updates. However, available research indicates similarities between 
these countries and Saudi Arabia in the predicaments facing them regarding the 
management of metabolic disorders. Bayoumi and Yardumian (2006) believe that the 
reasons hindering the progress of preventative genetic programmes in the Arab Gulf 
region are not financial, but rather cultural and legal issues. They argue that there is a 
need for a change in the attitudes of the public, the professionals, and the policies to 
institute comprehensive programmes. They stress that public debate and education 
can motivate change and improve awareness about the different needs of patients with 
metabolic disorders.  
Jabbour (2003) recommends coordination among countries in the Middle East, in their 
efforts to tackle issues of public health. Collaboration would help countries starting 
newborn screening to pool their resources and expertise, and to enhance the impact of 
their programmes. Interest in tackling newborn screening and genetic disorders in the 
Middle East and North Africa (MENA) has grown tremendously in recent years. 
Many countries either started their own NBS programmes or partnered with other 
countries for technical support. This is evident through the organisation of a regional 
conference on strengthening newborn screening in the MENA region in 2006. This 
was followed by two subsequent conferences in 2008 and 2010 to evaluate the 
progress of the NBS programmes in the area, share knowledge and experiences, 
promote collaborations between countries, and encourage population studies that 
would help establish the incidence of metabolic and genetic disorders (Krotoski et al., 
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2009). These meetings are essential to foster relationships and cooperation between 
nations to help overcome problems that may arise with developing new and 
challenging programmes. 
2.4 Consanguinity in the Middle East 
Studies from Saudi Arabia and other countries in the Middle East express the strong 
associations between consanguinity and some health problems. They include 
craniofacial anomalies, congenital heart disease, hearing impairments, and autosomal 
recessive disorders (Abdulrazzaq et al., 1997; Al-Kandari & Crews, 2011; Aziza, 
Kandasamy, & Shazia, 2011; Becker, Al, Molina, & Paterson, 2001; Bener, Hussain, 
& Teebi, 2007; El Mouzan, Al Salloum, Al Herbish, Qurachi, & Al Omar, 2008; 
Ravichandran et al., 2012; and Yunis et al., 2006). 
The prevalence of consanguinity in different regions of Saudi Arabia has been 
reported to be between 51.3% and 57.7% (al-Abdulkareem & Ballal, 1998; Al Husain 
& Al Bunyan, 1997; and El-Hazmi et al., 1995). A more recent comprehensive study, 
covering all regions of Saudi Arabia, reports that consanguinity remains high at 56% 
of all marriages (El-Mouzan, Al-Salloum, Al-Herbish, Qurachi, & Al-Omar, 2007).  
This level is similar to the neighbouring Gulf countries with similar social and 
cultural make up. The United Arab Emirates has a consanguinity rate of 50.5% (Al-
Gazali et al., 1997). In Kuwait it is 44.8%, in Qatar 54%, and in Oman 56.3 % (Al-
Kandari & Crews, 2011; Bener & Hussain, 2006; and Rajab & Patton, 2000). 
Consanguinity in Lebanon and Syria is less than in the Gulf region, but still high at 
35.5% and 35.4% respectively (Barbour & Salameh, 2009; and Othman & Saadat, 
2009). Consanguinity in Jordan varies between 25.5% and 49% depending on the 
region, and it has been declining in the younger generations (Hamamy, Jamhawi, Al-
Darawsheh, & Ajlouni, 2005; and Obeidat, Khader, Amarin, Kassawneh, & Al, 
2010). In Jordan, a study found that 85.9% of patients with autosomal recessive 
conditions had consanguineous parents (Hamamy, Masri, Al-Hadidy, & Ajlouni, 
2007). 
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The Arab world has high rates of consanguinity. The custom of consanguineous 
marriages is rooted in the tribal character of the Arab countries and believed to have 
considerable economic and social advantages (Tadmouri et al., 2009). It is preferred 
because it provides ease of marriage and assurance in knowing the partner and the in-
laws well, which prevents financial, health, or social uncertainties (Bittles, 2001). 
Consanguineous unions are believed to strengthen family ties, improve the status of 
women, and be more stable than non-consanguineous unions (AlKhaja et al., 2012; 
and Modell & Darr, 2002). 
Many associate consanguinity with Islam, though it is a cultural norm rather than 
religious (Modell & Darr, 2002). Islam merely allows cousin marriages, and prohibits 
uncle-niece and aunt-nephew unions. Consanguinity is not encouraged in any text in 
the teachings of Islam (AlKhaja et al., 2012; and Bittles, 2001). Indeed, marrying out 
of the family is encouraged (Al Aqeel, 2007).  
Researchers from the Middle East and the West agree that recessive autosomal 
diseases are evidently more widespread in consanguineous communities (Al-Gazali, 
2005; Al-Kandari & Crews, 2011; Bittles, 2001; El-Hazmi et al., 1995; Hamamy et 
al., 2007; Jaouad et al., 2009; Modell & Darr, 2002; Ozand, Devol, & Gascon, 1992; 
and Tadmouri et al., 2009). Some Arab tribal groups and villages even have 
conditions that are confined to them because they descend from limited ancestry (Al-
Gazali et al., 2006). Researchers in Saudi Arabia believe that the high level of 
consanguinity and the tribal nature of marriages have led to the preservation of rare 
mutations kept in a genetically homogenous population, leaving genetic diseases to 
thrive (Al-Odaib, Abu-Amero, Ozand, & Al-Hellani, 2003; and Rashed, Rahbeeni, & 
Ozand, 1999). 
The Centre for Arab Genomic Studies maintains a growing database on genetic 
disorders in Arab populations: the Catalogue for Transmission Genetics in Arabs 
(CTGA) (AlKhaja et al., 2012; and Tadmouri, Al Ali, Al-Haj, & Al, 2006). Tadmouri 
and colleagues (2009) found that a high proportion (63%) of the disorders in the 
CTGA database are autosomal recessive disorders. They present this as clear 
confirmation of the positive correlation between consanguinity and autosomal 
recessive diseases in the Arab communities. 
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Consanguinity, however, is expected to decline globally due to many current social 
aspects, such as the leaning of younger generations towards smaller family sizes, 
urbanization, and increased female education. This, with time, will cause a reduction 
in the prevalence of autosomal recessive disorders (Bittles, 2002; Bittles & Black, 
2010; and Hamamy, Al-Hait, Alwan, & Ajlouni, 2007). 
Discouraging consanguinity in general to prevent genetic diseases would be 
ineffective because this ignores that it is a significant and valued social culture in the 
communities that practice it. The ethics of genetic counselling dictates that customs 
and traditions, even if not the best for health outcome, need to be respected (Al-Aqeel, 
2005; Bittles, 2008; El-Hazmi, 2009; and Meyer, 2005). Therefore, in communities 
with high levels of consanguinity, researchers consider the best way of tackling it is 
through directed prospective genetic counselling. It is recommended to identify 
families at risk of developing autosomal recessive disorders, then offer them genetic 
counselling, risk information, and provide premarital carrier testing when possible 
(Abdel-Meguid, Zaki, & Hammad, 2000; Albar, 2002; El-Hazmi, 2004a; Koc, 2008; 
and Meyer, 2005). 
2.5 Inborn errors of metabolism and newborn screening in Saudi 
Arabia 
The Metabolic Services of the Medical Genetics Department at King Faisal Specialist 
Hospital and Research Centre (KFSH&RC) in Riyadh, Saudi Arabia, is one of the 
major tertiary care referral centres for metabolic disorders in the region of Saudi 
Arabia and some neighbouring countries. It has always collaborated with other health 
care centres in Bahrain, Kuwait, Qatar, Oman, and United Arab Emirates for the 
diagnosis of genetic disorders (Al-Odaib et al., 2003; and Therrell, 2003). 
The disorders seen at KFSH&RC include organic acidaemias, amino acidaemias, fatty 
acid oxidation defects, and lysosomal storage and peroxisomal disorders among 
others. In the past the affected infants were identified through diagnosis after 
symptomatic presentation or through selective screening at KFSH&RC and affiliated 
hospitals. Selective screening included infants born at these hospitals and infants born 
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to families with known history of any of the disorders. A newborn screening 
programme started in 2005 as a pilot, and gradually increased the number of screened 
newborns each year becoming a national programme in 2011 (more details in the 
following section). 
2.5.1 Incidence of IEM in Saudi Arabia 
The true incidence of each metabolic disorder in Saudi Arabia is yet to be identified. 
There are a few small studies conducted to measure the incidence of metabolic 
disorders in different regions of the country.  
Rashed and colleagues (1999) carried a pilot study of newborn screening using 
MS/MS at KFSH&RC. They screened 27,624 samples from KFSH&RC and two 
other Saudi hospitals, and diagnosed 20 cases of metabolic disorders. They reported 
that this yielded a frequency of 1:1381 live births for a collection of 10 metabolic 
disorders. This newborn screening continued on a small scale until the start of the 
national newborn screening pilot programme in 2005 (Saadallah & Rashed, 2007).  
However, these results need to be interpreted with caution. The study was carried out 
in hospitals catering for high risk patients; mothers of previously diagnosed children 
with any metabolic disorder are followed-up here during pregnancy until they give 
birth to test the new baby. Additionally, KFSH&RC is a tertiary hospital, many 
infants with unknown diagnoses are referred to it.    
Moammar and colleagues (2010) carried out a retrospective study in the Saudi 
Aramco Medical Centre, a major hospital at the Eastern Province of Saudi Arabia. 
They reviewed the medical records of Saudi patients at the hospital from 1983 up to 
2008, in an effort to measure the incidence of metabolic disorders in that region. They 
identified 248 patients, who had 55 different metabolic disorders, yielding a 
prevalence of 1:667. The most commonly seen disorders were lysosomal storage 
disorders, organic acidopathies, and aminoacidopathies. Nearly all the patients in the 
study were children from consanguineous marriages. The authors believe that this 
warrants a prompt expansion of the newborn screening programme. They recommend 
providing regional treatment and follow-up care facilities with the availability of 
genetic counselling for the families.  
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Another retrospective study was conducted by Al Bu Ali and colleagues (2011) in 
AlAhsa city of the Eastern Province in Saudi Arabia. They reviewed the files of all 
the babies born in the AlAhsa Maternity and Children hospital from April 2006 till 
2009. They identified 43 patients, who had 14 different metabolic disorders, reporting 
a prevalence of 1:774. The most common metabolic disorders found in this population 
were 3-methylcrotonyl-CoA carboxylase deficiency and biotinidase deficiency, 
followed by medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and glutaric 
acidemia type II.  
The Saudi Ministry of Health has reported the rate of metabolic disorders among 
newborns as 1:1000 (Afifi & Abdul-Jabbar, 2007). This early information from the 
pilot newborn screening programme speculated that there will be approximately 500 
new cases of metabolic disorders each year. This validated the necessity of having a 
national newborn screening programme, to help reduce harm and disability in the 
community. 
The most recent report about the progress of the newborn screening programme in 
Saudi was published on the PSCDR website describing progress up to the end of the 
year 2010 (Al-Odaib et al., 2011). It summarises the expansion plans for the 
programme, and states that the rate of the 16 disorders screened for is 1:1000 live 
births after 5 years of increased screening.  
The incidence of metabolic disorders in Saudi Arabia is comparable to the reported 
incidence from the Arab Gulf region, as reviewed in the previous section. However, it 
is higher than what is reported from Europe and Canada. The overall incidence of 
metabolic diseases in British Columbia was approximately 1:2500 (Applegarth, 
Toone, & Lowry, 2000). In Italy the incidence of approximately 200 diseases was 
reported as 1:2555 (Dionisi-Vici et al., 2002). An incidence of 1:2517 was reported 
from Germany (Lindner et al., 2007). While in the West Midlands, UK, the overall 
birth prevalence of metabolic disorders was 1:784 live births (Sanderson, Green, 
Preece, & Burton, 2006).  
One reason for the higher incidence of metabolic disorders in the West Midlands is 
thought to be the high ethnic diversity of the study population (Sanderson et al., 
2006). The other studies reported low ethnic minority groups in their study 
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populations. Although these studies have included different disorders in their 
calculations, but they give an understanding of the disease burden in each area.  In a 
previous study in the West Midlands metabolic disorders were reported to be 1:2691 
for Whites and 1:318 for Pakistanis (Hutchesson, Bundey, Preece, Hall, & Green, 
1998). This demonstrates the variation of incidence among different ethnic groups and 
the importance of knowing the prevalent disorders in each community to provide 
adequate services.  
In an important step towards obtaining the epidemiological data needed for service 
planning and provision of care, the Saudi National Genetic and Birth Defects Registry 
(NGBDR) project started in January 2003. It is funded by the Prince Salman Centre 
for Disability Research (PSCDR) in collaboration with the KFSH&RC to establish 
and maintain a national registry of genetic disorders, birth defects, and developmental 
disabilities in Saudi Arabia (PSCDR, 2012). 
2.5.2 Newborn screening in Saudi Arabia 
Health care is considered a right for Saudi citizens, thus health services and 
medications are provided nationally for free. There are ample private health care 
providers as well. Health services have improved vastly during the past 30 years in 
Saudi Arabia, but establishing preventative medicine was slow. Services such as 
premarital screening and newborn screening took a long time to develop, in spite of 
the high incidence of manageable metabolic disorders in Saudi Arabia. Since 1993 
researchers from the KFSH&RC have asserted that the use of new technology such as 
MS/MS for newborn screening in Saudi Arabia is efficient, cost-effective, and 
prevents the community from dealing with the emotional and financial burden of 
caring for many disabled children. They have highly recommended it, especially 
because KFSH&RC have acquired the technology for diagnostic and selective 
screening purposes (Nasserullah et al., 1998; Rashed & Ozand, 1993; and Ozand, 
1998). Yet it was not until 2005 that a pilot for a national newborn screening 
programme started in Saudi Arabia.   
The pilot started with the aim of screening 50,000 newborns per year from 24 
hospitals in the main cities of Saudi Arabia, and gradually involving more hospitals 
and increasing the number of screened newborns. The disorders screened for are: 
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Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Arginosuccinase 
Deficiency (ASL), Citrullinemia (ASD), HMG-CoA Lyase Deficiency (HMG), 
Isovaleric Acidaemia (IVA), Methylmalonic Acidaemia (MMA), Propionic 
Acidaemia (PA), Beta-ketothiolase Deficiency (BKT), Methylcrotonyl-CoA 
Carboxylase Deficiency (3MCC), Glutaric Acidaemia type-I (GA-I), Medium-chain 
acyl-CoA dehydrogenase deficiency (MCAD), Galactosemia (GAL), Congenital 
Hypothyroidism (CH), Congenital Adrenal Hyperplasia (CAH), and Biotinidase 
Deficiency (BD) (Afifi & Abdul-Jabbar, 2007; and Ministry of Health, 2012).  
The programme has expanded gradually, screening 130,000 newborns in the year 
2011. Samples were sent from 86 hospitals around the country. They predict that by 
the end of the year 2014 they would be screening all newborns (S. Alabdulmunem, 
personal communication, May 16, 2012). The latest statistics show that Saudi Arabia 
has a total of 408 government and private hospitals, more than two thirds with 
maternity and child services. The number of newborns in Saudi Arabia in the year 
2010 was estimated to be just over 600,000 live births (Ministry of Health, 2010). 
The Saudi newborn screening programme, now named “The National Programme for 
Reducing Disability through Early Examination of Infants”, is a collaboration 
between the Ministry of Health (MOH), KFSH&RC, and PSCDR. Administration is 
by the PSCDR, supervision and finance are by the MOH, and The National 
Laboratory for Newborn Screening (NLNBS) is housed at the KFSH&RC and 
equipped to screen all newborns in the country (Afifi & Abdul-Jabbar, 2007; and Al-
Odaib et al., 2011). 
The programme was not mandatory, but rather a collaborative effort, where hospitals 
were asked to collaborate in sending the samples to the NLNBS. It has been 
announced that in 2012 the programme has become mandatory and all public, 
military, and private hospitals were urged to ensure their readiness for participation 
(Ministry of Health, 2011).  
The PSCDR has established a secure web portal, to allow direct access for hospitals to 
the results of newborns screened at their facilities. The aim is to expedite and 
facilitate the process of conveying the results to the families and their health care 
providers as quick as possible (Al-Odaib et al., 2011). This is a crucial measure to 
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employ early in the programme, as timely reporting of positive results is one of the 
main challenges to newborn screening programmes as discussed by Downing et al 
(2010). They advocate the use of electronic health information technology to advance 
the quality and effectiveness of newborn screening.  
Abhyankar and colleagues (2010) describe the development of a template for an 
electronic message to report the results of newborn screening to hospitals and care 
providers. Several states in the US are implementing this technology, which made 
communicating results more rapid and effective. Making use of existing technologies 
would benefit the developing Saudi newborn screening programme. Such 
technologies could in addition facilitate the dissemination of educational material for 
the health care providers and the families regarding newborn screening and 
interpretation of results (Downing, Zuckerman, Coon, & Lloyd-Puryear, 2010). 
The PSCDR has also started building a database for the newborn screening results 
(Al-Odaib et al., 2011). This is important for long-term surveillance of services, 
quality improvement, and research (Berry et al., 2010; and Kemper et al., 2008). 
Recording all results in one database will give a true measure of the incidence of each 
disorder within the screening programme.  
With the high incidence of metabolic disorders in Saudi Arabia there are evidently 
commendable efforts for expanding the newborn screening programme to all 
newborns in the country. It is crucial to implement a public health education 
programme to increase the level of public awareness about newborn screening, 
metabolic disorders, and their management. This is elemental for the understanding 
and acceptance of a new programme by the community, and ultimately its success 
(Afifi & Abdul-Jabbar, 2007; and Moammar, Cheriyan, Mathew, & Al-Sannaa, 
2010). 
Educating parents should start before the birth of their infants. Primary health care 
providers, midwives, and obstetrics need to be educated and involved in educating 
parents about newborn screening and its importance (Downing et al., 2010). Davis 
and colleagues (2006) discovered through interviewing new parents and health care 
providers that they had inadequate information about newborn screening. Parents and 
providers wanted concise and brief information on newborn screening and agreed that 
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it should be given before the birth of the baby. The availability of trained health care 
providers to cater for diagnosed patients from recall after positive results, to 
education, to follow-up, and management are essential for the success of the 
programme (Burgard et al., 2011; Howell & Lloyd-Puryear, 2010; and Therrell et al., 
2010). 
Newborn screening should not be viewed as an end in itself. It should be part of a 
comprehensive public health programme encompassing follow-up, confirmatory 
diagnosis, family education, counselling, management, and provision of various 
services for affected individuals and their families, including continuous evaluation 
(Kaye & the Committee on Genetics, 2006; and Pass et al., 2000).  
Researchers affirm the importance of a timely and well planned follow-up system for 
the well-being of the patients detected by newborn screening programmes (Downing 
et al., 2010; and Kuroda & Ito, 1999).  Long-term follow-up needs systemic and 
comprehensive planning to ensure seamless high quality care and treatment 
throughout life for the patients. This needs continuous staff training, quality 
assurance, care coordination, updated treatments, and research (Berry et al., 2010; and 
Kemper et al., 2008). 
One of the challenges for the newborn screening programme in Saudi Arabia could be 
the limited health personnel and resources in small towns and remote villages. 
Difficulties in managing cases from remote areas were in reaching them and in 
persuading their families to follow up at specialised centres (Nasserullah et al., 2003). 
This highlights the need for public education about the newborn screening programme 
and the disorders, and the need for more specialised health care providers. Many 
workshops have been organised and training programmes are being developed to 
improve the knowledge and expertise of health care providers (S. Alabdulmunem, 
personal communication, May 16, 2012). 
Cultural issues, politics, education, technology, and financing will always be 
challenging obstacles to implementing newborn screening programmes (Saadallah & 
Rashed, 2007; and Therrell, 2003). Educating policy and decision makers about the 
benefits of the programme, setting laws and regulations to govern important issues 
such as confidentiality and accessibility, continuous training for professionals, and 
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instituting public health education programmes about newborn screening can 
positively help overcome these challenges (Therrell, 2003; and Therrell et al., 2010). 
Quality development and evaluation have been part of the Saudi newborn screening 
programme due to its participation in the Newborn Screening Quality Assurance 
Programme (NSQAP) since 2004. The programme is sponsored by the Centres for 
Disease Control and Prevention (CDC) and the Association of Public Health 
Laboratories (APHL), and housed in the CDC. The programme provides guidelines, 
training, consultation, technical assistance, and quality control material for newborn 
screening laboratories, to help improve their screening accuracy and reliability 
(Centers for Disease Control and Prevention, 2013; and De Jesús, Mei, Bell, & 
Hannon, 2010). The Saudi newborn screening programme is also a member of a 
member of the European Research Network for Evaluation and Improvement of 
screening, Diagnosis and Metabolism (ERNDIM) Quality Assurance Programme (Al-
Odaib et al., 2011). 
All the components may not be fully ready in the Saudi newborn screening 
programme. Nonetheless, it is improving and steadily heading towards reaching the 
goal of screening all newborns in the country. 
2.5.3 Schemes implemented in Saudi Arabia to reduce the burden of genetic 
diseases 
Premarital screening 
Premarital carrier detection for sickle-cell disease and thalassaemia has been 
implemented in Saudi Arabia since 2002. The Saudi MOH instituted legislation 
mandating premarital screening from 2004, but it does not prevent identified at risk 
couples from choosing to take the risk and marry (Al-Odaib et al., 2003; and 
El-Hazmi, 2004b). Testing for the human immunodeficiency virus (HIV), and the 
hepatitis viruses B and C (HBV and HCV) was added to the programme in 2008 
(Alswaidi & O'Brien, 2009). It was accepted by the community as a step towards 
prevention, as it enables would-be couples to make informed decisions about marriage 
and the risks involved (Al-Aama, 2010; Alam, 2006; and Meyer, 2005).  
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Memish and Saeedi (2011) evaluated the effects of the Saudi premarital screening 
programme after six years of its implementation. The number of couples who were 
found to be carriers of sickle-cell or thalassaemia traits and cancelled their marriage 
plans increased five folds, from only 9% at the start of the programme in 2004 to 52% 
in 2009. The remaining 48% of couples still went ahead with their wedding plans 
even though they were carriers and at high risk of having affected children. 
Several researchers believe that the timing of the screening test is not optimum. It is 
usually done after the couple’s engagement and just before issuing the marriage 
certificate; therefore the couple’s commitment to each other or their worry of social 
stigma may be the reason for not cancelling their marriage plans. Other reasons could 
be the failure of proper referral of carrier couples to genetic counselling, or the 
couples have been given inadequate information about the risk factors (Al-Aama, Al-
Nabulsi, Alyousef, Asiri, & Al-Blewi, 2008; Alhamdan, Almazrou, Alswaidi, & 
Choudhry, 2007; and Memish & Saeedi, 2011). 
The effects of this programme can be improved through providing more information 
in the media, including information about it in high school and college curriculums, 
strengthening education about the disease for at-risk couples, encouraging couples to 
test early on before any wedding plans, and by offering singles the screening test right 
after high school (Al-Aama et al., 2008; Alhamdan et al., 2007; Ibrahim et al., 2011; 
and Memish & Saeedi, 2011). Screening could also be offered to the extended family 
of patients before any plans of marriage (Al-Shahrani, 2009; and Ozand, Odaib, 
Sakati, & Al-Hellani, 2005). 
Prenatal diagnosis 
Prenatal diagnosis has been well received among Muslims in many countries, as Islam 
allows pregnancy termination in the first trimester for health reasons (Modell & Darr, 
2002). In Islam, pregnancy termination is permitted if the foetus is diagnosed with a 
severe and untreatable condition, and both parents agree. This must be carried out 
before the pregnancy reaches 120 days from conception (Albar, 2002).  
Saudi parents accept prenatal diagnosis, and many are starting to accept the idea of 
pregnancy termination after understanding that religiously it is permitted for severe 
conditions (Alkuraya & Kilani, 2001; Alsulaiman & Hewison, 2007; and Alsulaiman 
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et al., 2012). Families affected by a serious condition had more favourable views 
towards abortion than families who didn’t. However, induced abortion is rarely 
practised in Saudi hospitals. Religious interpretations are strong in the Saudi culture, 
and abortion conveys ethical dilemmas for many families (Al-Odaib et al., 2003; and 
Alsulaiman & Abu-Amero, 2013). 
Pre-implantation genetic diagnosis (PGD) 
PGD is a procedure used for couples at high risk of having children with genetic 
disorders. It is best suited for monogenic disorders and structural chromosome 
abnormalities (Geraedts & De Wert, 2009). PGD involves testing of embryos, 
produced through in-vitro fertilization (IVF), for the genetic disorder. One or two of 
the unaffected embryos are then implanted into the uterus. It has almost universally 
assured the delivery of a healthy infant and is recognized as a significant alternative to 
prenatal diagnosis. It eliminates the dilemma of terminating an affected pregnancy. It 
has been accepted by families and applied around the world in IVF and PGD centres 
(Harper & SenGupta, 2012; and Lavery et al., 2002). Nonetheless, it is a challenging 
procedure, and patients need to understand that risk of misdiagnosis cannot be 
eliminated (Harton et al., 2011; and Wilton, Thornhill, Traeger-Synodinos, Sermon, & 
Harper, 2009). 
With PGD there is a need for IVF and embryo testing, both are invasive procedures 
not free from risk. Risks include high patient discomfort, stress and anxiety, reaction 
to fertility drugs, some embryos may be damaged by the process of cell removal for 
testing, failure of procedure, miscarriage, ectopic pregnancy, and ovarian 
hyperstimulation syndrome (Bhattacharya, 2003; El-Hazmi, 1999; Heijnen, Macklon, 
& Fauser, 2004; and Olivennes, 2003). In addition, there are risks to the infant. These 
include low birth weight, congenital abnormalities, and peri-natal mortality (Harton et 
al., 2011).   
A few studies have examined the acceptance of PGD among Saudi couples. Most 
welcomed the idea as a way of preventing the birth of an affected child (Alkuraya & 
Kilani, 2001; Alsulaiman, Al-Odaib, Al-Rejjal, & Hewison, 2010; and Alsulaiman & 
Hewison, 2006). Families who had undergone PGD report experiencing more ethical 
and psychological stress than anticipated (Alsulaiman et al., 2010). PGD is a complex 
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procedure that continues to evolve and develop with new tools and approaches. It is 
not an easy process for the families, therefore counselling services should be an 
integral part of care to help the families through the difficult stages of this technology 
(Alsulaiman et al., 2010; and Harper et al., 2012).  
2.5.4 Knowledge about IEM in Saudi Arabia 
General knowledge and awareness are fundamental issues and it is essential to address 
them. Al-Essa and colleagues conducted a survey study among randomly selected 
families with children seen at the clinics of KFSH&RC in Saudi Arabia. The study 
was to evaluate the knowledge of 500 parents of children with metabolic disorders 
and it clearly indicated that the majority of parents (over 50%), particularly those with 
a lower level of education, are unaware of aetiologies, symptoms, inheritance, and 
therapies for various inborn errors of metabolism. The authors recommend that a 
broad-based public health education programme is needed in order to secure early 
referrals, particularly from high-risk families, i.e., families with metabolic disorders, 
or those who have experienced unexplained infant death (Al-Essa, Ozand, & Al-Gain, 
1997). There are no recent measures of current knowledge about IEM in Saudi 
Arabia, but there have been no major educational programmes to believe that this has 
vastly improved. 
2.6 Nutritional management of IEM 
2.6.1 Special diets 
The importance of optimal nutrition and dietary manipulation, as an essential part of 
treatment, needs to be emphasized. Often it is not fully comprehended by families, 
leading to incomplete compliance with the prescribed diet. In fact, adhering to the 
special diets require a great deal of effort and adjustment, the diets are absolutely 
crucial to successful management of a considerable number of metabolic disorders. A 
special and specific diet is prescribed for each patient with a metabolic disorder that 
has dietary influences, for example, for patients with inborn errors of protein 
metabolism (aminoacidopathies) the diet involves restricting the dietary intake of 
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protein to limit the intake of the amino acid/s (specific to each disorder) that cause the 
metabolic distress, and substituting this part of the diet with special formulas to 
provide essential nutrients which have been limited with the restricted diet (Clarke, 
2002; and Walter & MacDonald, 2006). 
Special diets often mean the difference between developmental disability and normal 
functioning of individuals with metabolic disorders (Brumm & Grant, 2010; 
Cockburn & Clark, 1996; and Hoffmann, Helbling, Schadewaldt, & Wendel, 2006). 
Children with metabolic disorders and their families need to comprehend the genetics 
of their particular disorders, the treatment of the disorder including the specific 
dietary restrictions, the reasons for these restrictions and how they work in preventing 
harmful effects of each disorder. It is important for families to know that the patients 
will be monitored through regular clinic visits and laboratory tests, be trained to take a 
blood sample, to adjust the diet to maintain metabolic control, and to handle social 
situations concerning food. This will help patients recognize that they can be effective 
individuals in society without compromising their health or being a burden on carers. 
Nonetheless, compliance with these restricted diets is difficult, and tends to decrease 
around adolescence. Therefore identifying compliance barriers and learning how to 
help patients overcome them is an essential aspect of care (MacDonald, Gökmen-
Ozel, van Rijn, & Burgard, 2010). 
Effective nutritional programmes are in place to support and counsel patients and their 
families in most of the European countries and North America. They have regular 
clinic attendance, and when not able to attend patients are trained to send blood 
samples to their laboratories. Results are then given to the dietitians who can easily 
communicate these to the patients and families through the phone, and discuss the 
needed course of action, whether it is to continue with current diet or to implement 
changes in formula or food intake to improve blood levels. Having such systems in 
place and training patients and their families in dealing efficiently with them vastly 
improves the quality of care for each patient, and greatly helps patients and their 
families in dealing with their disorders. Nutrition counselling and education can be 
provided in many effective ways; it could be through one to one sessions or in group 
sessions, with the use of visual aids; such as posters; food models; videos; and stories 
and games for children (Bernstein et al., 2013; Schwandt et al., 1999; and Williams et 
53 
al., 1998). To be most effective education materials need to be adapted to suite the 
population they are intended for (Winkleby et al., 1997).  
Fisch (2000) argued that  “The effectiveness of our treatment is always in the shadow 
of the compliance of our patients” clearly elucidating how essential patient 
compliance is to outcome. Many studies showed how non-compliance with diet and 
intake of prescribed protein substitute formulas negatively affect amino acid levels, 
IQ levels, and cause some vitamins and minerals deficiencies and decreases in bone 
mineral content (Chang, Gray, & O'Brien, 2000; Huijbregts et al., 2002; Przyrembel 
& Bremer, 2000; and Robinson et al., 2000). 
2.6.2 Formula compliance and vitamin and mineral needs  
With all low or restricted protein diets there is a risk of deficiencies in some vitamins 
and minerals. Current research indicates particular deficiencies when the patients do 
not comply with their formula intake. Hanley et al (1996) followed 96 adolescents and 
young adults with PKU in their clinic in Canada; only 66% of them continued with 
their prescribed dietary therapy, and not all of those had good control or took their 
formula regularly. They tested 37 of their patients for several micronutrient 
deficiencies because the formula contains important supplements of vitamins and 
minerals that are lacking in the low phenylalanine diet, 12 (32%) of them had 
suboptimal levels of vitamin B12; five of those patients were off diet. They 
recommend periodic monitoring of serum B12, red blood cell folate, and ferritin in 
adolescents and young adults with PKU, and additionally monitoring of 
methylmalonic acid and homocysteine because they increase with lack of vitamin B12 
and could be good indicators for early detection of B12 deficiency (Hanley, 
Feigenbaum, Clarke, Schoonheyt, & Austin, 1996).  
Another study reported that 77% of the adult PKU patients in their sample, who are 
off diet, had biochemical signs of vitamin B12 deficiency (Hvas, Nexo, & Nielsen, 
2006). They have also measured their vitamin B6 intake through food diaries and 
found that 71% of the patients get less than the recommended intake. Vitamin B6 is 
found in beans, meat, poultry, fish and some fruits and vegetables, but mainly in high 
protein foods. The authors recommend daily vitamin supplementation for PKU 
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patients who are off diet and continued dietary management throughout adult life 
(Hvas et al., 2006).  
Robinson and colleagues (2000) found that vitamin B12 is adequately supplied within 
the formula or additional supplements for adolescents and adults with PKU on a strict 
diet, while patients on a relaxed or unrestricted diet had inadequate intake of vitamin 
B12. This was due to their tendency to avoid animal protein because they either find 
the taste unpleasant or because they recognize it is harmful to them and try to avoid it. 
Vugteveen et al (2011) has shown that patients who were continuously treated and 
have been taking their formula have been found to have functional vitamin B12 
deficiency, which is defined by the authors as an increase of methylmalonic acid 
levels even if vitamin B12 levels were normal. They recommend yearly monitoring of 
serum methylmalonic acid levels in PKU patients to detect B12 deficiency in the 
earliest stages. The researchers speculate that finding more vitamin B12 deficiencies in 
PKU patients could be due to lower bioavailability of B12 from the protein substitute 
formula and due to taking the formula less than three times a day; increased intake of 
B12 in one meal reduces its availability (Vugteveen et al., 2011). The main dietary 
source of B12 is animal protein. Untreated vitamin B12 deficiency may lead to a wide 
range of psychiatric and neurologic problems, some irreversible, in addition to the risk 
of macrocytic anaemia (Hvas et al., 2006; and Robinson et al., 2000). 
Several studies report high incidence of iron deficiency in patients with PKU despite 
being compliant with the diet and the protein substitute formulas; all patients in these 
studies had an adequate iron intake within the recommended level (Acosta et al., 
2004; Acosta, 1996; Arnold, Kirby, Preston, & Blakely, 2001; Bodley, Austin, 
Hanley, Clarke, & Zlotkin, 1993; Miranda da Cruz, Seidler, & Widhalm, 1993; and 
Tavil et al., 2006). The researchers questioned the bioavailability of iron through the 
protein substitute formula and called for further research. Iron deficiency could affect 
growth levels and cause cognitive, motor, and behavioural disturbances, therefore the 
researchers recommended regular monitoring of complete blood counts, haemoglobin, 
and ferritin for early assessment of any deficiency. One of the previous studies gave 
iron supplements (5 mg elemental Fe/kg daily) for 4 months to the patients with low 
iron levels, the patients benefited from this treatment and showed improved levels 
(Miranda da Cruz et al., 1993). 
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Only one study looked at vitamin A levels for patients with PKU (Acosta, 1996). All 
patients had intakes of vitamin A greater than the recommended dietary allowance for 
age but the plasma retinol concentrations for 48% of them were in the marginal or 
deficient range. Again the bioavailability of vitamin A from the formula was 
questioned and further research is warranted.  
A few studies looked at selenium levels in patients with PKU and found that high 
percentages of the patients had low plasma selenium levels, but the patients didn’t 
present any selenium deficiency symptoms (Barretto et al., 2008; Jochum et al., 1997; 
and MacDonald et al., 2004). This was explained by the low level of selenium in 
some of the formulas or due to noncompliance with the formula intake. In addition to 
selenium deficiency Barretto and colleagues found that 37.5% of their patients had 
below normal levels of erythrocyte zinc even though their intake of zinc was more 
than the dietary recommended intake. Dietary fibre and phytate content of grains, 
nuts, and legumes may reduce the bioavailability of zinc by forming insoluble 
complexes with zinc (Barretto et al., 2008). 
Low bone mineralization has been reported in older children with PKU and associated 
with high levels of blood phenylalanine (Adamczyk et al., 2011; Al-Qadreh et al., 
1998; and McMurry, Chan, Leonard, & Ernst, 1992). In all of these studies older 
children and adolescents who were not compliant with the PKU diet and formula 
intake had significantly lower bone mineral density than compliant patients and 
normally developing children. This puts the non-compliant patients at increased risk 
of not reaching the optimum bone mineral content increasing their risk for fractures 
and adult osteoporosis. Furthermore, Adamczyk and colleagues (2011) reported that 
non-compliant patients had significantly lower muscle mass than compliant patients. 
The researchers recommended continuous dietary compliance with good blood 
phenylalanine control to protect the bone mineral development of patients with PKU 
and to reduce the risk of abnormalities in the fat and muscle tissues (Adamczyk et al., 
2011; Al-Qadreh et al., 1998; and McMurry et al., 1992).  
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2.7 The focus of this research 
There are a large number of inborn errors of metabolism; it would be too broad and 
unrealistic to try and address all the disorders in this initial study. The research was 
thought to be best focused on a group of disorders which has similar nutritional 
approaches to treatment, and which are of relatively high incidence in Saudi Arabia. 
Choosing disorders that required dietary management was essential as well, this 
would guarantee that the outcomes were related to diet and compliance with it and not 
confounded by other factors. 
To accomplish this, the research focused on aminoacidopathies, mainly 
phenylketonuria (PKU), tyrosinaemia I, and maple syrup urine disease (MSUD) for 
Phase 1 of the research. As these aminoacidopathies are prevalent in Saudi Arabia and 
have clear dietary requirements. At the time of the study KFSH&RC had 55 active 
patients with PKU, 24 with tyrosinaemia I, and 73 with MSUD. 
These are all autosomal recessive disorders. In aminoacidopathies there is a need to 
restrict dietary intake of one or more amino acids which may be toxic themselves or 
be precursors of toxic metabolites, thus limiting protein intake from food and 
providing special diets and formulas that provide patients with other essential amino 
acids, vitamins, minerals, and energy (Walter & MacDonald, 2006). With all low or 
restricted protein diets there is a risk of deficiencies in some vitamins and minerals, 
deficiencies should always be assessed in patients and supplements given as needed. 
Section 2.6.2 above explored this issue in detail.  
The clearest of these disorders in outcome is PKU; good dietary compliance is very 
well correlated to favourable outcome (Donlon, Levy, & Scriver, 2006; and Smith & 
Lee, 2000). The relationship is clearly defined in PKU between control of the amino 
acid phenylalanine and the Intelligence Quotient (IQ) levels where IQ is the ultimate 
outcome measure. Burgard’s review of studies of intelligence of patients treated early 
for PKU showed that IQ level decreases by half a standard deviation for each 300 
μmol/l increase in the blood concentration of phenylalanine during pre-school and 
early school age (Burgard, 2000). In addition, PKU outcome is much less affected by 
acute illness episodes than MSUD.  
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For tyrosinaemia I and MSUD the determinants of outcome are less certain and can be 
affected by other factors; for tyrosinaemia I there is uncertainty around acceptable 
levels of tyrosine and whether there is a need to avoid low phenylalanine levels, and 
which of these is negatively related to learning disabilities. MSUD outcome is 
affected by the severity, duration of the presenting illness and delays in diagnosis. It is 
also highly affected by acute illness episodes leading to acutely elevated leucine blood 
levels (Chakrapani & Holme, 2006; and Wendel & de Baulny, 2006).  For these 
reasons Phase 2 of this research focused only on PKU, it is reviewed below in more 
detail than the other two disorders.  
2.7.1 Maple syrup urine disease (MSUD) 
MSUD is a disorder of branched-chain amino acid metabolism in which blood 
concentrations of leucine, isoleucine, and valine are highly elevated. The fundamental 
defect is in the activity of the branched-chain α-ketoacid dehydrogenase complex. 
MSUD is classified as classic, intermediate, intermittent, or responsive to thiamine, 
all of the patients in this study have classic MSUD (Chuang, Chuang, & Wynn, 2006; 
and Chuang, Wynn, & Shih, 2006). Around 80% of patients with MSUD have the 
classical phenotype, they have 2% or less of the normal enzyme activity. The 
remainder of the patients have the intermediate phenotype with higher residual 
enzyme activity, and rarely some patients have intermittent manifestation of the 
disease and some patients respond to dietary treatment with thiamine. Patients with 
intermediate or intermittent forms of MSUD have a milder clinical course and late 
onset of the symptoms, but they can experience severe metabolic crises (Simon et al., 
2006; and Strauss, Puffenberger, & Morton, 2006).  
Early symptoms include vomiting, feeding difficulties, irritability, ketonuria, and the 
odour of maple syrup in cerumen and urine. Clinical abnormalities for classic MSUD 
usually manifest within the first week of life (Strauss et al., 2006). Untreated infants 
with MSUD present with metabolic acidosis, acute encephalopathy, spastic 
quadriplegia, convulsions, then coma and central respiratory failure. Serious central 
nervous system conditions may develop in the form of cerebral oedema and death 
may result from brain-stem compression (de Baulny, Dionisi-Vici, & Wendel, 2012; 
and Pandor et al., 2004).  
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Outcome is thought to be most influenced by the severity of illness at diagnosis, the 
age at diagnosis, and the long-term biochemical control of the branched-chain amino 
acids (Chuang et al., 2006; Hoffmann et al., 2006; and Naughten, Jenkins, Francis, & 
Leonard, 1982). Early diagnosis followed by lifelong dietary management can prevent 
developmental delay, the best outcome is seen when treatment starts before the age of 
10 days (Hilliges, Awiszus, & Wendel, 1993; and Kaplan et al., 1991). Researchers 
advocate the inclusion of MSUD in newborn screening programmes as it allows early 
diagnosis and management before the onset of severe symptoms, which is 
fundamental for reducing the risk of brain damage if accompanied with long-term 
good dietary management (Heldt, Schwahn, Marquardt, Grotzke, & Wendel, 2005; 
Muelly et al., 2013; and Simon et al., 2006). 
Dietary treatment requires following a protein restricted diet with the intake of a 
special formula free from branched-chain amino acids. This is aimed at limiting the 
branched chain amino acids to prevent episodes of decompensation while providing 
sufficient levels for normal development (de Baulny et al., 2012; and Strauss et al., 
2006). Patients are susceptible to acute deterioration during acute illness episodes, 
such as infections, therefore, dietary modifications should be prompted when parents 
notice behavioural changes, unsteadiness or lethargy (Morris & Leonard, 1997; and 
Morton, Strauss, Robinson, Puffenberger, & Kelley, 2002). The amino acid leucine is 
the most toxic, while isoleucine and valine are more tolerated. Dietary protein 
restriction for the reduction of high leucine blood levels may require cautious 
supplementation of a small amount of free valine or isoleucine if either of their levels 
fell below minimum requirements, this is important for normal growth and to prevent 
amino acid deficiency and the risk of catabolic stress (Chuang et al., 2006; and 
Morton et al., 2002). 
MSUD has been corrected by liver transplantation, although previously it was not 
considered a better option than strict dietary treatment; due to the risks, uncertain 
outcome, and cost (Wendel, Saudubray, Bodner, & Schadewaldt, 1999). More 
successful liver transplantations have been reported in recent years as treatment for 
MSUD. Researchers report the benefits of liver transplants in effectively controlling 
the blood levels of the branched-chain amino acids and allowing the patients to be on 
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normal diets with no restrictions (Chuang et al., 2006; Shellmer et al., 2011; and 
Strauss et al., 2006). 
Liver transplantation does not reverse any cognitive delay caused by MSUD, but it 
stops the progression of impairment and it provides the patients and their families 
with the relief from the risks of metabolic crises. Therefore, the best outcome is 
believed to be when the transplantation is done early in life before experiencing any 
neurological or intellectual impairment (Mazariegos et al., 2012; Muelly et al., 2013; 
Shellmer et al., 2011; and Strauss et al., 2006). 
Liver transplantation is advised to be decided on each case individually, as 
circumstances of patients vary, and consideration for a transplant is mostly for 
patients with severe enzyme deficiency (Mazariegos et al., 2012). Liver 
transplantation remains complicated and holds the risks of immune suppression, graft 
complications, and surgery; these are all issues for careful consideration (Chuang et 
al., 2006; and Strauss et al., 2006). However, in countries with limited availability of 
the special dietary formula and inadequate management of acute episodes, liver 
transplantation might be the best option for MSUD patients (Mazariegos et al., 2012). 
2.7.2 Tyrosinaemia 
There are two types of tyrosinaemia observed in Saudi Arabia, type I (Hepatorenal 
tyrosinaemia) and type II (Oculocutaneous tyrosinaemia). Tyrosinaemia type I is the 
type most seen in Saudi Arabia, and all of the patients with tyrosinaemia in Phase I of 
this study had tyrosinaemia type I.   
Tyrosinaemia type I 
Tyrosinaemia type I causes hepatic and renal toxicity. Progressive liver disease is the 
major complication of untreated tyrosinaemia I, eventually the patients develop liver 
cirrhosis or hepatocellular carcinoma, or both, in late childhood or adolescence 
(Chakrapani, Gissen, & McKiernan, 2012). Renal dysfunction is seen in most 
patients, from mild tubular dysfunction to renal failure. Other common symptoms 
include rickets, failure to thrive, hepatosplenomegaly, hypotonia, and neurological 
crises of acute peripheral neuropathy, pain and paresthesia (Chakrapani et al., 2012; 
Mitchell, Grompe, Lambert, & Tanguay, 2006; and Pandor et al., 2004). The severity 
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of these symptoms varies, as the disease has a variable phenotype depending on the 
age at onset of symptoms (Holme & Lindstedt, 1998). 
Tyrosinaemia type I is caused by the deficiency of the enzyme fumarylacetoacetate 
hydrolase (FAH). It is the last enzyme in the catabolism pathway of tyrosine, and it is 
mainly expressed by the liver and kidneys (Mitchell et al., 2006). Its deficiency stops 
the process of tyrosine catabolism, which leads to the accumulation of the 
intermediate metabolites fumarylacetoacetate and maleylacetoacetate, and their 
reduced derivatives succinylacetoacetate and succinylacetone. These are thought to 
cause the hepatorenal damage (Chakrapani et al., 2012; and Holme & Lindstedt, 
1998).  
Tyrosinaemia type I is treated by the drug NTBC (2-(2-nitro-4-trifluoromethyl 
benzoyl)-1,3-cyclohexanedione), also known as Nitisinone, in addition to dietary 
restrictions of phenylalanine and tyrosine and the intake of a special dietary formula 
free from tyrosine and phenylalanine to meet the nutritional requirements of the 
patients (Chakrapani et al., 2012). NTBC is an inhibitor of the enzyme 4-
hydroxyphenylpyruvate dioxygenase which blocks the metabolic pathway of tyrosine 
at the second step, and inhibits its degradation before reaching the toxic metabolites 
(Lock et al., 1998). Liver transplantation has been the choice of treatment, but NTBC 
greatly reduced the need for it. Transplantation is currently indicated for patients with 
suspected liver cancer or for patients who do not respond to NTBC treatment 
(McKiernan, 2006). 
The first use of NTBC for patients with tyrosinaemia type I was in 1991 by Lindstedt 
and colleagues (1992). They found marked improvements in the clinical condition of 
the patients after treatment with NTBC and dietary restrictions of phenylalanine and 
tyrosine to keep plasma tyrosine level less than 500 μmol/1. It helped in the 
treatment of renal tubular dysfunction, reduced the need for liver transplants, and for 
patients who started treatment at an early age it decreased the risk of developing liver 
cirrhosis and liver cancer (Holme & Lindstedt, 1998; Holme & Lindstedt, 2000; and 
Lindstedt, Holme, Lock, Hjalmarson, & Strandvik, 1992). The prevention of liver 
disease when NTBC is started early after birth signifies the importance of having 
tyrosinaemia type I on newborn screening programmes (McKiernan, 2006; Santra & 
Baumann, 2008; and Schulze, Frommhold, Hoffmann, & Mayatepek, 2001).  
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The sources of tyrosine in the body are the diet and the hydroxylation of 
phenylalanine. Given that the metabolism of tyrosine and phenylalanine is blocked, 
dietary restriction of these amino acids is essential (Nyhan & Ozand, 1998; and Santra 
& Baumann, 2008). Dietary treatment accompanies NTBC treatment, and the aim is 
to keep blood tyrosine level below 400 μmol/l. The diet consists of limiting 
phenylalanine and tyrosine intake by limiting protein intake and by providing a 
special dietary formula that provides essential amino acids needed for growth 
(Mitchell et al., 2006). 
NTBC with dietary management is still the best available treatment for tyrosinaemia 
type I. Studies continue to report the benefits of this treatment for the patients. 
Larochelle et al (2012) describe the clinical outcome for 78 patients with tyrosinaemia 
type I in Quebec. They report that the patients who were treated with NTBC in 
addition to complying with low protein diet did not suffer acute episodes. 
Additionally, patients detected by newborn screening and treated before one month of 
age were free from liver disease for the follow up period of the study, over five years. 
Couse et al (2011) report improved outcome for their patients in Spain when treated 
with NTBC and dietary restriction of tyrosine and phenylalanine. Only six patients, 
out of the 34 in this study, were detected by newborn screening, the remainder were 
diagnosed after clinical symptoms. Nonetheless, treatment improved their prognosis 
and none of the patients developed hepatic carcinoma.   
A similar experience was reported by Masurel-Paulet et al (2008). They detail the 
long term effects of treatment with NTBC for 46 patients with for tyrosinaemia type I 
in France. Forty two of the patients were diagnosed after clinical symptoms, 38 of 
them had liver failure. Treatment with NTBC improved the quality of life and the 
prognosis for the patients. Two patients developed hepatocellular carcinoma, they 
were treated after the age of 2 years, this asserts the importance of early treatment. 
Some of the patients had cognitive problems and school difficulties, the authors report 
that it is not clear if this is due to noncompliance with the dietary restrictions of 
tyrosine and phenylalanine, or due to NTBC treatment, or just due to the disease 
itself. Continued follow up and further investigation is important.  
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In their review of NTBC, as treatment for tyrosinaemia type I, Santra and Baumann 
(2008) affirm that NTBC has shown great benefits for the patients, but it requires firm 
compliance with the dietary restrictions of phenylalanine and tyrosine. Treating 
patients early with NTBC prevented liver disease, considerably reduced the risk of 
hepatocellular carcinoma, and improved renal tubular function. Treatment with NTBC 
improved the symptoms of patients with advanced disease as well. The authors 
caution that even if patients were on NTBC they should continue to be screened for 
malignancy in the liver, as the effect of NTBC on reducing the risk of developing 
hepatocellular carcinoma in not fully clear and needs to be studied further.  
Tyrosinaemia type II 
Tyrosinaemia type II is rare in Saudi Arabia, and none of the patients were 
encountered during the data collection of this research. It is caused by a defect in the 
hepatic tyrosine aminotransferase (TAT); the first enzyme in the catabolism pathway 
of tyrosine (Mitchell et al., 2006). Tyrosinaemia type II is characterized by causing 
corneal and skin lesions, in addition to variable degrees of neurological manifestations 
and learning difficulties, one or all of these effects could be present. Eye symptoms 
include photophobia, tearing, corneal ulceration, eye pain, and inflammation. Skin 
lesions are painful hyperkeratotic plaques on the hand palms and feet soles. It is 
thought that the eye and skin lesions are due to the intracellular accumulation of 
tyrosine crystals (Chakrapani et al., 2012; and Scott, 2006). Developmental delay 
occurs in nearly half of the patients with tyrosinaemia II, it has not been linked to age 
at diagnosis, but it is thought to be affected by very high blood tyrosine levels early in 
life (Mitchell et al., 2006). 
Treatment is through dietary restriction of tyrosine and phenylalanine and the intake 
of a special dietary formula free from tyrosine and phenylalanine to meet the patients’ 
nutritional requirements. Blood levels of tyrosine below 800 μmol/l resolve the skin 
and eye symptoms, but there is no definite agreement on an ideal level that allows the 
best cognitive development and prevents delay, although some researchers suggest 
600 μmol/l (Chakrapani et al., 2012; Mitchell et al., 2006; and Scott, 2006). 
A report by Al-Essa and colleagues (1998) describes the first four patients with 
tyrosinaemia II in Saudi Arabia. The patients had skin lesions and mild mental 
63 
disability, their eyes were not affected. They were put on dietary restriction of 
tyrosine and phenylalanine. The patients improved dramatically after complying with 
the diet and reducing their blood tyrosine level to below 1000 μmol/l (Al-Essa, 
Rashed, & Ozand, 1998).  
2.7.3 Phenylketonuria (PKU)  
PKU is caused by a defect in the enzyme phenylalanine hydroxylase (PAH), PAH is 
required for the conversion of the essential amino acid phenylalanine to tyrosine 
(Donlon et al., 2006). Without the activity of the PAH enzyme phenylalanine 
concentrations increase in the blood and reach toxic concentrations in the brain (Blau, 
van Spronsen, & Levy, 2010; and van Spronsen & Enns, 2010). The expression and 
activity of PAH is mainly in the liver, but is seen in the kidney as well (Donlon et al., 
2006; and Scriver, 2007). Oxygen, iron, and the cofactor tetrahydrobiopterin (BH4) 
are needed for the activity of PAH (Blau et al., 2010; and Donlon et al., 2006).  
The phenylalanine hydroxylase gene has more than 500 different disease causing 
mutations described, hence the wide spectrum in the genotype and phenotype of the 
disorder (Scriver, 2007). Variations range between mild defective activity of the 
enzyme to severe complete inactivation of the enzyme, where blood phenylalanine 
concentrations could go up to 30 times the normal level. The normal range of blood 
phenylalanine concentration is 35-120 µmol/l (Walter, Lachmann, & Burgard, 2012). 
Patients are considered to have mild hyperphenylalaninaemia if their blood 
phenylalanine levels are 120–600 μmol/l, levels of 600–1200 μmol/l are classified as 
Mild PKU, and levels over 1200 μmol/l are classified as Classic PKU (Blau et al., 
2010).  
Progressive developmental delay is the most significant sign of untreated PKU. Other 
symptoms in untreated or late diagnosed patients include infantile spasms, 
microcephaly, neuromotor deficits, their eyes, hair and skin would be lightly 
pigmented compared to their parents, an unusual 'mousy' odour may be observed early 
in life, and in about a third of the patients other symptoms can manifest such as 
dermatitis, and seizures. Hyperactivity, behavioural problems, psychiatric symptoms, 
and decreased executive function is seen in older children and adults (Blau et al., 
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2010; MacDonald, Nanuwa, Parkes, Nathan, & Chauhan, 2011; van Spronsen & 
Enns, 2010; and Walter et al., 2012). 
2.7.3.1 Main PKU Treatment 
Low phenylalanine diet  
Dietary treatment through the restriction of phenylalanine intake has been the basis of 
PKU management for the past sixty years. PKU is one of the first metabolic disorders 
to be understood biochemically and to have a treatment available (Bélanger-Quintana, 
Burlina, Harding, & Muntau, 2011; and van Spronsen & Enns, 2010). To prevent the 
symptoms of PKU diagnosis should be made in the neonatal period through newborn 
screening and treatment should promptly start following confirmation of diagnosis, 
and continue for life (Donlon et al., 2006). 
The main goal of dietary treatment for PKU is to provide a low phenylalanine diet 
that maintains blood phenylalanine within a reasonable range of 120-360 µmol/l. 
Limiting phenylalanine blood levels has been established to prevent developmental 
delay, yet provide enough phenylalanine to meet the need of this essential amino acid 
for normal growth and body repair (Koch et al., 1996; and Walter et al., 2012). The 
upper and lower limits of the acceptable blood phenylalanine level differ slightly 
between countries and changes for different age groups (Blau et al., 2010). Patients 
keeping their blood phenylalanine levels within the required limits are in metabolic 
control. 
A nutritionally complete low phenylalanine diet is achieved by allowing patients to 
consume a controlled quantity of low protein natural foods that provide a measured 
amount of dietary phenylalanine and by consuming a special phenylalanine free 
protein substitute formula. The formula should provide the needs of amino acids, 
carbohydrates, fats, vitamins, minerals, and energy. Foods with minimal amounts or 
free from phenylalanine are allowed without measurements, and all animal protein 
sources and legumes are not allowed. Low-protein alternatives of some products are 
available, such as low-protein bread, pasta, and biscuits, they are used to increase 
dietary variety and provide needed energy. The amount of the allowed dietary 
phenylalanine is adjusted for each patient until their phenylalanine blood levels 
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become stable (Feillet & Agostoni, 2010; MacDonald, Gökmen-Ozel, & Daly, 2009; 
MacLeod & Ney, 2010; and Walter et al., 2012).  
It is essential to regularly monitor the phenylalanine blood levels of PKU patients to 
ensure metabolic control and adherence to diet, and to prevent the harmful effects of 
high levels (Feillet, MacDonald, Hartung, & Burton, 2010; and van Spronsen & 
Burgard, 2008). In addition, it is important to monitor the nutritional status of the 
patients to prevent any deficiencies, since this is a risk with PKU as reviewed 
previously, especially if the patients were not consuming the prescribed amounts of 
their formula (Feillet & Agostoni, 2010; and Lammardo et al., 2013).  
Researchers also recommend close monitoring of the growth and weight of patients to 
prevent overweight and obesity (Burrage et al., 2012; and Rocha, MacDonald, & 
Trefz, 2013). Some studies have found that there are high levels of overweight and 
obesity among PKU patients, especially in girls (Burrage et al., 2012; and White, 
Kronmal, & Acosta, 1982), while others report that PKU patients have normal growth 
and body composition, and overweight and obesity levels are not higher than the 
levels seen in the normal population (Huemer, Huemer, Moslinger, Huter, & Stockler-
Ipsiroglu, 2007; Robertson et al., 2013; and Rocha et al., 2012). Nonetheless, 
overweight levels are high and increase with age especially for women, Robertson et 
al (2013) reported overweight in 51% of adult patients with PKU in the UK. 
Overweight, even if it was similar to the general population levels, may lead to other 
health problems, which complicates the dietary management for PKU patients. 
Studies could not identify if obesity in PKU is due to the condition itself, to 
inadequate metabolic control, or is a result of the dietary treatment (Rocha et al., 
2013). More studies are needed to identify the underlying cause of overweight among 
PKU patients to enable its early prevention.  
Adherence to the strict diet of PKU is extremely burdensome and hard for the patients 
and their families. They face difficult social, emotional, and economical issues 
relating to the complex dietary management of this disorder (Di Ciommo, Forcella, & 
Cotugno, 2012; Sharman, Mulgrew, & Katsikitis, 2013; and Simon et al., 2008). 
Consequently, compliance decreases with age, and becomes more difficult for 
adolescents to keep metabolic control (Blau et al., 2010; Freehauf, Van Hove, Gao, 
Bernstein, & Thomas, 2013; MacDonald et al., 2006; and Walter et al., 2002). These 
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reasons have compelled researchers to seek alternative therapies for PKU to help 
patients maintain metabolic control for life (Bélanger-Quintana et al., 2011; and 
Giovannini, Verduci, Salvatici, Paci, & Riva, 2012). 
2.7.3.2 New treatment options for PKU 
Some new dietary and treatment options have emerged in the past few years, such as 
glycomacropeptide, large neutral amino acids, and sapropterin dihydrochloride 
(BH4). They have helped specific patients to reach metabolic control, but they are not 
suitable for all PKU patients and not available in many countries. 
Sapropterin dihydrochloride (BH4) 
Sapropterin dihydrochloride, also known as BH4, is a synthetic form of the naturally 
occurring tetrahydrobiopterin (6R-BH4), the commercial pharmaceutical name is 
Kuvan (Burnett, 2007). It was noticed that not only patients with 
hyperphenylalaninaemia due to tetrahydrobiopterin deficiency (reviewed below) were 
responsive to the loading test of BH4, some patients with hyperphenylalaninaemia 
due to PAH deficiency were observed to have lower levels of blood phenylalanine 
after being given the oral BH4 screening test (Kure et al., 1999; Michals-Matalon, 
2008; and Sanford & Keating, 2009).  
In combination with dietary management, BH4 is believed to boosts residual PAH 
activity and improves metabolic control. There are several theories on the mechanism 
of how BH4 works; the main one is that it acts as a pharmacological chaperone. It 
corrects the misfolding in the PAH enzyme, stabilising it, restoring some of its 
function, and increasing the amount of active enzyme (Burton et al., 2011; Santos-
Sierra et al., 2012; and Staudigl et al., 2011). 
Numerous studies have tested the efficiency and safety of BH4 and found that it 
is effective for some patients with PKU in reducing their blood phenylalanine levels 
and increasing tolerance to dietary phenylalanine. It had no serious adverse effects 
and was tolerated well at doses of up to 20mg/kg/day (Burton et al., 2011; Lee et al., 
2008; Levy et al., 2007; and Somaraju & Merrin, 2012). Several other studies have 
tested the use of BH4 with infants and children, they found it to be effective and well 
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tolerated (Burton et al., 2011; Hennermann, Bührer, Blau, Vetter, & Mönch, 2005; 
Leuret et al., 2012; and Shintaku et al., 2004). 
Keil et al (2013) studied the long-term effects of treating with BH4. They followed up 
147 patients with PKU; the patients have been treated with BH4 for at least 6 months 
and up to 12 years. They found that patients treated with BH4 had improved 
metabolic control, increased tolerance to dietary phenylalanine, improved compliance 
with diet and treatment, and many believed they had a better quality of life. They did 
not report any severe adverse effects to treatment, and minor side effects were gone 
after reducing the BH4 dose (Keil et al., 2013). 
Their results are in agreement with several other studies that have reported on the 
efficacy of long-term treatment with BH4. Trefz, Scheible, and Frauendienst-Egger 
(2010) followed 14 patients on treatment for a mean time of 4.6 years, Couce et al 
(2012) followed 16 patients on treatment for a mean time of 5 years, and Hennermann 
et al (2005) reported on treating five infants for two years. They have all shown 
improved metabolic control, significant increase in phenylalanine tolerance, and the 
ability of many patients to reduce their intake of the protein substitute formula. 
It is reported that 20% to 50% of PKU patients are responsive to oral treatment with 
BH4; most of these patients have mild to moderate PKU (Burnett, 2007; Fiori, Fiege, 
Riva, & Giovannini, 2005; Keil et al., 2013; Levy et al., 2007; and Lindegren et al., 
2013). Patients responsive to BH4 are reported to have lower baseline phenylalanine 
and phenylalanine/tyrosine ratio than non-responsive patients. Additionally severe 
mutations were seen more in non-responsive patients (Elsas, Greto, & Wierenga, 
2011; and Keil et al., 2013). Nonetheless, there are reports of some patients with 
severe PAH mutations (classic PKU) responding to BH4 treatment (Fiege & Blau, 
2007; Hennermann et al., 2005; and Vernon, Koerner, Johnson, Bergner, & Hamosh, 
2010). Therefore, the BH4 loading test is seen as an important test for all patients 
diagnosed with PKU before initiating treatment (Blau et al., 2009). 
Blau et al (2011) recommend that after the diagnosis of PKU, through newborn 
screening, patients should be screened for BH4 deficiency, and then investigated for 
their responsiveness to treatment with BH4 through a 24-48 hour loading test. This 
differs between centres, but usually involves administering a single oral dose of 20 
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mg BH4/kg body weight/day. The patients are classified as responsive if their blood 
phenylalanine levels showed a reduction of at least 30% after 24 hours of the loading 
test, or 48 hours in some centres. This is recommended to be followed by efficiency 
testing for several weeks to ensure responsiveness and to adjust the dose of BH4 and 
the dietary phenylalanine intake for each responsive patient to attain optimum 
metabolic control (Anjema et al., 2013; Blau et al., 2009; and Blau, Hennermann, 
Langenbeck, & Lichter-Konecki, 2011). Researchers recommend repeating the 
loading test or extending its trial for non-responsive patient to ensure there are no 
false negative results and to identify patients who are slow responders to the BH4 
treatment (Cerone et al., 2013; Couce, Bóveda, Valerio, Pérez-Munuzuri, & Fraga, 
2012; and Staudigl et al., 2011). 
Some researchers believe that genotype identification would facilitate predicting BH4 
responsiveness (Anjema et al., 2013; Blau et al., 2011; Elsas et al., 2011; Keil et al., 
2013; and Utz et al., 2012). This is not always the case, as patients with the same 
genotype have shown different response to BH4. Therefore, identifying responsive 
patients according to genotype needs further investigation (Blau et al., 2009; Ponzone 
et al., 2010; and Staudigl et al., 2011). 
It is important to note that the definition of BH4 responsiveness as blood 
phenylalanine level reduction of at least 30% is arbitrary. Smaller reductions may still 
be clinically significant for some patients, especially if they had low baseline 
phenylalanine levels or were on a strict low phenylalanine diet (Cerone et al., 2013). 
A survey of clinicians in the USA has shown that they extend the measures of 
response to include other clinical parameters such as improved behaviour and 
improved dietary phenylalanine tolerance (Gordon, Thomas, Suter, & Jurecki, 2012). 
Physicians in Europe are given the freedom to set the criteria of responsiveness for 
individual patients (MacDonald et al., 2011). 
Two studies have evaluated the impact of BH4 treatment on the nutritional status of 
patients with PKU (Singh, Quirk, Douglas, & Brauchla, 2010; and Thiele et al., 
2013). Thiele and colleagues reported that the intake of some micronutrients was 
particularly below recommendations for the patients who reduced or stopped taking 
the protein substitute formula as a result of BH4 treatment. The intake of 
carbohydrates and energy was below the recommendations as well. Singh et al found 
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that it was important to give micronutrient supplements to the patients who have 
stopped the protein substitute formula as dietary protein tolerance was increased on 
BH4 therapy.  
Due to the potential risk of nutrient deficiency it is essential to continuously evaluate 
the nutrient status of patients under BH4 therapy as they relax their diets and reduce 
their intake of the protein substitute formula. The authors recommend vitamin and 
mineral supplements during the dietary changes that the patients go through while 
liberalizing their diets, until they can get sufficient supply of nutrients from natural 
food. Nutrition education is essential to accompany BH4 therapy, as the dietary 
recommendations with BH4 is dramatically different than what the patients have been 
taught since diagnosis with PKU. Each patient should have an individualised 
nutritional plan due to the variations in BH4 responsiveness among patients 
(MacDonald et al., 2011; Singh et al., 2010; Somaraju & Merrin, 2012; and Thiele et 
al., 2013).  
Two recent reviews have documented the key issues and recommendations relating to 
the optimal use of BH4 therapy and dietary treatment for patients with PKU.  
MacDonald and colleagues (2011) from the UK and nine other European countries 
formulated a comprehensive guidance for combining BH4 treatment and diet for 
patients with phenylketonuria. Similarly Cunningham and colleagues (2012), a group 
of metabolic dietitians and physicians from across the US and Canada, participated in 
formulating recommendations for the use of BH4 therapy with PKU patients. The 
researchers based the recommendations on the latest evidence and their clinical 
experience; it includes guidance on determining BH4 responsive patients, target 
phenylalanine levels, nutritional monitoring, compliance issues, educating patients 
and their families on treatment targets and expectations, and the need for further 
research for long-term outcomes for growth and nutritional adequacy.  
In a systematic review of BH4, as an adjuvant treatment of PKU, Lindegren et al 
(2013) argue that even though many studies have shown the benefit of BH4 treatment, 
there is still a great need for more research and larger studies. They describe that 
available evidence does not ascertain the potential effects of BH4 on longer-term 
outcomes such as nutritional status, behavioural change, executive function, cognitive 
ability, and quality of life.  
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Additionally, the cost of BH4 is much higher than dietary therapy, hindering its use in 
many countries (Burnett, 2007; Couce et al., 2012; and MacDonald et al., 2011). BH4 
has caused a big leap in the treatment of PKU, as the first effective non-dietary agent 
to be approved for treating PKU. Yet not all patients with PKU can benefit from it, 
due to non-responsiveness, cost, or unknown long-term effects. Dietary treatment 
continues to be the basis of treatment for the time being.  
Large neutral amino acids 
Large neutral amino acids (LNAA) have been used with selected PKU patients to 
improve their metabolic control. LNAA include the essential amino acids valine, 
isoleucine, leucine, tryptophan, threonine, methionine, and histidine, in addition to 
tyrosine. Tyrosine becomes an essential amino acid for PKU patients (van Spronsen, 
de Groot, Hoeksma, Reijngoud, & van Rijn, 2010). 
There are several theories for the effect of LNAA supplementation. It may reduce the 
brain phenylalanine concentrations, since phenylalanine and LNAA use the same 
transport system, LNAA compete with phenylalanine for transport across the blood-
brain barrier. This can obstruct the influx of high levels of phenylalanine into the 
brain and this may help prevent neurological damage (Lindegren et al., 2012; and 
Rocha & Martel, 2009). Another treatment theory is that LNAA supplementation 
would reduce blood phenylalanine levels by competing with the transport of 
phenylalanine through the carrier protein in the gastrointestinal tract (Lindegren et al., 
2012; Matalon et al., 2006; and Matalon et al., 2007). In addition, it has been 
suggested that LNAA supplementation would be beneficial to PKU patients by 
increasing their cerebral neurotransmitter synthesis, and by elevating brain levels of 
essential amino acid other than phenylalanine. There are limited studies to confirm 
these modalities (van Spronsen et al., 2010). 
The systematic review by Lindegren and collegues (2012) of adjuvant therapies for 
PKU explained that eventhough LNAA suplementaion for PKU patients has potential 
benefits, there is insufficient evidence concerning the safety and efficacy of long-term 
use. They concluded that it is not a feasible treatment alternative to reduce blood 
phenylalanine levels or increase phenylalanine tolerance for PKU patients. More 
comprehensive studies are needed to examine the possible benefits, composition, and 
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dosage of LNAA for all PKU patients (Lindegren et al., 2012; and van Spronsen et 
al., 2010). In clinical practice, LNAA supplementation is usually offered to patients 
who are unable to maintain dietary compliance and have chronically elevated 
phenylalanine blood levels, or adult patients who have been off the PKU diet to help 
them reach some level of metabolic control. There are several compositions of LNAA 
available and they do not require FDA approval because they are considered as 
nutritional supplements. The dosage should be calculated by the medical 
professional for each individual patient (Camp, Lloyd-Puryear, & Huntington, 2012; 
Lindegren et al., 2012; and MacLeod & Ney, 2010).  
Glycomacropeptide 
Glycomacropeptide (GMP) is a natural protein found in cheese whey, and in its pure 
form it is the only known protein to be naturally free from phenylalanine, which 
makes ideal for the PKU diet (MacLeod & Ney, 2010). GMP is rich in some essential 
amino acids, but to be used as a nutritionally complete protein, it needs to be 
supplemented with the remaining essential amino acids for PKU patients (Laclair, 
Ney, MacLeod, & Etzel, 2009).  
A study by van Calcar and Ney (2012) has shown that an assortment of food products 
and beverages made from purified and supplemented GMP provided a nutritionally 
complete and acceptable source of protein for PKU patients. This reduced their need 
for the protein substitute formula and allowed for more variety in their diet. The GMP 
products increased the patients’ feelings of satiety and enhanced their protein 
utilization compared with the synthetic protein substitute formula (van Calcar & Ney, 
2012).  
Nutritionally complete food products made from purified GMP can improve the 
nutritional management of PKU through improving the variety and taste of the low 
phenylalanine diet and decreasing the needed amounts of the protein substitute 
formula. This would help in improving compliance, metabolic control, and quality of 
life for PKU patients (Laclair et al., 2009; MacLeod & Ney, 2010; and Ney, Blank, & 
Hansen, 2013). The study by van Calcar and Ney (2012) has established the short-
term safety of GMP for PKU patients, but further evidence is needed to identify the 
long-term efficacy,  safety, and effects on nutritional status of GMP products on PKU 
patients (van Calcar & Ney, 2012; and van Spronsen, 2010). 
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2.7.3.3 Future treatment possibilities 
Several treatment approaches for PKU are being studied in clinical and preclinical 
trials. These include enzyme therapy, gene therapy, and chaperone molecules. The 
goal is to find a sustainable treatment for PKU that would reduce blood phenylalanine 
levels and allow liberation from the strict PKU diet to help the patient achieve a better 
quality of life.   
Enzyme therapy 
Enzyme therapy with phenylalanine ammonia lyase (PAL) is showing promising 
results in reducing blood phenylalanine levels and may well increase tolerance to 
phenylalanine for patients with PKU. PAL converts phenylalanine to the harmless 
metabolite trans-cinnamic acid and trace amounts of ammonia. It has shown positive 
results in reducing blood levels of phenylalanine in animal models, but the host’s 
immune response prevented a sustained effect after repeating the PAL injections 
(Sarkissian et al., 1999; and Sarkissian & Gámez, 2005).  
Researchers have modified the PAL chemically with polyethylene glycol (PEG), to 
protect the PAL from immunogenicity, which should lead to a longer and more 
efficient reduction in blood phenylalanine levels (Gamez et al., 2005; and Gamez et 
al., 2007). The new formulation (PEG-PAL) has a prolonged plasma half-life and 
improved activity. Weekly subcutaneous administration of PEG-PAL to PKU mice 
was effective in achieving and sustaining long-term low blood phenylalanine levels 
(Sarkissian et al., 2008).  
This PEG-PAL formulation is now in clinical trials with PKU patients to test its safety 
and efficacy. It has completed phase I trials and has entered phase II trials as a 
possible adjunct treatment for PKU (Belanger-Quintana, Burlina, Harding, & Muntau, 
2011; and Sarkissian, Kang, Gamez, Scriver, & Stevens, 2011). The phenylalanine 
restricted diet may still be needed, but less rigorous. 
The PEG-PAL in trials is administered through a subcutaneous injection; offering a 
non-invasive form would be more desirable since it would be a lifelong therapy for 
PKU patients. Researchers are working on developing an oral form of the PEG-PAL 
that can resistant intestinal digestion long enough to metabolise phenylalanine in the 
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intestine before its absorption. In theory oral administration would evade 
immunogenicity (Kang et al., 2010; Sarkissian et al., 2011). 
Gene therapy  
Several laboratories are studying the possibility of developing clinical gene therapy 
for PKU patients. PKU is caused by a defect in the enzyme phenylalanine 
hydroxylase (PAH), which is due to a mutation in the PAH gene. Gene therapy aims 
to add a non-mutant copy of the PAH gene into the liver or muscles, through the use 
of vectors, to produce PAH and correct hyperphenylalaninaemia (Harding & Blau, 
2010; and Thöny, 2010).   
Liver directed gene therapy, in PKU mice, has been successful in achieving reduction 
of high blood phenylalanine levels for up to one year, without adverse effects. 
However, normal liver cell regeneration leads to the elimination of the gene therapy 
vector and the loss of PAH expression, preventing the accomplishment of a 
permanent correction of liver PAH activity (Ding, Georgiev, & Thöny, 2006; Harding 
et al., 2006; and Rebuffat, Harding, Ding, & Thöny, 2010). Administration of the 
same vector again was ineffective, because it was destroyed by an immune-mediated 
rejection developed in the mice in response of the initial vector injection (Rebuffat et 
al., 2010). 
The liver is the predominant metabolic source of PAH normally, but researchers have 
succeeded in examining the possibility of gene therapy in non-hepatic tissue, such as 
skeletal muscles. Unlike the liver, muscles provide a stable environment for protein 
expression due to the lack of ongoing cell regeneration, have large total mass, and 
have easier accessibility, which theoretically leads to a more sustainable and feasible 
therapy (Belanger-Quintana et al., 2011; and Thöny, 2010).  
Ding and colleagues (2008) managed to achieve sustained and long-term (over one 
year) reduction of blood phenylalanine levels in PKU mice, through the expression of 
a complete system that replicated the function of hepatic phenylalanine hydroxylation 
in the muscle cells. This included the expression of PAH and two biosynthetic 
enzymes for BH4 (GTPCH and PTPS) to synthesize enough BH4 to support 
phenylalanine metabolism. Researchers suggest that muscle-directed gene therapy 
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might be a more practical approach for the management of PKU and other inborn 
errors of metabolism (Ding et al., 2008; and Thöny, 2010). 
Immunity against repeated injection of gene therapy vectors is a serious obstacle for 
application in humans. The success of gene therapy depends on developing a method 
that leads to permanent gene expression in liver or muscle cells to reach a sustainable 
therapeutic effect. Gene therapy is a promising treatment option, but it should be 
thoroughly evaluated before a human trial can be considered (Harding & Blau, 2010; 
and Thöny, 2010). 
Chaperone molecules 
Most of the mutations causing PKU impair correct protein folding in the PAH protein, 
making PKU a suitable candidate for pharmacological chaperones to correct the 
misfolding (Underhaug, Aubi, & Martinez, 2012). The cofactor BH4 acts as a natural 
chaperone for PAH, and as discussed earlier, it has shown great results in normalizing 
blood phenylalanine levels for some patients with mild PKU mutations. The cost of 
BH4 is high and it is not effective with all PKU patients, therefore, the search for 
alternative molecules continues. The aim is to find other chaperone compounds that 
can promote the correct folding of mutant PAH protein, to enhance stabilization or to 
restore activity, in other mutations of PKU (Santos-Sierra et al., 2012; and Underhaug 
et al., 2012). 
Pey and colleagues (2008) have identified two chaperone molecules that have 
increased the activity of PAH in mice to levels similar to the BH4 effect, but at a 
much lower dose. They believe that further examination and modification of these 
molecules, or other new molecules, has the potential of identifying a more potent 
pharmacological chaperone with a larger effect on PAH (Pey et al., 2008). 
Santos et all (2012) tested several newly chosen compounds as possible 
pharmacological chaperones for treating PKU. Two of these compounds increased the 
activity of PAH and reduced blood phenylalanine levels in PKU mice that are BH4 
responsive, one of them even showed double the effectiveness of BH4 treatment 
(Santos-Sierra et al., 2012). Additional studies are needed to assess if these 
compounds would also be effective with other PKU mutations. 
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The field of pharmacological chaperones, though challenging, has shown promising 
potential for drug development to attain effective molecules that can treat a wider 
range of patients with PKU and other inborn errors of metabolism. The researchers 
envision that continued research would hopefully enable patient-tailored treatment by 
the use of mutation-specific pharmacological chaperones (Pey et al., 2008; Santos-
Sierra et al., 2012; and Underhaug et al., 2012). 
2.7.4 Maternal phenylketonuria  
Damage to the infants born to mothers with inadequately treated PKU, due to the 
teratogenic effect of elevated maternal phenylalanine levels, is identified as maternal 
phenylketonuria syndrome (MPKU) (Koch, Trefz, & Waisbren, 2010). The risk to the 
infant is proportionate to the level of phenylalanine in the mother’s blood. The risks 
include low birth weight, facial dysmorphism, microcephaly, reduced growth, mental 
disability, learning difficulties, and congenital heart disease (Donlon et al., 2006; 
Koch et al., 2010; and Walter et al., 2012). 
To protect the infants from these risks, ideally, women with PKU should aim to reach 
metabolic control few months before conception till the end of pregnancy. The infants 
of mothers who start dietary phenylalanine restriction before conception have better 
developmental outcome than the infants of mothers who start after conception 
(Donlon et al., 2006; Maillot, Lilburn, Baudin, Morley, & Lee, 2008; and Walter et 
al., 2012). Nonetheless, research has shown that there are many unplanned 
pregnancies; therefore it is highly advisable for women with PKU of childbearing age 
to stay on phenylalanine-restricted dietary treatment (Koch et al., 2010; and Rouse & 
Azen, 2004). 
The International Maternal PKU Collaborative Study has stated that maternal blood 
phenylalanine levels between 120 and 360µmol/l are the most favourable for a good 
birth outcome (Koch et al., 2003). Their analysis has shown that the IQ outcome for 
the children was not significantly different between children born to mothers who had 
reached metabolic control before conception, children born to mothers who had 
reached control before 10 weeks of pregnancy, or children born to mothers who had 
mild hyperphenylalaninaemia. Therefore, they concluded that it is best to reach 
metabolic control when planning a pregnancy, but if the pregnancy was unplanned, 
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normal outcome for the foetus is still achievable if the control was reached by 8 to 10 
weeks of gestation and maintained all through the pregnancy.  
However, some researchers believe that to get the best possible outcome for the 
children maternal metabolic control is vital before pregnancy. In a recent review, 
Prick and colleagues (2012) has shown that the risks of maternal PKU were 
significantly linked to mean phenylalanine levels in each trimester, apart from facial 
dysmorphism, which was linked to the levels in the first trimester only. This indicates 
that early restriction of phenylalanine intake to reach metabolic control before 
pregnancy is important, as the face and major organs are developed in the first 
trimester. Maillot et al (2008) found that it is essential to start metabolic control 
before conception to prevent congenital heart disease and body malformations. 
In addition, it is important to ensure adequate pregnancy weight gain and sufficient 
intake of vitamins and protein, as they have protective effects against microcephaly 
and congenital heart disease (Maillot, Cook, Lilburn, & Lee, 2007; and Matalon, 
Acosta, & Azen, 2003). Frequent monitoring is needed to help avoid fluctuations in 
blood phenylalanine levels, which was reported to have a negative effect on the 
infants, even if the mean phenylalanine levels were within the target limits (Maillot et 
al., 2008).  
The high rate of pregnancy while off dietary restrictions among women with PKU 
reveals that health services for adults with metabolic disorders may be insufficient 
(Lee, Lilburn, & Baudin, 2003). Preventing the risks of maternal PKU should be a 
public health concern, as the benefits of newborn screening in preventing disability 
might be diminished with the increased number of disability related to the outcome of 
maternal PKU Brown (Brown et al., 2002; and Scriver, 2007).  
Education for girls with PKU and their families is essential about the importance of 
continuing follow up, maintaining metabolic control, and getting reproductive 
counselling before planning a pregnancy to avoid the risks of maternal PKU 
syndrome. This effort needs to be shared between the metabolic specialists, 
paediatricians, gynaecologists, and family doctors. These specialists need to be aware 
of the maternal PKU syndrome to give the appropriate guidance and support to 
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females with PKU in childbearing age (Brown et al., 2002; Donlon et al., 2006; Koch 
et al., 2010; and Walter et al., 2012). 
Reaching metabolic control and maintaining it throughout pregnancy is very difficult, 
especially if the patient was off the PKU diet before pregnancy. Some researchers 
have recommended the use of sapropterin dihydrochloride (BH4) to help pregnant 
women with PKU maintain metabolic control, if its safety during pregnancy has been 
established (Trefz & Blau, 2003). Several reports documented positive outcomes after 
the use of BH4 in addition to phenylalanine restriction to treat three pregnant women 
with PKU (Koch, Moseley, & Guttler, 2005; Koch, 2008; and Moseley, Skrabal, 
Yano, & Koch, 2009). No adverse effects were reported, blood phenylalanine levels 
were maintained within the recommended range throughout the pregnancies, the 
infants did not have any of the maternal PKU symptoms, and they showed normal 
development after follow up (Koch, 2008; Koch et al., 2010; and Moseley et al., 
2009). There were no pregnancies among the patients in this study. 
2.7.5 Tetrahydrobiopterin (BH4) deficiency 
Another cause of hyperphenylalaninaemia is the deficiency of tetrahydrobiopterin 
(BH4), which is an essential cofactor in the phenylalanine, tyrosine, and tryptophan 
hydroxylation reactions. BH4 is also needed for the biosynthesis of nitric oxide and 
the neurotransmitters serotonin, dopamine, norepinephrine, and epinephrine. Around 
2% of patients with hyperphenylalaninaemia worldwide have inherited mutations in 
the genes encoding for enzymes that are needed for the biosynthesis or regeneration 
of BH4 (Erlandsen & Stevens, 1999; Hyland, Cotton, Thöny, & Blau, 2006; Scriver, 
2007; and Shintaku, 2002).  
It has been reported by Blau and colleagues (1996) that disorders of BH4 deficiencies 
account for 60% of hyperphenylalaninaemias in Saudi Arabia. There are no official 
statistics on the actual numbers of patients with PKU compared to BH4 deficiencies, 
but two studies from KFSH&RC in Saudi Arabia reported about their patients. Ozand 
(1998) reported the diagnosis of 16 patients with Classic PKU and only two patients 
with BH4 deficiency (6-pyruvoyl-tetrahydropterin synthase deficiency) after 
screening 26,063 infants in a period of 18 months. In a follow up study, Ozand and 
colleagues (2005) reported the diagnosis of 42 patients with Classic PKU and 30 
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patients with BH4 deficiency (6-pyruvoyltetrahydropterin synthase deficiency) over a 
five year period.   
BH4 deficiency disorders are due to impaired synthesis or recycling of the BH4 and 
are all autosomal recessive disorders (Mitchell, 2000; and Shintaku, 2002). BH4 
synthesis defects are due to a deficiency in the enzyme guanosine triphosphate 
cyclohydrolase (GTPCH) or the enzyme 6-pyruvoyl-tetrahydrobiopterin synthase 
(PTPS). While BH4 recycling defects are due to a deficiency in the enzyme 
dihydropteridine reductase (DHPR) or the enzyme pterin-4α-carbinolamine 
dehydratase (PCD) (Hyland et al., 2006). 
It is important to test patients with hyperphenylalaninaemia for BH4 deficiency to 
differentiate it from PKU and to distinguish between the different variants of BH4 
deficiency. This is done by analysing pterin metabolites in the urine, measuring the 
DHPR enzyme activity in blood from the newborn screening dried blood spot, and by 
analysing the level of phenylalanine in blood before and after a BH4 loading test 
(Blau, Thöny, Spada, & Ponzone, 1996; Hyland et al., 2006; and Mitchell, 2000). 
BH4 deficiencies vary from mild forms of the disease, needing minimal treatment, to 
severe forms that can be difficult to treat. However, early diagnosis and treatment is 
effective in providing good outcome for many patients (Blau et al., 1996; and 
Opladen, Hoffmann, & Blau, 2012). Treatment is by supplementation of BH4 to 
normalize blood phenylalanine levels, and by replacement therapy of the 
neurotransmitter precursors 5-hydroxytryptophan and L-dopa (with carbidopa). 
Additionally, folinic acid supplementation and diet are needed for patients with 
DHPR deficiency (Hyland et al., 2006; and Longo, 2009). 
Patients with BH4 deficiency, if untreated, suffer from the symptoms of both 
hyperphenylalaninaemia and neurotransmitter deficiency. These include 
microcephaly, seizures, lethargy, irritability, muscular hypotonia, peripheral 
spasticity, progressive developmental and physical delay, and neurological 
deterioration (Longo, 2009; Opladen et al., 2012; and Shintaku, 2002). Patients with 
BH4 deficiency were not included in this study. 
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Focusing on a single group of disorders, the major aminoacidopathies present in Saudi 
Arabia, will help develop a model for examining nutrition management, and assessing 
risk factors associated with unsatisfactory dietary compliance for other disorders. This 
study can potentially help target future interventions for improving nutritional 
management of inborn errors of metabolism in Saudi Arabia. 
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CHAPTER 3  
METHODS 
 
3. Methods 
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3.1 Study site 
The research was carried out at the King Faisal Specialist Hospital & Research Centre 
in Riyadh, the capital city of Saudi Arabia. The KFSH&RC is the largest tertiary care 
facility in Saudi Arabia, and one of the largest in the Middle East. The research was 
undertaken in collaboration with the Medical Genetics Department of KFSH&RC. 
This department was the first of its kind in Saudi Arabia, and is the main referral 
centre for patients with inborn errors of metabolism. 
3.2 Subjects  
Subjects were patients with PKU, tyrosinaemia type I, and MSUD and their families 
attending care services at KFSH&RC. During the study period the KFSH&RC had on 
record 67 patients with PKU, 24 patients with tyrosinaemia I, and 73 patients with 
MSUD. The age range of patients was wide, from infancy to early adulthood (birth to 
21 years of age). 
3.2.1 Inclusion criteria 
Phase 1: Patients diagnosed with PKU, tyrosinaemia I, or MSUD and their families. 
Phase 2: Patients diagnosed with PKU and their families. 
3.2.2 Exclusion criteria 
Phase 1: None of the families or patients were excluded. 
Phase 2: None of the families or patients were excluded.  
82 
3.3 Ethical considerations 
The study had minimally invasive procedures. The only additional process to what 
was routinely followed with the patients and their families at their clinic visits to the 
KFSH&RC was the interviews in Phase 1 and the questionnaires in Phase 2. 
A Consent Form was signed by each participating family (Appendix 1). Participating 
patients gave verbal assents after their parents’ permission. Refusal to participate or 
the choice to drop out of the study was respected as stated in the Consent Form. To 
establish confidentiality the patients and their families were assigned codes and no 
names or identifiable information were entered into the databases. 
The study had ethical approval from the UCL Institute of Child Health (ICH) and the 
KFSH&RC’s Research Ethics Committee of their Research Advisory Council. A 
collaboration agreement was signed between ICH and KFSH&RC. 
3.4 Study design 
This was a cross-sectional study of a group of patients with aminoacidopathies in 
Saudi Arabia. It was a 2-phase study design with a mixed method approach; using the 
sequential exploratory strategy as recommended by Creswell (2009) and Morgan 
(1998a). Phase 1 was an exploratory qualitative study, and Phase 2 was a quantitative 
assessment of the risk factors contributing to poor outcome for the patients with PKU 
at the KFSH&RC.  
3.4.1 Preliminary phase 
Before planning for the research I contacted the KFSH&RC; the feasibility of 
conducting the study at the hospital was discussed with the head of the Research 
Centre, the Head of the Medical Genetics Department, and the dietitian responsible 
for patients with metabolic disorders. Prior to the data collection process for Phase 1 
of the study I met with some of the medical genetics doctors, the dietitian, and the 
laboratory technicians responsible for handling the blood samples and running the 
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tandem mass spectrometer (MS/MS), used for measuring blood levels of amino acids, 
to informally discuss the project and familiarize myself with their work. It was 
important to observe them in their work environment and to observe some of the 
patients and their families to be able to formulate the questions of the interviews 
(Silverman, 2006). Having spent my clinical nutrition internship at the KFSH&RC 
made this phase much easier, as I am acquainted with the way their clinics are 
conducted and have good rapport with the dietitians and many of the nurses there. 
3.4.2 Phase 1 
This phase was a qualitative study that explored the current status of care and 
nutritional management of patients with PKU, tyrosinaemia I, and MSUD and their 
families at KFSH&RC and informed the second phase of the study.  
A. Interviews: Qualitative data was collected from semi-structured interviews 
(Appendix 2, 3, and 4): 
• Interviews with key informants from the health care team  
• Focus groups with supporting health care providers  
• Interviews with the patients 
• Interviews with the families of patients 
B. Observations: Observations were based on purposefully selected participants 
to examine: 
• Formula preparation by patients/carers  
• Dietitian counselling sessions 
• Doctor clinic sessions 
C. Market survey: A market survey was conducted to observe the availability 
and accessibility of the special low protein food products that are needed for the 
diets of the patients.  
D. Medical records review: The medical history, developmental assessments and 
past blood levels of the patients were reviewed. 
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3.4.2.1 Phase 1 study sample 
Purposive sampling (non-probability sample) was used for this qualitative phase. 
Participants were chosen purposefully because they had particular experiences or 
characteristics which are reflective of the sampled population and were the best to 
enlighten the researcher about the study question (Creswell, 2007; and Patton, 2002). 
This enabled detailed exploration and understanding of the central themes being 
studied (Mays & Pope, 1995). All health care providers directly involved in the 
management of the patients were identified and included as key informants in addition 
to supporting health care providers. The families were interviewed until the data 
reached redundancy and no new information was generated (Creswell, 2007; and 
Ritchie, Lewis, & Elam, 2003). 
Stakeholders identified at KFSH&RC: 
• Health care providers: medical genetics doctors, nurses, metabolic disorders 
dietitians, and general dietitians. 
• Patients: patients with PKU, MSUD, or tyrosinaemia I. 
• Families: families or carers of patients with PKU, MSUD, or tyrosinaemia I. 
3.4.2.2 Phase 1 data collection 
Qualitative research in this study was conducted as an essential preliminary to the 
quantitative research in Phase 2. The purpose was to provide an understanding of the 
current situation and to reach aspects of behaviours and attitudes that quantitative 
methods cannot reach (Creswell, 2009). Pope and Mays (1995) emphasized that in 
areas that have had little or no previous investigations, as is the case for this study, 
qualitative research is a prerequisite for good quantitative research. The framework 
approach was recommended for this form of research (Pope, Ziebland, & Mays, 
2000), this is described in detail below in section 3.4.2.4 Phase 1 data analysis.  
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The research in this phase was based on 4 components. The flow chart in Figure 2 
illustrates these components: 
A. Interviews (Knowledge, attitudes, and practices study): Comprehensive 
information on the current status at the Medical Genetics Department at the 
KFSH&RC were gathered through: 
• Key informants from the health care providers: Interviews and observations 
of key informants such as the metabolic disorders specialist dietitians and the 
physicians who represent the main points of contact with the patients and their 
families. Interviews covered their perceptions on care and health services, 
relationships with other health care providers, relationships with patients and 
their families, perceived nutrition knowledge of patients and carers, suggested 
dietary management, and compliance issues. The key informants were chosen 
because they had particular knowledge and insight related to the study 
question (Patton, 2002) (Appendix 2). 
• Health care providers: Focus groups with health care providers (HCP) who 
support the main health care providers such as the nurses and the general 
dietitians. General dietitians may see patients with metabolic disorders during 
the weekend shifts or they may cover for the metabolic dietitians when 
needed. Discussions included perceptions of the provided health services, 
interrelations between health care providers and families, nutrition knowledge, 
management, and compliance issues (Appendix 2). 
• Families: Interviews with the families included mothers, fathers, carers, and 
siblings when available. Interviews and discussions looked at metabolic 
disorders, acceptance, perceived nutrition and diet knowledge, management, 
compliance barriers, hospital services, relationships with health care providers, 
and relationships with other families affected by metabolic disorders in order 
to determine knowledge, attitudes, and practices. The interview schedule is 
shown in Appendix 3, and a sample of an interview is in Appendix 4.  
• Patients: Interviews with the patients explored knowledge of their disorders, 
perceived nutrition and diet knowledge, compliance barriers, hospital services, 
and relationships with health care providers and others (Appendix 3). 
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The interview formats 
 Interviews 
Open-ended interviews allow the researcher to explore participants’ thoughts, 
feelings, and perspectives (Patton, 2002). The standardized open-ended interview is 
the type of interview used in this study. Open-ended interviews have the advantage of 
being structured, but at the same time flexible. They have an interview schedule with 
specific questions and topics to cover but this structure is flexible in its sequence 
allowing the topics to be covered in the order that is most suitable for the participant, 
and allow the responses to be explored and probed further by the researcher 
(Silverman, 2005). 
The construction of the questions in the interviews in this study followed the rules and 
suggestions described by Patton (2002), for example, how to avoid leading questions 
and dichotomous questions. This was aided by the experience of the language used 
and information gathered during observations of the clinics at KFSH&RC. Questions 
in the family and child interviews were created from clinical experience and from 
issues raised through the interviews with health care providers. The interviewing 
strategy followed the recommendations of Legard, Keegan, and Ward (2003). 
 Focus groups 
In qualitative research it is recommended to use more than one method of data 
collection for triangulation, as explained in section 3.4.2.5 below. In addition to the 
one-to-one interviews with key informants, focus groups were conducted with the 
general dietitians’ group and the nurses’ group. Focus groups are focused informal 
group discussions by a small group of people to gather opinions on specific issues, 
moderated by the researcher, who asks open-ended questions to the whole group and 
then moderates the discussions (Krueger & Casey, 2000; and Morgan, 1998b). 
An advantage of the focus groups is the interaction among the participants, listening 
to others and responding, thus enriching the discussion (Finch & Lewis, 2003; and 
Patton, 2002). Another advantage of focus groups is that it facilitates the collection of 
data from a homogenous group of participants in a relatively short period of time 
(Wilkinson, 2008). Focus groups are also beneficial in providing the foundation for 
subsequent questionnaire development (Krueger & Casey, 2000). The procedures and 
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protocols for conducting focus groups in this research followed the recommendations 
in the focus group references by Krueger (1998), Krueger and Casey (2000), and 
Morgan (1998c). 
The interview process 
The health care providers’ interviews were carried out in English, as this is the official 
language used at the hospital by all health care providers. Interviews with the families 
and the patients were carried out in Arabic, except for one interview which was done 
in English; because the mother didn’t speak Arabic well and English was her first 
language. The interviews were held in a quiet meeting room to minimise distractions. 
The opportunity for interviewees to ask questions was always provided.  I conducted 
and facilitated all of the interviews and focus group sessions. 
The interview schedules were all designed in English. The family and patient 
interview schedules were translated to Arabic then back translated to English; to test 
the accuracy and validity of the content and meaning (Ercikan, 1998). The translation 
and back translation were done by two independent translators. The back translated 
interview forms were compared to the original English forms; there was good 
agreement between the two English versions.  
The interview questions for the health care providers were pre-tested with other non-
participating health care providers and the questions for the families and the patients 
were tested with four Saudi families, and then piloted with three of the families at 
KFSH&RC. This was necessary to ensure clarity and comprehensibility of the 
questions asked, relevance and coverage of the research problem, and to monitor the 
length of the interviews and comfort of the interview setting (Creswell, 2007). Two of 
the questions needed to be modified to clarify them.  
The next steps, in line with the recommended protocols for the interviews and the 
focus group sessions, were followed in every session after general introductions and 
consent signing: 
 I asked permission to record the session. 
 I confirmed confidentiality of the interviews, and participants’ freedom 
to not answer a question when uncomfortable to do so.  
88 
  
 I briefly went over the purpose and objectives of the study with the 
participants and how the results are planned to be used. 
 I told them the maximum amount of time expected for the session to 
last. 
 I gave them opportunity to talk and ask questions at the end, even if not 
research related; the objective was to have them leave feeling good. 
B. Observations: 
• Formula and diet preparation: Formula and diet preparations by mothers 
were observed to get a clear perception of their practices.  
• Dietitian counselling sessions: The metabolic disorders dietitians were 
observed at random counselling sessions to ascertain how the families are 
counselled and learn about their relationships with the dietitians. 
• Doctor clinic sessions: The metabolic disorders doctors were observed at 
random clinics to determine how the families are counselled and learn about 
their relationships with the doctor. 
The observations 
The purpose of the observations is to get a direct personal experience of the 
participants’ environments and behaviours (Creswell, 2009; and Patton, 2002). Patton 
described several other advantages for direct observations; they provide better 
understanding of the context in which participants interact, give the opportunity to 
notice things and routines that may be missed by participants and not mentioned in 
interviews because they are routinely immersed in them, help learn about things that 
the participants might not be keen to mention in interviews, and finally observations 
give the researcher an objective view of the settings away from the participants’ 
perceptions (Patton, 2002). The settings, actions and behaviours of the observed 
individuals at the research site were recorded in field notes, these notes were then 
incorporated in the qualitative data analysis. 
C. Market survey: The major markets in four areas -two urban areas and two rural 
areas- were surveyed to form an awareness of the low protein products available 
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and accessible for patients with aminoacidopathies. The products could be ready- 
to-eat products such as low protein bread, breakfast cereals and biscuits, or 
ingredients to make low protein dishes such as low protein flour, pasta and rice. 
These areas were believed to be representative enough of the Saudi market. 
D. Medical records review: The medical history, developmental assessments, and 
past blood levels of the relevant amino acids for a sample of patients from each 
disorder, were recorded. The purpose of this process was to get a preliminary idea 
of trends in compliance among patients before embarking on Phase 2 of the study 
and to test the quantitative analysis procedure.   
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Qualitative research that explored the current status at KFSH&RCPhase 1
MARKET SURVEY
MEDICAL 
RECORDS 
REVIEW
OBSERVATIONS
Interviews with the metabolic disorders specialists  
Focus groups with health care providers  
Interviews with the patients  
Interviews with the families of patients  
5 Interviews
2 Focus groups
17 Interviews
5 Interviews 1 Group interview  (3 sisters)
Formula preparation by patients and carers  
Dietitian counselling sessions  
Doctor clinic sessions  
4 Observations
4 Sessions recorded 
4 Sessions
40 Sessions attended
To examine the availability and accessibility of the 
special low protein food products
2 Urban areas
2 Rural areas
Medical history
Developmental assessments
Past blood levels 
19 Patients
INTERVIEWS
open and semi-
structured interviews
 
 
 
Figure 2: Flow chart illustrating the different components of Phase 1, methods used, and number of participants in each part. 
 
  
91 
3.4.2.3 Phase 1 data management 
The principal investigator (SA) facilitated the sessions. The sessions were audio tape-
recorded. All of the interviews with the health care providers and the children were 
audio recorded, for the interviews with the families seven out of the seventeen 
declined audio recording their interviews. The families’ answers in these interviews 
were written down during the interview by the principal investigator then reviewed 
with them at the end of the interview to ensure accuracy of the written notes. The 
interviews were transcribed verbatim by the principal investigator. The Arabic 
interviews were translated to English for analysis. The translation was done by the 
principal investigator and another translator to check for accuracy and validity 
through the discussion of their translations till agreement was reached on the content 
and meaning of the final translation. The aim was to be as closely representative as 
possible of the Arabic transcripts (Birbili, 2000). Both people who translated the 
interviews were from Saudi Arabia, fluent in Arabic and English, and familiar with 
the cultures of Saudi Arabia and the United Kingdom.  
Findings from the interviews, focus groups, and observations of this phase were used 
for triangulation (refer to section 3.4.2.5); to see how much health care providers and 
families agree on issues concerning the care of patients (Fontana & Frey, 2003). 
Findings from this phase were compared to the related results from Phase 2 of this 
study. 
3.4.2.4 Phase 1 data analysis  
Quantitative analysis 
Amino acid blood levels were obtained from patients’ medical records and were 
entered for analysis into SPSS 15.0 for Windows (SPSS Inc., 2006). Approximately 
six past blood levels were available for nine patients with PKU, five patients with 
tyrosinaemia I, and five patients with MSUD. Descriptive, correlation and regression 
statistics were used to test the associations and relationships of the blood levels over 
time and with related variables. This was to test the analysis process and prepare for 
Phase 2 of this study. 
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Qualitative analysis 
The qualitative data were analysed using the concept of analytic hierarchy in a 
thematic framework approach to enable the best interpretation of meaning (Spencer, 
Ritchie, & O'Conner, 2003). This approach is recommended where the analysis needs 
to be linked with quantitative findings, as in this study (Pope et al., 2000). Guidelines 
from qualitative researchers such as Creswell (2007), Silverman (2005) and Denzin 
and Lincoln (2003) on thematic data analysis were incorporated. The process of the 
analysis is represented in Figure 3. 
This thematic framework of coding allowed for a dynamic content analysis based on 
understanding the evidence and interpretation of meaning. Going backward and 
forward repeatedly within the data to identify the key concepts and themes from the 
interview texts and refine the developed analytical account.  
The concepts that represented a common thought, idea, or experience were grouped 
together to form one theme. Each theme was then organised into sub-themes; a 
hierarchical organization of the data in each theme. This was carried out until the data 
was all organised into independent themes. This was done by the principal 
investigator and a researcher expert in qualitative analysis. The list of themes and 
their sub-themes were then reviewed by both of the researchers, this step is important 
to ensure agreement on the conceptualisation and classifications of the themes and to 
confirm the validity of the analysis. The analysis was discussed with another 
independent expert researcher and changes were made when required. The emerging 
analytic concepts facilitate the enhancement of the final analytical findings.  
The findings are presented in Chapter 5; they are arranged in the major themes that 
have emerged from the data. The themes were described using presentation of direct 
quotes from participants to give a feel of the original data. These steps were 
performed manually using Microsoft Office Word and Microsoft Office Excel spread 
sheets, as depicted in Figure 3. 
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The interviews were organized and converted into a workable format, such as organized 
files and folders
The transcripts were read thoroughly several times to understand the participant’s overall 
views
The transcripts were scanned initially to identify the major organizing ideas and highlight 
the relevant statements for the initial exploring of the data; this includes writing notes or 
memos in the margins of the transcripts; to describe the key concepts or ideas that are 
being discovered
The concepts that represented a common thought, idea, or comment, were grouped into 
one theme. These themes were referenced to the relevant interview and the relevant line 
in the transcript. This was done by the principal investigator and an independent 
researcher expert in qualitative methods
The list of themes and their sub-themes were reviewed by both of the researchers to 
ensure agreement and confirm the validity of the analysis
The transcripts were read again to confirm the inclusion of all possible themes and sub-
themes. Each theme was given a code to be assigned to all quotes in the transcripts
The themes and sub-themes were reviewed several times to ensure that they were 
mutually exclusive
The analysis was discussed with another independent researcher and changes were made 
as required
The themes were described using presentation of direct quotes from participants to give a 
feel of the original data
Visual displays were utilised to appreciate the interrelations of the major themes
Interpretation of the data involved making sense of the information and deciding what 
things mean, noting patterns, and developing explanations
 
Figure 3: The process of the qualitative data analysis as followed in this research.  
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3.4.2.5 Triangulation  
Triangulation has been recommended and used to strengthen the research study and 
add to its credibility by mixing methods which provide varied ways of looking at the 
same issue (Patton, 2002). Four types of triangulation have been described in the 
literature: data triangulation, a range of data sources are used for the study; 
methodological triangulation, more than one method is employed to study one 
phenomenon; theory triangulation, a combination of viewpoints are utilized to 
investigate a data set; and investigator triangulation, various researchers are used to 
counteract the potential bias of a single researcher (Denzin & Lincoln, 2003; Patton, 
2002; and Silverman, 2006). 
With triangulation the research benefits from adding the strength of one method to the 
strength of the other methods used reducing any weakness in one method (Creswell, 
2009). Triangulation provides cross data validation, corroboration, and test for 
consistency in results (Patton, 2002). One example of triangulation advantages is to 
reduce research bias when information and data are gathered from more than one 
source such as interviews and observations which could help in avoiding biased or 
untrue responses and it gives a richer, more comprehensive image of the issue under 
study (Foss & Ellefsen, 2002; and Patton, 2002).  Another use of triangulation, that is 
applicable for this study, is the use of qualitative quotes that support or do not support 
the quantitative results (Creswell, 2009). However, some researchers state that the 
benefit of triangulation is only in its ability to expand and deepen the comprehension 
of the subject under study and to give a more complete depiction of the phenomenon, 
and not essentially to validate the data (Ritchie, 2003). 
Three types of triangulation have been used in this study. First, data triangulation, 
combining data from interviews, focus groups, observations, and document analysis 
in Phase 1, and combining data from questionnaires, assessment measurements, and 
document analysis in Phase 2. The second type of triangulation used is 
methodological triangulation, in which both qualitative and quantitative methods 
have been used in this study in an effort to get well validated and substantiated results. 
The third type of triangulation used in some stages of this research is investigator 
triangulation, more than one researcher was employed at various parts of the study, in 
Phase 1 the principal researcher (SA) and two other researchers checked the thematic 
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analysis of the qualitative data to ensure agreement on themes. In Phase 2 several 
researchers worked on the translation and back translation of the Vineland-II survey, 
because the process of translation and its validation require more than one researcher. 
3.4.2.6 Applications of Phase 1 results 
Findings from the data collected in this phase were used to inform the structuring of 
the questionnaires for Phase 2 of the study.  Creswell (2009) has recommended this 
sequential approach, using the accounts and themes that have emerged from the initial 
qualitative data collection phase to construct a questionnaire that is based on the 
views of the participants and key informant to be used in the second phase with a 
wider range of participants and with quantitative components. 
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3.4.3 Phase 2 
Phase 2 was a quantitative cross sectional survey. The purpose of Phase 2 was to 
identify the risk factors for patients with aminoacidopathies in Saudi Arabia that lead 
to poor nutritional control of the disorder and hence unsatisfactory blood amino acid 
levels and a poor neuropsychological outcome. The qualitative findings of Phase 1 
from the purposive sample were used to develop the questionnaires; ensuring context 
specific questions were included and posed to a larger sample group.  
A feasibility decision was made to determine whether Phase 2 would focus on one 
metabolic disorder (PKU) or all three disorders. Out of the three disorders (PKU, 
MSUD, and tyrosinaemia I) PKU has the clearest relation between dietary compliance 
and outcome in terms of developmental ability (Donlon et al., 2006). Therefore it was 
decided to focus Phase 2 on PKU patients and their families. The forms and 
questionnaires used in Phase 2 are in Appendices 5 to 10. 
This phase included: 
A. Nutritional assessment: 
- Anthropometric measures 
- Clinical measures: current morbidity data and blood levels 
- Diet analysis 
B. Questionnaires (For the patients and their families), covering: 
- Socio-economic status 
- Quality of life 
- Nutrition knowledge, attitudes and practices 
- Dietary compliance  
C. Medical records review: 
- Medical history 
- Past blood levels  
D. Development assessment: 
- Past developmental assessments from medical records 
- The Vineland-II Survey Interview Form 
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3.4.3.1 Questionnaire development and pilot  
The Family and Child Questionnaires were developed after studying the findings of 
Phase 1 of this study. The main themes and issues that were raised by the families and 
the health care providers were used to inform the development of the questions. The 
questions were constructed using information and the vocabulary learnt through Phase 
1 findings and by following the guidelines described by Oppenheim (1992) and 
Peterson (2000). It was designed as a structured questionnaire with limited responses 
and only few open ended questions, this has the advantage of reducing the time 
needed from the interviewee, limiting the interviewer bias, and can be administered 
either as a face-to-face interview or by the phone (Creswell, 2009; and Peterson, 
2000). 
The initial Family Questionnaire contained 106 items covering questions about socio-
economic status, health, education, social activities, attitudes and practices, disorder 
and nutrition knowledge, dietary habits, personal concerns, seeking help, and getting 
information. It had a section for diet history (24 hour recall) and food frequency 
questionnaire. A simple Child Questionnaire was developed to find out the children’s 
perspectives and knowledge of the disorder and their diet, it included 11 questions. 
The metabolic dietitian and one of the metabolic clinic doctors read the questionnaires 
and gave their feedback, which was incorporated within the process of improving the 
questionnaires.  
It was then important to pilot the questionnaires to refine and develop the questions, 
to ensure that they are clear and serve the purpose of the research (Oppenheim, 1992). 
The pilot was essential to test for the duration and the setting of the interview as well. 
The Child Questionnaire was piloted with three patients; one question appeared to be 
redundant so it was deleted and one question needed rewording to improve clarity. 
Then it was re-tested with 4 more patients and it was received well in both clarity and 
duration; none of the children misunderstood any of the questions and none of them 
seemed agitated or bored by the end of the questionnaire.  
The Family Questionnaire was piloted with 5 families and was found to be too long. 
The mothers felt that some of the questions were irrelevant, some were not easy to 
understand, and the food frequency questionnaire was too long and tedious for them; 
only two mothers completed it. After considering the mothers’ comments and 
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reviewing their responses to ensure they actually answer what is asked, twenty two 
questions were deleted from the questionnaire, seven questions were reworded and 
modified, and an “other” category was added to all possible questions so the 
respondents would not feel limited to the listed choices. The food frequency 
questionnaire was cancelled, as the mothers were not used to it and did not see the 
benefit of it. They were more comfortable with the 24 hour recall, as this is what they 
are used to giving at the dietitian’s clinic. Therefore it was kept and it was used twice 
for most of the patients. The modified Family Questionnaire was re-piloted with 3 
families; it was well-received. Only the order of a few questions was changed, after 
the second pilot, to improve the sequential flow of the questionnaire. As many 
families have more than one child with PKU a Sibling Questionnaire was created; it 
only included the questions pertaining to the patients, so the mothers would not have 
to answer the other questions more than once.  
Family Questionnaires  
The Family Questionnaire and Sibling Questionnaire (Appendices 7 and 8) were 
administered in an interview format to ensure completion of all the questions. Several 
of the mothers had low literacy levels and therefore it was not feasible to give them a 
questionnaire to complete in writing. Also due to the many appointments the families 
need to attend at their visit to the hospital and the length of the questionnaire 
sometimes it was necessary to start it at the hospital with the mother but complete it 
by phone when she was relaxed in her home environment and not stressed about being 
late at hospital or missing their return travel. The questionnaire had a few open ended 
questions, and there are several limitations to having the participants answer them in 
writing; they might not answer an open-ended question, because it takes more effort 
than selecting from a list of answers; it also depends on their writing skills, and the 
researcher cannot probe to extend the responses if needed (Creswell, 2007; and 
Oppenheim, 1992). Therefore administering the questionnaires in a structured 
interview format was considered to be the best method with this population. It  helped 
to overcome the known drawbacks of using a questionnaire, such as low response 
rate, not answering all the questions, misunderstanding some questions, respondent 
literacy issue, and respondent motivation (Gillham, 2000). 
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Child Questionnaire 
School age patients with the ability to communicate with others were asked to 
participate to answer the Child Questionnaire (Hameen-Anttila, Juvonen, Ahonen, 
Bush, & Airaksinen, 2006; and Knox & Burkhart, 2007). After getting the parent’s 
consent the Child Questionnaire was explained to the child and a verbal assent was 
taken from each participating child. The child was then taken to another room for the 
interview or to a quite side within the clinic while the mother talked with the dietitian. 
The questionnaire was conducted in a structured interview format. The questions 
focused mainly on the child’s dietary choices, knowledge and attitudes towards the 
diet (Appendix 10).  
3.4.3.2 Phase 2 study sample 
All the patients diagnosed with PKU who have their medical care and follow up at 
KFSH&RC were invited to participate in the study.  
3.4.3.3 Phase 2 data collection 
A research assistant was hired to assist with some data collection in this phase 
(anthropometric measurements and medical records reviews). She was also needed to 
entertain and engage the children while I interviewed the parents to answer the 
questionnaire. The flow chart in Figure 4 illustrates the four components in this phase 
of the study: 
 
A. Nutritional assessment: A comprehensive clinical assessment of the 
nutritional status of each patient with PKU was carried out:  
• Anthropometric measurements: 
Height, weight, waist circumference, mid-upper arm circumference, 
and triceps skin-fold thickness. 
 
• Clinical measures: 
Morbidity data: Illnesses or admissions to hospitals were recorded to 
take into account the changes in blood levels due to illness. 
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Blood level: The blood levels of phenylalanine (Phe) were monitored 
throughout the study whenever the patients were required to send a 
blood sample. The analytical method used at KFSH&RC to determine 
blood levels of phenylalanine is tandem mass spectrometry (MS/MS). 
This test is standard and reliable, with high sensitivity and specificity 
for PKU (Strathmann & Hoofnagle, 2011; and Wilcken, 2006). 
Internationally there is no consensus on the desired target levels of 
amino acids for aminoacidopathies; there are variations between clinics 
in different countries. The target blood levels of phenylalanine for 
PKU followed at KFSH&RC∗ are shown in Table 1, and the target 
levels in other countries are listed in Table 2. 
Table 1: The acceptable blood Phe levels at KFSH&RC by age group. 
 
Age Group Phe μmol /l 
<2 years 120 - 350 
2-6 years 120 - 450 
>6 years 120 - 600 
 
Table 2: The acceptable blood Phe levels in different countries by age group. 
 
Age groups 
(years)  
Phe μmol/l 
UK1, 2 Germany3 France4 USA5 
< 7 120 - 360 40 - 240  120 - 300 120 - 360 
7 -9 120 - 480 40 - 240  120 - 300 120 - 360 
10 - 12 120 - 480 40 -900 < 900 120 - 360 
13 - 15 120 - 700 40 -900 < 900 120 - 600 
16 - 18 120 - 700 40 - 1200 < 900/1200 120 - 600 
>18 120 - 700 40 - 1200 < 1200/1500 120 - 900 
1Blau, van Spronsen, & Levy, 2010. 2 Medical Research Council, 1993. 3Burgard et al, 1999. 
4Abadie et al, 2005. 5National Institutes of Health Consensus Development Panel, 2001.  
 
∗ Gold standards for target Phe blood levels are not available for PKU. Target levels differ from one 
country to another. 
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• Diet analysis: The phenylalanine content and the quality of the diet for 
the patients were assessed through taking two 24 hour food recalls for 
the patients’ intakes from their mothers. 
B. Questionnaires: The Family and Patient pre-tested questionnaires (Appendix 
7, 8 and 10 ) were administered with the mothers and the patients: 
• Socio-economic status: Information from the structured questionnaire 
was used to assess indicators of the socio-economic status of the 
families; such as employment, parental education, level of monthly 
spending, number of siblings, number of siblings with the same 
disorder, and medical history.  
 
• Aspects of quality of life: Information from the questionnaire was used 
to assess aspects of the quality of life, social behaviour and wellbeing 
of the patients and their families.  
 
• Nutrition knowledge, attitudes and practices: Information from the 
questionnaire was used to assess medical history, level of care, level of 
disorder knowledge, level of nutrition knowledge, attitudes and 
practices of the patients and their families towards the diet and the 
nutritional management of their disorders.  
 
• Dietary compliance: Compliance with dietary treatment was 
monitored through reviewing dietary patterns using the 24 hour recalls 
and answers to related questions in the Family Questionnaire. The 
families were asked in the questionnaire about the difficulties they 
experience in following the diet, and if they were not following the diet 
the barriers and reasons for that. Understanding their struggles will 
help us help the families in overcoming these difficulties. 
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C. Medical records review: 
• Medical history: The medical history of each patient was reviewed and 
any medical problem was recorded. 
 
• Past blood levels: Past blood levels of the amino acid phenylalanine 
were obtained from the medical records for the patients to look at 
patterns of blood levels over time and to establish an understanding of 
patients’ diet management and compliance history. 
 
D. Development assessment: 
• Past developmental assessments from medical records: All of the 
developmental assessments done for the patients were noted and final 
reports copied for analysis.  
 
• The Vineland-II Survey Interview Form: Many of the patients (13 out 
of 40) had not had any kind of developmental assessment done; 
therefore it was decided to use the Vineland-II with all of the patients 
for better analysis. Chapter 4 describes the rationale for using the 
Vineland-II, the translation, adaptation, and testing process of the 
instrument. 
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Quantitative cross sectional surveyPhase 2
MEDICAL 
RECORDS 
REVIEW
DEVELOPMENT 
ASSESSMENT
For the Patients
QUESTIONNAIRES
For the Patients & 
their Families
Anthropometric measures
Clinical measures: current morbidity data and blood levels
Diet analysis
Dietary compliance
40 Patients
Socio-economic status
Quality of life
Nutrition knowledge, attitudes and practices
12 Patients
24 Mothers answered 24 full 
questionnaires and 16 sibling 
questionnaires
Medical history
40 Patients
Developmental assessments from medical records
The Vineland-II Survey Interview Form
27 Patients
NUTRITIONAL 
ASSESSMENT
For the Patients
Past phenylalanine blood levels
38 Patients
 
 
Figure 4: Flow chart illustrating the different components of Phase 2, methods used, and number of participants in each part. 
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3.4.3.4 Phase 2 data management 
Quantitative data was double entered, for accuracy, into PASW Statistics 18 for 
Windows (SPSS Inc., 2009) for analysis. Correlation, regression, t-test and analysis of 
variance statistical techniques were used to generate models and explore statistical 
relationships in this risk factor analysis (Kirkwood & Sterne, 2003; Pallant, 2007; and 
Tabachnick & Fidell, 2007). All tests were set to an alpha level of 0.05 (confidence 
level of 95%). 
3.4.3.5 Phase 2 data analysis 
1. Questionnaires 
Data from the Family Questionnaire and Child Questionnaire (Appendix 7, 8 and 
10) were summarised for all participants through frequencies and percentages. 
Descriptive statistics were used to determine the mean and standard deviation of key 
indicators. The data included gender, age at diagnosis, education levels, social life, 
health care practices, and knowledge about PKU. Age, education level and 
employment status for the mothers and the fathers, household information, 
including monthly spending and other indicators of socio-economic status were 
summarised and tabulated. Knowledge of families regarding PKU was summarized 
and frequencies of the correct answers were tabulated. Families’ concerns and 
suggestions were listed. 
2. Assessments and measurements 
 
i. Normality testing 
Preliminary analyses were performed to ensure the assumption of normality was 
not violated. Dependant variables were tested for normality using the 
Kolmogorov-Smirnov statistic, histograms, and Normal Probability Plots of the 
regression standardized residuals. The data was normally distributed thus 
parametric statistics were used for the analysis. 
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ii. Gender differences 
An independent-samples t-test was conducted to determine if there were any 
differences between male and female patients in terms of the Vineland-II score, 
age at start of treatment, diagnosis phenylalanine level, mean blood 
phenylalanine level, and dietary phenylalanine intake. 
iii. Anthropometric measurements 
Z-scores were calculated for length/height-for-age, weight-for-age, and BMI 
using the Saudi age and gender specific reference values (Foster & Kecojevi-ç, 
2010). The one-sample t-test was used to compare the z-scores with the Saudi 
reference standards (Al Herbish et al., 2009; El-Mouzan, Al-Herbish, Al-
Salloum, Qurachi, & Al-Omar, 2007). Three patients were over the age of the 
reference data (over 19 years of age), the BMI was calculated for them and 
compared to the WHO classification (WHO, 2000). 
The mid-upper-arm circumference (MUAC) and triceps skin-fold thickness 
(TST) measurements were used to calculate the upper arm fat area (UFA). Due 
to the absence of Saudi references the UFA and TST were compared to the USA 
reference data (Addo & Himes, 2010; and Mahan & Escott-Stump, 2003). The 
waist circumference (WC) measures were compared to the UK reference data 
(McCarthy, Jarrett, & Crawley, 2001) due to the unavailability of a Saudi 
reference for WC as well. 
iv. Dietary intake 
The dietary phenylalanine content of patients’ diets was calculated using the 
references used at KFSH&RC: the Nutrition Support Protocols (Acosta & 
Yannicelli, 2001) and a reference developed at KFSH&RC by the dietitians for 
the local foods. The daily dietary intake of phenylalanine for patients was used 
in an independent-samples t-test to compare difference in intake between 
patients with acceptable mean blood Phe levels and patients with high mean 
blood Phe levels. The Pearson product-moment correlation coefficient test and 
multiple regression analyses were used to investigate the relations between the 
dietary Phe and the mean blood Phe levels and the Vineland-II scores.  
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v. Outcome measures analyses 
Descriptive statistics were used for the main variables used in the analyses 
(minimum, maximum, mean, and standard deviation). The independent-samples 
t-test was conducted to determine if there were any differences between the 
patients who were treated early (≤1month of age) and patients who were treated 
late (>1 month of age). It was also used to determine if any differences existed 
between patients with Mild PKU (diagnosis Phe 600-1200 µmol/l) and patients 
with Classic PKU (diagnosis Phe >1200 µmol/l), and between patients with 
adequate formula intake and patients with unsatisfactory formula intake.  
The Pearson product-moment correlation coefficient, linear regression, and 
multiple regression tests were utilised to determine the relations and associations 
between the Vineland-II scores, age at start of treatment, diagnosis Phe level, 
mean blood Phe level, dietary Phe intake, and the socio-economic status 
indicators. There were few missing data values and they were treated as missing 
in the analyses. Imputation of missing values in a small sample is not 
recommended (Kirkwood & Sterne, 2003). 
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CHAPTER 4 
ADAPTATION OF THE VINELAND-
II SCALES TO ARABIC 
 
4. Adaptation of the Vineland-II Scales to 
Arabic 
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Introduction  
During the process of this research it became apparent that many of the participating 
patients had not had any developmental assessment done, and those that had, were not 
all assessed by the same tool making comparisons impossible. Therefore, the 
Vineland-II was chosen to be used with all of the patients to facilitate analysis. This 
chapter describes the rationale for using the Vineland-II, the translation and 
adaptation of the Vineland-II scales to Arabic, and the testing process of the 
instrument. 
4.1 The Vineland Adaptive Behaviour Scales, second edition 
(Vineland-II) 
The Vineland-II is a measure of adaptive behaviour for individuals from birth to 90 
years of age (Sparrow, Cicchetti, & Balla, 2005). Adaptive behaviour is defined as the 
age-appropriate conceptual, social, and practical skills learned and needed by people 
to function in everyday living (Schalock et al., 2007). Adaptive behaviours include 
skills needed for daily life activities such as washing, brushing teeth and hair, 
toileting, dressing, playing, food handling, following rules, being able to work, 
managing money, having personal responsibility, communicating and having social 
skills. 
The Vineland-II is designed to aid in diagnosing and classifying intellectual and 
developmental disabilities in a range of conditions including autism spectrum 
disorder, emotional and behavioural disturbances, many genetic disorders, disorders 
causing developmental delay, and many other physical, mental, and injury-related 
conditions. It is an important tool for determining the eligibility of a child for special 
services through measuring the child’s development. It provides valuable information 
to help develop educational, intervention, or treatment plans and programmes through 
identifying strengths and weaknesses of individuals. The Vineland-II facilitates 
monitoring and reporting progress of individuals during such programmes. In addition 
the Vineland-II has been recommended for use in research when the development and 
functioning of participants need to be examined (Sparrow et al., 2005).   
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The Vineland-II has three versions of the scales: 
1. Two survey forms: The Survey Interview Form and the Parent/Caregiver Rating 
Form provide a targeted assessment of adaptive behaviour in four domains: 
Communication, Daily Living, Socialization and Motor Skills (Motor Skills for 
children <7 years of age only), with sub-domains in each domain. It also includes 
an optional Maladaptive Behaviour Index designed to assess problem behaviours. 
The Survey Interview Form is administered to a parent or caregiver using a semi-
structured interview format and the Parent/Caregiver Rating Form uses a rating 
scale by the parent or caregiver. An Adaptive Behaviour Composite score is 
provided when all domains are administered. It is a standardised score and 
describes the individual’s overall functioning. 
2. The Expanded Interview Form: This form provides an in-depth assessment of 
the previous four domains of adaptive behaviour. It is useful in facilitating the 
preparation of individual educational or treatment programme planning. 
3. The Teacher Rating Form: This form assesses the adaptive behaviour in the four 
domains but focuses on content that teachers would observe in classroom settings 
in addition to basic academic performance (Sparrow et al., 2005).   
The Survey Interview Form, without the optional Maladaptive Behaviour Index, was 
translated and adapted for the use in this research study. 
The Vineland-II scores 
The Vineland-II uses standard scores to describe functioning. A standard score tells 
the distance of the individual’s raw score from the mean raw score of a normative 
reference population, taking into account the standard deviation of the distribution of 
raw scores. The standard score scale of the Vineland-II has been normalised and has a 
mean of 100 and standard deviation of 15 (Sparrow et al., 2005). 
 
The Vineland-II defines five adaptive levels for the scores of the Adaptive Behaviour 
Composite (ABC), the domains, and the subdomains. These adaptive levels describe 
an individual’s performance using virtually universal terms.  
  
 
111 
The Vineland-II adaptive levels 
- Low (20-70):  
A score in this level is lower than 97% of the individuals in a given age. 
- Moderately low (71-85):  
A score in this level is lower than 84% of the individuals in a given age. 
- Adequate (86-114):  
A score in this level indicates normal adaptive functioning. It includes about 68% of 
the individuals in a given age from the normative reference population. 
- Moderately high (115-129):  
A score in this level is higher than 84% of the individuals in a given age. 
- High (130-160):  
A score in this level is higher than 97% of the individuals in a given age. 
 
 
The Vineland-II consists of four main domains each with sub-domains. The Vineland-
II manual gives a description of the sub-domains, listed in Box 1 on the following 
page (Sparrow et al., 2005). In Box 2 and Box 3 there are two examples illustrating 
the most notable adaptive behaviours in each subdomain for two patients. The first 
patient has a Low adaptive level, and the second patient has a Moderately Low 
adaptive level on the ABC score levels. It is important to note that other patients 
within the same adaptive levels would differ slightly in their behaviours within each 
subdomain, as the Vineland-II ABC score is a composite of all of the domains. 
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Box 1: Description of the content of the Vineland-II subdomains (Sparrow et al., 2005). 
1. Communication Domain: 
Receptive: How the individual listens and pays attention and what he or she understands.   
Expressive: What the individual says, how he or she uses word and sentences to gather and provide information.  
Written: What the individual understands about how letters make words, and what he or she read and writes.  
 2. Daily Living Skills Domain:  
Personal: How the individual eats, dresses, and practices personal hygiene.  
Domestic: What household tasks the individual performs.  
Community: How the individual uses time, money, the telephone, the computer, and job skills.  
3. Socialization Domain: 
Interpersonal relationships: How the individual interacts with others.  
Play and leisure time: How the individual plays and uses leisure time.  
Coping skills: How the individual demonstrates responsibility and sensitivity to others.  
4. Motor Skills Domain:  
Gross motor: How the individual uses arms and legs for movement and coordination.  
Fine motor: How the individual uses hands and fingers to manipulate objects. 
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Box 2: This example illustrates the notable adaptive behaviours in each subdomain of 
the Vineland-II for a 20 year old patient with a Low adaptive level. 
1. Communication Domain:  
Receptive: He follows two part instructions, but would not listen to a story for 15 minutes. 
Expressive: He has conversations that last at least 10 minutes and explains ideas in more than one way. He knows 
own telephone number when asked, but does not say complete address. He cannot describe long-term goals. 
Written: He can read and understand material of at least second grade level and can put words in alphabetical 
order, but cannot write simple correspondence of three sentences or more. 
2. Daily Living Skills Domain:  
Personal: He can shower by himself, can find and use appropriate public restrooms, and cares for minor cuts. He 
cannot use a thermometer to take own temperature or another’s, cannot take medicine as directed, or arrange 
doctor appointments. 
Domestic: He is careful when using sharp objects, he clears breakable items from own place at table, and can use 
simple appliances such as a toaster or a bottle opener. He cannot use microwave, tools, or vacuum. He does not 
clear table fully or use household cleaning products correctly.  
Community: He demonstrates understanding that some items cost more than others, can tell time by the half hour 
on an analog clock, and can make telephone calls to others. He cannot evaluate quality and price when selecting 
items for purchase, does not count change after purchase, and does not have computer skills to carry out complex 
tasks such as accessing the internet or word processing.  
3. Socialization Domain:  
Interpersonal relationships: He uses words to express happiness or concern for others, acts when others need 
help such as holding a door open or picking up a dropped item, and recognises likes and dislikes. He does not meet 
friends regularly, he is not careful when talking about personal things, and he does not understand hints or indirect 
cues in conversations. 
Play and leisure time: He asks permission before using objects belonging to others, and can go places with a 
group of responsible friends. He cannot follow rules in complex games or sports and does not show good 
sportsmanship.  
Coping skills: He acts appropriately when introduced to strangers, refrains from talking with food in mouth, and 
accepts helpful suggestions from others. He does not say sorry after hurting another’s feelings, does not control 
anger or hurt when plans change for reasons that cannot be helped, and does not understand that gentle teasing 
with family is a form of humour or affection.  
4. Motor Skills Domain: The patient is older than required for this domain. 
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Box 3: This example illustrates the notable adaptive behaviours in each subdomain of 
the Vineland-II for a 19 year old patient with a Moderately Low adaptive level. 
1. Communication Domain:  
Receptive: His level is adequate for this subdomain; he follows instructions given earlier, understands the sayings 
that are not meant to be taken word for word, and can listen to informational talk for at least 30 minutes.  
Expressive: His level is adequate for this subdomain; he gives complete home address, gives complex directions 
to others, and describes a realistic long-term goal.  
Written: He can read and understand at least sixth-grade level material, and at least two newspaper articles per 
week, but does not write advanced correspondence of 10 sentences or longer and does not edit or correct own 
written work before handing it in. 
2. Daily Living Skills Domain:  
Personal: He can use a thermometer, seek medical help in an emergency, and follow directions for medical 
treatment or diet, but does not keep track of medications well enough and cannot always arrange doctor 
appointments. 
Domestic: He can clear the table fully, use household cleaning products correctly, use a sharp knife, and clean one 
or more rooms other than own bedroom. He does not prepare basic food that requires cooking and cannot perform 
maintenance tasks.  
Community: He evaluates quality and price when selecting items for purchase, counts change after purchase, 
obeys time limits for breaks, and notifies school when he will be late or absent. He has limited computer skills to 
carry out a few complex tasks such as accessing the internet or word processing. He does not use a bank account, 
cannot travel for at least five miles to familiar or unfamiliar destinations alone using a bike, public transport, or 
driving, and does not earn money.  
3. Socialization Domain:  
Interpersonal relationships: His level is adequate for this subdomain; he is careful when talking about personal 
things, he understands hints or indirect cues in conversations, he cooperates with others to plan or be part of an 
activity, and he goes out in single and group outings.  
Play and leisure time: His level is adequate for this subdomain; he follows rules in complex games or sports, he 
plans activities with more than two things to arrange, and he goes places with friends without adult supervision.  
Coping skills: His level is adequate for this subdomain as well; he keeps secrets, thinks about what could happen 
before making decisions, and uses caution when encountering risky social situations. 
4. Motor Skills Domain:  The patient is older than required for this domain. 
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4.2 Use of the Vineland-II in this study 
4.2.1  The need for a uniform outcome measure for all the patients 
After the data collection for Phase 2 was completed and the analysis had been 
commenced, it became evident that the developmental assessments of the patients, 
obtained from their medical records at KFSH&RC, were inconsistent and 
incomparable. The patients were assessed using one or more of the following tools: 
∗ The Bayley Scales of Infant and Toddler Development. 
∗ The Leiter International Performance Scale. 
∗ The Test of Nonverbal Intelligence (TONI). 
∗ The Beery-Buktenica Developmental Test of Visual-Motor Integration 
(Beery VMI). 
∗ The McCarthy Scales of Children's Abilities. 
∗ The Vineland Adaptive Behaviour Scales (Vineland ABS). 
There was no apparent system for the use of this array of assessment tools. Diversity 
in the available developmental test results made sound analysis impossible. Dividing 
the patients into groups according to their age at assessment proved difficult because 
there was no consistency in using the same assessment tool at any specific age-group 
for the patients, and it was not possible to combine the results of different tools in one 
analysis. Dividing the patients into groups according to the type of assessment tool 
resulted in groups of very small numbers making the statistical analysis impossible. In 
addition, 13 patients had not had any developmental assessment done at KFSH&RC 
or elsewhere. 
The problem of the inconsistent data on development was discussed with Dr Kathryn 
Bond, a clinical psychologist who works with PKU patients at Great Ormond Street 
Hospital (GOSH). She recommended that a new assessment be undertaken for all the 
patients using the Vineland-II. It has been used successfully for patients with PKU, 
and it has the ability to identify developmental delay through an easy and straight 
forward survey form with the mothers or caregivers; it is designed to be administered 
through an interview or to be given to the caregiver to fill out. Dr Bond provided 
training on administering, scoring and interpreting the Vineland-II results.  
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4.2.2 Rationale for using the Vineland-II 
The Vineland-II measures the important behaviours and skills needed for adaptive 
functioning; it is not a measure of cognitive functioning, so it does not provide an 
Intelligence Quotient (IQ) score as many of the papers in the literature report for PKU 
patients. 
Cognitive ability and IQ scores are considered to be relatively stable over time for 
children older than 5 years of age (Shevell, Majnemer, Platt, Webster, & Birnbaum, 
2005; and Sparrow et al., 2005), while functional outcomes can improve or deteriorate 
according to interventions or changes in the environment (Sparrow et al., 2005). 
Assessing functional outcomes for the patients serve in setting realistic expectations 
for them where eventual outcome can be modified with improved access to available 
resources and planned interventions that are targeted to minimize disability (Shevell 
et al., 2005).This gives the Vineland-II an advantage for planning specific educational 
interventions for the patients, but at the same time there is a theoretical possibility that 
the Vineland-II scores might be influenced by access to special education currently 
received by some individual patients who would be included in the research. 
Assessment of an individual’s daily functioning is increasingly becoming an 
important outcome measure to identify for patients. Research has shown that it is 
essential to utilize assessment tools that evaluate children’s development through 
daily activities and functioning which, at the same time, are age appropriate and 
sensitive to different cultures and social settings; this is in order to adequately identify 
the support vital for the children and their families to achieve functional independence 
(Hogan, Rogers, & Msall, 2000; and Ottenbacher et al., 2000). Msall (2005) argues 
that focusing on the medical impairments and developmental disabilities of children 
portrays their deficits and does not account sufficiently for their skills in functional 
adaptation and their daily performance in their environments. In two reviews of 
measuring functional outcomes the authors recommended functional assessment of 
children as an important part of the evaluation. It captures the children’s typical 
performance in their own environments, demonstrating both their strengths and 
challenges, and it facilitates planning the supports they need (Msall & Tremont, 2002; 
and Msall, 2005). 
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Assessing the current function of patients with PKU in this study serves to indicate 
how the disorder is affecting the patients’ everyday lives. The Vineland-II satisfies the 
recommended criteria discussed above. It gives a score for the typical functioning and 
performance of the patients, the Adaptive Behaviour Composite score; this score can 
be used in statistical analyses with the different variables that are believed to affect 
the outcome for patients with PKU, such as age at diagnosis and start of treatment, 
level of blood Phe at diagnosis, mean of blood Phe levels and dietary Phe intake. 
One of the advantages of the Vineland-II is that it does not cause any burden to the 
patients; they are not involved in the assessment, the Survey Interview Form of the 
Vineland-II is carried out with the mother or the primary caregiver of the patient 
(Sparrow et al., 2005).  It has been shown that the mother or the primary caregiver is a 
valid and reliable source of information. There is a very high correlation between 
independent assessments of adaptive behaviour levels for patients and the estimation 
of these levels by primary caregivers (Sparrow & Cicchetti, 1985). Interviewing the 
mothers should prove straightforward as they had been previously interviewed by me 
and a good rapport had been established. Another advantage was that interviews could 
be done over the phone (Limperopoulos, Majnemer, Steinbach, & Shevell, 2006).  
4.3 Background information about the Vineland 
The Vineland ABS and the updated Vineland-II∗ have been widely and effectively 
used in clinical and research settings for the past 26 years (Middleton, Keene, & 
Brown, 1990; Sparrow, Balla, & Cicchetti, 1984; Sparrow & Cicchetti, 1985; and 
Sparrow et al., 2005). It has been used with patients with PKU (Kalkanoglu et al., 
2005; Lee et al., 2009; and Matthews, Barabas, Cusack, & Ferrari, 1986), children 
with Down syndrome (Kishnani et al., 2010), children with neurodevelopmental 
disabilities (Msall, 2005), and individuals with autism (Carter et al., 1998; Freeman, 
Del'Homme, Guthrie, & Zhang, 1999; Kanne et al., 2010; Kraijer, 2000; Paul et al., 
2004; and Ray-Subramanian, Huai, & Ellis, 2011). It has also been used to study the 
effects of early maltreatment of children on their development (Becker-Weidman, 
∗ The Vineland-II was updated in 2005 with new norms, improved items, expanded age range, and improved 
overall organisation of the domains and sub-domains. 
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2009) and to compare the similarities and the differences in the adaptive behaviours 
of several common genetic syndromes (Di Nuovo & Buono, 2011). 
4.3.1 The Vineland and PKU 
The Vineland scales have been used with some patients with PKU at GOSH and 
KFSH&RC, and there are several reports of research studies that have used the 
Vineland with patients with PKU. It was used with PKU patients in two double blind 
placebo-controlled studies (Kalkanoglu et al., 2005; and Lee et al., 2009). Both 
studies involved untreated adult PKU patients who were diagnosed late and had 
severe intellectual disabilities. Lee and colleagues tested the benefits of phenylalanine 
restricted diet on their group in the UK. The Vineland was part of the assessment 
process at several points of this trial. The other study by Kalkanoğlu and colleagues 
looked at the effects of phenylalanine-free essential amino acid tablets on the 
performance of their group of PKU patients in Denmark. They used a simplified 
version of the Vineland to assess their patients at specified intervals. 
Matthews (1986) used the Vineland to demonstrate that early treated children with 
PKU had deteriorated in social functioning after discontinuing the low phenylalanine 
diet at the age of 5.5 years on average; the scores of these patients were negatively 
correlated with their blood phenylalanine levels. In one report of the Maternal PKU 
Collaborative Study Waisbren and colleagues (2000) used the Vineland, among other 
tests, to assess the children of mothers with PKU. Their objective was to establish 
how the development of these children is affected by the timing of dietary treatment 
and metabolic control, or lack of it, of the mothers during pregnancy.  
4.3.2 The relation of the Vineland to other scales  
The Vineland-II validation studies, reported by Sparrow and colleagues (2005), show 
a very high correlation between the Vineland-II and the Vineland ABS, indicating a 
high degree of consistency between the two scales. The Vineland-II scales have 
retained most of the original items in the Vineland ABS. It has been improved by 
deleting a few items related to behaviours that are no longer common, by adding new 
items to expand the age range of the tool, and by increasing the density of the items in 
the first 3 years of life to improve the measure of adaptive behaviour in this 
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vulnerable period of development. The updated items also reflect the changes in 
culture and incorporate new knowledge about development. Having this strong 
relationship between the Vineland-II and the Vineland ABS is essential. It allows the 
transfer of the experiences gained from using the Vineland ABS for many years to the 
Vineland-II, and permits the research carried on with the Vineland ABS to support the 
Vineland-II as well (Sparrow et al., 2005). 
Several studies have demonstrated high concurrent validity and correlation between 
the scores of the Vineland ABS and different tests of intelligence. Middleton et al 
(1990) examined the relation between the scores of the Vineland ABS and that of the 
Scales of Independent Behaviour (SIB), which is another measure of adaptive 
behaviour, and found high correlation between them (r = 0.83). Sattler (2002) and 
Rosenbaum et al (1995) report good correlation between the Vineland ABS and 
several tests of intelligence, language, motor functions and academic achievement. 
The authors of the Vineland-II report its validity in its ability to support the diagnosis 
of a range of disorders and describe deficits and levels of adaptive performance 
(Sparrow et al., 2005). To confirm this, individuals with intellectual disability, autism, 
emotional or behavioural disturbance, attention deficit hyperactivity disorder, learning 
disability, and visual or hearing impairments were assessed with the Vineland-II. 
Individuals in each of these clinical groups were previously diagnosed and assessed 
by the appropriate clinical or psychometric assessments particular to each diagnosis, 
for example the Autism Diagnostic Interview-Revised or the Autism Diagnostic 
Observation Schedule for autism patients, and the Wechsler Intelligence Scale for 
Children for mental disability patients. The scores were compared with a normally 
developing reference group. The Vineland-II differentiated between the clinical 
groups and the normal group, it identified the adaptive deficits found in the patients 
and distinguished between the different levels of severity in each disorder (Sparrow et 
al., 2005). This provided evidence that the Vineland-II would be a good measure to 
use with patients with PKU. 
4.3.3 Developmental assessment tools used for assessing patients with PKU 
Research and studies involving patients with PKU have used many different tools to 
assess the developmental levels of the patients. There is no consensus on the best tests 
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to be used with patients with PKU which makes comparability of research results 
somewhat limited. Formerly IQ tests were the main measures to assess the effects of 
PKU on patients. Lately the patients are assessed more through neuropsychological 
evaluations (Griffiths, Demellweek, Fay, Robinson, & Davidson, 2000). This includes 
behavioural, cognitive, language, motor, and executive functioning assessments, as a 
distinct psychosocial profile for patients with PKU is still unidentified (Weglage, 
2000).  
DeRoche and Welsh (2008) carried out a meta-analysis of 33 studies from 1980 to 
2004. They were studies that investigated executive function and intelligence for early 
treated patients with PKU. There were many tools used to assess intelligence in the 
analysed studies, but there was no significant difference between their results. 
However, there was a significant difference between the results of executive function 
studies that were analysed. The difference was in the measurement tools and date of 
the study, more recent studies showed a higher incidence of executive function 
deficits and some executive function test tools reported more deficits than others. The 
authors pointed out that the research community has no agreement on the best tool to 
measure the executive function domain for PKU patients (DeRoche & Welsh, 2008). 
In another meta-analysis, Burgard (2000) reviewed longitudinal studies that looked at 
the IQ of early treated patients with PKU. Smith and Knowles (2000), in a systematic 
review, looked at the research that studied behaviour for early treated patients with 
PKU. Various tools to measure intelligence and behaviour were used in these 
reviewed studies as well. Below are the tools used in the reviewed studies (Burgard, 
2000; DeRoche & Welsh, 2008; and Smith & Knowles, 2000), however this is not a 
comprehensive list of all the tools used for patients with PKU.  
Tools used to assess intelligence:  
∗ Stanford Binet 
∗ Cultural Fair Intelligence test 
∗ Wide Range Achievement test (WRAT) 
∗ Colombia Mental Maturity Scale (CMMS)  
∗ Wechsler Intelligence Scale for Children (WISC) 
∗ Wechsler Intelligence Scale for Children- Revised (WISC-R)  
∗ Wechsler Preschool and Primary Scales of Intelligence (WIPPSI) 
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∗ Wechsler Adult Intelligence Scale (WAIS)  
∗ Wechsler Adult Intelligence Scale-Revised (WAIS-R) 
∗ Hamburg Wechsler Intelligenztest für Kinder (HAWIK, German WISC)  
∗ Hamburg Wechsler Intelligenztest für Kinder-Revision (HAWIK-R, German 
WISC-R) 
∗ Hannover Wechsler Intelligenztest für das Vorschulalter (HAWIVA, German 
WIPPSI) 
∗ Hamburg Wechsler Intelligenztest für Erwachsene- Revision (HAWIE-R, 
German WAIS-R) 
∗ Terman-Merril method 
∗ Raven’s Progressive Matrices 
Tools used to assess executive function: 
∗ Amsterdam Neuropsychological Test 
∗ Behavior Rating Inventory of Executive Function (BRIEF) 
∗ Contingency Naming Task 
∗ Wisconsin Card Sorting Task (WCST) 
∗ Stroop Tests 
∗ Rey complex Figure Task 
∗ Tower Tests 
∗ Continuous Performance Task 
∗ Corsi-Millner 
∗ California Verbal Learning Test 
∗ Design Fluency Task 
∗ Luria-Nebraska 
∗ McCarthy Scales 
∗ Thurstone Letter Fluency 
∗ Other experimental executive function measures created by different authors 
Tools used to assess behaviour: 
∗ Rutter Behaviour Scale for Teachers (RBST) 
∗ Personlichkeitsfragebogen für Kinder (PFK, German Personality 
Questionnaire for Children) 
∗ Freiburger Personlichkeits-Inventar (FPI, German Freiburg 
Personality Inventory) 
∗ Mannheimer Biographical Inventory (MBI) 
∗ Mannheimer Eltern Interview (MEI) 
∗ The Minnesota Multiphasic Personality Inventory (MMPI) 
∗ Mobility Inventory (MI) 
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Waisbren and White (2010) called for or the use of what their group have named as 
the “Uniform Assessment Method” for PKU. It is a battery of specific tests and tools 
to be used with patients with PKU to screen for problems in adaptive behaviour, 
social/emotional function and executive function. The tests are the Adaptive Behavior 
Assessment System - Second Edition (ABAS-II) for patients 0-2 years; the Behavior 
Rating Inventory of Executive Function (BRIEF) and Behavior Assessment System 
for Children - Second Edition (BASC-II) for patients 2-17 years; and for adult 
patients the BRIEF, Beck Anxiety Inventory (BAI), and Beck Depression Inventory - 
Second Edition (BDI-II). The authors recommended that these specific tests be used 
in PKU clinics in routine visits, they do not need to be administered by psychologists 
and they take less than an hour to be administered. This would identify patients who 
need further assessments early on, provide long-term monitoring of PKU outcome, 
and provide a uniform source of results and research data that is from a uniform set of 
assessment tools across many clinics. They then recommended another battery of tests 
for patients who are identified to need further assessments and for high risk patients 
(Waisbren & White, 2010). This appears to be a good idea for all PKU clinics to 
follow, but there is no evidence yet that this has become regular practice.  
4.4 Issues with the Vineland 
4.4.1  Availability of the Vineland in Arabic 
Although the Vineland ABS has been used for many years at the KFSH&RC it had 
never been officially translated into Arabic or adapted to the local culture. One of the 
lead authors of the Vineland, Professor Sara Sparrow, visited the KFSH&RC in 1996 
to train the team at the Neuropsychology Clinic there on using the tool. She trained 
them on the administration, scoring, and interpretation of the Vineland ABS and on 
how to change some of the items to fit the Saudi culture without losing the meaning of 
the questions. They have been using it since then with many families including some 
families with PKU patients.  
The psychologists were translating the items in the Vineland verbally when they 
administered it with the caregivers and they adapted any irrelevant questions to what 
123 
was more appropriate to the culture in Saudi Arabia. This might have served them 
well in their clinical setting but it would not work in a research setting; consistent 
translation and adaptation was definitely required. 
A search was undertaken for an official translation of the Vineland-II or the Vineland 
ABS in several medical centres and universities in Saudi Arabia, United Arab 
Emirates, Kuwait, Jordan, Lebanon and Egypt. Unfortunately none of these 
institutions had had it translated officially; many were using it by translating the 
questions orally while they administered the tool for each patient, as is the practice in 
the KFSH&RC. Therefore a decision was made to formally translate the Vineland 
scale into Arabic. 
4.4.2 Translation and adaptation of the Vineland to other languages 
The Vineland has been translated and adapted to other non-western cultures. Goldberg 
and colleagues (2009) translated the Vineland ABS into Vietnamese. In the processes 
of its adaptation, 17 items of the scale were reworded to be more relevant to the 
Vietnamese culture and one item, regarding the use of irregular plurals, was 
eliminated because it didn’t have an equivalent in the Vietnamese language. They 
tested the translated and adapted instrument with 120 normally developing children 
and 31 children with intellectual disabilities; it was successful in distinguishing 
between the two groups. They affirmed that the Vietnamese Vineland is reliable and 
valid for the use within the Vietnamese culture. The authors stated that the cultural 
adaptation of the Vineland was flexible and successful, and they recommended further 
adaptations of the Vineland to other cultures to benefit from this tool (Goldberg, Dill, 
Shin, & Nguyen, 2009). 
The Vineland was also translated and adapted to the Indonesian culture by 
Tombokan-Runtukahu and Nitko (1992). Seven items of the Vineland ABS were 
modified to incorporate content that is more relevant to the Indonesian culture, and 
seven items were eliminated because they were unsuitable to the Indonesian culture 
and were difficult to substitute. The authors tested the translated and adapted 
instrument with 43 normally developing children and 43 children with intellectual 
disabilities. They were satisfied that the adapted instrument was reliable and valid for 
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use in Indonesia and that it has similar psychometric qualities to the original English 
version (Tombokan-Runtukahu & Nitko, 1992). 
Zhang et al (2006) examined the Vineland ABS, among other instruments, as a tool 
for the initial screening for autism for Chinese children. The authors did not translate 
the Vineland but inspected/scrutinized each item in the scales based on their Chinese 
cultural perspective to judge if the Vineland is appropriate to be used within a Chinese 
culture or not. They reported that 12 items are unsuitable for Chinese families and 
they need to be adapted to give valid results. 
4.4.3 Translation and adaptation of standardized assessment tools to Arabic and 
different Arab cultures 
Many assessment tools have been translated from the original English form to the 
Arabic language. With the translation, the tools have been culturally adapted to the 
local Arab culture of the study populations including several in Saudi Arabia (Al-
Ansari & Bella, 1998; Brown & Al-Khayal, 2006; and Malki, Mesallam, Farahat, 
Bukhari, & Murry, 2010), in other Arab countries (Harifi et al., 2011; Sabbah, 
Drouby, Sabbah, Retel-Rude, & Mercier, 2003; Saleem & Natour, 2010; and Shehab, 
al-Jarallah, & Moussa, 1998), or, through collaboration between several Arab 
countries (El Meidany, El Gaafary, & Ahmed, 2003; el Miedany, Youssef, & el 
Gaafary, 2003; and Madi, Al-Mayouf, Grainger, & Bahabri, 2004). The researchers 
have all produced Arabic instruments valid for use in their cultures.  
For example, Al-Ansari and Bella (1998) have translated the Revised Denver Pre-
screening Developmental Questionnaire (R-PDQ). They made changes to it to adapt it 
to the Saudi culture and validate it for the use with Saudi children. Shehab et al (1998) 
translated the Health Assessment Questionnaire (HAQ) to Arabic and adapted it to for 
use in Kuwait. Another study translated and adapted the HAQ to the culture of a 
collection of Arab countries in North Africa and the Middle East including Saudi 
Arabia (El Meidany et al., 2003). The Childhood Health Assessment Questionnaire 
(CHAQ) has been translated and culturally adapted as well. It was validated in Egypt 
and Saudi Arabia (el Miedany et al., 2003; and Madi et al., 2004). In Lebanon the 
short form 36 health survey (SF-36) was adapted to their Arab culture as a quality of 
life measure (Sabbah et al., 2003). 
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4.5 The translation and adaptation of the Vineland-II to the Arabic 
language and the Saudi Arabian culture 
4.5.1 Translation and cultural adaptation of instruments 
Many surveys and instruments are developed in English and, when proved successful, 
they are translated to numerous different languages. Translation of well-established 
instruments has the advantage of saving time, money, and energy that could be spent 
on developing a new instrument in each language (Hambleton & Patsula, 1998; and 
Peters & Passchier, 2006). It also has the benefit of facilitating cross-cultural 
awareness and comparability between research results from different countries (Lloyd 
et al., 1998; and Yu, Lee, & Woo, 2004) and examining any similarities or differences 
between cultures (van de Vijver & Hambleton, 1996). 
It is established that literal or simple translation of instruments from one language to 
another is ineffective due to the various differences between languages and cultures, 
therefore cross-cultural adaptation of instruments is recommended (Ercikan, 1998; 
Hilton & Skrutkowski, 2002; Scientific Advisory Committee of the Medical 
Outcomes Trust, 2002; van de Vijver & Hambleton, 1996; and Yu et al., 2004). 
Cultural and language adaptations involve adapting the instruments to suit specific 
regions, countries, and diverse life-styles. The translated instrument must be relevant 
to the culture of the target population and equivalent to the concepts of the original 
instrument while capturing the same concepts cross-culturally (Guillemin, 
Bombardier, & Beaton, 1993; Hilton & Skrutkowski, 2002; and Peters & Passchier, 
2006). The adaptation should reflect the meaning and maintain the relevance of the 
original instrument so it does not alter what the items are intended to measure 
(Ercikan, 1998). 
One of the most recommended and used approaches for cross-cultural translation is 
forward and back translation (Ercikan, 1998; Hambleton & Kanjee, 1995; Hilton & 
Skrutkowski, 2002; and Peters & Passchier, 2006). It involves translating the 
instrument from the source language to the target language. A second translator then 
takes the translation and translates it from the target language back into the source 
language. Finally the original instrument and the back-translated version are 
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compared and any discrepancy or ambiguity in meaning clarified (Beaton, 
Bombardier, Guillemin, & Ferraz, 2000; Ercikan, 1998; and Peters & Passchier, 
2006). One of the important aims of this comparison should be to attain conceptual 
equivalence (Bowden & Fox-Rushby, 2003). 
Swaine-Verdier et al (2004) recommend a “two panel” approach as a thorough 
technique for translating and adapting instruments. One panel of 5-7 people is 
recruited to translate and adapt the instrument, and another panel of 5-7 lay people to 
test the adapted instrument. Other researchers suggest the use of an additional third 
panel for back-translation (Peters & Passchier, 2006). Combining translation 
techniques have been reported to produce positive results (Maxwell, 1996; and Peters 
& Passchier, 2006). 
It is recommended to have at least two translators and they should have excellent 
knowledge of English and the target language (Hambleton & Patsula, 1998; and 
Maxwell, 1996). However, to translate and adapt instruments effectively, it is not 
enough that the translators are proficient at the language, it is essential that they have 
adequate knowledge of the culture of the research population (Hambleton, 2005; 
Hambleton & Patsula, 1998; and Vulliamy, Lewin, & Stephens, 1990). 
To ensure appropriate translation it is important to pre-test and pilot the translated 
instrument in the new target culture (Beaton et al., 2000; and Birbili, 2000). This is 
essential to verify the validity and reliability of the translated instrument (Peters & 
Passchier, 2006). 
4.5.2 The translation and cultural adaptation process for the Vineland-II 
The translation and cultural adaptation of the Vineland-II followed the guidelines 
recommended by Beaton and colleagues (2000). They recommend following a series 
of rigorous stages to achieve high quality cross-cultural adaptation and to come up 
with an equivalent and applicable tool. 
The Vineland-II was translated into Classic Arabic. This is not the same as spoken 
Arabic but it is the official Arabic used in all the written forms in Saudi Arabia and 
other Arab countries. It is the form of Arabic that is taught in schools, and it is widely 
understood in the Arab world. It can be easily read out in any local dialect.  
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The following process summarizes the translation and adaptation procedures we 
undertook with the Vineland-II, ten individuals were involved in this process: 
1. The Vineland-II was translated in Saudi Arabia at a professional translation 
agency that specializes in translating scientific English documents to Arabic. It 
was also translated by an independent professional translator, who is a native 
Arabic speaker proficient in English. 
2. An independent assessor and I reviewed the initial translations to examine 
content, semantic and conceptual equivalence with the English version. We 
suggested some modifications and alternative translations to some items.  
3. We met with the independent translator and discussed the two available 
versions of the translation. Discrepancies were resolved to create one mutual 
translation. This was done to ensure that the Arabic items gave the same 
meanings as the English items, not by literal translation of the words from 
English to Arabic but by using words that are more appropriate in giving the 
meaning in the Arabic language. 
4. Two experts in Arabic linguistics reviewed the Arabic translation to ensure 
correct grammatical structure and punctuation of the Arabic items. They did 
not have any knowledge of the English version.  
5. The Arabic Vineland-II was back-translated from Arabic to English by two 
other independent translators. One was an English literature and linguistics 
specialist and the other was a health care professional, both were not familiar 
with the original Vineland-II in English. 
6. The translators and I discussed and compared the back-translations with the 
original English Vineland-II to ensure conceptual equivalence and to identify 
any translation errors. The two back-translations had high agreement with the 
original. We identified few discrepancies between the original and the two 
back-translations and discussed them with the first translator. This led to 
modification of a few items in the Arabic translation to improve compatibility 
with the English meanings.   
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7. We adapted some items and examples in some items to fit with the culture of 
Saudi Arabia, such as replacing some words or activities by others that better 
represent the local culture (e.g. changed Western names to Arabic names and 
changed some Western activities to activities that are practised more in Saudi 
Arabia). Section 4.5.3 below lists these adaptations in detail. The two 
translators and I are from Saudi Arabia and have first-hand experience of its 
cultural norms. We have all lived for at least 2 years in the USA, and, 
therefore, are also familiar with the cultural norms that provide the basis for 
the Vineland-II. 
8. The Arabic Vineland-II was checked for its cultural adaptation and 
comprehensibility by a senior clinical neuropsychologist at Riyadh Armed 
Forces Hospital and a senior neuropsychology technician at KFSH&RC (who 
has been using and adapting the Vineland ABS -first edition- since 1996 with 
patients at KFSH&RC). Their comments were incorporated into the Arabic 
Vineland-II. 
9. One of the Arabic language experts checked the linguistic and grammatical 
structure again. 
10. A technical expert worked to arrange the Arabic Vineland-II in a comparable 
style as the original English Vineland-II. I wanted the Arabic version to have 
the same organization and aesthetics as the original, so people who have used 
the English Vineland-II would easily find their way using the Arabic version. 
11. To test the language of the Arabic Vineland-II, its understandability, 
acceptability, and clarity to different people, I read it to two women and gave 
it to three other people to read it through. They were not familiar with it 
previously and they were asked to give their feedback on any item they didn’t 
understand or which was ambiguous. A few items were highlighted; we 
discussed these items till we reached agreement on the best way to reword 
them or add more information to clarify the meaning. 
12. The Arabic scales were piloted on normally developing children of both 
genders and different age groups to test all the items on the Arabic Vineland-
II. Section 4.5.4 below describes this pilot study.  
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4.5.3  Adaptations to the Vineland-II in the Arabic version 
A couple of adaptations were carried out all through the Vineland-II: 
1. All mention of miles, feet, and inches were changed to kilometers, meters, and 
centimeters, as these are the measurements used in the region. 
2. All the Western names in the Vineland-II were changed to local Arabic names. 
Some examples of the adaptations and adjustments are listed in Table 3 below. 
Specific adaptations for each item, or adaptation of the example in an item and the 
reason for the adaptation, are detailed in Appendix 11.
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Table 3: A sample of the items adapted for the Arabic Vineland-II, the adaptations and adjustments, and the reasons for the adaptations. 
Page 
Number 
Item 
Number Item in English Vineland-II Adaptation Reason 
5 11 
Points to at least three five minor body parts when asked 
(for example, fingers, elbows, teeth, toes, etc.). 
Replaced the word “toes” with 
“thumb” 
Language: translation of toes is “feet fingers”, 
and fingers were included already  
6 12 
Names at least three objects (for example, bottle, dog, 
favourite toy, etc.). 
Replaced “Dog” with “Cat” Cultural: cats are a more common pet  
7 38 
Pronounces words clearly without sound substitutions 
(for example, does not say “wabbit” for “rabbit”, 
“Thally” for “Sally,” etc.). 
Replaced examples using the 
word “chair”.  
Language: this example can illustrate the point of 
letter substitution better in Arabic. Chair in 
Arabic is pronounced as “kursi” the substitution 
could be “tursi” 
8 52 
Describes a short-term goal and what he or she needs to 
do to reach it (for example, says, “I want to get an A on 
my test, so I’m going to study hard”; etc.). 
Replaced “A” with “high 
grades” 
Cultural: different grading system 
9 6 
Identifies all printed letters of the alphabet, upper-and 
lowercase. 
Replaced “upper- and lower 
case” with “different forms”  
Language: Arabic does not have upper or lower 
cases but letters change forms according to their 
place in words 
10 19 Wipes or blows nose using tissues or handkerchief. 
Replaced “handkerchief” with 
etc. 
Language: tissue and handkerchief are translated 
to the same word in Arabic 
12 
8 
Helps prepare foods that require mixing and cooking 
(for example, cake or cookie mixes, macaroni and 
cheese, etc.). 
Replaced “macaroni and 
cheese” with “macaroni and 
tomato sauce”  
Cultural: this is a more common dish 
9 
Uses simple appliances (for example, a toaster, can 
opener, bottle opener, etc.). 
Deleted the example “Bottle 
opener” 
Language: the previous example of can opener 
translates the same as bottle opener 
16 37 Goes on group dates. 
Replaced “dates” with 
“gatherings or meetings” 
Cultural: there is no dating in Saudi, but meetings 
with friends without parents is acceptable  
18 24 
Plays simple games that require keeping score (for 
example, kickball, pickup basketball, etc.). 
Replaced examples of games 
with more common ones 
Cultural 
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4.5.4 Testing of the Arabic Vineland-II 
For the purpose of this research a small pilot study was done to ensure the reliability 
and validity of the Arabic version of the Vineland-II. The pilot was done for 15 
normally developing children; it was administered with 5 mothers in a face to face 
interview and with 10 mothers in a phone interview. All of the children were 
considered normally developing children, 7 were male and 8 were female. Their ages 
ranged from 4 months up to 16 years. The Vineland-II has 383 items that cover 
adaptive behaviour from birth to 16 years of age and over, mothers would be 
interviewed about the behaviours relevant to their children’s age group rather than go 
through the whole scales. Therefore it was necessary to have two to three children in 
every age group to ensure coverage of all the items more than once.  
The tested children all had ABC scores within the normal “Adequate” level of the 
Vineland-II except two. One child had a score in the “Moderately High” level and the 
other had a score in the “Moderately low” level. This was expected because the child 
with high scores was classified as gifted by his school. As for the other child, his 
mother indicated that he was spoiled and everything was done for him, being the 
youngest in a large family, and she thought he was slow in progress compared to his 
siblings at his age (2 years). The ability of the Arabic Vineland-II to distinguish these 
two children out of the group was very encouraging and a testament to its validity. 
The best measure of validity is to administer another adaptive behaviour instrument to 
the same group of children and compare the results with their scores from the Arabic 
Vineland-II. This was beyond the scope of the current research; nonetheless it should 
be carried out before using the Arabic Vineland-II on a larger scale. 
Two small scale reliability tests were done. The first, to ensure that the Arabic 
Vineland-II is reliable in measuring what the English Vineland-II intends to measure, 
both the Arabic and the English versions were administered with bilingual mothers of 
four children. All of the four children had similar scores yielding the same adaptive 
behaviour level on both the Arabic and the English Vineland-II.  
The second was a measure of test-retest reliability, the Arabic Vineland-II was 
administered twice with the mothers of three of the children, there was 7-10 days 
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between the first and second administration. The children had almost the same scores 
on both administrations of the Arabic Vineland-II. 
The numbers in this pilot study were too small to consider it a validation study for the 
wider use of the Arabic Vineland-II in Saudi Arabia. However, for the purposes of 
this study, it was believed to provide sufficient evidence to go ahead and use the 
Arabic Vineland-II for the patients in this research. Further reliability and validity 
tests with larger numbers and varied developmental levels need to be carried out on 
the Arabic Vineland-II to ensure the appropriateness of its use with the wider 
population in Saudi Arabia and other Arab countries.  
4.6 The Arabic Vineland-II in the current study 
4.6.1  Administration of the Arabic Vineland-II 
The families in this study live in different parts of Saudi Arabia. Travelling to these 
different parts to administer the Vineland-II was not feasible, and waiting for them to 
attend their appointments at the KFSH&RC and administer the Vineland-II then 
would have taken a very long time to accomplish, as many patients only come to 
clinic every 6 months. Furthermore there was no guarantee that the families would be 
able to complete the Vineland-II interview due to a full day of clinic appointments 
and arrangements for travel home that could not be changed, as had been experienced 
in the data collection period. 
Administration of the Arabic Vineland-II by phone was therefore considered. 
Limperopoulos et al (2006) examined the equivalence reliability of the Vineland 
Adaptive Behaviour Scales; their objective was to test if the scores of the Vineland 
obtained by in-person interviews were comparable to scores obtained by phone 
interviews through a cross-sectional comparative design. They establish that the in-
person interview scores were highly correlated with the phone interview scores (r = 
0.99), indicating that administrating the Vineland through phone interviews gives 
results consistent with the in-person administration. They have examined the 
Vineland ABS not the updated Vineland-II, but given that there is a very high 
correlation between the Vineland-II and the Vineland ABS (Sparrow et al., 2005), it 
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was assumed that this consistency between phone and in-person interviews would still 
be present. It is vital to have tools that can give reliable and comparable results when 
administered through face to face interviews and through phone interviews, this 
makes gathering data easier, more flexible, and cost effective, it facilitates continuous 
monitoring of progress and improves access to families in remote areas 
(Limperopoulos et al., 2006; and Msall & Tremont, 2002). 
It was decided best to administer the Vineland-II with the mothers and caregivers over 
the phone. I had established a good rapport with the families when I met them and the 
patients during the data collection of Phase 2, and I had talked to them over the phone 
at least two times to follow up and to take the 24 hour diet recalls. I had had many 
more contacts when the mothers had more than one child with PKU.  
I carried out all of the Vineland-II phone interviews. Administration of the Vineland-
II was according to the outlined instructions in the manual (Sparrow et al., 2005). I 
was trained to conduct and score the Vineland-II by Dr Kathryn Bond, a clinical 
psychologist working at GOSH. In addition, I had numerous discussions concerning 
the administration of the Vineland in Arabic with Ms Lina Moncari, the 
neuropsychology technician at KFSH&RC who administers the Vineland. She gave 
me valuable tips and insights. 
The average time spent on the phone with the mothers for each patient was two hours 
and twenty minutes. This included introduction of the Vineland-II and the reasons for 
administering it, conversing with the mothers and listening to their complaints and 
difficulties with PKU, administering the Vineland-II, and reporting back the scores to 
the mothers who requested them. 
4.6.2  Scoring and interpretation of the Arabic Vineland-II results  
The scoring of the Vineland-II was done by Dr Bond and me to ensure accuracy, and 
then we discussed the interpretation of the results. We decided that for the purposes of 
this research the Vineland-II Adaptive Behaviour Composite score (ABC score) 
would be used in the analyses. The ABC score is defined as a global measure of 
adaptive functioning. Statistically it is the most dependable general estimate of 
adaptive functioning as it is based on all of the items in every domain (Sparrow et al., 
2005). Further analysis of the scores of each domain may prove valuable for future 
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research. These scores would facilitate identifying each patient’s strengths and 
weaknesses and are good for monitoring and re-evaluating them periodically to help 
the patients improve in their daily functioning with planned interventions. 
4.6.3 Correlation of the Vineland-II scores with scores from other assessments 
for the patients 
Twenty seven of the patients had had at least one assessment completed at the 
Neuropsychology Clinic at the KFSH&RC. The scores they had are from one of these 
assessment tools: the Beery VMI, the Leiter, the TONI, the Bayley, the McCarthy, 
and the Vineland ABS. To explore the association between the Vineland-II and other 
assessments I ran correlation test between the Vineland-II ABC scores for each of the 
patients with the latest scores they had from previous assessments.  
The Pearson product-moment correlation coefficients between the Vineland-II scores 
and the other scores was high (r = 0.92, p < 0.0001). This indicated that the Vineland-
II had successfully identified the level of development for each patient, as it was in 
agreement with the scores of other tests. 
4.6.4  Experience with the Arabic Vineland-II after its administration  
Although Saudi society and culture are very different to the American culture, much 
of the day to day routine is very similar. The main differences in culture were the 
games and sports of choice, and issues with regard to dating and the places to go out 
to. These were easily modified as described in section 4.5.3 above. 
After administering the Arabic Vineland-II with the mothers of the patients in this 
study there was no need for additional modifications in relation to culture except for 
two items. One is concerned with writing and sending letters, packages or greeting 
cards, as it is becoming less practised by Saudis unless in businesses. As this 
behaviour is expected at an older age only few of the patients reached this item on the 
Vineland-II, a couple of mothers answered by saying their children sent emails. This 
item needs to be tested further with a larger sample and modified as required or 
substituted with another example more relevant to the culture.  
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The other issue is related to coin use. The use of coins in the Saudi Arabian currency 
is not fundamental as it is with the pound, dollar or euro, and when used only the 50 
halala and 25 halala coins are used (halala is the Saudi equivalent of a pence or cent, 
Saudi currency: 1 Riyal = 100 halala). Many of the larger shops are starting to 
abandon the use of coins and many would give out a pack of gum if the change was 
less than a complete Riyal, instead of giving the change back in coins. We did not 
change this item in the initial adaptation because we were under the impression that 
the coins were still in good use in many small grocers and local shops, but most of the 
mothers reported no use of the coins. This might not be the case in other Arab 
countries. 
Most of the families in this study live in cities or small towns; I didn’t find any 
difference between them in administering the Arabic Vineland-II. Nonetheless it was 
administered to only 38 children in this study. Some cultural differences may come up 
if administered with larger numbers of families from villages or rural areas.  
One area that needs to be looked at closer is the acquisition of language skills across 
age. The language skill items in the Vineland-II relate to the rate of learning the 
English language at different ages. When translating and testing the Vineland-II, we 
discussed this issue and came to the agreement that the questions are asked at the right 
ages even for Arabic. Validating the Arabic translation on a larger number of 
normally developing children will give better evidence for this. 
4.6.5 Request for the Arabic Vineland-II 
Researchers from the Yale University Child Study Centre approached me requesting 
the Arabic translation of the Vineland-II, after hearing about it through Prof Sara 
Sparrow. They intended to use it with children in Saudi Arabia in a collaborative 
research project between them and the King Faisal University in Saudi Arabia. 
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Summary  
This chapter portrayed the translation of the Vineland Adaptive Behaviour Scales 
(Vineland-II) to Arabic, the adaptation of the scales to the culture of Saudi Arabia, 
and the testing process of the instrument in Arabic with Saudi families. This chapter 
also described how the Arabic translation of the Vineland-II was administered, 
scored, and interpreted for this research study.  
The results of the Vineland-II Adaptive Behaviour Composite scores for the patients 
in this study are shown and analysed with other variables from Phase 2 of this study in 
Chapter 7. These results are then discussed in Chapter 8.  
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CHAPTER 5 
FINDINGS (PHASE 1) 
 
5. Findings (Phase 1) 
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Introduction 
This chapter describes the findings of the qualitative study from Phase 1 of this 
research. The aim of this phase was to gain an understanding of the current situation 
of the patients with aminoacidopathies at KFSH&RC with a view to inform the 
quantitative and second phase of this study. The findings here were used to structure 
the questionnaires for Phase 2, and this was then used with a larger number of 
participants and with quantitative components following the sequential approach 
recommended by Creswell (2009).  
The interviews  
Interviews with health care providers: There were five interviews with the key 
informants: three interviews with the metabolic medicine doctors, one interview with 
the senior metabolic dietitian, and one interview with two dietitians; the metabolic 
dietitian in training and the dietitian who covers the metabolic clinic when both the 
metabolic dietitians are not available.  
Focus groups with health care providers: There were two focus group sessions. 
One was with 5 general dietitians who work at the hospital and occasionally see 
patients with aminoacidopathies. The other was with 7 nurses who work at the 
metabolic clinic.  
Interviews with patients: Eight patients were interviewed. There were five 
interviews with individual patients and one group interview with three sisters. They 
had MSUD, PKU, or tyrosinaemia type I. Their average age was 11.6 years, with a 
range of 7 to 16 years of age.  
Interviews with families: There were 17 interviews with families of patients with 
MSUD, PKU, or tyrosinaemia type I. The families, in between them, had 41 affected 
children with one of these aminoacidopathies. The interviews were mainly with the 
mothers and some of the fathers contributed.  
  
140 
  
Six major themes were identified from the interviews, focus groups, and observations. 
Each theme encompasses the related subject ideas, concepts, and experiences that 
were identified from the data. Each theme is then organised into sub-themes, which is 
a hierarchical organization of the data in each theme. Figure 5 shows the themes and 
their sub-themes.  
The analysis process of deriving these themes is described in the Methods chapter 
(Qualitative analysis under section 3.4.2.4). The key findings and concepts identified 
from the participants’ perspectives within each theme are presented with examples of 
direct quotations from the interview texts as evidence. Each quote is followed by the 
unique code of the person who said it and where it appeared in the transcribed text for 
reference. 
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Themes
DIETARY 
PRACTICES AND 
COMPLIANCE
KNOWLEDGE
Diagnosis and referral process
Experience with health care services at 
KFSH&RC
Perceptions of services
Knowledge of condition
Knowledge of treatment and diet importance
Knowledge source
Perspectives of the families
Perspectives of the health care providers
SERVICES
Perception of and satisfaction with knowledge
Health care providers
Seeking knowledge or treatment in places 
other than KFSH&RC
Preferred form of information provision
SOCIAL ISSUES
Social support
Social coping
NEEDS
Knowledge needs
Support needs
NEWBORN 
SCREENING
Current situation
Perceived implications of the Newborn 
Screening Program
Sub-themes
 
Figure 5: Phase 1 findings organized in themes and sub-themes (derived from 28 
interviews and 2 focus groups).  
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5.1 Services 
5.1.1 Diagnosis and referral process 
Parents and health care providers had strong views on the process of diagnosis and 
referral. The doctors believe early diagnosis is improving in Saudi Arabia with the 
introduction of newborn screening. However, most of the patients in this study were 
diagnosed late or were diagnosed early through selective screening of families with a 
known history of a disorder. Many of the families talked about the anguish and 
distress they and their children have endured due to misdiagnosis or delayed 
diagnosis. Out of the 17 interviewed families 14 families have lost a child or more, or 
have a disabled child due to delayed diagnosis of the metabolic disorder they had 
(Nine families have lost 15 children, and 11 families have 13 delayed children). They 
talked a lot about “constant crying”, “hospitalizations”, “pain”, “coma”, and “dying”.  
“He was diagnosed at birth. I have a daughter before him; she has the same disorder, but 
was diagnosed late...” MSUD Parent F9, 13 
“Six before her and they all died!  They all had the same disorder but we did not know, 
they were not properly diagnosed.. After we discovered her and got to know her smell; the 
smell of her sweat and urine, the same things and symptoms that she went through the 
children before her went through. They were not diagnosed at the hospital.” MSUD Parent 
F13, 17 
When a metabolic disorder was diagnosed in a family all their newborns would be 
screened after that. Some families think they were fortunate to have their newborns at 
hospitals that were involved in the new newborn screening programme.  
“If the family has a history of a disorder once the mother gets pregnant they will follow her 
up at the hospital.”  Dietitian D, 51 
“ I have two daughters, the first daughter, after the first week of birth at the Military 
Hospital, in Jeddah, they were suspicious of the blood test; they said we should repeat the 
blood analysis and send it to Riyadh to be sure. From Riyadh they said she has high amino 
acids and she should not breast feed milk from her mother. My second daughter, soon after 
delivery we asked for blood test because the doctor told us that her siblings may have the 
same disorder. They sent the blood test to Riyadh and they said she has amino acids like 
her sister.” MSUD Parent F12, 10 
“She was diagnosed at 11 days of age, and she is the first with this disorder. We have two 
other normally developing children.” PKU Parent F7, 13 
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The health care providers considered that the referral system was good when the 
family has a known history of the disorder. However, they reported that problems 
arose in identifying and dealing with new cases, due to limited expertise of general 
paediatricians in the field of Metabolic Disorders in most parts of the country. 
Nevertheless, they believe the situation has improved in recent years with early 
referrals due to training of some paediatricians at KFSH&RC’s Medical Genetics 
Department and the start of the newborn screening programme. 
“Referral comes from two sources; either through the newborn screening if they are born 
here, or referral from hospitals across the country. So usually physicians outside this 
hospital send Tandem MS if the patients are sick or suspected to have metabolic disease 
they send the metabolic screening to the hospital and if it comes positive they contact us...” 
Doctor R1, 15 
“It is much better in the last two years than when we first started; because some physicians 
started to come to our hospital to take their fellowship which includes metabolic 
disorders.” Dietitian D, 73 
5.1.2 Experience with health care services at KFSH&RC 
Frequency of clinic visits 
Patients are seen at different intervals, depending on their doctor’s schedule and on 
their case. The dietitian and some doctors like to see the patient weekly for the 1st 
month, then twice a month, then every 1-3 months after the age of 3 months, then 
every 6 months after the age of 1 year if they were stable. But often the clinic 
schedule is full or the patients do not want to schedule the doctor’s visit on a different 
day than the dietitian, so their visits become further apart.  
“For the 1st month we see the new patient weekly and do the necessary changes in the 
diet.…but if everything is stable we see them every 2 weeks during the second and third 
month of life. This is the way of some of our doctors, others follow different schedules. I 
prefer this way and I follow it when I schedule for the patients. After that we see them 
monthly or every 3 months.” Dietitian D, 110   
“My clinic again, is very busy, so I do a less often follow-up for all the people.” Doctor R2, 
33 
“When she was first diagnosed we came every 2-3 months and now every 6 months.” PKU 
Parent F15, 94 
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Access to health care providers and contact between visits 
Usually families can reach their doctor or the metabolic dietitian by phone or pager, 
or even their mobile phones, but it is not always easy to get through to them. Some 
families who live in Riyadh just come to the hospital when they need to. 
“Sometimes the clinic is so busy, sometimes we can't answer them [phone calls], but 
usually we answer them as much as possible.” Dietitian D2, 153 
“We also receive calls at night sometimes even, after working hours on our pagers or 
mobile phones.” Dietitian D, 151 
“Calling is not that easy, it is hard to get the dietitian on the phone; they don’t transfer the 
calls easily.” PKU Parent F4, 78 
“When I need something I come.” MSUD Parent F10, 121 
The dietitians and the doctors do not have the time to regularly call and follow up 
with the patients. Therefore they ask the families to call after having a blood test to 
check the levels and discuss any changes needed in the diet. 
“I ask them to call me, they call and we check the labs and discuss any needed changes.” 
Dietitian D, 136 
“We do not contact them, they usually contact us. So we ask them to send the samples and 
to call us 1 week or 10 days after that, because we have dozens and dozens of these 
patients; for MSUD we have a huge population. So if you just keep tracking you need one 
person doing nothing but this, it is a huge list!” Doctor R1, 79 
Referral to the metabolic dietitian and follow-up appointments 
Referral to the metabolic dietitian is considered essential and it is regular procedure 
for all patients as soon as they are diagnosed. Some families need to see her more 
often than the doctor but due to travel issues they usually schedule the dietitian’s 
appointment on the same day as the doctor’s appointment.  
“They diagnose the disorder and refer the patient right away to the metabolic dietitian. 
And we start with the patient from day one if born at KFSH, if the patient is from outside 
the hospital we do as much as we can to communicate with other hospitals to start the diet 
as soon as possible, as soon as they contact us.” Dietitian D, 20 
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“When she first got sick and we saw the doctor he transferred us here [to the dietitian].” 
MSUD Parent F11, 121 
“Always [see dietitian] with the doctor’s appointment” MSUD Parent F10, 154 
Blood amino acid level tests 
Families are asked to have regular blood tests to check the relevant amino acid levels 
for their children, but that is not always easy for the families when they live far from 
the hospital. They usually just do a blood test when they come to see the doctor at 
clinic, or few days before the clinic visit if they live in Riyadh.  
“It depends on the situation and diagnosis. I like to ask for blood levels before the clinic 
time, just to get the results so I can decide on this in the clinic… I tell them to come before 
each clinic visit to do blood levels... My philosophy is to ask for it before to be more 
practical in making necessary changes. Some physicians do the blood tests at the same 
day, they may forget to communicate results or leave it till next visit.” Doctor R3, 60 
“I had to pay a lot for sending the blood samples to Riyadh and got tired of that.” PKU 
Parent F16, 94 
5.1.3 Perceptions of services 
Services at KFSH&RC 
Patient care at KFSH&RC was satisfactory to most families. It is viewed as providing 
good services for the patients and their families with few exceptions. The long waiting 
times at the hospital to be seen by the doctor and the dietitian were the most voiced 
complaint. Families mentioned that the health care providers are very busy and 
overworked and they think this reduces quality time with them. Another problem for 
many of the families who do not live in Riyadh, where KFSH&RC is located, was 
travelling to get to their appointments (only six of the interviewed families live in 
Riyadh). 
“Sometimes we come on the appointment and we are seen right away, and some other 
times we are delayed. We stay for 3 or 4 hours!” MSUD Parent F11, 78 
“I feel that [the dietitian] is over worked and I don’t have time to ask her every question 
that I want to ask her.” PKU Parent F7, 146  
“The difficulties are in the transportation, no one is available to bring me from Kharj [a 
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town 2 hours drive from Riyadh].” (Mother became tearful) MSUD Parent F8, 57 
“A lot of time is wasted in the airport. This is my dilemma. Now we finished from the 
dietitian and we will have to wait to see the doctor. It takes too long for seeing the doctor!” 
PKU Parent F16, 155 
From the point of view of the patients they like the crayons they are given at the clinic 
to colour and the cafeteria at the hospital, but they dislike coming to the hospital 
because of the blood test and they do not like the fact that there are no playground or 
play facilities for them at the hospital. 
“I don’t like to come because of the needle prick” PKU Patient P4, 39 
“It is better not to come here. I don’t like the blood tests. I only like them to take my weight 
and pressure.” MSUD Patient P13, 20 
“There are no swings... If they had swings, we would’ve played.” PKU Patient P16b, 12 
On the other hand, the health care providers at KFSH&RC perceived the services as 
“inadequate” due to limited availability of dietitians trained in the field of metabolic 
disorders, limited time for patient counselling, limited specialized staff, limited 
educational material, and language barriers between families and non-Arabic speaking 
staff. A positive aspect seen in KFSH&RC services is that the special diet formulas 
prescribed for metabolic disorders are given free of charge.  
“It is inadequate [hospital service], I think.” Dietitian D, 472 
“I think they are fairly good, except that the only thing is that they are strained. Of course, 
there is room for improvement in what could be provided.” Doctor R2, 217 
“If the system doesn't help you, doesn’t provide you with clinics, with more staff then you 
cannot say that your system is efficient! You cannot describe it as efficient!” Doctor R1, 272 
“There should be somebody to guide these people; they come from faraway places. There 
should be somebody to coordinate them to assist and so forth. It is a lot of stress for them.” 
Nurse N1, 253 
“They have to sit there with the child for how many hours, but you know we cannot help it 
if the clinics are very busy - 20, 25, 30 to 40 patients a day and everybody has to wait to be 
seen!” Nurse N2, 169 
“Of course it is great for them to get the formula free, because otherwise it would be 
costly!” Dietitian D, 484 
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Services at health care facilities other than KFSH&RC 
Services at health care centres other than KFSH&RC were perceived as satisfactory 
for general health care, but unsatisfactory in relation to providing care related to 
metabolic disorders. That was especially evident in the lack of expert dietitians. 
“If the doctors in other cities know what to do they don’t refer the patients to our doctors, 
but there are no dietitians. So even if we didn’t see the patient they send all the needed 
information for the dietitian at KFSH&RC to do the formula calculations and dietary 
requirements.” Dietitian D, 96 
“We tell the doctors [in other cities] that she has PKU. Of course, no one knows much 
about this illness, we alert them about some medications that she should not take.” PKU 
Parent F15, 140 
5.1.4 Health care providers 
Health care providers involved in patient care 
The patients and their families are regularly seen by the metabolic team, which 
consists of the specialist doctors, the metabolic dietitians and the nurses. They are 
referred to other specialist such as the psychologist, neurologist, and social worker as 
needed. 
“The doctors, dietitians, nurses [the metabolic team].” Dietitian D2, 448 
“We involve the neurologist, ophthalmologist, and paediatricians. Sometimes our 
problems go to other systems like the liver, kidneys, and other parts of the body, so we 
involve related healthcare providers. We involve also other medical services like social 
services” Doctor R2, 126 
Relationships between health care providers, families and patients 
Relationships with health care providers were viewed as good and satisfactory by the 
families. The patients’ relationships with the health care providers were not as clear, 
some felt they were listened to and their opinions mattered and some felt that they 
were not involved. 
“I used to feel shy, but then a woman told me not to be shy and be honest with them, and 
that is what I did. The doctor does his best.” MSUD Parent F8, 83 
“I like the dietitian, I always see her and she explains everything to me, I understand her 
and she teaches me, but the foreigner dietitians before her I didn’t understand them 
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because of the language.” MSUD Parent F13, 144 
“No, I don’t tell them what I like.”  (referring to communication with doctors) PKU Patient 
P4, 49 
“He [the doctor] speaks English and I only understand Arabic.” MSUD Patient P13, 16 
Relationships and communication between the different health care providers within 
the metabolic team appear to be good. The relationships of the health care providers 
with the families and the patients were portrayed as good and strong as well. 
“My relationship with the physicians and nurses is rather strong.” Dietitian D, 455 
“We have a good rapport with them [doctors and dietitians].” Nurse N5, 346 
“I feel I have a very strong relationship with them [families and patients], at the hospital 
they call them my kids!” Dietitian D, 266 
“I hope it is good.  I try to make my best to deliver a good care... I try to listen to them.  I 
try to establish a good rapport, establish good trust...” Doctor R2, 99 
 
Work setting for the metabolic team 
All of the doctors, dietitians, and nurses in the metabolic team agreed that the 
metabolic clinics were very busy with high work load, long hours, and high stress. 
There were four main doctors and two dietitians in the metabolic team, with rotating 
nurses and trainees. There were 7 clinic sessions per week for the metabolic disorders, 
each session was 4 hours long and covered by one doctor, one medical trainee, one 
dietitian, and two nurses or three if the patient numbers were high. The number of 
patients varied from 10 to 24 per clinic session. 
“It is very strenuous, you need the dedication.” Dietitian D2, 22  
“You know the coordination for the patients, coordination for education; we are so busy 
every day you know our practice goes from 8am to 6pm sometimes finishing at 7 or 8pm.” 
Nurse N1, 411 
“It is difficult for us during the clinic, because at the same clinic we need to deal with the 
patient in front of us, deal with the patients on the phone, and deal with the patient who is 
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waiting outside the door, and it is only one person in the clinic, it is really too much. If we 
have help in the clinic, at least a clerk or a training dietitian, it would help a lot in giving 
better care to the patients and reducing strain on the dietitian.” Dietitian D, 129 
“The only thing they [hospital administration] are thinking about is that the load is 
covered and the patients are seen. They don't care how you are covering it, if you are 
being killed by covering this load or not!!” Dietitian D, 532 
“My clinic is very busy, let us say the average number we see per clinic is 24, out of the 24 
I would say, 10 to 12 will be aminoacidopathy cases.” Doctor R2,26 
The main dietitian has been working with metabolic disorders for the over 10 years 
and she has trained the second dietitian. Both are highly motivated and well respected 
at the Medical Genetics Department, but overworked with the high load of duties. 
Workload is a major stress factor; nonetheless, they enjoy the work and have good job 
satisfaction. 
 “Thank God when I'm working with these patients I don't feel it's a hospital duty. I 
work with them because I like them, I like this area, and I am enjoying it.” Dietitian D, 537 
“Sometimes I go up to the clinic from 8am and don't go down till 6pm. The whole day is 
with them but still I'm happy because I see the results of what I am doing.” Dietitian D, 543 
“Definitely it would be satisfying!” General dietitian FD, 124 
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5.2 Knowledge 
5.2.1 Knowledge of condition 
The knowledge of the families about their children’s conditions appeared to be limited 
to knowing that it is genetic and it is related to protein intake. Only three families 
knew more detailed information about the conditions, and their knowledge was 
through their research and reading from the internet or available books. Most children 
knew the name of their conditions, but didn’t appear to understand a great deal 
beyond that, such as the reason for their blood testing or how would they be affected 
by high amino acid levels in the blood. 
“I don’t have a complete knowledge, but I do know it is genetic, because of the family 
relation between me and her mother.” PKU Parent F4, L16 
“I don’t know anything about his disorder!” MSUD Parent F14, L15 
“No, I don’t understand.” PKU Patient P4, L36. When asked: “Do you understand what the 
doctors or your parents tell you about your condition PKU?” 
“Protein” PKU Patient P16b, L27. When asked: “What do you know about your condition? 
Do you know what is it called?” 
Knowledge of metabolic conditions among general health professionals in the country 
is perceived to be limited but improving for paediatricians due to the fellowship 
programme that is now offered at the Medical Genetics Department at KFSH&RC 
and the out-reach clinics at different cities from this department as well. As for other 
health care providers working with children with inborn errors of metabolism, such as 
dietitians and nurses, they report that there are no training programmes about 
metabolic disorders or knowledge-improvement opportunities available other than 
occasional symposiums and lectures. 
“Oh, very limited…very limited! If you are talking about specialists in metabolic diseases, 
our services are probably the only one across the country that provides comprehensive 
care to those patients...” Doctor R1, 325 
“We have the fellowship programme here, at KFSH&RC at the medical genetics 
department...Only doctors who choose to come here are trained; this is the only facility 
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that trains in this field.” Doctor R2, 244 
“I think it is better than before, but still not the optimum you want to hear or see… We are 
getting more invitations for talks and symposiums.” Doctor R3, 216 
“No, if they want teaching at least they would send a dietitian to be trained… But there is 
no interested dietitian till now. I feel if you are interested in something you will really nag 
to go to learn it. The problem is everybody is feeling that the metabolic nutrition is ‘oh 
something nobody can do it’. It is just real calculations. You need to concentrate and to 
have the ability to listen, and the ability to be patient with these kinds of patients.” Dietitian 
D, 598 
5.2.2 Knowledge of treatment and diet importance 
Families seemed to have good knowledge about their children’s treatment and good 
comprehension of diet importance in managing the conditions (PKU, MSUD, and 
tyrosinaemia I). Most of the children interviewed showed fair knowledge of the 
treatments and formulas they were taking, but not all seemed to be fully aware of the 
diet importance. 
“Doctors told me if she didn’t follow the diet she will get convulsions, become lethargic, 
and her brain will be different.” MSUD Parent F11, 110 
“When I really comply with her diet I see that my daughter becomes proper, good in her 
head... Sometimes when I’m sick or something and they don’t give her the diet correctly 
you will see something wrong with her either her gait wobbly or her hand shaking or eyes 
rolling, I can feel she is not all right.” MSUD Parent F13, 175 
“If we don’t follow the diet the brain will be affected and acidity increases.” PKU Parent 
F2, 89 
“NTBC and the formula.” Tyrosinaemia I Patient P6, 24. In answer to, “Can you tell me 
something about your treatment?” 
Health care providers agree on the importance of the diet and the dietitian’s role in the 
management of these disorders. Non-metabolic dietitians admit that their knowledge 
of the metabolic diets is very limited. 
“Very important, especially the acidopathies, without a dietitian we cannot manage them!  
It is a very vital role for the management.” Doctor R2, 187. 
“Diet is a very big part of the care really; because if they don't stick to their diet they 
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might die. That's what I hear over and over from Doctor Ozand, he will be screaming to 
the mothers, ‘How come you didn't come back!’... Doctor Ozand stresses the importance of 
the dietary supplement or treatment.” Nurse N1, 63 
“If the patient was newly diagnosed it would be difficult for us to calculate the formula… 
We would need to consult the metabolic dietitian.” General dietitian FD, 79 
5.2.3 Knowledge source 
Knowledge sources regarding the aminoacidopathies for families were limited to 
health care providers at KFSH&RC; namely doctors and the metabolic dietitians. 
Only three of the interviewed families read books or searched the internet for 
additional information, while the majority (82% of interviewed families) believed that 
the hospital was the only source for information pertaining to their children’s 
conditions. 
“Only from the doctor. When I come here the doctor and the dietitian tell me.” PKU Parent 
F16, 103 
“There is no source except the dietitian. For this disease the only source is the hospital.” 
MSUD Parent F5, 120 
Health care providers believed they were the main source of information for families 
as well. The reason for that is thought to be the unavailability of information 
resources in the Arabic language and the low literacy levels in many families. 
“I think their knowledge depends on what we tell them; very few can go and research 
about their disorder. Till now there is no material in Arabic, all the resources are in 
English, and it is difficult for most of them to read English.” Dietitian D, 317 
“We have different kinds of patients. Most of the patients of these diseases in Saudi Arabia 
come from tribal areas. Most of them if you give something to read, I don’t think they read 
it. With the new generation they look in the internet and prepare questions for you, but 
most of our patients (90%) they get the knowledge from what you give them.” Doctor R3, 
127 
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Health professionals not specialized in metabolic disorders get their knowledge about 
specific conditions from the internet, literature review, the Ross Protocol manual for 
metabolic nutrition, lectures, and by asking the metabolic team. 
“We research on them when we encounter them.”General dietitian FD,59 
“Doctors [as source of information], if you ask them questions, they are really going to 
answer you.” Nurse N1, 139 
5.2.4 Perception of and satisfaction with knowledge 
Some families perceived themselves as having good knowledge of their children’s 
conditions and good understanding of their dietary requirements, and they were 
satisfied with their knowledge (n= 9). Other families were not as confident; they felt 
they did not have enough information or good understanding of the conditions or the 
dietary requirements (n= 8). 
“Yes, I’m not scared anymore; I have a grasp on it.” PKU Parent F7, L28 
“A little bit [understand disorder], I don’t understand it very well, I know the diet only.” 
MSUD Parent F9, L25 
“Not really [good understanding], but I think I understand what I need to know.” 
Tyrosinaemia I Parent F6, L45 
In agreement with this, health care providers see that some families have good 
comprehension of the conditions while others have only the minimum knowledge. 
This is thought to be due to different literacy levels and knowledge of the English 
language among families. 
“I think they grasp the minimum of that. Lots of them here have a level of education that 
does not allow them to go and seek the full knowledge and the information you would like 
them to have.  It is not accessible sometimes or not in the language they understand. I 
would say they understand the ‘yes’ and ‘no’ and to follow the example, if they want of 
course.  But in terms of prognosis, they are behind.” Doctor R2, 138 
“Clearly there is a big difference between those who can speak English and those who 
cannot. They can communicate with you very well. They will tell you for example: ‘Why did 
you do succinylacetone’, ‘What is the result’, they would contact me through the Internet 
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and email me. So there is a big difference in types of care between these two different kinds 
of populations, if you would say.” Doctor R1, 172 
“Most of them know their [dietary] restrictions.” General dietitian FD, 199 
“Some of them with low education we need to explain more.” Dietitian D2, 302  
5.2.5 Seeking knowledge or treatment in places other than KFSH&RC 
Many families had particular queries about their children’s conditions; they wanted to 
know more, but very few actually took action and tried to search for answers. This 
was also true in regard to seeking treatment in other places. Most families believed 
that KFSH&RC was the only place for treating their children, only two families 
travelled abroad to seek other opinions. 
“I would like to know how does acidity rise, soon after he eats one thing or after eating 
many things will it accumulate and rise?” MSUD Parent F9, 127 
“I want to learn more about the disease. I have heard once the patient makes it to 
adulthood it resolves, but people at the hospital say ‘no’; because these are enzymes in the 
blood and they don’t go, so I don’t know!” MSUD Parent F5, 40 
“Thanks to Allah, the doctors are sufficient for me.” MSUD Parent F11, 154 
Health care providers and observation confirm that there is low interest in researching 
and seeking information from families and general health care providers not 
specializing in metabolic disorders. 
“People have to be trained on how to get needed information. That is why ‘knowledge-
wise’ we are not mature here. They don’t have more information in the rest of the world, 
but when they need it they know how to find it and that is the difference!!” Doctor R2, 249 
5.2.6 Preferred form of information provision 
Families showed interest in the idea of receiving new and additional information and 
messages to take home. The preferred method of receiving information differed 
according to literacy levels. Many families requested video or audio tapes to have as 
information sources in addition to requests for more leaflets and printed material with 
pictures. Some parents asked for lectures to attend and have open discussions. 
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“Cassette tapes to hear are better; because I can’t write or read.” Parent F14, 120 
“By cassette, video tape and pictures.” Parent F1, 131 
“By video tape we can watch and listen, and face to face meetings, I mean someone 
explains and if I didn’t understand I can ask.” Parent F6, 234 
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5.3 Dietary practices and compliance 
5.3.1 Perspectives of the families 
Diet 
Dietary knowledge and practices of most of the families appeared to be derived from 
the recommendations that they receive from the dietitians. Food choices, likes, 
dislikes, knowledge of allowed and non-allowed foods and compliance were 
expressed. Many of the children knew what food should be avoided and the main 
permitted foods in their diets and said that their mothers prepared these foods for 
them. Two of the children were not sure about the food that they should avoid. 
“She is prohibited from all foods of animal origin, and allowed vegetarian food only.” 
PKU Parent F4, 40 
“When we visit others he eats salads or potatoes, he knows his food.” MSUD Parent F10, 48 
“Biscuit allowed, a little, not too much, because it would affect my brain. Cake has high 
protein, and I don’t eat tea biscuits. Cheese is forbidden and eggs are not good for me.” 
MSUD Patient P13, 43 
“I don’t eat meat or food containing proteins.” PKU Patient P6, 49 
Some mothers confessed that they try their best to follow the diet but did not always 
manage to comply. They understood the importance of following the diet, but the 
difficulty of following such a limited diet was overwhelming for some mothers. 
“Fruits and allowed food she doesn't eat, because she is fed up with them too.” PKU Parent 
F15, 72 
“I don’t really follow it, I won’t lie to you. Their instructions are very strict... I feel sorry 
for him; I feel that he needs to eat a bite of meat once in a while. I want to give him from 
the food his siblings eat; you know a mother’s heart.”  MSUD Parent F5, 127 
“She gets frustrated when she sees her sisters eat anything they like-cheese or meat- and 
she can’t.” PKU Parent F4, 30 
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Formula 
Another difficulty the families faced was with the formula; many of the children 
would not drink it easily, especially if they were diagnosed late. Nonetheless, the 
mothers tried hard because they saw the positive effect it has on their children. On 
observation, the mothers prepared the formula as directed by the dietitian. None of the 
interviewed children complained about the formula, they all said that they drink what 
is given to them. Only three said they helped their mothers to prepare their formula. 
“I give her Cornflakes for breakfast with a cup of tea. Her formula milk has a strong smell 
she can’t eat it with it.” MSUD Parent F13, 97 
“The formula she doesn’t accept it unless it’s mixed with juice or flavouring like Tang.” 
MSUD Parent F3, 75 
“We notice if they do not take their formula they become abnormal in their balance.” 
MSUD Parent F12, 113  
Barriers to compliance 
The families identified several barriers to complying with the diet and formula. 
Limited dietary choice was the major barrier; there were no low protein food products 
available for the children to offer them a variety of choices. The children become 
bored of the diet and start trying other foods that should be avoided. This was 
confirmed through the market survey. There were no low protein products available, 
only low protein flour was found in one specialty store and it was sold at 12 times the 
price of regular flour.  
Other barriers included children unsupervised around food at school or social 
occasions, time needed to prepare the patient’s meals in addition to the family’s 
meals, the need to travel from their towns to get to the hospital, and emotional barriers 
where the mothers feel sorry for their children and give them non-allowed food. The 
identified barriers are in Table 4 in the following section. 
“They got bored with the same breakfast, lunch, and diner, even though we are doing our 
best to give them food similar to ours.” MSUD Parent F12, 41 
“I need the special food from the U.S. so she can eat from it freely. They have special food 
that is low in amino acids.” MSUD Parent F3, 60 
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5.3.2 Perspectives of the health care providers 
Diet 
Diet is a major concern as it is crucial in the management of aminoacidopathies. The 
importance of prompt dietary intervention is stressed and explained to families as 
soon as they are diagnosed. Dietary counselling for the patients had to be adapted to 
the culture and customs of life in Saudi Arabia. The dietitian explained that the use of 
measuring scales was not common because the hospital does not provide them and 
they are costly for the families to get. Families were trained to use scoops for 
measuring the needed amount of formula. Breast feeding is common in Saudi Arabia, 
but the dietitian found expressing breast milk to give the baby a measured amount was 
not a welcomed practice by the mothers, so they were instructed not to breastfeed. 
“The measuring scales are too expensive for the hospital to give to families, and even if it 
was given to them there is no interest to use it…” Dietitian D, 196 
“Here if you tell them breast-feed measured amounts, they will just carry the baby on the 
breast and feed it, so we don’t allow it at all for any one.” Dietitian D, 185 
Formula  
Issues related to the special dietary formula were evident through the interviews and 
observations. The dietitians reiterated what some of the families have said regarding 
the difficulty of getting their children to drink the entire prescribed amount of 
formula. The provision of free formula by KFSH&RC is considered a blessing but 
also a potential problem should the hospital run out of stock. Although a rare event, 
this could put patients at risk because there is no other source for the formulas in the 
market.  
“There isn't any other way [to get formula]. It has to be through the hospital and they have 
to come to get it.” Doctor R2, 133 
Compliance 
Compliance with appointments, formula, and diet emerged as essential aspects 
concerning patient care. The dietitians perceived that most patients comply with 60-
70% of the diet. Some of the families failed to realize the importance of watching and 
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recording the dietary intake of their children and a few families would not travel to 
come to the nutrition appointment if it was scheduled on a different day than their 
appointment with the doctor. Some of the perceived factors affecting compliance were 
the type of disorder, early or late diagnosis, and frequency of follow-up.  
“Patients are different; some ignore the dietitian’s appointment, if they don’t have a 
doctor’s appointment they do not come at all, although the importance of the diet is 
explained to them by the doctors!!” Dietitian D, 121 
“Many will not bring it [food record]; they would say ‘Oh my God! Every time you want 
us to bring it!!?’ or ‘Every time you ask us these questions?’ They don’t understand that I 
need this information to calculate how much they are eating…” Dietitian D, 212 
“...for any patient if they are diagnosed early and take the formula early and get used to 
the formula, so there is no problems they will get used to it because they don’t know the 
taste of the other foods, but when they are diagnosed late already there is problem later to 
the restricted diet, it is more difficult.” Dietitian D2, 331 
“Tyrosinaemia & MSUD are more towards the compliance group. The reason is if they 
find that by restricting their food and following their diet they will prevent acute episodes... 
they will stick to it.” Doctor R2, 160 
 
Some of the barriers identified by health care providers were personal issues that 
needed to be dealt with by the families, but they recognize that unfortunately many 
barriers were beyond the family control. Such limitations in resources and 
unavailability of products become barriers for providing optimum services, which 
hinder compliance. The barriers to compliance identified by the health care providers 
and the families are listed in Table 4. The dietitian empathized with the families in 
regard to the difficulties they face in following a restricted diet. 
“Sometimes the families will come and say ‘We are fed up, what can we give them?’ I can 
understand their frustration because there is nothing in the market for them.” Dietitian D, 
258 
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Table 4: Compliance barriers identified by the health care providers and the families  
Compliance Barriers 
Limited product availability  
Limited educational materials 
Limited nutrition experts  
Limited counselling time 
Limited knowledge about the disorders and the diet 
Travel to Riyadh to get to KFSH&RC 
Language barriers 
Formula unavailable in local areas  
Financial and time burden of preparing a special diet  
Social barriers: unsupervised patients at schools and social occasions  
Emotional barriers: feeling sorry for the child, depression, anxiety, stress 
Cultural issues: over-protection of child, wanting the child to be equal to others 
Measures to facilitate compliance were implemented by the hospital, such as paying 
for travel expenses of the families when they attend appointments and providing 
housing when they cannot afford it. The health care providers recognized that 
continuous follow-up, reinforcement and having more than one child with the same 
disorder were factors that improved compliance. They acknowledged that more 
efforts were needed to tackle all the barriers to compliance. 
“The hospital pays travel expense for the mother, the father and the patient. Even if they 
need to come back just to take the formula we give them follow-up slip, so their travel will 
be paid for.” Dietitian D, 309 
“Education, establishing trust with the family, and reinforcement -positive reinforcement- 
over time, all would help.” Doctor R2, 181 
“I think the most important reason for compliance is if the family knows the nature of the 
disease... For some families, their first child with the disorder is mentally disabled, due to 
late diagnosis... So these families know the outcome so they are compliant with their other 
diagnosed children.” Doctor R3, 169 
“Reinforcement, continuous follow-up, like clinic visits are very important. 
Reinforcement!” General dietitian FG, 313 
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5.4 Social issues 
5.4.1 Social support 
Many parents seek social support from family members or even the metabolic 
dietitian. This is necessary due to the pressures they encounter when dealing with 
metabolic disorders on daily basis. 
“After Allah we have my sister, she does her best. She loves them and treats them well.” 
MSUD Parent F12, 46 
“The dietitian does her best. When I talk to her with a problem she advises and tries to 
help out, but I feel it is not in their hands. They say foods with minimal protein are all 
right, but you know they are kids and they need more. Food like cheese and eggs are 
totally forbidden, but I can see in their eyes that they want to eat these foods when they see 
someone or their brother [healthy brother] eating from it. This is my dilemma, it breaks my 
heart.” Tyrosinaemia I Parent F6, 76 
There are no support group services available for the families at KFSH&RC. Some of 
them ask the health care providers about other families with children with the same 
diagnosis in an effort to connect with others in the same situation. 
“Some of them ask for it, sometimes we have the numbers to give them to contact each 
other, if they agree, and if they see each other in the waiting area…” Dietitian D, 497 
5.4.2 Social coping 
Diet in social settings 
Social coping skills and adaptations were very important for the families and patients 
to help them cope with the dietary isolation that the children have to live with. Most 
families found some coping strategies for feeding their children in social settings, 
such as taking their food with them or selecting appropriate food from what is offered 
in a social occasion or a restaurant. Nonetheless, some families found it hard to go out 
or socialize with the affected child. 
“We take her food with us. Her condition didn’t prevent us from going out.” PKU Parent F4, 
43 
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“Nothing special [when going out], I leave them like other children, they know well not to 
eat meat, and they only eat rice and other things. Thanks to Allah I don’t worry about them 
regarding meat and such foods, even if they visit others. You know, some people offer 
children food, they say no thanks we can’t eat this, they know.” Tyrosinaemia I Parent F6, 93 
“We try not to go for social visits a lot, but if we did, we take their meal with us. We prefer 
our family to visit us.” MSUD Parent F12, 57 
“I don’t go out; I just stay at my family’s house.” MSUD Parent F8, 47 
Education and school enrolment  
Children with mild development disabilities were placed in mainstream schools. 
Families explain their children’s condition to schools, which in most instances are 
cooperative with the families. Few families complained that their schools were not as 
accommodating as desired. 
“Yes [teachers know about her condition], they call us when they have something to ask 
about.” PKU Parent F15, 84 
“To some extent [school cooperative], not that great!” Tyrosinaemia I Parent F6, 105 
The situation was not as easy for the families of children with moderate or severe 
developmental disabilities. It was hard for them to find special education schools in 
their areas and some schools would not accept them, either due to their dietary 
restrictions or due to the severity of their disability. 
“The eldest was not accepted in school [special education school].” PKU Parent F16, 128 
“No, we enrolled her in a private school but we saw she wasn’t benefiting; it wasn’t a 
special education school and the tuition was expensive so we took her out.” MSUD Parent 
F13, 112 
Children are coping differently at school and with friends. Some have no problems 
with telling friends about their conditions and diets, while others prefer not to mention 
it. 
“Yes, they know. [Friends know about patient’s condition]” PKU Patient P4, 96 
“No [friends at school don’t know about formula], at home they know.” PKU Patient P15, 
92 
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Family issues 
There were many stresses and fears facing the families. One recurrent fear was 
pregnancy and having other affected children, another was living far from where 
services are available. 
“She is the first one. We have a healthy boy and her, and that's it, we stopped.” PKU Parent 
F15, 20 
“No, it’s just pregnancy; I’m thinking about it but scared [of having another child with 
Tyrosinaemia].” Tyrosinaemia I Parent F17, 170 
“Originally we are from out of Riyadh, and we can go back, but because of the boys’ 
appointments we thought it would be better to stay here.” Tyrosinaemia I Parent F6, 149 
Health care providers were aware that families faced many stresses and frustrations at 
the hospital and at their homes. These included long waiting times at the hospital, 
social stresses, financial burdens, limited dietary choices for their children, 
unavailability of many local services, and the fear of having more affected children. 
Frustrations were mainly due to service barriers faced by families as well as health 
care providers. 
“The waiting time!” Dietitian D, 278 
“The nature of these diseases, the fear that it’s inherited diseases; genetics. They will 
panic when they know it might affect other members of their family in the future, even they 
worry about the previous kids! Even if they are healthy and normal. Situations of formula, 
diet in the families, the socio economic status, if the father works or mother works, all of 
these stress the family.” Doctor R3, 99 
“Every day they ask us if there is any new food that is allowed.” Dietitian D2, 254 
“It is too much for the family if they have four or five kids with the same problem.” Nurse 
N2, 162 
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5.5 Needs 
5.5.1 Knowledge needs 
The families and the health care providers called repeatedly for the need to understand 
more and to improve the knowledge of these metabolic conditions. This improvement 
was thought to be needed in many different aspects, for both the families and the 
health care providers. Table 5 lists the knowledge needs voiced by families and 
different health care providers. 
“I want to know about the adult cases of this condition, see how they lived, and learn from 
them. We are always worried about the future.” Parent F15, 193 
“I wish and it would be great if there was an Arabic website about MSUD available for 
us.” Parent F3, 222 
“I wish there could be workshops for the families.” Dietitian D, 442 
“Training, training is really important, even if I have the manual, it is very difficult for 
me.” General dietitian FD, 149 
Table 5: Knowledge needs as perceived by the families and the health care providers 
Knowledge needs perceived by the families 
More information to understand the conditions better 
More information about disease prognosis and the future 
Detailed nutrition information 
More information on dietary choices 
Contraception counselling 
More general information about care and education of patients 
Knowledge needs perceived by the health care providers 
Improve general public awareness of metabolic disorders 
Workshops for families to improve their knowledge of metabolic disorders 
Better patient education 
Better training for dietitians 
Continuous training for staff 
Better education for health professionals in general around the country 
165 
5.5.2 Support needs 
The families indicated that support was needed to assist them in dealing with the 
metabolic disorders. The families felt isolated, not knowing other families dealing 
with the same disorders, they asked about them and wished for support groups. They 
wanted to get to know others and learn about their experiences. Many of the families 
wished for financial support and support at home with their children, this was 
especially evident with the mothers of children with disabilities. Some of the families 
asked for more support for the dietitians so they would get more time during their 
appointments with them. 
“We can exchange different experiences, learn from each other and talk about our 
difficulties, it will be kind of a support for us, and that will bring us some comfort. People 
who have their hands in the fire are not like who don’t! Many think there is no patient 
except their child but when you see others with sick children you accept your situation. 
Thanks to Allah.” Parent F13, 224 
“I thought of bringing in a house helper, but how can I pay her wages?” Parent F16, 104 
“Financial stress as we have four children with the same disease.” Parent F1, 35 
“I think they need a lot more, and also dietitians, they need more, they are over worked 
and under staffed!” Parent F7, 130 
The health care providers echoed the families’ views in their need for family support 
groups and provision of more supportive services. At the same time they expressed 
that they themselves require support in many aspects to aid them in providing optimal 
services. They needed an increase in the number of dietitians and other staff 
specialised in working with patients with metabolic disorders. This would support 
them in increasing the number of clinics to see the patients, which would reduce the 
numbers of patients per clinic session and would give them more time for counselling 
and educating the families. They agreed that there is a great need for providing the 
special low protein food products for the families or providing financial support for 
the families to be able to afford such products. 
“I feel that the family support groups is one of the most important things that would help 
the patient to know more and have better communication with each other and not only with 
us as medical staff.” Dietitian D, 366 
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“These patients need social services, support groups which are not provided. They need 
psychological assessments, psychological input from different aspects... There is only one 
neuropsychologist in the whole hospital and the waiting list for him is up to nine months to 
one year!” Doctor R1, 282 
“We need more clinics, we need more metabolic dietitians...” Dietitian D2, 482 
“There are no special food products for the patients; they can only get it through the 
internet, which is very expensive!” Doctor R2, 221 
 
  
167 
5.6 Newborn screening  
5.6.1 Current situation 
The National Newborn Screening Programme in Saudi Arabia has started, and it is in 
its early phases. The health care providers agreed that the programme was long 
overdue and it still needs to grow and reach smaller towns to cover all newborns in 
the country. There are concerns among health care providers in regard to the 
insufficient planning for this programme 
“...unfortunately most of our patients are mentally disabled!! Because we don’t have the 
newborn screening programme across the country and the vast majority of our patients 
come from referral hospitals, local hospitals outside this hospital.” Doctor R1, 204 
“We should have started this programme a long time ago!” Doctor R1, 311 
“It's excellent if all the members are there; if one angle is not there it will collapse!” 
Dietitian D, 574 
5.6.2 Perceived implications of the newborn screening programme 
Health care providers all agreed that the impact of newborn screening is good because 
early diagnosis can prevent deterioration in many patients. At the same time they 
predicted that the programme will increase their work load at KFSH&RC. They had 
concerns regarding the readiness of health care providers around the country and the 
availability of services for new cases. It was strongly articulated that training of health 
care providers is fundamental for the success of this programme. 
“I think it would be more rewarding... And less stressful on our part, good we saved that 
beautiful baby.” Nurse N2, 388 
“I think the impact would be good. Diagnosis of some metabolic diseases early on can 
make a lot of difference, provided that these patients receive good care at the time of 
diagnosis!” Doctor R2, 235 
“Impact on our practice will be bigger load, unless they would think about education and 
training programmes!” Dietitian D, 609 
“We will be overloaded with cases! We are already overloaded... I think if the Ministry of 
Health and the health care in this country do not appreciate the importance of genetics and 
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the importance of this kind of diseases and the high frequency and incidence of these 
disorders in this country…we will have great difficulty!” Doctor R1, 346 
“Screening is not a test it is a programme; from getting the results to getting the patients 
and treating them. It is part of the programme to train people to deal with these cases. You 
can’t screen without the facility to treat!!” Doctor R3, 231 
Summary 
The thematic analysis of the interviews and the focus groups in this phase resulted in 
the emergence of six major themes. The observations supported these themes. The 
themes are mutually exclusive in their evidence, but they are all interrelated and have 
an impact on one another.  
The findings from this phase gave vital insights into the circumstances and struggles 
of the patients with aminoacidopathies, their families, and the health care team 
managing their treatment in Saudi Arabia. It provided valuable information to help 
understand the condition of current health care management at KFSH&RC. This was 
the first time that this form of enquiry has been carried out with a population of 
patients with metabolic disorders in Saudi Arabia. The next chapter discusses the 
implications of these findings and how it helped shape the creation of the 
questionnaire for Phase 2 of this study.
169 
  
170 
  
 
CHAPTER 6 
DISCUSSION (PHASE 1) 
 
6. Discussion (Phase 1)
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Introduction  
The qualitative study in Phase 1 provided a wealth of information about the situation 
of patients with aminoacidopathies at KFSH&RC from the perspectives of the 
families, the patients, and their health care providers. Their knowledge, attitudes, and 
practices were explored. The results informed the development of comprehensive 
questionnaires for the use with the patients with PKU and their families in Phase 2 of 
the research, as recommended in the literature (Creswell, 2009; Pope & Mays, 1995; 
Pope et al., 2000; and Thomas et al., 2004).  
6.1 Services 
Early diagnosis and referral to treatment were important issues that came up from the 
interviews with the families and the health care providers. Early diagnosis and 
treatment is essential to prevent illness and disabilities in patients with 
aminoacidopathies (Abadie et al., 2005; Burgard et al., 1999; Medical Research 
Council Working Party on Phenylketonuria, 1993; Schulze, Frommhold, Hoffmann, 
& Mayatepek, 2001; and Simon et al., 2006). Early diagnosis is improving in Saudi 
Arabia; currently the Saudi Newborn Screening Programme is in its formative years, 
and it is gradually expanding to increase the number of screened newborns (Afifi & 
Abdul-Jabbar, 2007; and Ministry of Health, 2012). 
Families mentioned that the health care providers were very busy and overworked 
which increased waiting time at the hospital, reduced quality time with the families 
during hospital visits, and reduced access to the staff when needed between scheduled 
appointments. From the patients’ point of view, these waiting times were boring. The 
waiting areas are bland with no play facilities or activity corners for the children. 
Providing a fun and relaxed environment for the patients when they visit the hospital, 
in addition to alleviating boredom, reduces the fear and anxiety that many children 
feel upon entering hospitals. This is an essential part of providing a positive 
experience for the patients and their families (Doverty, 1992; and Jun-Tai, 2008). This 
could improve their interest in attending appointments and following the 
recommendations that they hear from the health care providers (Sylva, 1993). 
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The busy schedules of the health care providers lead to scheduling follow-up 
appointments after longer than ideal intervals. This is in disagreement with the 
recommendations of increasing accessibility to health care providers and increasing 
patient monitoring to improve adherance to diet and metabolic control of 
phenylalanine blood levels (Feillet & Agostoni, 2010; Feillet et al., 2010; van 
Spronsen & Burgard, 2008; Wappner, Cho, Kronmal, Schuett, & Seashore, 1999; and 
Wendel & Langenbeck, 1996). 
Another side to this concern is the follow-up with the dietitian. The interviews 
showed that the importance of the role of the metabolic dietitian was emphasized by 
the health care providers. This was understood by the families but not put into 
practice by having regular appointments to see the dietitian and monitor the blood 
amino acid levels for their children. Regular and close nutrition monitoring is 
essential for optimum outcome (Feillet & Agostoni, 2010). The burden of travel for 
many of the families leads to combining all the appointments (i.e. doctor, dietitian, 
and blood test) on one visit to the hospital every 6 or 9 months.  
Another cause of infrequent follow-ups could be the limited number of metabolic 
dietitians. Two dietitians alternate to cover the clinics and inpatient care, therefore 
there are not enough clinic appointment slots to cover frequent follow-up 
appointments. In addition, when families are given appointments with the dietitian 
only, many do not show up because they do not find it easy or worth the trip to travel 
to Riyadh for one appointment. This wastes valuable time from the metabolic 
nutrition clinic. Therefore the dietitians schedule their appointments to coincide with 
the doctors’ appointments only. This reduces nutritional monitoring. 
This is both a service and a compliance issue that should be investigated further to 
understand from more of the families their perspectives regarding frequent follow-ups 
and nutritional monitoring. Improving the local health care services for metabolic 
disorders is key, so the families would not need to travel to Riyadh so often. Local 
family physicians and dietitians can provide regular health care, family support, 
monitoring, and coordination with specialists. Training them on the circumstances 
that need referral to specialised medical management will instil confidence in their 
care (Casey, 2013). This might be a solution for improving nutritional follow-up and 
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monitoring which, as mentioned earlier, is recognized to help improve metabolic 
control. 
6.2 Knowledge 
Knowledge of the conditions (MSUD, tyrosinaemia type 1, and PKU) by the families 
and the patients was not optimum. The families were well aware of the treatments, 
formulas and the importance of dietary restrictions for their children. Their knowledge 
fell short when it came to understanding details about the disorders that their children 
have: the long-term prognosis, the minor side effects, or future expectations in terms 
of education, employment, marriage and pregnancy. Their knowledge appeared 
centered on the present needs of care. This could be a consequence of the busy 
schedules of the metabolic doctors and dietitians. They appear to focus their time with 
the families on informing them of what they need to be doing at the present for the 
best health care for their children. Detailed information about the disorders or extra 
information regarding the future may be viewed as too technical for the families, or as 
unnecessary details that may confuse the families, or merely the time constraint of the 
busy clinic schedule does not allow for it. Similar experiences were reported in two 
other qualitative researches involving patients with PKU or their families (Awiszus & 
Unger, 1990; and Ievers-Landis et al., 2005).  
The families were keen to obtain more information and many felt a strong need to 
know about the future for their children. Providing adequate information and 
education for the families and the patients to fully comprehend their disorders may 
help in the acceptance process of having a lifelong disorder, as not accepting the 
disorder may lead to bad metabolic control (Crone et al., 2005). Knowing that they 
can learn to control many aspects of their disorders may empower them to improve 
their skills to deal with problems related to their diet and treatment, and therefore, 
through modifying behavior, they would improve their compliance (Ievers-Landis et 
al., 2005). The patients may also benefit a great deal if they were given the 
opportunity to learn more about their disorders and the importance of their dietary 
restrictions and formula intake (Bekhof et al., 2005; and Feillet et al., 2010). Good 
understanding of one’s illness has been shown to have a positive improvement in 
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adherence to treatment or at least reduce deviation from the required treatments 
(Landolt, Nuoffer, Steinmann, & Superti-Furga, 2002; van Spronsen & Burgard, 
2008; and Vegni, Fiori, Riva, Giovannini, & Moja, 2010).  
Antshel and colleagues (2004) found that families and patients with internal 
attribution styles, where they construe the cause of events as due to personal factors, 
have better compliance with treatment than families with external attribution styles. 
People with external attribution styles perceive their conditions as controlled by 
external factors, which may be explained by their limited knowledge of their 
disorders. Improving the families’ knowledge and understanding of the disorders 
could be helpful in arming them against attributing control of their disorders to 
external factors, and therefore may improve their adherence to the diet. 
Knowing more about the views of more of the families through the questionnaire in 
Phase 2 would verify if this was a true need for the families. The number of patients 
who were interviewed in Phase 1 was small (8 children), insufficient to judge the 
knowledge of the patients. Therefore learning further about the patients and their 
knowledge in regards to their conditions and dietary needs would be valuable in 
understanding their knowledge needs and to informing the recommendations.  
The knowledge source regarding the disorders, for nearly all of the families, was 
limited to what was provided by the staff at the hospital. Learning from the families 
what they need to know and what form of information provision appeals to them most 
would help in improving the information provision practices at KFSH&RC. This 
would hopefully have a positive impact on improving the knowledge and 
comprehension of the families regarding their children’s conditions and dietary needs. 
It is important to offer different tools and sources of information to the families and 
the patients, and to involve them, so they can find the most suitable ways for them to 
learn and to improve their confidence and satisfaction with their knowledge and 
comprehension (Bernstein et al., 2013; Durham-Shearer, Judd, Whelan, & Thomas, 
2008; and Vegni et al., 2010). 
The language barrier was another important issue to address. Nearly all the 
information available about aminoacidopathies is in English, and only a few families 
can fully comprehend it. This limits the information that can be accessed by the 
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families to the few leaflets that were written and offered by the dietitians at 
KFSH&RC in Arabic. Translating a whole variety of information including recipes or 
creating a website in Arabic to present information related to the disorders for the 
families was seen as an extra work load that the dietitians’ time and that their 
schedules do not permit.  
For comprehensive care and to help the patients and their families understand their 
conditions and adhere to the recommendations, the hospital would need to provide 
them with ample information in the Arabic language. In addition to the medical 
information this should include recipes and food serving ideas that are not just 
translated, but suited to the food culture in Saudi Arabia and uses the food products 
that are available in the country. Many western recipes call for ingredients that are not 
available in Saudi Arabia for the families. The need for this service was evident from 
the qualitative findings.  
The health care providers expressed the opinion that the knowledge of other health 
care providers, who are not specialized in metabolic disorders, such as family doctors 
or general pediatricians, was not sufficient to take care of the patients at their local 
clinics. They agreed on the need to improve the knowledge of other health care 
providers and to train more dietitians in the field of metabolic disorders. This could 
definitely have a positive impact on advancing the services provided for the families 
and it could improve the quality of the time spent with the families (Nasserullah et al., 
2003). 
6.3 Diet  
Dietary compliance appeared to be a central issue for the families. The difficulty and 
restrictions of the diet was a cause of anxiety and frustration for many of the mothers. 
Some did not comply due to incomplete understanding of the grave consequences of 
noncompliance, and some just felt sorry for their children and believed that this 
restricted diet is unjust. Jusienė and Kučinskas (2004) evaluated Lithuanian children 
with PKU and their parents in regard to their coping and psychological adjustment to 
the illness. They reported that the parents may pity their children and therefore 
indulge them with foods that are not allowed. Feeding and nourishing to them was 
176 
  
associated with love and care, so feeding the child with PKU differently could be 
interpreted as unfair (Jusienė & Kučinskas, 2004). This explanation was heard 
repeatedly from the families in Saudi Arabia. 
The formula, like the diet, was reported to be difficult to consume by many of the 
families. Though the interviewed patients did not complain about it or report hating it, 
this could be because they knew they should be drinking it, and chose not to report 
that they miss some doses. Formula intake is crucial for keeping good metabolic 
control and for providing essential amino acids. Not drinking it has detrimental effects 
for the patients (Acosta et al., 2004; Adamczyk et al., 2011; MacDonald et al., 2004; 
and Tavil et al., 2006). 
Ievers-Landis and colleagues (2005) investigated the challenges of the dietary 
treatment for PKU that are faced by the patients and their families. Nearly all of the 
interviewed children declared having problems and challenges with following the diet 
and drinking the formula. Most of their interviewed caregivers reported problems with 
the diet and half of them had problems with their children’s consumption of the 
formula. Di Ciommo and colleagues (2012) interviewed children, adolescents, and 
young adults with PKU about their experiences with adherence to diet. The main 
concerns were fear of social stigma and social limitations due to their restricted diet. 
The need to adhere to the PKU diet negatively affected their quality of life. These are 
a couple of the few qualitative studies that have been done for patients with PKU, and 
their findings are comparable to the findings from this qualitative study. 
The families have identified many barriers to their adherence to the diet and formula 
intake. The difficulties with the diet and formula intake are challenges that many of 
the families of patients with metabolic disorders have been documented to face 
(Bernstein et al., 2013; Bilginsoy, Waitzman, Leonard, & Ernst, 2005; Demirkol, 
Gizewska, Giovannini, & Walter, 2011; and MacDonald, 2000). 
The health care providers at KFSH&RC reported more noncompliance from patients 
with PKU, since they do not get acute symptoms due to high blood phenylalanine 
levels. Patients with MSUD had better compliance due to the immediate effects they 
experience after noncompliance. This is reported for MSUD due to the acute episodes 
or metabolic crises that the patients would get due to high blood levels of leucine that 
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result from noncompliance or acute illnesses (Morton et al., 2002; and Strauss et al., 
2010).  
The health care providers reiterated the compliance barriers that the families have 
mentioned and added a few more that prevented them from providing the best service 
for their patients. Some dietary related services are not available for the families, such 
as continuous nutritional management at their local towns, continuous education, and 
low protein products to offer the patients a wider variety of food choices. Under such 
circumstances the recommendations for the families must be adjusted according to 
their individual needs. The health care providers were already making some 
adjustments according to the culture of the area. Some researchers suggest instructing 
the families to follow the diet strictly, but to be slightly flexible when there is 
noncompliance with the formula, however, the continuation with the dietary 
restrictions without taking the formula could lead to nutrient deficiencies (Brenton, 
2000; and Crone et al., 2005). 
It was important to learn and find out more about the barriers of compliance that the 
families and the patients face. This information is essential to help find ways to 
overcome these barriers. This qualitative study revealed that more efforts are 
necessary to tackle the service barriers that the health care providers recognized as 
hindering the patients’ compliance with diet and formula intake.  
6.4 Social issues 
Having a life long illness to deal with requires a lot of adjustments by the families 
(Awiszus & Unger, 1990; Brenton, 2000; and Dellve, Samuelsson, Tallborn, Fasth, & 
Hallberg, 2006). Some of the families found coping mechanisms that worked for them 
in dealing with dietary restrictions, while some families struggled with these 
issues. Research found that when families internalize the problems they face and 
find coping strategies, their children tend to have better metabolic control (Antshel, 
Brewster, & Waisbren, 2004; and Awiszus & Unger, 1990). Learning through the 
questionnaire how many parents struggle with coping and managing their children’s 
conditions, then identifying the best practices to improve their situations may 
immensely help the metabolic control of the patients at KFSH&RC. 
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The lack of family support services for the parents and the patients, to share their 
difficulties and stresses with each other, increases the feelings of defeat and confusion 
that some of the families have. Many of the families seek social support from other 
close family members, but due to the limited knowledge about these disorders, many 
turn to the dietitians, even for issues not related to diet. Identifying vulnerable 
families who are in need for support is vital for a comprehensive care provision. It is 
important to empower the parents to maintain a social support system because it 
improves their coping skills and quality of life (Fidika, Salewski, & Goldbeck, 2013). 
Some of the prominent issues that bothered the mothers were the fear of having 
additional affected children and living far from KFSH&RC. Provision of genetic 
counselling services and focused education about family planning may help ease the 
stress regarding future pregnancies (Albar, 1999; Al-Gazali, 2005; and Meyer, 2005). 
Living far from the relevant health services was voiced as a barrier to compliance. 
The monitoring of blood levels tends to be less frequent, and in some instances if the 
formula runs out there are no other places but KFSH&RC to get it. If the families are 
not organized enough to arrange for someone to get more supply of the formula 
before they run out, their child could be without formula for a few days. Some 
families cannot arrange that and they end up waiting several days until their 
appointment at KFSH&RC, then they travel for the appointment and get their supply. 
Patients are usually given enough supply to last them until their following 
appointments, but delaying the appointment or extra intake of the formula may cause 
the need for additional supply before the follow-up appointment. This is another 
reason for providing more specialised care at other centres around the country. Then 
the families would have somewhere closer to home to go to for general follow-up, 
dietary counselling, blood level monitoring, and formula supply.  
Another important aspect of the social life for the families is the schooling system. 
The families struggle with finding appropriate schools for their children, whether they 
have learning disabilities or not. Mainstream schools that cater for children with mild 
learning disabilities are increasing, but they can still only be found in the main large 
cities in Saudi Arabia (e.g. Riyadh, Makkah, Jeddah, Medina and Dammam). Special 
education and rehabilitation schools for children with moderate to severe learning 
disabilities are available, but again limited to the main cities and have long waiting 
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lists to get into them. Due to this some of the families have to travel long distances to 
get their children to school and some of the families have moved to the larger cities 
for their children to be in school. This situation leaves the families with limited 
choices, either move to a major city or keep their child at home; neither is an easy 
choice. 
Even when the patients do not have learning disabilities, the families have some 
difficulties explaining their cases to the schools regarding the dietary restrictions for 
their children. Not all schools show cooperation in this regard, there is no 
governmental mandate of care between the health care system and the education 
system. The entire burden falls on the families to convince the schools that their 
children can fit in with other children with the help of some education to the teachers 
and the students about the disorders and the dietary restrictions. 
This is a daily battle that the families need not fight. Frustrations were mainly due to 
service barriers faced by the families as well as the health care providers. Knowing 
more about these barriers and finding the best ways to overcome them are 
fundamental to providing the best care for the patients.   
6.5 Needs  
Through the interviews and observations, many service, support, knowledge, and 
education needs were evident, as discussed earlier. These needs revealed how 
imperative it was to have a better and more detailed understanding of the situation of 
the patients of metabolic disorders and their families, to enable appropriate planning 
for improvements.  
Support was clearly needed by the families and the patients to assist them in dealing 
with their daily struggles in relation to their disorders. Services such as family support 
groups, home visits, and home support for the families with children with disabilities 
may give the families better motivation and continuous reminders to comply with the 
recommendations and metabolic control. Many studies have demonstrated the 
effectiveness of support groups for patients with metabolic disorders and their 
families. Meeting other patients has been shown to provide social, psychological, and 
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metabolic advantages and positive influences (Awiszus & Unger, 1990; Bernstein et 
al., 2013; Brenton, 2000; MacDonald et al., 2010; Vegni et al., 2010; and Wappner et 
al., 1999). 
Knowledge needs were equally pointed out by the families and the health care 
providers on many different aspects of the disorders. Therefore it was important to 
learn through the questionnaires if these knowledge needs were shared by many other 
mothers and to find out their preferred ways of meeting these needs.  
The health care providers highlighted the need for improving the awareness of other 
health care providers, and providing training for more dietitians. They acknowledged 
the need to support the metabolic clinic to improve its services by adding more staff 
to enable them to spend more time with each patient. In addition, the provision of low 
protein food products, in their opinion, would improve their level of service. These 
are in line with recent recommendations for improving compliance (MacDonald et al., 
2010). 
6.6 Newborn screening 
The newborn screening programme in Saudi Arabia started in 2005 as a pilot. It 
started in twenty four of the main hospitals in Saudi Arabia with the aim to screen up 
to 50,000 newborns per year. It has expanded gradually, screening 130,000 newborns 
in the year 2011 (S. Alabdulmunem, personal communication, May 16, 2012). The 
programme has become mandatory in 2012 (Ministry of Health, 2011), and it is 
predicted that all newborns will be screened by the end of 2014∗. 
The perceptions of the health care providers about this programme were that the 
readiness and training of the relevant health care providers around the country were 
not optimum. A review of the effectiveness and benefit of the Saudi newborn 
screening programme agrees with these perceptions and anticipates challenges for the 
public health system in Saudi Arabia. It primarily expresses concern that the 
interconnections between primary health care services and specialists are limited, 
∗ Detailed information about the newborn screening programme in Saudi Arabia can be found in 
Chapter 2 Literature Review, section 2.5.2. 
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especially for small villages and remote areas. It affirms the importance of training of 
staff and planning a thorough referral system to ensure proper follow-up of identified 
patients (Afifi & Abdul-Jabbar, 2007).  
Nasserullah and colleagues (2003) reported their experience with screening for sickle 
cell disease and other hemoglobinopathies in the Eastern area of Saudi Arabia. They 
asserted that shortage of staff and low levels of knowledge were the main barriers to 
successful newborn screening. In another report from the Eastern Province of Saudi 
Arabia, Moammar et al (2010) reviewed the prevalence of inborn errors of 
metabolism in that region. They stressed the importance of expanding the newborn 
screening programme and providing regional follow-up, treatment, and genetic 
counselling for the families to advance the quality of care. It is absolutely essential to 
have adequate services to meet the needs that arise from implementing a country wide 
screening programme (Berry et al., 2010; and Therrell, 2003).  
Summary  
A wealth of information was gained from this qualitative study. All of the above 
issues informed the development of the questionnaires for Phase 2. The questionnaires 
were to investigate and include the opinions of more patients with PKU and their 
families. The questionnaires were not divided into sections according to the findings 
from Phase 1, but were designed to be flowing in meaning and relevance to cover all 
the significant issues that came out in Phase 1. 
The health care providers directly involved with the care for patients with 
aminoacidopathies were all interviewed in Phase 1 of this study. Therefore, they were 
not interviewed further in Phase 2, which focused only on the patients and their 
families. The views and suggestions of the health care providers were incorporated 
into the final recommendations of this research. 
 
182 
  
 
CHAPTER 7 
RESULTS (PHASE 2) 
7. Results (Phase 2) 
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Introduction 
This chapter presents the results from Phase 2 of this research. Results are presented 
in four sections: the research group, data from the Family Questionnaire, data from 
the Child Questionnaire, and data from the different assessments and measures done 
with the patients. 
7.1 Research group 
The King Faisal Specialist Hospital and Research Centre had 67 patients with PKU on 
record. Four of these patients have emigrated; 18 have not visited the hospital for two 
years or more, and were unreachable. Five refused to participate: three were siblings 
in one family who did not want to participate. The fourth was a sibling of two patients 
who participated in the study; the mother did not want to include him because he was 
doing well. The last one was as well a sibling of two patients who participated, but 
she was a newborn and the mother didn’t want to include her.  
 
The remaining 40 patients all participated in the study. The patients’ ages ranged from 
1 month to 21 years. Their ages at diagnosis ranged between 2 days and 17.5 years. 
Twenty six patients are female and 14 are male. The questionnaire was answered by 
the mothers except for two families; the step mother answered one and the eldest 
sister answered the other. 
 
Two of the families had another child with PKU (in each case the first child with 
PKU) in addition to the participating child. Both were not patients at KFSH&RC, and 
therefore it was not possible to include them in the study. They were diagnosed late 
and were profoundly delayed, and they have been placed in assisted care facilities. 
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7.2 Family Questionnaire 
7.2.1 Socio-economic status 
The 40 patients are from 24 families∗.  Five families each have three children with 
PKU, ten have two children with PKU, and nine have one child with PKU♣. All the 
children live with both of their parents, except one child; she lives with her father and 
step mother. Five families live in extended households, the remainder nuclear. Eighty 
percent of the families live in urban areas, 15% in peri-urban areas, and 5% in rural 
areas. Fifteen families (37.5%) live in Riyadh, other families live in cities or towns 
that are a 3 to 14 hour drive to Riyadh (45 min – 2 hr flight). 
There is a wide range in parents’ education and occupations, although most mothers 
are homemakers. Table 6 shows parents’ ages, education level, and occupation. The 
monthly spending of the families varies, most families (66.7%) spend less than 5000 
Saudi Riyals per month (1 Pound Sterling = 6 Saudi Riyals SR). The average 
spending in Saudi Arabia is SR 4700 (Saudi Central Department of Statistics & 
Information, 2007). Table 7 and Table 8 give details of the number of children born to 
mothers, the number of children still alive, birth order of child with PKU, and 
statistics of household inhabitants.    
∗ When the information in the analysis is related to the parents it is shown in the tables as a total of 24, 
when the information is related to the patients, the total is 40. 
♣ Four children not included in the study: two declined, and two were not patients at KFSH&RC, as 
explained in the research group section. 
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Table 6: Age, education level, and occupation of the participating parents (N=24). 
  Frequency (%) 
Father Mother 
Age 26-30 0 (0%) 3 (12.5%) 
31-35 2 (8.3%) 7 (29.2%) 
36-40 7 (29.2%) 8 (33.3%) 
41-45 7 (29.2%) 4 (16.7%) 
46-50 3 (12.5%) 1 (4.2%) 
>50 5 (20.8%) 1 (4.2%) 
Total 24 (100%) 24 (100%) 
Education level Read & write 0 (0%) 1 (4.2%) 
Primary school 2 (8.3%) 4 (16.7%) 
Middle school 2 (8.3%) 5 (20.8%) 
High school 6 (25%) 7 (29.2%) 
Less than Univ. Dip 3 (12.5%) 3 (12.5%) 
University 10 (41.7%) 4 (16.7%) 
Higher graduate degree 1 (4.2%) 0 (0%) 
Total 24 (100%) 24 (100%) 
Occupation 
category 
Professional 13 (54.2%) 5 (20.8%) 
Technician 4 (16.7%) 1 (4.2%) 
Worker 2 (8.3%) 0 (0%) 
Military officer 2 (8.3%) 0 (0%) 
Unemployed 1 (4.2%) 0 (0%) 
Retired 2 (8.3%) 0 (0%) 
House-wife 0 (0%) 18 (75%) 
Total 24 (100%) 24 (100%) 
 
Table 7: Number of children born to mothers and birth order of child with PKU. 
 Frequency (%) 
Number of children 
born to mother 
2 1 (4.2%) 
3 6 (25%) 
5 3 (12.5%) 
6 6 (25%) 
7 4 (16.7%) 
8 2 (8.3%) 
9 1 (4.2%) 
10 1 (4.2%) 
Total 24 (100%) 
Birth order of child 
with PKU 
1 8 (20%) 
2 5 (12.5%) 
3 7 (17.5%) 
4 6 (15%) 
5 6 (15%) 
6 4 (10%) 
7 1 (2.5%) 
8 1 (2.5%) 
9 1 (2.5%) 
10 1 (2.5%) 
Total 40 (100%) 
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Table 8: Descriptive statistics for number of children born to the mothers, number of 
children with PKU in the families, and household inhabitants (N=24). 
Statistics 
Number of 
children born to 
mother 
Number of 
children with 
PKU 
Number of 
children in the 
household 
Number of 
adults in the 
household* 
Mean 5.58 1.83 3.96 4.88 
Mode 3 and 6 2 3 3 
Std. Deviation 2.145 .761 2.074 1.985 
Minimum 2 1 1 2 
Maximum 10 3 10 8 
*Includes adult siblings 
 
7.2.1.1 Food budget 
The fathers are the main food buyers (15/24). The food budget for half of the families 
(12/24) in this study is within the average food expenditure for all Saudi families, 
which is 447 Saudi Riyals (SR) per week (Saudi Central Department of Statistics & 
Information, 2007). Ten families spend much more on food than the national average. 
This high spending is due to ordering low protein products from abroad, as they are 
not available in the Saudi market.  
7.2.2 Diet and formula 
7.2.2.1 Food and formula preparation 
The primary carer for all patients is the mother, except for the one child whose parents 
are divorced; the domestic helper is the primary care giver. The secondary carer is 
mostly the sister when available, the father, or a domestic helper. 
 
The patient’s meals are prepared separately from the family meals in most families 
(21/24), only three families cook their own food to be suitable for their child with 
PKU. Meals are usually prepared by the mothers, except for three families where the 
domestic helper prepares the meals. Formula is mainly prepared by the mothers as 
well (31/40); only two children, who are siblings, are given a chance to make their 
formula with their mother. Most mothers prepare the formula just before the child 
needs to drink it (18/40), or prepare the prescribed amount for the whole day and 
leave it in the fridge for the child to drink from (17/40). Most of the mothers need less 
than 5 minutes to prepare the formula. Some of the flavours that the mothers add to 
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the formula to improve its taste are salt, instant coffee, orange juice, honey, and 
mostly sugar.  
7.2.2.2 Formula intake 
Most of the children drink their formula 2 to 3 times a day (19/40). Others drink their 
formula 4 to 5 times a day or whenever hungry (12/40). The remaining 9 only drink 
their formula occasionally or never (Table 9). Drinking the formula is not easy for all 
children, 16 children have difficulty drinking their formula. The mothers believe the 
smell and taste of the formula are the main reasons of this difficulty. All causes of 
difficulty and the frequency in which they are mentioned by the mothers are listed in 
Table 9. 
Table 9: Adherence to formula intake and the causes of difficulty in drinking the 
formula. 
 Frequency  
Drink formula Always 23 
Usually 8 
Occasionally 7 
Never 2 
Total 40 
Difficulty causes Smell of formula 9 
Taste of formula 8 
Fed up with the formula 3 
Consistency of formula 2 
Will not drink formula when sick 1 
 
 
7.2.2.3 Diet adherence 
Only three of the mothers felt that complying with the PKU diet is easy, others felt it 
was difficult or even very difficult (Table 10). The mothers face many barriers to 
adhering to the diet; children being unattended around food and children’s insistence 
on eating banned foods are the two main barriers. Table 10 lists all the barriers faced 
by the mothers. Only two mothers felt that they did not have any barriers to comply 
with the diet.  
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Table 10: Difficulty of adhering to the PKU diet; opinions of the mothers (N=24), and 
the barriers to adhering to the PKU diet as recognized by the mothers (N=24). 
Diet adhering Frequency 
Easy 3 
Difficult 11 
Very difficult 10 
Total 24 
Barriers Frequency (%) 
Child unattended around food 13 (54.2%) 
Child’s insistence on eating banned food 11 (45.8%) 
Social visits 9 (37.5%) 
School teachers or pupils 8 (33.3%) 
Other children or friends of child 8 (33.3%) 
Family members: siblings, grandparents, aunts, or uncles 7 (29.2%) 
Limited dietary choices 7 (29.2%) 
Refusal to eat what’s offered 1 (4.2%) 
Has a big appetite 1 (4.2%) 
Limited knowledge of diet 0 (0%) 
 
7.2.3 Education and social life  
7.2.3.1 School attendance 
Seven of the children (17.5%) are under school age, and 6 (15%) do not go to school - 
due to unavailability of specialist schools to cater for their learning disabilities in their 
areas. Twenty seven of the children (67.5%) go to school. More than half of the 
children who go to school (16/27) are thought to need special education by their 
mothers. Most of them get some type of special education or special classes, although 
not always as appropriate as the mothers wish (Table 11). The schools the children 
attend are regular schools, regular schools with special education classes, or special 
education schools. They are a mix of private and public schools (Table12). 
 
Table 11: School attendance, perceived need for special education, and provided special 
education. 
 
Frequency (%) 
Yes No Total 
Go to school 27 (67.5%) 13 (32.5%) 40  (100%) 
Need special education 16 (59.3%) 11 (40.7%) 27  (100%) 
Get special education 14 (51.9%) 13 (48.1%) 27  (100%) 
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Table12: Types of schools the patients attend. 
School Type Frequency (%) 
Public school (regular) 6 (22.2%) 
Public school (has special education classes) 5 (18.5%) 
Private school (regular) 7 (25.9%) 
Private school (has special education classes) 3 (11.1%) 
Special education school 6 (22.2%) 
Total 27 (100%) 
 
7.2.3.2 Social activities 
Most of the families go out at least once a week accompanied by their children with 
PKU (Table 13). Mainly they go out for family visits, but a large number take their 
children out for recreational outings and shopping as well (Table 13). One mother 
rarely goes out; she finds it very difficult to deal with her child when out, she stays 
home with him and they go out for their hospital appointments only. Nearly half of 
the families face difficulties or limitations when going out with their children. The 
main limitations they endure being the diet and difficulty in dealing with the child in 
public (Table 13). 
Table 13: Frequency of going out as a family (N=24) with the child/children with PKU, 
places that families go to, and the limitations or difficulties that they face when going out 
due to the child's condition. 
Go out with child Frequency 
Daily 1 
Weekly 18 
Monthly 4 
Rarely 1 
Total 24 
Places to go to accompanied by child  
Family visits 23 
Family recreation outings 21 
Shopping 15 
Other places 0 
Outing limitations  
Child’s diet 6 
Difficulty with child 5 
General anxiety (worried about child) 4 
Embarrassment 2 
Disability of child 2 
Formula 1 
Influence of others 1 
Child’s condition 0 
Other limit: child becomes ill after outing 1 
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7.2.4 Health care practices 
Most of the patients visit KFSH&RC twice a year, but the frequency of visits varies 
and ranges up to 12 visits a year (Table 14). This usually depends on the health status 
and age of the patient. Ninety percent of the patients visit other facilities for general 
health care, such as dental care and intercurrent illnesses. Table 14 lists the frequency 
of these visits. There is a difference in the frequency of testing phenylalanine blood 
level between patients, although many of them will have a blood test only when they 
visit KFSH&RC every six months (Table 14). Most of the mothers perceived that 
their child’s health is excellent or good in general, only 4 children are perceived to 
have fair health (Table 14). 
 
Five of the patients have other health problems in addition to PKU (two have glucose-
6-phosphate dehydrogenase deficiency, one has insulin dependent diabetes, one has 
myoclonic encephalopathy, and one has a ventricular septal defect). All of these 
conditions are managed with PKU and do not have an effect on child development 
except in the case of one patient who has myoclonic encephalopathy, which impairs 
development. Therefore he was excluded from the analyses involving development 
and assessments. Data from his mother’s questionnaire was kept in this analysis 
because it covered her knowledge, concerns, and care for her child in relation to PKU. 
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Table 14: Frequency of healthcare visits to KFSH&RC, visits to other facilities, and 
blood Phe testing, and mothers' perceptions of their children's health. 
  Frequency (%) 
Appointment frequency 
at KFSH per year 
1 2 (5.0%) 
2 16 (40.0%) 
3 9 (22.5%) 
4 7 (17.5%) 
6 2 (5.0%) 
12 4 (10.0%) 
Total 40 (100%) 
Frequency of visits to 
another healthcare 
facility 
Once a month 4 (10%) 
Every 3 months 8 (20%) 
Every 6 months 19 (47.5%) 
Never (only go to KFSH) 4 (10%) 
Other 5 (12.5%) 
Total 40 (100%) 
Frequency of sending 
blood to KFSH&RC for 
Phe level 
Once a month 2 (5%) 
Every 3 months 9 (22.5%) 
Every 6 months 19 (47.5%) 
Other 10 (25%) 
Total 40 (100%) 
Mother’s perception of 
child’s health 
Excellent 23 (57.5%) 
Good 13 (32.5%) 
Fair 4 (10%) 
Poor 0 (0%) 
Total 40 (100%) 
 
7.2.5 Knowledge 
7.2.5.1 Knowledge about PKU 
Many of the mothers perceived their knowledge of PKU to be good or excellent 
(17/24), but there were some who felt they do not understand the condition well 
enough (7/24). More mothers though (21/24) were confident in their knowledge of the 
dietary requirements of PKU. Nearly all the mothers understood the importance of 
their children’s compliance to the diet and formula intake; only one mother felt that 
following the diet is not important to her child’s health and another mother felt that 
both the formula and diet are somewhat important but not fundamental to her child’s 
health. All the mothers knew the basics of the dietary restrictions; that is fruits and 
vegetables are allowed, while meats and dairy products are not allowed. Two of the 
mothers thought that lentils are allowed in the diet when they are not, due to their high 
protein content, and one mother did not know if they were allowed or not. Similarly 
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two of the mothers thought that diet drinks were allowed and didn’t know that they 
had phenylalanine in them (in the sweetener, aspartame), and two of the mothers 
didn’t know if they are allowed or not (Table 15). When the mothers need information 
regarding the PKU diet many call the dietitian to ask (15/24), some of the mothers 
(8/24) would look for the information in the written material that they have and some 
(7/24) would wait till their next appointment to ask the dietitian. Only one mother said 
she would look for dietary information on the internet. 
Table 15: Mothers' knowledge about some food choices for their children. 
Is it all right for a child with PKU to eat 
or drink: 
Frequency (%) 
Yes No Do not know 
Dates (allowed) 24 (100%) 0 (0%) 0 (0%) 
Meat stew (not allowed) 0 (0%) 24 (100%) 0 (0%) 
Lentils (not allowed) 2 (8.3%) 21 (87.5%) 1 (4.2%) 
Diet cola (not allowed) 2 (8.3%) 20 (83.3%) 2 (8.3%) 
 
The mothers' perceptions of what the dietitian would recommend if their children had 
high blood Phe levels were mostly correct. They were aware that the child needs to 
drink all the prescribed formula, reduce dietary protein intake, and in some cases the 
dietitian might increase the formula intake to cover the child’s needs when some food 
choices are reduced (Table 16). Most of the mothers, but not all, knew that a 
prolonged elevated blood Phe level would cause permanent learning disability for 
their children. Some understood that elevated levels cause hyperactivity and only a 
few believed that high levels would cause irritability. Table 17 lists the risks of 
prolonged high blood Phe levels as perceived by the mothers. Most of the mothers 
believed that the PKU diet is to be followed for life, as recommended by the 
KFSH&RC specialists. Still, some believed that it is only needed until their children 
grow up or are cured from this disorder (Table 18).  
Table 16: Mothers' perceptions of what the dietitian may recommend if blood Phe level 
was high. 
If high Phe level 
(correct answer) Answered correctly (%) 
Reduce the formula (no) 24 (100%) 
Increase dietary protein intake (no) 24 (100%) 
Reduce dietary protein intake (yes) 22 (91.7%) 
May increase the formula (yes) 6 (25%) 
Ask if ill (yes) 1 (4.2%) 
Ask about the diet (yes) 1 (4.2%) 
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Table 17: Mothers' knowledge of the risks of prolonged high blood Phe level. 
Risk of prolonged high Phe level in blood 
(correct answer) Answered correctly (%) 
Permanent learning disability (yes) 19 (79.2%) 
Hyperactivity (yes) 7 (29.2%) 
Irritability (yes) 3 (12.5%) 
Illness (no) 21 (87.5%) 
Paralysis (no) 23 (95.8%) 
No effect (no) 24 (100%) 
Other risks perceived by the mothers Frequency 
- Low/decreased concentration 5 
- Aggressiveness/anger 4 
- Change in hair colour  2 
- Sleep problems 2 
- Seizures 1 
- Nausea 1 
- Coma 1 
- Death 1 
 
Table 18: Mothers' beliefs of the length of time needed to follow the PKU diet. 
Diet Period Frequency (%) 
All his/her life 17 (70.8%) 
Until he/she grows up 4 (16.7%) 
Until he/she is cured 2 (8.3%) 
Don’t know 1 (4.2%) 
Total 24 (100%) 
 
 
7.2.5.2 Seeking information 
The families wanted to learn more about many issues relating to PKU. Learning more 
about diet choices and what the future holds for their children were highest on their 
lists. They wanted to understand the effects of PKU on growth, puberty, marriage, and 
pregnancy. They wanted more information about food choices and recipes to improve 
their children’s limited diet. Some families just wanted to understand the condition 
and its effects on brain and development. They were interested to learn about other 
patients similar to their children; how they are doing, how their families are coping, 
and how they are at school. A few families also were interested in learning about new 
advances in research in terms of a cure or a medicine for PKU that would improve 
dietary choices or replace the formula.  
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Box 4 lists some of what the families are interested in learning about. When asked 
how they would like to have this information provided to them most preferred the 
material to be given to them on videos, pamphlets, or CDs to take home; to watch, 
read, or listen to in their own time and keep as a reference. Many families were also 
interested in having a designated time that they can easily reach their health care 
provider by phone to ask any question they might have. All the ways of information 
provision according to preference of mothers are listed in Table 19. The main sources 
of information for families currently are the doctors and the dietitians (Table 19). 
 
Box 4: Topics the families are interested to learn more about. 
Future 
• Do his food choices now affect him negatively in the future? 
• How can I prevent them from getting worse, in their brain functions? 
• How are other patients doing mentally, when they grow up? 
• How to deal with them at puberty? 
• Her future when she grows up. 
• Her growth and puberty. 
• What to do in the future. What is the future like for them? 
• Pregnancy issues. 
• Understand future of PKU. 
• When they grow up and get married how would PKU affect them in the future? 
• Would like to understand if there would be improvements in the future. 
• What will happen when she grows up? 
Diet 
• Diet. 
• Understand more about the formula and how it benefits my son. 
• How to improve the diet choices from the allowed food, to introduce new recipes. 
• More information about the diet in the future. 
• The diet is very limited, how to improve it? 
• Know about more options of food. 
• More information about allowed foods. 
• Something to help with the diet. 
• How to count protein grams in food items? 
• What kinds of food can we give them more of? 
Condition 
• How does it affect their brains? 
• How are other children here doing? 
• I need to understand her condition. 
• Know more about dealing with learning disability. 
• More information about this disorder. 
• Is the stress level of the child affected by their phenylalanine blood level? 
• I would like to meet and know about older children similar to my daughter, what happened to them, 
how are the families coping, how are the schools? 
New advances in PKU 
• Information about new improvements. 
• Would there be medications instead of the formula and diet? 
• I would like to know about any advances. 
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Table 19: Mothers' preferred ways of information provision and the information source 
for families regarding PKU. 
Form of information provision Frequency (%) 
Video tapes/ DVDs 24 (100%) 
Written material (e.g. pamphlets) 21 (87.5%) 
Designated time to call HCP to answer specific questions 21 (87.5%) 
Audio cassettes / CDs 18 (75%) 
Informal sessions with healthcare providers (HCP) during clinic visits 17 (70.8%) 
Group lectures 16 (66.7%) 
Email 2 (8.3%) 
Email with doctors & professionals out of Saudi Arabia 1 (4.2%) 
Website regarding PKU in Arabic 1 (4.2%) 
PKU information source  
Doctor 22 (91.7%) 
Dietitian 21 (87.5%) 
Internet 7 (29.2%) 
Another person with same diagnosis 5 (20.8%) 
Books 4 (16.7%) 
Nurse 2 (8.3%) 
 
7.2.6 Personal concerns 
The mothers had many concerns for their children regarding PKU (Box 5). Most of 
the mothers were concerned about the diet; its difficulty to comply with, limitations of 
choices, and the inability to control their children around food. The unknown future 
was a big concern for the mothers as well; they worry about their children’s 
development, ability to complete school and have proper education, puberty issues, 
and the ability to lead a normal adult life. Some mothers were concerned about the 
increased weight of their children due to the continued intake of Phenex-I after 2 
years of age.  Phenex-I is a Ross product formula that is designed for infants and 
toddlers with PKU. Until recently (2010) KFSH&RC had only Phenex-I available for 
all PKU patients, providing older children with higher energy content than their needs 
and causing an overweight problem for them. This issue was resolved when the 
administration at KFSH&RC finally listened to the pleas of the dietitians and the 
families and started importing Phenex-II. 
The mothers feel isolated and alone in dealing with PKU, not all have family support 
when needed. Nearly all felt that caring for a child with PKU makes them depressed 
or stressed. Many felt that it affects their own health (Table 20). Some mothers think 
that PKU is not understood clearly by their family and friends (Table 21), most of 
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them would like their families to know more about PKU. All the mothers except one 
welcomed the idea of having a family support group for PKU. 
Box 5: Concerns of the mothers for their children regarding PKU. 
• Difficulty with diet 
o Diet compliance  
o Control of Phe blood level 
o Want special schools that understand metabolic disorders to control the children’s eating and 
prevent eating food from friends 
o To protect her child the mother avoids social gatherings 
 
• The future  
o Brain function 
o Education 
o Puberty 
o Marriage and having children 
 
• Weight increase due to Phenex-1 use 
• General worry, worry about health and condition 
• Worry about child’s disability 
• Worry about taking care of child properly 
• Feel sad for child 
• Formula difficulties 
Table 20: Wellbeing and support for the mothers, their answers to some quality of life 
questions. 
 Wellbeing and support questions Yes Frequency (%) 
Do you think caring for a child with PKU affects your 
health? 10 (41.7%) 
Do you think caring for a child with PKU makes you sad, 
depressed or stressed?  21 (87.5%) 
Do you have a family member(s) available to help you 
when you need help?  17 (70.8%) 
Would you want a family member(s) to know more about 
your child’s illness? 19 (79.2%) 
Would you be interested in joining a family support group? 23 (95.8%) 
Table 21: Understanding of PKU by family and friends. 
Rate the degree to which 
your child’s condition is 
understood by 
Frequency (%) 
Does not apply 
to me Misunderstood Understood 
Completely 
understood 
Your spouse 0 (0%) 1 (4.2%) 6 (25.0%) 17 (70.8%) 
Other children 1 (4.2%) 0 (0%) 9 (37.5%) 14 (58.3%) 
Family members 0 (0%) 5 (20.8%) 15 (62.5%) 4 (16.7%) 
Friends 10 (41.7%) 2 (8.3%) 11 (45.8%) 1 (4.2%) 
 
 
197 
7.2.7 Suggestions and requests for service improvement 
All the mothers had some suggestions and requests on ways to improve health care 
and services for their children (Box 6). The two key requests that most mothers asked 
for were to reduce the waiting time at the clinic and to provide some low protein food 
products to improve diet choices. The families’ concerns, need for information, 
suggestions, and requests all echo the findings from Phase 1 of this study. 
Box 6: Suggestions of and requests by the mothers to improve the healthcare services at 
KFSH&RC. 
 
Hospital and care issues 
• Reduce the long waiting time at KFSH&RC. 
• Waiting time in the hospital is very long, there are many things to do on the same appointment day; lab 
work, paper work, see the doctor, then the dietitian. All is very tiring for me and the children especially 
that we come travelling on the same day.  
• We have difficulties in obtaining the formula because they do not send it by mail, so we have to send 
someone to Riyadh to get it, and that is not always easy, and it is not available where we live.  
• Blood level results not given to us easily, we have to call several times to be able get them. I hope this 
could improve. 
• Do the blood test at the clinic rather than the lab. They take blood from the arm at the lab and they hurt 
the children, they should only do a prick at clinic.  
• I do not benefit from visiting the doctor; they keep asking the same questions but do not give me new 
information or educational material.  
• I wish that reception and nursing staff become nicer, they are rude sometimes. 
• The non-Arabic speaking staff are rude sometimes. 
• A call from the dietitian periodically to check on the patients.  
• A call from the hospital to remind us with our appointments. 
• Provide health care in our area. 
 
Diet issues 
• Provide low protein food products to allow more food options. 
• Give more dietary guidelines and specific diets. 
• Try to find a solution for those children with high Phe blood levels. 
 
Social issues 
• The children need to meet each other and see other kids with the same disorder.  
• Provide schools that understand their conditions and diet. 
• If the hospital could help in providing an exercise area for the kids to help them to keep acceptable 
weights or even if they only provide swimming sessions for them. 
 
Information provision 
• More research about genetic disorders.  
• Provide the latest information available about PKU and any medication for it. 
• Educate young people about these disorders before marriage. 
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7.3 Child Questionnaire  
7.3.1 Participants 
Twelve children answered the questionnaire out of the 27 children who go to school. 
The main reason for not participating was time constraint. The families either had 
another appointment at the hospital to attend or needed to leave the hospital as soon as 
they were able to travel back to their homes. Their mothers barely had time to answer 
the main questionnaire and asked to forego the child’s questionnaire. 
 
The average age of the children who participated was 10.6 years (SD = 3.07). They all 
went to school and had good communication ability. Their Vineland-II ABC scores 
were a mix of adequate and low levels (mean = 76.82, SD = 13.77). 
 
Most of the children answered all the questions, but two of the children didn’t answer 
two questions each and one child didn’t answer three questions. Two of them were 
uncomfortable when asked about their feelings on their diet and formula and chose to 
skip to the following question. The third child didn’t understand a couple of 
questions; I repeated them in a different format, but she lost interest and wanted 
another question. 
 
All the children enjoyed the questionnaire chat and the attention it brought. Many 
continued on telling stories and recipes, or complaining about the diet restrictions and 
bargaining with me to ask the dietitian to allow some restricted foods to be added to 
their diets. 
7.3.2 Dietary practices and knowledge 
When asked about their food choices, all the children, except one, listed low protein 
foods (Table 22). One child listed chicken and beans among his food choices. Seven 
children listed French fries or chips as favourites; French fries are allowed in 
restricted amounts, but many children eat more than the amount prescribed by the 
dietitian. The mothers say that their children do not like vegetables. Potatoes are the 
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only thing they like to eat, although they are, like rice and bread, restricted to specific 
amounts per day. 
 
The children’s knowledge about their dietary restrictions and allowances was good. 
All of them knew that fruits and vegetables are freely allowed while dairy products 
and meats are not allowed. They knew that they should not eat milk chocolate or drink 
diet soda. The main foods they were confused about were chickpeas and French fries. 
Chickpeas are one of the highly consumed legumes in the Saudi diet; they are eaten as 
“hummus” (mashed chickpeas mixed with yogurt and sesame seed paste). It is high in 
protein and not allowed for PKU patients. Only five children knew it was not allowed 
while three thought it was a freely allowed food. French fries was thought to be a free 
food by half of the children, only four knew that it is a low protein food and restricted 
to a limited amount per day as prescribed by the dietitian. Most of the children seem 
to understand the importance of drinking the formula and complying with the diet 
(Table 23). 
Table 22: Food choices for some of the children with PKU (N=12). 
What do you like to eat? 
Apple, banana, grapes, and cucumber 
Salad, rice, pineapple, chips, and French fries 
Rice, formula, and grape leaves stuffed with rice 
French fries and ketchup, pizza, and lollypops 
French fries and rice 
Biscuits, formula, and chips 
Rice and bread 
Potatoes and salad 
French fries, chicken burger, cabbage and carrots salad, and beans salad 
Green beans, banana, pasta, and chips 
Apple, orange juice, and bread (made from rice) 
Salads, corn salad, French fries, cocktail juice, and mango with melon juice 
 
Table 23: The children’s understandings of the importance of adhering to PKU diet and 
formula intake. 
  
Frequency 
Very 
important 
Somewhat 
important 
Not 
important Total 
What do you think is the importance of 
drinking your formula? 10 0 1 11 
What do you think is the importance of 
eating your specific diet? 9 3 0 12 
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7.3.3 Social life 
Nearly all the children go out with their families to visit others or to go shopping. 
Only four of the children perceive themselves as different from other children because 
of PKU. Ten of the twelve children do not choose their daily food, and only two of 
the twelve feel that it is difficult to eat differently from others (Table 24).  
Table 24: The children’s answers to questions regarding going out and diet (N=12). 
  Yes 
Do you go out shopping with your family? 11 
Do you go out with your family to visit others? 12 
When you are playing with other children do you feel you are 
different from them? 4 
Do you choose your food? 2 
Is it difficult that you have to eat differently from others? 2 
It is okay to drink only some of your formula? 2 
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7.4 Assessments and measurements 
Several assessments and measurements were taken for the children: 24 hour food 
recall, mean blood phenylalanine level, the Vineland-II questionnaire, and 
anthropometric measurements. This section includes the results of these assessments 
and the results of analysing the relations between them, including the children’s 
phenylalanine levels at diagnosis, and ages at treatment initiation. The main 
descriptive statistics for these variables are listed in Table 25. One of the 40 children 
was excluded from these analyses because he has myoclonic encephalopathy, which 
impairs development confounding the results in relation to PKU. Data from 39 
patients is included in this section. 
Table 25: General descriptive statistics for the variables used in the analyses (N=39). 
 N Missing Minimum Maximum Mean SD 
ABC score 38 1 23 112 68.84 23.22 
Diagnosis Phe (μmol /l) 33 6 235* 2770 1487.88 736.25 
Age at start of treatment 
(Years) 39 0 0.005 17.6 2.45 3.41 
Mean blood Phe level 
(μmol /l) 39 0 245 1764 791.79 318.37 
Dietary Phe intake (mg/day) 39 0 88 1551.5 466.45 335.01 
*Taken early after birth due to sibling affected with PKU, subsequent blood Phe levels were in range of PKU. 
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7.4.1 Gender differences 
There was no significant difference between male and female patients in the main 
outcome measure, the Vineland-II Adaptive Behaviour Composite (ABC) scores 
(Table 26), or the other main variables in the analyses. Therefore they were analysed 
as one group. 
Table 26: Mean, standard deviation (SD), and confidence interval (CI) of ABC scores by 
gender. 
Gender ABC Score 
Mean SD 95% CI 
Male 65.69 26.411 (49.73 - 81.65) 
Female 70.48 21.774 (61.49 - 79.47) 
 
7.4.2 Anthropometry 
The study children had significantly higher Body Mass Index (BMI) z-scores than the 
Saudi reference population (p=0.001, t=3.73). The BMI z-scores varied from -1.76 to 
3.28 (Mean=0.72, SD=1.12). The height-for-age z-scores (Mean=-0.10, SD=1.23) and 
weight-for-age z-scores (Mean=0.52, SD=1.42) were not significantly different from 
the Saudi reference population (El-Mouzan et al., 2007). Three of the patients were 
over 19 years of age, which is over the reference data age group. The BMI was 
calculated for them. One female was underweight (BMI=16.98), one male was within 
normal weight (BMI=18.81), and one male was class 2 obese (BMI=39.95) (WHO, 
2000). 
 
The triceps skin-fold thickness (TST), available for 26 of the study patients, ranged 
from 4mm to 18mm (<5thpercentile to 90thpercentile). The upper arm fat area for them 
ranged from 0.75cm2 to 32.5 cm2 (<5thpercentile to 95thpercentile). The waist 
circumference (WC) measurements were available for 33 patients, but due to the age 
range of the UK reference data (5-17 years) only 25 patients were included in this 
analysis. The WC ranged from 451mm to 1230mm (5th percentile to >95th percentile). 
Twelve (48%) of the 25 patients had WC over the 90th percentile, indicating high 
number of patients with high level of abdominal fat tissue. The use of over the 90th 
percentile for WC as a cut-off for overweight was defined as a reliable marker in 
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several studies (Garnett, Baur, Srinivasan, Lee, & Cowell, 2007; McCarthy, Ellis, & 
Cole, 2003; and Ness-Abramof & Apovian, 2008). 
7.4.3 Diet and formula intake 
Dietary phenylalanine intake 
Twenty four hour food recall was taken twice for 35 patients. Four patients had one 
24 hour food recall; their mothers were unreachable for the second recall. Patients are 
allowed up to 400 mg of dietary phenylalanine per day if their blood Phe levels were 
within the acceptable limits (Table 27). Only 21of the 39 patients had a dietary Phe 
intake within the prescribed limit (less than 400 mg per day) (Table 28). 
Table 27: The acceptable blood Phe level at KFSH&RC by age group. 
Age Group Phe μmol /l 
<2 years 120 - 350 
2-6 years 120 - 450 
>6 years 120 - 600 
 
Table 28: Mean blood Phe level and dietary Phe intake of the patients (N=39). 
  
Frequency (%) 
Yes No 
Dietary Phe intake within daily limit 21 (53.8%) 18 (46.2%) 
Mean blood Phe within limit for age 10 (25.6%) 29 (74.4%) 
 
 
Formula intake 
Compliance with the formula intake was better than the dietary compliance; 30 (77%) 
of the patients had good formula intake. This means they always or usually drank 
their prescribed amount of formula. The remaining nine did not drink their formula or 
only drank some of it occasionally. Seven of the non-compliant patients were 
diagnosed late, after 2.5 years of age. The age at start of treatment was significantly 
different between the patients who were compliant with formula intake and the 
patients who were not compliant (p = 0.024, t = -2.36, df = 37) (Figure 6). 
 
The formula intake status of patients was highly correlated with the mean blood Phe 
level; the patients who were non-compliant with formula intake had higher mean 
blood Phe levels (r = -0.525, p = 0.001). The age of patients at the start of treatment 
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and their dietary Phe intake were significantly associated with formula intake as well 
(Table 29). 
Table 29: Pearson product-moment correlation coefficients (r) for formula intake with 
correlating variables. 
Formula intake correlation with: Correlation coefficient (r) 
P-value 
(2-tailed) 
Number of patients in 
each analysis 
Mean blood Phe level (μmol /l) -0.525 0.001 39 
Age at start of treatment (years) -0.361 0.024 39 
Dietary Phe intake (mg/day) -0.360 0.024 39 
 
7.4.4 Mean blood phenylalanine level 
A. Mean blood phenylalanine level and formula intake 
The mean blood Phe level was significantly lower (p = 0.001, t = -3.75, df = 37) for 
the patients who were compliant with their formula intake (Mean = 701, SD = 248.5) 
than the mean Phe level for the patients who were not compliant with their formula 
intake (Mean = 1093, SD = 353.4) (Figure 6).  
 
 
Figure 6: Mean blood Phe level and age of start of treatment of the patients according to 
their formula intake (N=39). 
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B. Mean blood phenylalanine level and dietary phenylalanine intake 
Only 10 of the patients (25.6%) had mean blood Phe level within the acceptable limits 
for age (Table 1 and Table 28). The remaining 29 patients had higher levels, nine of 
them their mean blood Phe level was over 1000μmol/l. The dietary Phe intake was 
significantly lower (p< 0.0001, t=3.88, df=37) in patients who had mean blood Phe 
level within the acceptable limits for age (Mean dietary Phe=250.1 mg/d, SD=114) 
than in patients who had levels above limits for age (Mean=541.1 mg/d, SD=354.5) 
(Figure 7). 
 
 
Figure 7: Mean blood Phe level, shown as within or above target range for age, and 
dietary Phe intake of the patients (N=39). 
 
 
C. Mean blood phenylalanine level correlation and regression (associations and 
relationships with other variables) 
Significant statistical associations were found between the mean phenylalanine blood 
level and two variables - the age of the patient at the start of treatment and the 
patient’s phenylalanine dietary intake. This was demonstrated by analysis of the 
Pearson product-moment correlation coefficients (r) for the mean phenylalanine blood 
level with different variables (Table 30, Figure 8). Nearly 20% of the variation in the 
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initiation and nearly 13% is explained by phenylalanine dietary intake. There was a 
weak non-significant correlation between the Phe blood level at diagnosis with the 
mean blood Phe level (Table 30, Figure 10); therefore it was not included in further 
analyses. 
Table 30: Pearson product-moment correlation coefficients (r) for mean phenylalanine 
blood level with different variables. 
Mean phenylalanine blood 
level correlation with: 
Correlation 
coefficient 
(r) 
P-value 
(2-tailed) 
Coefficient of 
determination 
(% of shared 
variance) 
Number of 
patients in 
each 
analysis 
Age at start of treatment (years) 0.446 0.004 19.9% 39 
Dietary Phe  intake  (mg/day) 0.358 0.025 12.8% 39 
Diagnosis Phe blood level (μmol/l) 0.288 0.104 8.3% 33 
 
 
 
 
 
Figure 8: Correlation between mean blood Phe level and age at start of treatment for the 
patients (N=39). 
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 Figure 9: Correlation between mean blood Phe level and dietary Phe intake for the 
patients (N=39). 
 
 
 
Figure 10: Correlation between mean blood Phe level and diagnosis Phe for the patients 
(N=33). 
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The two variables correlating with blood phenylalanine concentrations (age of 
patients at treatment initiation and dietary intake of phenylalanine) were further 
analyzed in a standard multiple regression model to describe the relationships. The 
statistical significance of the model was high (p=0.005). The co-linearity diagnostics 
showed that the model did not violate the non-multicolinearity assumption. The 
model’s R2 was 0.259, indicating that this model explained 25.9% of the variance in 
the mean phenylalanine blood level (Adjusted R2=0.218). 
 
Table 31 lists the results of each variable in this model. The standardized coefficients, 
Beta, compare the contribution of each variable to explaining the variation in mean 
Phe level. The strongest contribution was made by the variable, age at start of 
treatment (Beta=0.376, p=0.016). Dietary Phe intake, although correlating with mean 
Phe level, lost its significance in this multiple regression model when controlling for 
age at treatment initiation. The next paragraph looks at the early diagnosed patients 
separately.  
Table 31: Multiple regression of mean phenylalanine blood level with correlating 
variables. 
N=39 Coefficient B 
Standard 
Error for 
B 
Standardized 
coefficient 
Beta 
P-
value 95% CI for B 
R2/ 
Adjusted 
Age at start of 
treatment (years) 35.154 13.931 0.376 0.016 (6.902 - 63.406) 
0.259 
/0.218 
Dietary Phe  
intake (mg/day) 0.242 0.142 0.255 0.097 (-0.046 - 0.529)  
 
 
D. Mean blood phenylalanine level for early diagnosed patients 
Ten of the patients were diagnosed and treated early (≤ 1 month of age). For this 
group of patients the mean blood Phe level showed a significant positive correlation 
with dietary Phe intake (r = 0.719, p = 0.019, R2 = 0.516) (Figure 11). Due to the 
small number of patients further analysis was not possible.  
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 Figure 11: Mean blood Phe level and dietary Phe intake for early treated patients 
(N=10). 
 
7.4.5 The Vineland-II scores (the outcome measure) 
Thirty eight out of the 39 patients had a completed Vineland-II assessment interview 
done with their mothers. One patient’s mother was unreachable and the Vineland-II 
score was treated as missing in the analysis. Table 32 and Figure 12 show a summary 
of results from Vineland-II Adaptive Behaviour Composite (ABC) scores for patients. 
Table 32: Adaptive Behaviour Composite (ABC) scores for the patients. 
ABC score Number of patients (%) 
Low (20-70) 19  (48.7%) 
Moderately Low (71-85) 10  (25.6%) 
Adequate (86-114) 9  (23.1%) 
Missing 1  (2.6%) 
 Total 39  (100%) 
 
 
R² = 0.5169 
0
200
400
600
800
1000
1200
1400
0 100 200 300 400 500 600 700 800 900 1000 1100
M
ea
n 
bl
oo
d 
Ph
e 
le
ve
l (
μm
ol
/l
) 
Dietary Phe (mg/day) 
210 
  
 
Figure 12: The number of patients in each category of the Vineland-II. 
 
 
A. The Vineland-II scores associations and relationships with other variables  
The relationships of the Adaptive Behaviour Composite score (ABC) of the Vineland-
II (as the dependant variable) were examined with all the variable factors that were 
thought to have an influence on the ABC scores (as independent variables):  
1. Phenylalanine blood level at diagnosis  
2. Age of patients at treatment initiation  
3. Mean of blood phenylalanine level 
4. Dietary intake of phenylalanine 
 
There was a strong negative association (correlation) between Vineland-II scores and 
age of patients at the start of their treatment (r=-0.56, p< 0.0001) indicating lower 
scores are associated with older age at treatment initiation. Vineland-II scores also 
correlated with phenylalanine blood level at diagnosis and mean of blood 
phenylalanine levels as shown in Table 33. The coefficient of determination shows 
that 31% of variation in the Vineland-II ABC scores can be explained by the age of 
patients at the start of treatment. 
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Table 33: Pearson product-moment correlation coefficients (r) for ABC scores with 
different variables. 
ABC score correlation with: 
Correlation 
coefficient 
(r) 
P-value 
(2-tailed) 
Coefficient of 
determination 
(% of shared 
variance) 
Number of 
patients in 
each 
analysis 
Age at start of treatment(years) -0.560 <0.0001 31.4% 38 
Diagnosis Phe blood level(μmol/l) -0.451 0.010 20.3 % 32 
Mean blood Phe level(μmol/l) -0.330 0.043 10.9 % 38 
Dietary Phe intake(mg/day) -0.203 0.222 4.1 % 38 
 
 
These variables were further analyzed in a standard multiple regression model to 
describe the relationships with the Vineland-II scores more precisely. The statistical 
significance of the model was high (p = 0.002). The co-linearity diagnostics showed 
that the model did not violate the non-multicolinearity assumption. The model’s R2 
was 0.456, indicating that this model explained 45.6% of the variance in the ABC 
scores (Adjusted R2 = 0.376).  
 
Table 34 lists the results for each variable in this model. The standardized 
coefficients, Beta, compare the contribution of each variable to explaining the 
variation in ABC scores. The strongest contribution was made by the variable age at 
start of treatment (Beta = -0.505, p = 0.004), followed by the level of phenylalanine at 
diagnosis (Beta = -0.383, p = 0.016). When adjusting for all the variables in this 
multiple regression model the significant association between the mean blood Phe 
level and Vineland-II scores, seen in correlation, disappeared.  
Table 34: Multiple regression for the Vineland-II ABC scores with different variables 
for all the patients (N=38). 
ABC scores Coefficient B 
Standard 
error for 
B 
Standardized 
coefficient 
Beta 
P-
value 95% CI for B 
R2/ 
Adjusted 
Age at start of 
treatment (years) -3.439 1.090 -0.505 0.004 (-5.676- -1.201) 
0.456 
/0.376 
Diagnosis Phe 
(μmol/l) -0.012 0.005 -0.383 0.016 (-0.022- -0.002)  
Mean blood Phe 
level (μmol/l) 0.001 0.011 0.019 0.914 (-0.024-0.027)  
Dietary Phe  
intake (mg/day) -0.002 0.012 -0.036 0.819 (-0.024-0.019)  
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B. The Vineland-II scores and the age at start of treatment 
The age at start of treatment had the strongest effect on the Vineland-II scores. 
Further examination of the linear relationship showed that linearity was very strong 
between the age at start of treatment and Vineland-II for an age at start of treatment of 
up to 3.6 years (Table 35). After that age the relation becomes not as linear (lower 
value for R2), although still highly significant (p<0.001) (Figure 13, Figure 14, and 
Figure 15). Therefore the regression analysis was repeated to include patients who 
started treatment at the age of 3.6 years or below (Table 36). 
 
For this group of patients, treated at 3.6 years of age or less, the most significant 
variables shown by univariate regression analysis to have an effect on the ABC scores 
were age at the start of treatment (p < 0.0001) and phenylalanine blood level at 
diagnosis (p = 0.007) (Table 36). However, fitting the same variables into a multiple 
regression model (Table 36), to account for confounders, seems to remove the 
significant association of phenylalanine blood level at diagnosis and illustrates that 
the dietary intake of phenylalanine is a significant predictor of the outcome measure 
the Vineland-II scores (p = 0.033).  
 
The statistical significance of the model was high (p < 0.0001). The model’s R2 was 
0.80, indicating that this model explained 80% of the variance in the ABC scores for 
patients treated at 3.6 years of age or below (Adjusted R2 = 0.760). Age at the start of 
treatment made the strongest contribution to the dependent variable (ABC scores), as 
illustrated by the standardized coefficient (Beta) = -0.855. There was a loss of 19 
points on the Vineland-II ABC score with every year of delay in treatment 
(Coefficient B = -19.173) (Table 36).  
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 Figure 13: Vineland-II ABC scores for all the patients with their ages at start of 
treatment (N=38). 
 
 
 
Figure 14: Vineland-II ABC scores for the patients with age of start of treatment 
ranging from birth until 7 years (N=36) (≤ 7 years was chosen because it removed the 
two most extreme cases). 
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Figure 15: Vineland-II ABC scores for the patients with age at start of treatment 
ranging from birth until 3.6 years (N=28). 
 
 
 
Table 35: Linear regression of the Vineland-II ABC scores with age at start of treatment 
for the patients treated at different age cut-offs. 
* ≤ 7 years was chosen because it removed the two most extreme cases 
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ABC scores  Coefficient B 
Standardized 
coefficient 
Beta 
P-value 95% CI for B 
R2 / 
Adjusted 
All ages at start of 
treatment (years) 
N=38 
-3.811 -0.560 <0.0001 (-5.72- -1.90) 0.313/0.294 
Age at start of 
treatment ≤ 7 years* 
N=36 
-7.01 -0.575 <0.0001 (-10.48- -3.54) 0.331/0.311 
Age at start of 
treatment ≤ 3.6 years 
N=28 
-18.745 -0.836 <0.0001 (-23.71- -13.78) 0.698/0.687 
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Table 36: Univariable linear regression and multiple regression of the Vineland-II ABC 
scores for the patients treated at ≤ 3.6 years. 
ABC scores 
Patients 
diagnosed 
≤ 3.6 years 
Univariable Multivariable 
Coeff’t B P-value 
95% CI 
for B 
R2 / 
Adjusted Coeff’t B 
P-
value 
95% CI 
for B 
R2 / 
Adjusted 
Age at start of 
treatment (years) 
N=28 
-18.745 0.000 (-23.71- 
-13.78) 
0.698 / 
0.687 -19.173 0.000 
(-24.81 -  
-13.53) 
0.800 / 
0.760 
Diagnosis Phe 
(μmol/l) N=25 -0.015 
0.007 (-0.026- 
-0.005) 
0.276 / 
0.245 0.000 0.930 
(-0.008 - 
0.007) 
 
Mean blood Phe 
level (μmol/l) 
N=28 
-0.026 0.099 (-0.058-
0.005) 
0.101 / 
0.067 -0.007 0.446 
(-0.027 - 
0.013) 
 
Dietary Phe  
intake (mg/day) 
N=28 
-0.020 0.328 (-0.062- 
0.021) 
0.037 / 
0.000 -0.028 0.033 
(-0.053 -  
-0.003) 
 
 
 
C. Comparison of Vineland-II scores for early and late treated patients 
There was a significant difference (p <0.0001, t=6.07, df =30) in the Vineland-II ABC 
scores for early treated patients (≤ 1 month of age) and late treated patients (>1 month 
of age) (Table 37).The magnitude of the difference between these two groups is large, 
as indicated by the large effect size shown by eta squared = 0.506. This represents 
50.6% of the variance in the ABC scores is explained by age at treatment. Guidelines 
for interpreting eta squared values were taken from Pallant (2007). 
Table 37: The Vineland-II ABC scores (Mean and SD) according to the age at start of 
treatment. 
Age at treatment Number of patients (%) 
Mean ABC scores SD 
Started treatment ≤ 1 month of age 10 (25.6%) 92.2 11.01 
Started treatment > 1 month of age 29 (74.4%) 60.5 20.59 
Total 39 (100%) - - 
  
7.4.6 Classic and Mild PKU 
Twenty two patients had diagnosis phenylalanine blood levels of more than 
1200µmol/l, consistent with Classic PKU (Guldberg et al., 1998; and Smith & Lee, 
2000), 11 patients had levels ≤ 1200µmol/l, and 6 patients did not have a diagnosis 
level on their medical records. For this analysis patients with diagnosis levels of 
phenylalanine >1200µmol/l are classified as Classic PKU patients, and patients with 
diagnosis levels of phenylalanine ≤ 1200 µmol/l are classified as Mild PKU patients 
(Table 38). At the KFSH&RC the distinction between Classic and Mild PKU is not 
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made and the care protocol for all patients is the same. None of the patients in this 
study have hyperphenylalaninemia (Phe levels of 300-600 µmol/l), as they are not put 
on dietary restrictions or followed up by dietitians at KFSH&RC. Both groups were 
analysed separately in a standard linear regression then in a multiple regression 
model. The Vineland-II ABC score was the dependent variable with the same 
previous independent variables: 
(1. Age of patients at treatment initiation, 2. Mean of blood phenylalanine level,  
3. Phenylalanine blood level at diagnosis, 4. Dietary intake of phenylalanine). 
Table 38: PKU categories. 
Category Number of patients (%) 
Mild PKU 11 (28.2%) 
Classic PKU 22 (56.4%) 
Missing diagnosis Phe level 6 (15.4%) 
Total 39 (100%) 
 
 
A. Classic PKU 
The most significant factor having an influence on the Vineland-II ABC scores in this 
group is the age of patients at treatment initiation. In the univariate linear regression 
age at the start of treatment of the patients had a significant effect on the ABC scores 
(Coefficient B = -2.463, p = 0.034). Then when analysing the variables in a multiple 
regression model, which takes into account all the other related variables to test for 
confounders, its significance became stronger (Coefficient B = -3.887, p = 0.016). All 
values are summarised in Table 39.  
Table 39: Multiple regression of the Vineland-II ABC scores for the patients diagnosed 
with Phe blood level >1200µmol/l. 
ABC scores, 
patients with 
diagnosis Phe 
>1200 µmol/l 
Coefficient 
B 
Standard 
error for B 
Standardized 
coefficient 
Beta 
P-
value 95% CI for B 
R2/ 
Adjusted 
Age at start of 
treatment (years) -3.887 1.437 -0.732 0.016 (-6.93- -0.84) 
0.431/ 
0.289 
Mean blood Phe 
level (μmol/l) -0.015 0.015 -0.255 0.322 (-0.046-0.016)  
Diagnosis Phe 
(μmol/l) -0.015 0.010 -0.385 0.131 (-0.036-0.005)  
Dietary Phe  
intake (mg/day) 0.044 0.019 0.610 0.036 (0.003-0.085)  
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B. Mild PKU 
In this group of patients, two variables (the age of the patient at treatment initiation 
and the dietary intake of phenylalanine) had a significant effect on the Vineland-II 
ABC scores in a univariate linear regression analysis for each; both had a p-value of 
0.027. However, when analysed in a multiple regression model with the other 
correlating variables (mentioned above), to account for confounders, this significant 
effect was lost and none of the variables appear to be a significant predictor of the 
Vineland-II scores for patients with mild PKU. 
C. The Vineland-II scores comparison between Mild and Classic PKU patients 
There was a significant difference (p = 0.008, t = 2.84, df = 30) in the Vineland-II 
ABC scores for Mild PKU patients (Mean = 85.27, SD = 17.39) and Classic PKU 
patients (Mean = 65.38, SD = 19.51). The magnitude of the difference between the 
groups is large, as indicated by the effect size statistic (eta squared = 0.212) (Pallant, 
2007). This represents 21.2% of the variance in the ABC scores is explained by PKU 
severity. 
7.4.7 Socio-economic status effect on outcome 
The socio-economic status indicators had no significant effects on the Vineland-II 
ABC scores of the patients, their mean blood Phe levels, or their dietary Phe intake. 
The socio-economic status indicators that were investigated were: age, education 
level, and occupation of the fathers and the mothers, monthly spending, family size, 
the number of children with PKU in the family, and the number of unaffected children 
in the family. 
7.4.8 The effect of special education on the Vineland-II scores 
Fourteen out of the 27 patients who go to school receive some form of special 
education. Six of the children were in special education schools, they were all 
diagnosed late and have low Vineland-II scores. Eight children go to regular schools 
that have one or more special education sessions every day. The sessions are usually 
to improve skill or performance on specific subjects that the children find difficult, 
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usually maths. Six of those children have low scores on the Vineland-II and two have 
moderately low scores. The potential effect of special education on the Vineland-II 
scores was not clear or measurable from the available data. The patients didn’t have 
previous Vineland-II scores to compare with the current scores, and they are all within 
the low level of the Vineland-II scores, so even if special education had a positive 
effect it was not enough to move the children from the low level to the adequate level 
of the Vineland-II.   
7.4.9 Observations and comments during the Vinland-II interviews 
Many of the mothers of patients who attended school said their children had 
difficulties in mathematics and in memorizing (13/27). During the Vineland-II 
interview, when the questions were related to reading and writing, the mothers added 
that their children usually have problems in the maths class and needed extra help. 
Many also said memorizing poetry and verses from the Qur’an was very difficult for 
their children. The mothers were not asked about these issues specifically during the 
interview, but since it came up as a problem very often faced by the children, it should 
be acknowledged, and may be investigated further in future research.   
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CHAPTER 8 
DISCUSSION (PHASE 2) 
 
8. Discussion (Phase 2) 
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Introduction  
This study explored the management of PKU in Saudi Arabia in order to understand 
the situation of the patients and their families and to answer the study question: “What 
are the risk factors associated with unsatisfactory nutritional management of patients 
with aminoacidopathies among a group of patients in Saudi Arabia?” 
This chapter examines the results of Phase 2 to identify the answer to the study 
question. The results of the study are discussed in relation to the literature.  
8.1 Research group 
The group of PKU patients in this study is unique. They are a mixture of patients 
diagnosed at different ages, some diagnosed late, some diagnosed through familial 
selective screening and some diagnosed through the newly introduced new born 
screening programme. They are all treated by the same medical team, aiming for the 
same blood phenylalanine target levels. 
The age range of the group is large (21 years). This study wanted to explore and 
understand the situation in Saudi Arabia for PKU patients in particular and patients 
with metabolic disorders in general. No other study has attempted this in the country, 
therefore it was essential to include all available patients and not only focus the study 
on a specific age group. 
8.2 Family Questionnaire 
8.2.1 Family size 
The family size in Saudi Arabia is larger than the average family size in the UK and 
the west (Population Reference Bureau, 2012). In the UK the fertility rate is estimated 
at 1.97 children per women (Zumpe, Dormon, & Jefferies, 2012) while the current 
overall fertility rate for Saudi women is 3.3 children, and the average number of 
children for Saudi women aged 45-49 years is 5.6 children (Saudi Central Department 
of Statistics & Information, 2007). The culture still encourages large families; the fact 
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that overall fertility rate is not as high as the rate for the 45-49 age group probably 
reflects the fact that there are high numbers of young couples in Saudi Arabia who 
will continue to have additional children. 
The families in this study have a higher fertility rate than the Saudi average. They 
have a very similar fertility rate to the older Saudi women, although only one of the 
mothers is in that age range. The mean number of children born to mothers in this 
study is 5.58, and more than 60% of the families have 2 children or more diagnosed 
with PKU. Having a child with PKU does not seem to affect the choices of the 
families to have more children. 
It would be interesting to explore the reasons behind parents choosing to have large 
families. Is it just cultural or does a diagnosis of a metabolic disorder lead to an 
increase in family size? One reason could be that they are trying to have a son without 
the disorder.  Knowing the reasons would be important given that the more children a 
family decides to have, the greater chance there is that they will have more affected 
children. 
Burns et al (1984) explored the effects of PKU on families’ decisions on having more 
children or not in the US. Among the main influencing factors they found were the 
birth order of the child with PKU; if it was the first then the families were more 
inclined to have at least one more child. The age of the parents was another factor; 
younger parents often had additional children after the child with PKU. When the 
families were asked if PKU was a reason for not having more children, families with 
lower levels of knowledge about PKU and families with a male child affected with 
PKU were more inclined to give PKU as a reason for not having more children. That 
could be because more PKU-aware and knowledgeable families felt more confident in 
their ability to deal with PKU, and families with a female child may still desire to 
have a male child (Burns, Azen, Rouse, & Vespa, 1984). This was the only study in 
the literature that looked at this aspect. In the Saudi culture, having a male child to 
carry the family name is very important and an extremely compelling reason for them 
to have more children. 
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8.2.2 Food choices and food budget 
Within the Saudi culture the responsibility for buying food lies mainly on the men of 
the household. This was demonstrated by the families in this study where over 60% of 
the fathers bought the food. This may pose a problem regarding appropriate food 
choices if the communications between the mothers and the fathers are not very clear. 
This could then lead to unintentional high availability of foods that should be avoided 
and limited availability of free foods in the home, ultimately encouraging non-
compliance (Neumark-Sztainer, Story, Perry, & Casey, 1999; and Story, Neumark-
Sztainer, & French, 2002). The mothers are the ones going to clinic with their 
children, talking to the dietitian, being educated on what to feed their children and 
what to avoid. Often the fathers are at the hospital with the family, but they are 
usually busy dealing with necessary paper work and future appointments, therefore on 
most occasions they are not present during the dietitian’s appointments. 
Low protein food products (such as low protein pasta, biscuits, flour, rice, and bread) 
are not given to patients by KFSH&RC and are not available in the local markets. In 
the UK, most of these products are available on prescription from the National Health 
Service (Paediatric Formulary Committee, 2012). This takes away the burden of 
locating and buying these products from the families. These special low protein 
products are very costly. Depending on the product the price could be from 4 to 20 
times the price of a comparable regular product.  
 
Table 40 lists the prices of some low protein products compared to the average prices 
of similar regular products in the UK. 
 
Table 40: Price comparison between some low protein products and regular products. 
Product type Price of low protein products from different companies 
Price of comparable regular 
products 
Breakfast cereal flakes 375g £6.39 £1.80 
Chocolate chip cookies 100g £5.64 £0.66 
Cream-filled biscuits 125g  £2.13 £0.25 
Cake bars 6×40g  £5.10 £1.35 
Rice pudding 4×69g £5.60 £0.75 
Plain flour mix 1kg  £13.54 £0.70 
Pasta 500g £6.35 £0.55 
Rice 500g  £6.87 £0.80 
224 
  
All the families are very keen that their children benefit from these products, but not 
all know how to get them or can afford them. Some families, through individual 
internet search, found some American and European companies that will ship low 
protein products to Saudi Arabia. This comes at a huge financial burden for them, 
especially as these companies usually only agree to ship orders in bulk and not just for 
individual use. Therefore, several of these families have organized to order together 
and plan orders for special occasions and celebrations in Saudi Arabia, such as Eid 
and Ramadan. For the families that can afford these special low protein products, their 
average spending on food is way above the Saudi National average (Refer to Results, 
Chapter 7, section 7.2.1.1). 
These special low protein food products are essential for the wellbeing of patients 
with PKU, they are important in helping patients achieve satisfactory blood 
phenylalanine levels (Ahring et al., 2009). They should be treated as medical food and 
prescribed for children as part of their treatment (Millner, 1993). Availability of these 
products should lead to much better dietary compliance, especially as the mothers 
currently find it very difficult to follow the diet with its restrictions, and one of the 
main compliance barriers they face is their children’s insistence on eating foods they 
should avoid. When low protein products are available for these children this should 
definitely help in satisfying their needs and cravings by providing a diet with more 
variability and some similarity to that of unaffected family members and friends 
(Singh, Kable, Guerrero, Sullivan, & Elsas, 2000). 
8.2.3 Formula intake 
The formula is a fundamental part of the PKU diet and treatment (Medical Research 
Council Working Party on Phenylketonuria, 1993). It provides up to 85% of the 
patients’ protein needs and the essential vitamins and minerals which are lacking in 
the low phenylalanine diet (MacDonald et al., 2006). As detailed in the literature 
review, studies have shown that patients with PKU would be at high risk of 
developing essential amino acids or micronutrient deficiencies if they are not taking 
their formula regularly and at the same time avoiding animal protein because they are 
not used to such foods and find the taste unpleasant or because they recognize it is 
harmful for them and try to avoid it. 
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Deficiencies of vitamin B12, vitamin B6, iron, selenium, and zinc have been frequently 
reported for patients with PKU who are mostly non-compliant (Acosta et al., 2004; 
Arnold et al., 2001; Barretto et al., 2008; Hanley et al., 1996; Hvas et al., 2006; 
Jochum et al., 1997; MacDonald et al., 2004; Miranda da Cruz et al., 1993; Robinson 
et al., 2000; and Tavil et al., 2006). Low bone mineral density and reduced muscle 
mass has been reported for non-compliant patients with PKU as well (Adamczyk et 
al., 2011; Al-Qadreh et al., 1998; and McMurry, Chan, Leonard, & Ernst, 1992). The 
researchers recommended continued dietary management throughout adult life and 
regular monitoring to asses deficiencies early, and some authors recommended daily 
vitamin and mineral supplementation for PKU patients who are off diet. 
Untreated vitamin B12 deficiency may lead to a wide range of psychiatric and 
neurologic problems, some irreversible, in addition to the risk of macrocytic anaemia 
(Robinson et al., 2000; and Hvas et al., 2006). Iron deficiency could affect growth 
levels and cause cognitive, motor, and behavioural disturbances (Acosta et al., 2004; 
and Arnold et al., 2001). Low bone mineral density increase risk for fractures and 
adult osteoporosis (Adamczyk et al., 2011). Deficiencies of essential amino acids may 
have detrimental consequences and also contribute to high Phe levels, as results from 
this study have shown that low formula intake lead to increased blood Phe levels 
(section 8.4.2 below). 
Seventy seven percent of the patients reported good compliance with formula intake; 
57% of them reported always drinking all the prescribed amount of formula daily, and 
20% reported usually drinking it daily. Many of the patients (16) had difficulties in 
drinking their formula (Table 9 in Results, Chapter 7). This seems to be a common 
and recurring issue with PKU patients at different parts of the world, even when using 
different types and brands of formula or protein substitutes, as generally their smell 
and taste are not appetizing (Prince, McMurray, & Buist, 1997). In the UK, 
MacDonald et al (1997) found only 38% of patients consume their prescribed protein 
substitute daily. In Germany Schulz and Bremer (1995) found that 20% of the 
adolescents and young adults in their study had stopped taking the formula. 
Only two children in this study, who are siblings, were given the opportunity to mix 
their own formula. The other children were not trained to prepare the formula by their 
mothers or at the clinic, many of the mothers didn’t trust their children to make up the 
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formula properly and it didn’t occur to some that they could teach their children how 
to prepare the formula. Clinic time is very busy and there are no sessions available for 
training children and adolescents on diet and formula preparation. When children and 
adolescents are involved in choosing their meals and preparing them, they are more 
likely to consume what they have prepared and eat healthier options (Birch & Fisher, 
1998; Larson, Perry, Story, & Neumark-Sztainer, 2006; and Larson, Story, Eisenberg, 
& Neumark-Sztainer, 2006). This might be very helpful in compliance with 
consuming the formula as well. Many of the children had difficulties drinking their 
formula; having the responsibility of mixing it and choosing a flavour to add to it 
might be a good incentive for them to consume it all.  
Finding ways to involve the patients and empower them to improve compliance with 
formula intake is an important part in PKU management and treatment. As this is a 
universal problem, learning from the experiences of other successful centres may help 
find ways to work with patients at KFSH&RC to overcome their difficulties. Given 
that deficiencies contribute to poor outcome it is highly recommended to provide 
regular monitoring of trace minerals and vitamins in addition to blood Phe levels for 
patients with PKU at KFSH&RC. Regular monitoring of micronutrient levels for the 
patients and teaching the families about micronutrient deficiencies and their 
deleterious, and sometimes irreversible, effects may motivate them to be more 
compliant with formula intake.  
8.2.4 Diet adherence 
Only 21 (53.8 %) patients reported dietary intake of Phe within the allowed daily limit 
(<400mg/day). Adhering to the PKU diet was difficult for nearly all the families at 
KFSH&RC, 21 out of 24 families found it difficult to comply with the diet (Table 10 
in Chapter 7 described the difficulties). The PKU diet is highly restricted and 
difficulties with the diet are commonly reported in the literature (Crone et al., 2005; 
Feillet & Agostoni, 2010; Fisch, 2000; MacDonald, 2000; Medical Research Council 
Working Party on Phenylketonuria, 1993; van Spronsen & Enns, 2010; and Wappner 
et al., 1999).  
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To improve dietary adherence it is necessary to work with the families and the 
patients to overcome their barriers to adherence (Bernstein et al., 2013; MacDonald et 
al., 2010; and MacDonald et al., 2011). In this group the main reasons for 
noncompliance seem to all materialize when the children are not under the mother’s 
strict supervision. Targeting dietary education sessions and materials to the patients 
themselves would improve comprehension of the diet and its importance to their 
health and wellbeing, which could highly improve compliance (Feillet et al., 2010). 
Shifting the responsibility of dietary choices to the patients when they are at an 
appropriate age may also empower the patients and improve compliance, especially 
when combined with social support and behaviour modification strategies (Demirkol 
et al., 2011; Singh et al., 2000; and van Spronsen & Burgard, 2008). 
8.2.5 Blood phenylalanine level monitoring 
Blood Phe level monitoring at specific regular intervals is recommended and 
practiced in Europe and the USA. Table 41 lists the recommended frequency of Phe 
monitoring in different countries. 
Table 41: Frequency of blood Phe level monitoring in the west. 
Frequency of Monitoring 
Age (years) 
UK1 Germany2 USA3 
Weekly ≤4 ≤4 ≤1 
Fortnightly 4-10 4-12 1-12 
Monthly >10 12-17 >12 
Every 2-3 months - >17 - 
1Medical Research Council, 1993.2Burgard et al, 1999.3National Institutes of Health Consensus 
Development Panel, 2001. 
The doctors and the dietitians at KFSH&RC encourage the families to monitor their 
children’s blood Phe levels monthly, but this rarely happens. The blood tests are 
usually done just before or at the day of their appointments at KFSH&RC, which are 
usually every 6 months for most of the families. The blood Phe levels from such tests 
may not be representative of the actual Phe levels because the families probably 
improve the patient’s diet before the blood test. This is natural; the families do not 
want to be labelled as noncompliant, as described by Weglage et al (1992) and 
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Bilginsoy et al (2005). More frequent monitoring would provide a better picture of 
typical blood Phe levels (Demirkol et al., 2011).  
Many of the families do not live in Riyadh, where KFSH&RC is located. They are not 
trained to do the finger prick blood sampling at home to mail blood samples on the 
filter paper (Guthrie cards) to the KFSH&RC laboratory. Therefore they have to go to 
a hospital in their area to get a blood sample taken and sent to KFSH&RC. The 
burden of setting this up and explaining to hospitals the need for these samples falls 
on the families. Therefore many are deterred from this procedure and just wait for 
their follow-up appointments every 6 months at KFSH&RC.  
Regular monitoring of the blood Phe level helps the families and the patients to 
understand the effects of diet and formula intake and helps them gain better control of 
their Phe levels (Bilginsoy et al., 2005; Feillet et al., 2010; Wappner et al., 1999; and 
Wendel & Langenbeck, 1996). It is important to have a specific protocol for regular 
blood Phe level testing at KFSH&RC, and set in place measures to help implement it. 
These might include educating the families about the importance and benefit of 
regular monitoring, and training them to do a finger prick at home to mail the blood 
samples, or liaising with regional hospitals to facilitate the process of sending the 
blood samples from the families’ towns to KFSH&RC. 
Many researchers recommend the introduction of self-monitoring of Phe levels by the 
patients (Bekhof et al., 2005; van Spronsen & Enns, 2010; and Wendel & 
Langenbeck, 1996), as this gives the patients more realization of their ability to 
control and influence their Phe levels, essentially educating them on how to improve 
their compliance. 
8.2.6 Knowledge about PKU 
The knowledge of the mothers about PKU and its diet could be described as good 
with some need for improvement. The families are given the basic information about 
PKU but it seems to concentrate only on the day-to-day management. This is evident 
by the families’ high level of interest in learning more about the disorder; how it 
could affect their children’s brains, what the future holds for their children, how they 
can improve those prospects, and how to improve their diet. 
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More detailed education sessions, support groups, cooking demonstrations of special 
PKU recipes, improved educational materials, and easier access to health care 
providers all may help the families to keep on track and to improve their adherence to 
diet (Bernstein et al., 2013; MacDonald et al., 2010; and Waisbren et al., 1997). These 
provisions would help support all patients with aminoacidopathies and not just PKU 
patients.  
The provision of regular family support groups for PKU and other metabolic disorders 
is much needed at KFSH&RC. The families are interested in joining support groups 
and the health care providers at KFSH&RC view them as a positive additional 
service. Support groups would provide a safe and relaxed environment for the 
families to improve their knowledge about their children’s disorder, share their 
experiences, discuss their concerns, bring family members or friends to learn more 
about PKU, and provide an opportunity for the families to meet one another (Awiszus 
& Unger, 1990; and Brenton, 2000). They also provide a great opportunity for the 
children to meet other children with their same diagnosis, and learn that they are not 
alone in their struggles with PKU. 
8.2.7 Concerns and suggestions of the mothers 
The mothers had many concerns regarding their children’s care and wellbeing. They 
also had many suggestions that they thought would improve the service provided to 
them at KFSH&RC and give their children a more positive experience. All these 
concerns, suggestions, and requests for information by the families echo the findings 
of Phase 1 of this study, presented in Chapters 5 and 6. Those findings were from 
families of children with PKU as well as families of children with other 
aminoacidopathies, who share the services and similar dietary restrictions. 
Listening to the families and addressing their needs is a significant part of the 
management and treatment of chronic conditions. This improves the relationship 
between the families and the health care providers; in turn this leads to positive 
attitudes towards the recommendations of health care providers and better compliance 
with these recommendations by the families (Bekhof et al., 2003; Bilginsoy et al., 
2005; Crone et al., 2005; Taanila, Jarvelin, & Kokkonen, 1998; and Vegni et al., 
2010). 
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8.3 Child Questionnaire 
It was a great pleasure having the opportunity to interview some of the children. They 
showed good comprehension and communication skills with great enthusiasm to be 
heard, qualities that would enable them to be more involved in the management of 
their disorder. 
8.3.1  Knowledge and diet adherence 
Most of the education and instruction during the clinic is directed to the mothers with 
occasional involvement of the children when they are available. Nearly all the 
children in this study did not mix their own formula and were not trusted to choose 
their own food, although they showed good basic knowledge of the PKU diet. The 
main confusion seemed to be around chickpeas, eaten as hummus. Many of the 
children thought they were allowed to eat hummus and did not know it was part of the 
“beans” group. This could be attributed to the translated educational material given to 
the families. These do not include a specific mention of “hummus” as a high protein 
food to avoid. Translated materials can frequently miss country-specific dietary habits 
and preferences. Having educational materials developed locally to include common 
food choices and habits is essential. 
Involving and engaging the children in the care process during their hospital visits 
will improve their knowledge and understanding of their condition and dietary 
requirements. As discussed earlier, giving the children some autonomy in their own 
health management, at an appropriate age, can have a positive effect and improve 
their dietary compliance (Bilginsoy et al., 2005; Medical Research Council Working 
Party on Phenylketonuria, 1993; van Spronsen & Burgard, 2008; and Waisbren et al., 
1997). 
8.3.2  Diet adherence and adolescence  
It is especially important to empower the adolescents and give them a sense of their 
ability to achieve good control because compliance is known to decline in 
adolescence (Antshel et al., 2004; Freehauf et al., 2013; MacDonald et al., 2011; 
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Medical Research Council Working Party on Phenylketonuria, 1993; and Walter & 
White, 2004). Patients during adolescence may refuse to follow their restricted PKU 
diets, as it is normal to act against limits and rules in this age group, but Crone and 
colleagues (2005) explain that the increase in blood Phe levels during adolescence 
could be due other factors in addition to decreased compliance. Decreased protein 
needs after a period of increased growth and hormonal changes may play a part in 
their increased blood Phe levels (Crone et al., 2005). Levy and Waisbren (1994) 
recommend developing support programmes targeting PKU patients during 
adolescence. Their research showed that positive perceptions towards treatment and 
social support with the PKU diet during adolescence are closely related to good 
dietary adherence, and support programmes helped achieve that. 
8.4 Assessments and measurements 
8.4.1 Anthropometry 
There was a trend in this group of PKU patients towards overweight and obesity as 
evident from the BMI and waist circumference (WC) levels. This is in concurrence 
with recent findings showing increased body fat, overweight, and obesity in children 
with PKU (Albersen et al., 2010; and Burrage et al., 2012). 
There is consistent evidence that waist circumference, as indicative of central 
adiposity, is related to cardiovascular disease risk factors in children (Katzmarzyk et 
al., 2004; Maffeis, Pietrobelli, Grezzani, Provera, & Tato, 2001; and Savva et al., 
2000) and diabetes mellitus and mortality in adults (Ness-Abramof & Apovian, 2008). 
Katzmarzyk et al (2004) have hypothesized that waist circumference in childhood 
could be used to predict adulthood disease outcomes, after more research, as has been 
demonstrated for BMI, while McCarthy (2006) recommends that WC should be 
measured routinely in clinical and epidemiological settings. However some studies 
still do not support the need to measure waist circumference in children, in addition to 
BMI, especially before puberty (Cameron, Jones, Griffiths, Norris, & Pettifor, 2009; 
Garnett et al., 2007; and Reilly et al., 2010). The National Institute for Health and 
Care Excellence in the UK does not recommend the use of waist circumference as a 
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routine measurement in children and young people, but suggests it could be used in 
some situations to give additional information on the risk of developing long-term 
health problems (National Institute for Health and Care Excellence, 2006). Due to the 
increased trend towards obesity in PKU patients it might be beneficial to have WC 
measurements as routine practice to identify at risk patients and prevent further health 
complications in this population, especially as it is an easy measurement to take and 
does not need equipment other than a measuring tape. 
8.4.2 Factors affecting mean blood phenylalanine level (determinants of blood 
Phe level) 
• Age of patient at start of treatment 
• Dietary intake of phenylalanine 
• Formula intake 
The strongest factor affecting the blood Phe level of the patients was their age at the 
start of treatment; the highest Phe levels were reported for the late treated patients. 
These patients had moderate to severe developmental delay due to late treatment; 
therefore their families may not have been strict in adhering to the diet or formula 
intake, which could explain the higher blood Phe levels. Another reason could be that 
they have not been treated by the health care providers as aggressively as the other 
patients with less or no developmental delay. Treatment of late diagnosed patients can 
be beneficial. Lee et al (2009) and Gassió et al (2003) studied the effects of following 
a phenylalanine restricted diet on late diagnosed adults; they showed that it had 
positive effects on the quality of life for the patients and their families. Trefz et al 
(2000) showed that late treated patients with PKU had improved intelligence level 
after treatment with a phenylalanine restricted diet. However these effects are much 
less obvious than the effects of treatment on an infant diagnosed and treated 
continuously from the first month of life, and this probably has an impact on the 
enthusiasm of parents and carers for pursuing a difficult form of treatment.  
The dietary Phe intake was significantly different between patients with acceptable 
blood Phe levels and patients with high blood Phe levels, illustrating the documented 
relation between dietary Phe intake and blood Phe levels (Blau et al., 2010; and 
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Burgard et al., 1999). This relation for the whole group of patients lost some strength 
when adjusting for age at the start of treatment in the multiple regression model; this 
could be attributed to the group not being homogenous in regard of age at diagnosis 
and treatment. When looking at the early diagnosed and treated patients the 
association between mean Phe blood level and dietary Phe intake is significant, 
corroborating what is reported in the literature. 
Compliance with formula intake, as discussed earlier, is essential for good blood Phe 
level (Medical Research Council Working Party on Phenylketonuria, 1993). In this 
study the patients with good formula intake had better mean blood Phe level than the 
patients who did not comply with formula intake. The patients who were diagnosed 
late were more likely not to comply with formula intake. This could be due to two 
issues; firstly the patients not being able to acquire a taste for the formula as it was 
introduced to them late, so they struggle to accept it or refuse to drink it (Donlon et 
al., 2006; and Owada, Aoki, & Kitagawa, 2000). Secondly this could be due to the 
fact that late diagnosed patients are delayed and their families do not see an 
immediate and clear benefit of treatment with the formula, as a result they may have 
low motivation and consequently are not very strict in having their children drink the 
formula when they refuse it or struggle to drink it. 
8.4.3 The outcome measure: what determines the Vineland-II ABC scores? 
• Age at diagnosis and treatment 
• Phenylalanine level at diagnosis (disease severity) 
• Dietary phenylalanine intake 
The main goal of examining all the aspects of PKU management at KFSH&RC in this 
study was to find out what gives the patients there the best outcome. The ultimate goal 
of treatment and management of patients with PKU is to get the best developmental 
outcome and prevent intellectual impairment (Brumm & Grant, 2010). 
The major determinant of outcome, measured by the Vineland-II ABC score, was age 
at diagnosis - the younger the patient at the time of diagnosis and treatment, the better 
the score. As reviewed earlier, this has been recognized by many researchers leading 
to emphasis on the huge importance of early diagnosis through newborn screening, 
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and early treatment, to prevent permanent learning disabilities. This has been central 
to the construction of guidelines for PKU management in the UK, the US, Germany 
and France (Abadie et al., 2005; Burgard et al., 1999; Medical Research Council 
Working Party on Phenylketonuria, 1993; and National Institutes of Health Consensus 
Development Panel, 2001).  
Patients treated within the first month of life scored in the adequate range of the 
Vineland-II (Mean score = 92.2), while patients treated after one month of age had 
much lower scores (Mean score = 60.5). This has been described since 1968 by 
Dobson and colleagues (1968). In their retrospective study they found that treatment 
by 1 month of age yielded better IQ outcome than treatment after one month of age. 
They found the same results in a later analysis of a subsample from the US PKU 
Collaborative Study (Dobson, Williamson, Azen, & Koch, 1977). Later research 
found even earlier treatment leads to better IQ results, and guidelines currently in the 
UK, USA and Europe recommend treatment as soon as possible after birth (Abadie et 
al., 2005; Burgard et al., 1999; Medical Research Council Working Party on 
Phenylketonuria, 1993; and National Institutes of Health Consensus Development 
Panel, 2001).  
The relation between the scores of the Vineland-II and the age at the start of treatment 
was strongest in linearity up to an age of start of treatment of 3.6 years. After that age 
the relation was still highly significant but less linear. It can be argued that the early 
years of life are the most vulnerable to progressive damage leading to an increased 
degree of developmental delay (Koch & Wenz, 1987; and Smith, Beasley, & Ades, 
1990).  Dobson and colleagues (1968) found similar observations to this study, the 
greatest impairment in their group was seen when dietary treatment started after 3 
years of life. In another study by Smith et al (1991), they found that the greatest effect 
of increased blood Phe levels on intelligence occurred up to 4 years of age, then from 
5 to 8 years of age the negative effect was still present but less severe, as seen in the 
group of patients in this study after the age of 3.6 years. This demonstrates that 
treatment in the first few months of life is the most essential to prevent permanent 
cognitive damage (Blau et al., 2010; and Burgard, 2000). 
The second most important determinant of the Vineland-II score was the Phe level at 
diagnosis which is a marker of disease severity (see next section below). A third 
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determinant of the Vineland-II score identified by some of the analyses was the 
dietary Phe intake as calculated from the 24 hour diet recall. This was significant only 
in the multiple regression analysis for the patients treated at 3.6 years of age or 
younger, and was of weaker significance than that of the age of the patient at 
treatment. Similarly the effect of mean blood Phe level on outcome was significant in 
simple linear regression but that was lost in the more robust test of multiple 
regression, when all the influencing factors are included.  
This group of patients is not homogenous; it is a mix of early and late diagnosed 
patients, with different severity of disease, some are on a strict diet and some are not. 
Therefore strong significant association of the outcome measure with the dietary 
intake of Phe and blood Phe levels such as is documented in the literature was not 
seen in this group. The Medical Research Council (1993) reported that poor quality of 
Phe control is linked to intellectual impairments during pre-school years. Burgard 
(2000) in a meta-analysis of longitudinal PKU studies concluded that patients who 
were treated early and had had good Phe control had the best outcome and near 
normal IQ scores. Smith and Knowles (2000) in a review of some PKU studies stated 
that bad Phe control is associated with lower IQ and behavioural problems. Aoki 
(2003) and Aoki et al (2007) reported that after long-term follow-up of patients with 
PKU in Japan the IQ was shown to be negatively related to blood Phe levels, and 
therefore stricter guidelines were introduced for the PKU diet. Dawson and colleagues 
(2011) showed that reaction time in adults with PKU was significantly related to their 
blood Phe levels and dietary control.  
Many studies report the clear effect of Phe dietary intake and blood level on the 
developmental outcome for patients with PKU. Normally dietary Phe intake is a 
measure of compliance: if the recommended Phe intake is 400 mg per day and the 
patient is ingesting 1,000 mg per day, this is likely to lead to higher blood Phe levels 
and a lower Vineland-II score. However for this group of patients the strongest 
significance in correlation, simple linear regression, and multiple regression was seen 
for the age of the patients at the start of treatment. This could be attributed to the fact 
that 74% of the patients in this group were diagnosed late, and therefore the effect of 
not starting treatment early is very strong on outcome, lowering the Vineland-II score, 
weather the patients were compliant with the diet or not. Another reason may be that 
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dietary Phe intake is a marker of disease severity: in a patient with mild disease and 
satisfactory Phe levels, the dietary Phe intake recommended by the clinic doctor and 
dietitian will be higher and still the outcome measure will not be affected negatively. 
8.4.4 Classic and Mild PKU: Effects on outcome 
The severity of disease was a factor affecting patients’ development and causing 
lower scores on the Vineland-II in this study. The level of developmental damage has 
been shown to depend on the severity of the disease (Koch et al., 2002; and Smith & 
Beasley, 1989); although some patients are very susceptible to increased levels of 
blood Phe concentrations while others do not seem to be affected by it (National 
Institutes of Health Consensus Development Panel, 2001; and van Spronsen & Enns, 
2010). Therefore it was essential to classify the patients in this study according to 
their disease severity to identify the factors affecting the Vineland-II ABC scores in 
each group. 
Classifying this group of patients into Classic PKU and Mild PKU revealed that the 
age at treatment initiation had a significant negative effect on the scores of the 
Vineland-II for the Classic PKU group. This was not the case for the Mild PKU 
group. The patients with mild disease were protected from severe developmental 
delay even when they were treated late or had higher than the desired range of blood 
phenylalanine on treatment. As a group their mean Vineland-II scores were much 
better than the patients with Classic PKU. The severity of the disease is clearly an 
important factor affecting the development of patients. 
8.4.5 Socio-economic status effects on outcome 
It has been suggested that higher levels of education and better knowledge of PKU by 
parents of patients lead to better compliance and outcome for patients (Cotugno et al., 
2011; MacDonald et al., 2008; and van Spronsen, 2010). The level of education of the 
mothers and fathers of the patients in this study, and their level of knowledge about 
PKU, did not have any effect on outcome. Olsson et al (2007), similarly, failed to find 
a relationship between parents’ education level and their children’s blood Phe levels. 
Bekhof and colleagues (2003) tested if parents’ knowledge of PKU and its diet 
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improved blood Phe levels and compliance; their level of knowledge was not 
significantly related to good control. They speculated that knowledge is influenced by 
psychosocial and emotional factors before it can be translated into behaviour towards 
compliance. This has been described by Durham-Shearer and colleagues (2008) as 
well. The authors suggested that knowledge improvement should be combined with 
other interventions to reach a positive effect on outcome, all while involving the 
patients in the development of these interventions (Durham-Shearer et al., 2008; and 
Singh et al., 2000). 
Holtzman and colleagues (1986) reported, from the US Collaborative Study of 
children with PKU, that unemployment in the families was one of the factors causing 
bad control of Phe levels in their children. There was only one unemployed father in 
this study sample, not enough to test a relation between unemployment of the parents 
and the quality of Phe control. Eighteen (75%) of the mothers identified themselves as 
house-wives, there was no relation between their status and the quality of Phe control 
in this study. 
8.4.6 Mathematical skills and recall memory of patients 
Mathematical skills and memorization (e.g. memorizing passages from the Qur’an) 
seemed to be problematic for many of the PKU patients who attended regular 
mainstream schools, even when they had good control. Patients with PKU have 
frequently been described as having difficulties with mathematics. Berry and 
colleagues found that early treated patients with PKU had similar achievement scores 
to their non-PKU siblings except in arithmetic scores, which was lower for the PKU 
group (Berry, O'Grady, Perlmutter, & Bofinger, 1979). Such difficulties continued to 
be described in the literature either through studies or as reports by PKU patients and 
their families, regardless of their quality of dietary and blood Phe control (Azen et al., 
1991; Pennington, van Doorninck, McCabe, & McCabe, 1985; Schmidt, Burgard, & 
Rupp, 1996; and Tiefenthaler, 2000). Feillet and colleagues (2010) suggest addressing 
the specific learning needs of these patients between the health care providers and the 
schools. It is necessary to provide the children with additional supportive services 
such as allowing them to use calculators or giving them more time during tutoring and 
tests (Feillet et al., 2010). 
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Memorization or recall memory problems for PKU patients are not reported in the 
literature as much as executive function deficits. White and colleagues (2001) 
reported impaired abilities in memory and learning in children with early treated 
PKU, and this impairment was more evident in older children. In contrast, another 
study did not find any significant difference in recognition and recall memory 
between early treated adults with PKU and controls (Channon, German, Cassina, & 
Lee, 2004). 
Janzen and Nguyen (2010) reviewed the limited research available on non-executive 
cognitive abilities in patients with early treated PKU. In regard to long-term and recall 
memory they found mixed reports; some research reporting deficits and some 
reporting normal ability. The authors speculate that these discrepancies in the findings 
are due to the different tools used to assess learning and memory in the different 
studies. Impairments were highlighted when the tools testing them required the 
patients to use executive function strategies, which are commonly reported to be 
impaired in patients with PKU (Janzen & Nguyen, 2010). Learning and recall 
memory appear to be under investigated in individuals with PKU, it is difficult to 
conclude if they may suffer from a genuine deficit due to PKU or if it is more of a 
consequence of their impaired executive abilities.  
It could as well be that the Western curricula, especially for younger school age 
children, does not require memorization skills as early as in Saudi Arabia, therefore it 
is not reported as a deficit. Arabic poetry and the Qur’an are taught from the first 
grade onwards; both subjects require a lot of memorization which was a cause of 
difficulty for many of the patients in this study. Janzen and Nguyen (2010) 
recommend developing specific strategies for patients suffering from learning and 
recall memory difficulties. They suggest the use of day planners or memory 
notebooks, making lists, using mnemonic devices, and dividing compound 
information into more controllable parts. 
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Summary  
There are many potential risk factors causing unsatisfactory control of PKU in Saudi 
Arabia and leading to developmental delay, but it has been evident from this research 
that the strongest factor affecting the development of a child with PKU is the age at 
diagnosis and treatment initiation. This demonstrates the unparalleled importance of 
the newborn screening programme. The other main causes of developmental delay are 
the severity of the disease, the quality of dietary control, and formula intake. The 
severity of the disease cannot be changed but ought to be determined to guide each 
patient’s treatment plan. Given that the PKU treatment involves following a very 
strict low protein diet and drinking the protein substitute formula, improving 
compliance with formula intake and the quality of dietary control is vital.  
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CHAPTER 9 
CONCLUSIONS 
9. Conclusions 
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Introduction  
A number of risk factors for non-compliance and key recommendations have emerged 
from the results of this study.  The recommendations are predominantly focused on 
overcoming the compliance barriers and enhancing the care experience of the patients 
and their families. Furthermore, the results of this study point to other areas that 
deserve additional research.  
9.1 The main risk factors for non-compliance identified from this 
research 
1. The families are dissatisfied; they feel their concerns and needs are not fully met. 
2. The need for social support and family support groups. 
3. Lack of detailed educational sessions for the families, educational sessions 
targeting the patients, and cooking demonstrations of special PKU recipes.  
4. The children are not being involved and engaged in the care process.  
5. Lack of easy access to the health care providers.  
6. Lack of regular blood Phe level monitoring, and monitoring of micronutrients. 
7. Unavailability of low protein food products.  
9.2 Key recommendations to overcome the risk factors 
1. Training for health care providers:  
a. Training for more staff at KFSH&RC as their workload is high and will be 
increasing with the newborn screening programme underway. More staff are needed 
to adequately serve the patients and their families. 
b. Training for health care providers at local hospitals and health care centres 
around the country to enable them to deal with the basic care and follow-up for the 
patients locally. This would reduce the strain on the KFSH&RC services. Having 
adequate local services provides regular access to health care providers and services. 
This would improve monitoring of the patients’ blood levels and nutritional intake, 
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allowing for prompt adjustments on the dietary advice according to the levels and 
needs of the patients.  
Local services would also provide the opportunity for regular support to the families, 
in terms of continuous education, opportunity for family support groups, and meeting 
other families from the same area with similar diagnoses. This would succeed if there 
were enough families locally or at least within the same province, where the commute 
to the health care centres would be easy. 
2. Information and education for the patients and their families: 
a. Varied information resources: There are limited information resources in 
Arabic for the families. This study showed that the families were interested in gaining 
more knowledge about the disorders and the diet. Many families requested video or 
audio tapes in addition to leaflets and printed material with pictures to have as 
information sources. Some parents asked for workshops to attend and have open 
discussions. Providing the families with a variety of materials in Arabic, in addition to 
organizing detailed education sessions and cooking demonstrations of special low 
protein recipes would improve their access to information. These can be helpful for 
the staff training as well.  
b. Targeted education for the patients: Tailoring dietary education materials 
and sessions to the patients’ needs improves their comprehension of the diet and its 
importance to their wellbeing, which could highly improve compliance (Feillet et al., 
2010). Empowering the patients by involving them and giving them the responsibility 
of their dietary choices, at appropriate ages, may improve compliance especially when 
combined with adequate support (Singh et al., 2000; and van Spronsen & Burgard, 
2008). 
c. Websites in Arabic: Many of the families access the internet but the 
language barrier prevents them from accessing relevant information. There are no 
websites targeting this population in Arabic. There are family forums that a few of the 
mothers use to chat to each other and learn from their experiences. Sometimes they 
invite an expert to contribute, but that is not a constant source of information for 
them. Offering websites with efficient information that cater for the patients and the 
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parents is essential for improving information access. Websites overseen by the 
KFSH&RC or the Ministry of Health would ensure reliable resources. 
3. Improve monitoring: More rigorous and regular monitoring of the diet and Phe 
levels would help the families and the patients understand the effects of diet and 
formula intake and help them gain better control of their Phe levels (Demirkol et al., 
2011; and Giovannini et al., 2012). Collaborations with local heath care facilities and 
providing the families with prepaid postage envelopes to regularly send dried blood 
spots on Guthrie cards may encourage regular blood testing.  
4. Enhance developmental assessments: Having a clear system for regular referrals 
to the psychologist for continuous developmental assessments would benefit many of 
the children and provide the parents with feedback to support compliance. 
Consistency in the use of assessment tools and tests would benefit future research and 
longitudinal comparisons. 
5. Offer alternative protein substitutes: Providing more than one choice for the 
formula may reduce some of the difficulties in drinking it and improve compliance 
(MacDonald et al., 1997).  
6. Provide low protein food products: These products are essential in helping the 
patients comply with their diets and attain better blood Phe levels. Having a variety of 
low protein food choices satisfies the patients’ needs and cravings by offering a diet 
with more variability and some resemblance to that of unaffected family members and 
friends (Ahring et al., 2009; and Singh et al., 2000). 
7. Organise support programmes: Support groups are greatly needed. The families 
showed high interest in joining support groups. Meeting other families has been 
shown to provide social, psychological, and metabolic advantages and positive 
influences for both the patients and their families (Brenton, 2000; MacDonald et al., 
2010; Vegni et al., 2010). 
Providing support for the children to equip them to be more involved in their own 
health management has constructive results and improves their dietary compliance 
(Bilginsoy et al., 2005; and van Spronsen & Burgard, 2008). Developing support 
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programmes particularly targeting adolescents is essential, as compliance is known to 
decline at this age (MacDonald et al., 2011; and Walter & White, 2004).  
8. Develop policy to involve schools: Schools are integral in the lives of the patients. 
Child development plans are not available between the schools, the parents, and the 
health care providers. Policy and programme development to ensure school 
engagement in the development plans for the patients are essential. This would 
provide needed support from the schools to the families and entice school cooperation 
with dietary requirements. 
9. Provide play facilities: The children spend many tiring hours at the KFSH&RC. 
Providing play facilities for the patients and their siblings while waiting for their 
appointments would offer them some enjoyable time and provide respite for their 
families. This would help in making the experience of going to the hospital less 
stressful for the families, leaving them more focused at clinic time.  
9.3 Products of this study 
1. A comprehensive questionnaire: The developed questionnaire can be used for 
future studies with other patients with aminoacidopathies or other metabolic 
disorders.  
2. The Arabic Vineland-II: The Vineland-II is an important tool, and having it in 
Arabic is invaluable to advance the assessment of children in the Arab world. 
3. An Arabic website for PKU: I have started the process of planning a website that 
would provide basic dietary information about PKU in Arabic, with sections for both 
the patients and the parents. It would be beneficial to follow this by exploring the 
possibilities of collaborating with KFSH&RC or the Saudi Ministry of Health on 
expanding it to cover all relevant metabolic disorders. 
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9.4 Plans and suggestions for future work 
1. Further research is needed to examine the quality of life for the patients with 
metabolic disorders and their mothers. This research included some questions related 
to that aspect and results showed that their quality of life is affected. Jusienė and 
Kučinskas (2004) pointed out that stressed parents have children who struggle. 
Understanding what the families go through would help organise support and 
counselling for them. 
2. Develop educational material for each disorder. Having a variety of educational 
material developed locally to include common food choices and habits is essential.  
3. Develop targeted nutrition management programmes, informed by the results of 
this study, to support patients with aminoacidopathies and their families. This can 
then be expanded to include all the patients with metabolic disorders in Saudi Arabia. 
4. Reaching the teachers of the patients was not feasible in this study. Carrying out 
research to investigate the teachers’ perspectives in addition to the accounts of the 
parents and the patients would give a broader picture about the risk factors. Involving 
the teachers would aid in the development of the needed policy for coordinating 
between schools and health care providers. 
5. Development of public education programmes to improve the public awareness of 
the newborn screening programme in Saudi Arabia and to educate them about the 
screened disorders. 
6. Finally, an essential next step for me is to validate the Arabic Vineland-II with a 
larger sample, and work with the Vineland-II developers to publish the Arabic 
version.    
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9.5 Strengths and Limitations 
9.5.1 Strengths of the study 
1. Study design: Preceding the quantitative study with a qualitative study provided 
an understanding of the current situation and aspects of behaviours and attitudes 
that quantitative methods cannot obtain. This approach strengthens the study and 
adds to its credibility (Creswell, 2009; and Patton, 2002).  
2. Language and cultural knowledge: The principal investigator, Sadeem 
Aljammaz, being from Saudi Arabia provided fluency in the language and 
familiarity with the culture of the participants. This allowed for ease of 
communication and valuable comprehension of social cues.  
3. Data collection: The interview data was collected by one researcher (the 
principal investigator Sadeem Aljammaz), and the Vineland-II was administered 
by the same investigator as well. This limited data collection bias or differences 
that might occur when more than one researcher is involved in data collection. 
4. The Vineland-II translation and adaptation: Translating the Vineland-II and 
culturally adapting it to the area was a major undertaking. It provided a reliable 
tool that gave uniform and comprehensive assessment of the patients in this 
study. Administering the Vineland-II and not using the available results of 
developmental assessments done by other health care providers gave stronger 
information. This also provided an Arabic tool that can benefit future studies. 
9.5.2 Limitations of the study 
1. The Hawthorne effect: This is the researcher’s impact on participants (Pope & 
Mays, 1995). To limit that effect and in an effort to put the respondents at ease so 
they would talk freely, time was given before the interviews to establish rapport 
with respondents, and it was made clear that the principal investigator (SA) was 
not part of the KFSH&RC’s hierarchy (Creswell, 2007; and Fontana & Frey, 
2003). 
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2. Sampling: Sampling the families and patients for Phase 1 of the study was done 
till reaching a point of saturation (where we expect no significantly new 
information) in an attempt to gather as wide a range of opinions as possible in that 
situation (Creswell, 2007; and Ritchie et al., 2003). Therefore with such 
qualitative enquiry it is not feasible to plan for a sample number in advance. For 
Phase 2 the sample size was relatively small, but included all the available PKU 
patients at the KFSH&RC. 
3. Observation: Observations of formula preparation by families were done at 
KFSH&RC; this might not be truly reflective of their home environment situation. 
Observing families and patients at the clinics might have altered their normal 
interactions with the dietitian or the doctor (Patton, 2002). Nonetheless 
KFSH&RC is a training hospital and families are generally used to having at least 
one trainee paediatrician or dietitian in the clinic.  
4. Market survey: Surveying more areas than the two urban areas and two rural 
areas, that were explored, was not feasible. These were believed to be sufficiently 
representative of the Saudi market. 
5. Dietary intake: Although the 24 hour food recall is the most practical method for 
measuring dietary intake for this sample, it is not the  most accurate or definitive 
measure of Phe intake. The mothers know what their children with PKU should 
and should not eat, so they may not fully report high Phe intake. 
6. Past Phe blood levels: Unfortunately most patients had their blood tests at 
irregular intervals which made some analyses impossible. 
7. Development assessments: Not having uniform and consistent assessments for all 
of the patients at the KFSH&RC was problematic, but this was overcome by 
administering the Vineland-II.  
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Conclusion  
This has been the first study in Saudi Arabia to qualitatively examine the perceptions 
of the patients, their families, and their healthcare providers about their 
aminoacidopathy disorders. It was followed by a quantitative study to identify the risk 
factors for non-compliance. The results offered initial understanding of the barriers to 
dietary compliance, and provided direction for future research investigation with 
different metabolic disorders. This research journey was enlightening and an 
inspiration to continue to advocate for the needs of patients with metabolic disorders.  
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Appendix 2: Health care providers interview & focus group questions 
(Phase 1) 
 
1. Dietitian interview  
 
Patient care: 
 
1. What are your duties as a dietitian at KFSH&RC? 
 
2. How do you view your work as “the metabolic disorders dietitian” at 
KFSH&RC? 
 
3. What/who are the patients that you see? 
 
4. I am particularly interested in patients with aminoacidopathies (PKU, MSUD, 
and Tyrosinaemia I), how often do you see such patients? 
 
5. How are they referred to you? 
 
6. How many patients do you see per day/clinic? 
 
7. How often do you see each patient? 
 
8. How often do you contact the carers between clinic visits? Do they contact 
you? 
 
9. What happens in your clinic (in detail please) when you are with a patient? 
 
10. How many or what percentage of these patients are with disabilities? 
 
11. Is there a difference in your management of patients with disabilities? How? 
 
12. How would you describe your relationships with the patients and their 
families? 
 
13. What are the pressures and stresses families face? 
 
Diet: 
 
14. What is your opinion about the knowledge and understanding of patients and 
carers regarding the causes, symptoms and treatments of the disorders they 
have? 
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15. What do you think about the nutrition knowledge of patients and carers 
regarding the nutrition management of their disorders?  
- Carers’ views 
- Children’s views 
 
16. What are you suggestions and ideas regarding the nutrition management for 
these patients?  
 
17. How is the compliance of the patients with their prescribed diets? 
 
18. In your opinion, what are the reasons for compliance or non-compliance with 
diet?    - Do you think family issues could be a factor? 
 - Social aspects, education, or economic factors? 
 
19. How do you think compliance can be improved? 
 
Services: 
 
20. How would you describe your relationships with other health care providers 
involved in the care of patients with metabolic disorders? 
 
21. Do you think you are adequately involved in the management of patients? 
 
22. What is your opinion about the hospital’s services for patients with metabolic 
disorders and their families? 
 
23. Do you think these services have room for improvements? 
 
24. What do you think could be provided to improve services? 
 
25. Do you think you have enough support? 
 
26. What do you think about the national screening programme pilot? What do 
you think its impact might be? How in your opinion dieticians around the 
country would handle IEM? 
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2. Doctor interview 
 
1. I am particularly interested in patients with aminoacidopathies (PKU, MSUD, 
and Tyrosinaemia I), how often do you see such patients? 
 
2. How are they referred to you? 
 
3. How many patients do you see per day/clinic? 
 
Patient care: 
 
4. How often do you see each patient? 
 
5. How often do you contact the carers between clinic visits? 
 
6. Do patients contact you between clinic visits? How do you address their 
needs? 
 
7. How often do you ask for blood levels? 
 
8. How do you communicate results to carers? 
 
9. What is the protocol you follow in your clinic (in detail please) when you are 
with a patient? 
 
10. How would you describe your relationships with the patients and their 
families? 
 
11. What are the pressures and stresses families face? 
 
12. Do you involve any other health care providers in the care of your patients? 
 
13. If yes, who and how? 
 
Diet: 
 
14. What is your opinion about the knowledge and understanding of patients and 
carers regarding the causes, symptoms and treatments of the disorders they 
have? 
 
15. What do you think about the nutrition knowledge of patients and carers 
regarding the dietary management of their disorders?  
- Carers’ views 
- Children’s views 
 
16. What are you suggestions and ideas regarding the nutrition management for 
these patients?  
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17. In your opinion, what is the importance of the dietician to the care of these 
patients? 
 
18. How is the compliance of the patients with their prescribed diets? 
 
19. In your opinion, what are the reasons for compliance or non-compliance with 
diet?    - Do you think family issues could be a factor? 
 - Social aspects, education, or economic factors? 
 
20. How do you think compliance can be improved? 
 
Services: 
 
21. How would you describe your relationships with other health care providers 
involved in the care of patients with metabolic disorders? 
 
22. What is your opinion about the hospital’s services for patients with metabolic 
disorders and their families? 
 
23. Do you think these services have room for improvements? 
 
24. What do you think could be provided to improve services? 
 
25. What do you think of the national screening programme pilot and its impact 
on the country? 
 
26. How do you think is the knowledge of physicians around the country 
regarding IEM?  
 
27. Do you think the national screening programme has any implications for your 
practice as a doctor and for the wider clinical practice? 
 
28. Have I missed anything? Would you like to add anything?   Thank you. 
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3. General dietitians’ focus group 
 
Experience: 
 
1. Were you ever involved in the management of patients with inborn errors of 
metabolism? 
 
2. What is your previous experience with IEM? (Professional training etc.) 
 
3. What is your knowledge about inborn errors of metabolism? 
 
4. Where did you get your knowledge from? 
 
5. Are there particular experiences you want to share with the group? 
 
6. If you had had an experience, how did you deal with it, how did you manage, 
were you able to easily get help/support? 
 
Patient care: 
 
7. How do you find dealing with patients with inborn errors of metabolism? 
- what aspects of care are satisfying 
- what aspects are difficult  
 
8. What in your opinion would help you in dealing with these patients? 
 
9. Where do you get information on the subject when you need it? 
 
Diet: 
 
10. What is your opinion about the knowledge and understanding of patients and 
carers regarding the causes, symptoms and treatments of the disorders they 
have? 
 
11. What do you think about the nutrition knowledge of patients and carers 
regarding the nutrition management of their disorders?  
- Carers’ views 
- Children’s views 
 
12. What are you suggestions and ideas regarding the nutrition management for 
these patients?  
 
13. How is the compliance of the patients with their prescribed diets? 
 
14. In your opinion, what are the reasons for compliance or non-compliance with 
diet?    - Do you think family issues could be a factor? 
 - Social aspects, education, or economic factors? 
 
15. What are the pressures and stresses families face? 
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16. How do you think compliance can be improved? 
 
Services: 
 
17. How would you describe your relationships with other health care providers 
involved in the care of patients with metabolic disorders? 
 
18. What do you think about the services provided for patients and their families? 
 
19. What do you think could be provided to improve services? 
 
20. What do you think about the national screening programme pilot?  
 
 
 
 
 
 
301 
 Appendix 2: Health care providers interview & focus group questions (Phase 1) 
 
4. Nurses’ focus group 
 
Experience: 
 
1. What are your previous experiences with IEM? 
 
2. What are your roles/duties in the metabolic clinic? 
 
3. What is your knowledge about inborn errors of metabolism? 
 
4. What is your knowledge about nutritional aspects of care for IEM? (formula 
preparation) 
 
Patient care: 
 
5. Do families ask you for information? 
 
6. Where do you get your knowledge/training from? Do you find it easy to get 
needed information? 
 
7. How would you describe your relationships with the patients and their 
families? 
 
8. What are the pressures and stresses families face? 
 
9. How is the compliance of the patients with their prescribed diets? 
 
10. In your opinion, what are the reasons for compliance or non-compliance with 
diet?    - Do you think family issues could be a factor? 
 - Social aspects, education, or economic factors? 
 
11. How do you think compliance can be improved? 
 
Services: 
 
12. How would you describe your relationships with other health care providers 
involved in the care of patients with metabolic disorders? 
 
13. What is your opinion about the hospital’s services for patients with metabolic 
disorders and their families? 
 
14. What do you think could be provided to improve services? 
 
15. What is your knowledge about the national screening programme pilot?  
 
16. Do you think the national screening programme has any implications for your 
practice as a nurse and for the wider clinical practice? 
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Appendix 3: Family and child interview questions (Phase 1) 
 
Family interview 
 
Date: 
Diagnosis: 
Interviewer:  
Interviewee:  
 
Start time: 
 
 
 
General start: 
 
 
1. Tell me about your child please. Probe: when diagnosed, is s/he first in the 
family with this illness, etc. 
 
1a. What do you know about your child’s illness? 
 
1b. Who explained the disorder to you? 
 
1c. Do you think you have good and enough understanding of this disorder? 
 
2. Where do you get your information from? 
 
Social: 
 
3. How do you and your child cope with this condition? 
 
3a. What are the main difficulties and pressures facing you? (Probe: stress, 
depression, frustration)  
 
3b. Who supports you and your child? Do you seek support?  
 
 
4. Describe the treatment your child receives? 
 
4a. Tell me more about the diet. 
 
4b. When you go out and during social occasions, what do you do? 
 
4c. Does your child go to school? 
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4d. Do the teachers know about his/her condition? Are they cooperative/ 
helpful? (Probe)  
 
 
Clinical care: 
 
5. How often do you come to KFSH&RC? 
 
5a. Do you find it easy to meet all appointments? Or do you have problems in 
attending? 
 
5b. What difficulties do you have? 
5c. How much time do you spend at the hospital when coming to visit the 
metabolic clinic? 
 
 
6. Tell me about your experience during your clinic visits here? 
 
6a. Who are the health care providers that you visit during your appointments 
here at the hospital? 
 
6b. Do you have enough time with each of them? 
 
 
7. Who are the health care providers that you visit at your local health clinic? 
 
7a. How is the care there? 
 
 
8. How do you contact health care providers when you need them between clinic 
visits? 
 
۸a. How would you describe your relationships with different health care 
providers? 
 
Diet: 
 
9. What do you think is the importance of the diet to your child’s wellbeing? 
 
10. How would you rate your understanding of the nutrition requirements of your 
child? 
 
11. Where do you get your nutrition knowledge from? 
 
12. When were you referred to a dietician? 
 
13. How often do you visit the dietician? 
 
14. Do you follow the dietician’s instructions on diet? 
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15. Do you have barriers to following the diet? What are they? 
Probe: 
- Time and effort to make formula and organise diet 
 - Products not found in market. 
 - Financial, expenses. 
 
Services: 
 
16. Have you met other families who have children with similar conditions? 
 
16a. Would you like to meet other families? Probe 
 
17. What is your opinion about the hospital services provided for you and your 
child? 
 
18. What further information are you seeking regarding your child’s condition and 
/or care? 
 
18a. In what form would you prefer to have that information? 
 
19. Have you sought treatment in other places? 
 
 
 
Thank you for your time and participation. 
 
Assure participant of confidentially. 
 
 
End: 
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Child interview          
 
Date: 
 
Interviewer:  
Interviewee:  
 
Start time: 
 
1. Why do you come here? 
 
2. What do you know about your illness? 
 
3. Do you understand what the doctors or your parents tell you about it? 
 
4. What do you like or dislike about coming to the hospital? 
 
5. Can you tell me something about your treatment? 
 
6. Do you give your opinion about your treatment or diet? 
 
7. Do you think your opinion matters to the doctors or to your family? 
 
8. What is your favourite food? 
 
9. Do you choose your food? 
 
10. Do you know what you are allowed to eat and what you are not allowed to 
eat? 
 
11. Is it easy to stick to this diet?  
 
12. Do you take formula? 
 
13. Who prepares it? Do you have a role in preparing it?  
 
14. Is it easy to take? Why? 
 
15. Do your friends know about it? How do you deal with friends? 
 
16. Is there anything you would like to ask me or tell me? 
 
 
 
Thank you for your time and participation. 
 
 
End:
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Appendix 4: Family interview sample (Phase 1) 
Date:  
Diagnosis: MSUD 
The interview was tape recorded and conducted with the mother at the dietitian’s 
clinic. The patient (13 years old) was colouring and her older brother came towards 
the end and gave a few comments. 
Interviewer: S=Sadeem 
Interviewees: M=Mother and B=Brother of patient. 
Start: 03:05 p.m. 
 
S. Tell me about your daughter, when was she diagnosed? 
M. A week after birth. 
 
S. Is she your first affected child? 
M. She is the seventh.    
 
S. How many of your children are affected with this disorder? 
M. Six before her and they all died!  They all had the same disorder but we did not 
know, they were not properly diagnosed. One lived up to her 4th year at the hospital, 
but she rally suffered, she disabled and blind. 
 
S. You mean 6 children died without knowing their diagnosis? 
M. I know their illness, now I know it was the same disease. After we discovered her 
and got to know her smell; the smell of her sweat and urine, the same things and 
symptoms that she went through the children before her went through. They were not 
diagnosed at the hospital. 
 
S. How many children who are not affected do you have? 
M. Three boys and two daughters. 
 
S. Are they older or younger than this daughter? 
M. Different ages. 
 
S. What do you know about her condition?  
M. They are fine when they are born, nothing wrong. At the 5th day of breast feeding 
they start to constantly cry then get convulsions and close the eyes and mouth. 
Nothing gets into their mouths, not milk, water or anything. They become stiff. At the 
hospital some slip into a come, some don’t. They don’t feed like other infants, the 
hospital gave them special feeding, I don’t know what it was. They stay at the 
hospital; they don’t come out with me. 
 
S. How did you know about your daughter? 
M.I delivered her by caesarean section, and the doctors were suspicious because I had 
a daughter before her and an American doctor at the hospital in Dhahran suspected 
that she had the disorder, we got two affected children after her. The doctor there told 
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us that we might get affected children in the future; one child might be affected and 
one might not be. Here, Dr. Ozand did an operation on her and dialysis; she stayed 45 
days at KFSH, and was started on formula and a special diet, which we follow till 
today. 
 
S. When this daughter was born, how did you realize she had the disease? Was 
the blood test done right away? 
M.She was born in Yanbu. The doctor called KFSH, and on her 5th day of birth she 
slipped into a coma. She was airlifted to KFSH in Riyadh from Yanbu. 
 
S. Who explained her condition to you? 
M.The doctor in Yanbu. 
 
S. Do you think you understand your daughter’s condition? 
M.Yes I do, from the smell of their body fluids, smells like fenugreek, when I start 
smelling that distinctive smell in the baby’s sweat and urine I know it is the disease, I 
even smell my grandchildren to know. 
 
S. Are there any grandchildren affected with the disorder? 
M. No, thank God. 
 
S. Do you feel you have a full understanding of the condition? 
M. Yes, I do. Her cousin has MSUD as well. 
 
S. Where do you get your information about the condition? 
M. Once the baby is born, I observe them and I know if they got the disease or not. 
First I know by the constant crying, and then the distinctive smell, most important the 
sweat and urine smell. The convulsions come from the 5th day after the proteins 
increase from breast feeding. 
 
S. How do you deal with the disorder? What are the difficulties you face? Do you 
face difficulties?   
M. Of course, the food difficulties! She is older now and sees what we eat and other 
people eat. She asks for food that is not allowed. She says; why don’t you give me 
from your food? I am your daughter! You don’t love me! You don’t want me! 
You know, her food is very limited. 
 
S. Do you need support? 
M. Yes. I am tired, my knees are bad, and I recently had surgery in my neck. I can’t 
keep up with her, she tires me. I can’t catch up with her when she grabs food and 
runs. She runs upstairs and I can’t go after her. 
 
S. Does she grab food and run away? 
M. Yes, like she grabs bread and runs away with it. 
 
S. Is there anybody who helps or supports you? 
M. My daughters try to help out, but they are married; one lives in Kharj, and the 
other is in Jeddah, sometimes I have a house helper. 
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S. Describe the treatment your daughter takes? 
M. Vitamins and iron tablets. 
 
 
S. Tell me about her diet in detail? 
M .I give her Cornflakes for breakfast with a cup of tea. Her formula milk has a 
strong smell she can’t eat it with it. I cook for her lunch two spoons of rice with 
carrots, courgettes and tomatoes. Dinner is the same or tomato and cucumber salad, 
this is her food. 
 
S. What about the formula? 
M. Her milk. 
 
S. Does she drink it? 
M. Yes. 
 
S. How do you manage when you go out or during social occasions? 
M. I take her food and her formula with me. I just have to. 
 
S. Does she go to school? 
M. No, we enrolled her in a private school but we saw she wasn’t benefiting; it wasn’t 
a special education school and the tuition was expensive so we took her out. 
 
S. Were you not happy with the school? 
M. She was not doing well at all, she didn’t learn anything. 
 
S. How many times do you visit KFSH? 
M. Since the day she was born. She is 13 years old now. 
 
S. How many times in the year? 
M. Since her birth appointments were every 2 weeks, then every month, then 2 and 3 
months and currently it is every 6 months. 
 
S. Is it easy to attend the clinics at KFSH or are there difficulties? 
M. Yes it is becoming difficult for us. Her dad and I are old, and tired, and we have to 
travel from Dammam. We used to live in Yanbu and travelled from there as well. 
 
S. You mean difficulty of travelling? 
M. Yes, of course the travelling difficulties and the preparation of her food, I have to 
cook for her. For the formula I have to take 2 thermoses one cold with ice to preserve 
the formula, and one with hot water to heat it up for her to drink it. I do get tired. 
 
S. How much time do you spend at the hospital? 
M. Differs, 3-4 hours, depending on the number of patients that day. 
 
S. What is your experience when you attend the clinic? Which healthcare 
providers do you see? 
M. The doctors change, we used to see Dr. Ozand, then Dr. Al-Owain, then Dr. 
Zahrani, and others. Even our dietitian Suhad there used to be 4 before her. 
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S. Who else do you see beside the doctor? Do you see the dietitian? 
M. I like the dietitian, I always see her and she explains everything to me, I 
understand her and she teaches me, but the foreigner dietitians before her I didn’t 
understand them because of the language. 
 
S. Do you feel you spend enough time with the doctor and the dietitian? 
M. Yes, thanks to God. They ask me about her and I explain, and they take her height, 
weight and blood test. The dietitian asks about how I feed her. 
 
S. Who are the health care providers you visit in your area? 
M. We have a copy of her medical report; we show it to the doctors if she gets a cold, 
it’s difficult. They should take care and just give her medicine for fever and 
antibiotics. 
 
S. How is the quality of their care? 
M. It is fine, but they don’t know about her disorder, they say we heard of but don’t 
know how to deal with it. They are not at the level of KFSH yet. 
 
S. How do you contact health care providers between clinic visits? 
M. We only call the dietitian when we run out of the formula, we call and my son 
picks it up for us. We don’t call the doctor. 
 
S. Is that easy for you? 
M. Yes it is easy, thank God. 
 
S. How are your relationships with the doctors and the dietitian? 
M. The dietitian, thanks to God! She does her best and gives us the formula. The 
doctor writes the blood tests and the treatment. They all do a great job, I have no 
problems. 
 
S. What do you about the importance of the diet to your daughter’s condition? 
M. When I really comply with her diet I see that my daughter becomes proper, good 
in her head. 
 
S. By proper do you mean stable or normal? 
M. Yes stable [laughs due to dialect differences]. Sometimes when I’m sick or 
something and they don’t give her the diet correctly you will see something wrong 
with her either her gait wobbly or her hand shaking or eyes rolling, I can feel she is 
not all right. 
 
S. So, you feel the diet is important for her? 
M. Of course, if the diet is right she becomes good. 
 
S. How would you rate your understanding of her diet? 
M. Yes I do understand her diet. 
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S. Where do you get your information from? 
M. I’ve memorised it. 
 
 
S. From where did you get the information before you memorised it? 
M. They told me about the diet, and I follow it, I don’t add or deduct. 
 
S. When were you referred to the dietitian? 
M. Since the day she was born. 
 
S. How many times you visited the dietitian? 
M. With the doctor’s appointments, currently every 6 months. 
 
S. Do you follow the dietitian’s instructions? 
M. Yes I do, if I don’t it affects my daughter and her health. 
 
S. Are there any barriers for following the diet? Like time, effort or finances? 
M. Yes, when we travel it is a problem; there are many things that affect her, not me. 
When traveling we need to carry a lot of stuff for her feeding; her food, water and a 
cooker, we have to take everything. 
 
S. Did you meet other families who have children with similar conditions? 
M. Yes, her cousin. Suhad knows her. 
 
S. It there anyone else? 
M. There is but not with the same disorder. 
 
S. In the family? 
M. Not from our family, but in the neighborhood. 
 
S. Are they following the same diet? 
M. I am not sure about their diet. 
 
S. Didn’t you ask them about their experience? 
M.I asked them, they say they follow what the dietitians told them, I don’t know 
what. I know they use the same formula, because when they ran out one time, they 
took a can from me, that was in Dammam. 
 
S. Would you like to meet other families with the same condition? 
M. Yes, I do wish to. We can exchange different experiences, learn from each other 
and talk about our difficulties, it will be kind of a support for us, and that will bring us 
some comfort. People who have their hands in the fire are not like who don’t! Many 
think there is no patient except their child but when you see others with sick children 
you accept your situation. Thanks to Allah. 
 
S. What is your opinion about the hospital services provided for you and your 
daughter? 
M. I think it is great, and like to thank them for that. 
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S. Is there further information you would like to know about your daughter’s 
condition and care? 
M. I want to know more about the diet. 
 
S. In what form would you prefer to receive this information in, such as in video, 
cassettes or written material? 
M.I think video is the best way, so I can watch and listen to understand, if I just listen 
may be things would be said and I don’t understand. 
 
*Her eldest son who drove them to the hospital came into the room towards the 
end of the interview and joined in. 
 
B. My mother suffers. The dietitian gives us a list of allowed food products, we go to 
the supermarket and find stuff they didn’t tell us about so we avoid them, she [the 
patient] is a child and sometimes wants stuff, all the kids chew gum and she wants 
like them. This is the problem we suffer; the dietitian gives us a list of may be 10 
products and we follow that; but there are new stuff all the time! 
 
M. If she finds candy she wants it, if she finds Pepsi she wants it as well. 
 
B. It became a hassle, when the kids bring sweets and we tell her no this is not good 
for you! She suffers from that the most. 
 
S. So you want to know exactly which items are allowed and those that are not 
allowed?  
B. Yes, we want to know all the allowed food items in the supermarket. I am afraid 
we are saying no to items that she is permitted to eat! Yesterday I took the kids with 
me to the supermarket everyone chose something and she kept saying I want this or 
that and I’d tell her no, just take what is allowed. There could have been something 
allowed for her but we don’t know! 
 
S. Right, that might happen if you don’t know. 
B. This is the problem! My mother brought today a crisp wrapper to show it to the 
dietitian, my sister wants to have it. 
M. She saw it on TV and with other kids. It is from corn and I read the protein portion 
is 6 but I am not sure if it is safe for her. Here at the reception she was given this 
juice; I told her not to drink it till we ask the dietitian to be sure. 
B. All foods have protein but we want to know the exact allowed amounts. 
 
S. Did you search for treatment somewhere else? 
M. No, I just bought her vitamins two years ago, other than that no way. 
 
S. Thank you all, I appreciate your time. 
 
End: 03:30 p.m.  
312 
 Appendix 4: Family interview sample (Phase 1) 
 
 
Comments on F#13 interview: 
 
I approached the mother while she was at the waiting area. She came with her son, a 
young man, and her daughter, the patient. She agreed right away to participate in the 
research, but she said “I’m illiterate; I can barely right my name!” 
I read the consent form for her and explained it and she wrote her name at the 
signature line. 
 
I gave the patient some colouring paper and crayons with the mother’s approval. She 
said that colouring will occupy her daughter while she talks to me. 
 
Although the mother is illiterate, she seemed to understand her daughter’s diet and its 
importance. They seemed to be a caring family. The brother came in at the end and 
expressed his concern regarding the different food products and sweets allowed for 
his sister, they prevents her from eating different sweets and gums from other children 
and feels sorry for her. He wanted to know all the allowed products. 
 
This shows that different family members are involved in the patient’s care and diet. 
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Appendix 5: List of obtained data (Phase 2) 
 
List Completed Missing data 
Consent form given to 
parent   
Consent form in MR   
Measurements taken   
Interview   
24 hrs food record #1   
24 hrs food record #2   
MR review   
Copy of developmental 
assessments   
Past blood levels    
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Appendix 6: Anthropometric data & medical records information 
(Phase 2) 
 
A. Anthropometric measurements 
 
Date:  
 
A1. Height / Length     _______ cm 
A2. Weight _______ kg 
A3. Mid Upper Arm Circumference    _______ mm 
A4. Triceps Skin Fold Thickness 
   _______ mm 
   _______ mm 
   _______ mm 
 
Ave: ____mm 
A5. Waist Circumference    _______ mm 
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B. Information obtained from medical records 
 
MR1. Child’s name: 
 MR2. MR #:  
MR3. Date of birth: MR4. Age: 
MR5. Sex: 1. Male           2. Female MR6. Age at diagnosis: 
MR7.1 Phenylalanine concentration at                       
diagnosis:_______ µmol/l MR7.2 Date: 
MR8.1 Age at start of treatment: MR8.2 Date: 
MR9. Medical problems: 
 
 
MR10. Morbidity in the past two weeks:                                1. Yes           2. No 
If yes:  
MR10.1 What? 
 
 
MR11. Did the child undergo developmental assessment:     1. Yes           2. No 
If yes 
MR12. Date of developmental assessment: 
 
1st report:____________               2nd:____________               3rd:____________ 
 
4th:_________________                 5th:____________               6th:____________ 
MR13. At what age:  
 
1st:_____      2nd:_____        3rd:_____         4th:_____          5th:_____    6th:_____ 
MR14. Is phenylalanine blood level taken at the day of interview:  1. Yes           
2. No 
If yes: 
MR14.1 Phe level: ________ 
µmol/l  
 
MR14.2 
Phe/Tyrosine ratio: MR14.3 Date: 
MR15.1 Last phenylalanine 
blood level: _______µmol/l 
MR15.2 
Phe/Tyrosine ratio: MR15.3 Date:  
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MR#: 
Name: 
 
 
Past blood levels: 
 
Date Phenylalanine blood 
level  µmol/l 
Phenylalanine /Tyrosine 
Ratio 
MR16.  MR16a.  MR16b.  
MR17.  MR17a.  MR17b.  
MR18.  MR18a.  MR18b.  
MR19.  MR19a.  MR19b.  
MR20.  MR20a.  MR20b.  
MR21.  MR21a.  MR21b.  
MR22.  MR22a.  MR22b.  
MR23.  MR23a.  MR23b.  
MR24.  MR24a.  MR24b.  
MR25.  MR25a.  MR25b.  
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Family Questionnaire  
ﺔﻠﺋﺎﻌﻟا ﺔﻧﺎﺒﺘﺳا 
 
1. Identification information  
 
103. Home phone number \ لﺰﻨﻤﻟا ﻒﺗﺎھ ﻢﻗر: 
104. Mobile number \ لاﻮﺠﻟا ﻢﻗر: 
105. Address \ ﺔﻣﺎﻗﻹا ﺮﻘﻣ: 
 
106. Town \ ﺪﻠﺒﻟا:  1. Urban \ ﺔﻨﯾﺪﻣ    2. Rural \ ﺔﯾﺮﻗ    3. Peri-urban \ 
ﺔﻨﯾﺪﻣ ﮫﺒﺷ 
 
 
2. Socio-economic Status 
 
Father \ بﻷا 
201. Age (yr) \ ﺮﻤﻌﻟا:        
<21         21-25         26-30         31-35       36-40         41-45         46-50         >50 
 
202.Education- What is the highest level of schooling that you have completed: 
ﺔﯿﺳارد ﺔﻠﺣﺮﻣ ﺮﺧآ ﻲھ ﺎﻣ :ﻲﻤﻠﻌﻟا ىﻮﺘﺴﻤﻟا  ﺎﮭﻠﻤﻛأ ؟ 
 
1. None \ ﺪﺟﻮﯾ ﻻ                           2. Read & write\ ﺐﺘﻜﯾو أﺮﻘﯾ 
3. Primary School \ ﺔﯿﺋاﺪﺘﺑﻻا          4. Middle school \ ﺔﻄﺳﻮﺘﻤﻟا 
5. High School \ ﺔﯾﻮﻧﺎﺜﻟا                6. Less than Univ. Dip.\ ﻲﻌﻣﺎﺠﻟﺎﻧوﺪﻣﻮﻠﺑد 
7. University \ ﺔﻌﻣﺎﺠﻟا                 8. Higher degree\ ﺎﯿﻠﻌﺗﺎﺳارد 
 
 
203. Occupation \ ﺔﻔﯿظﻮﻟا:    ______________ 
 
1. Professional \ ﻲﻨﮭﻣ        2. Technician \ ﻲﻨﻓ                    3. Worker \ ﻞﻣﺎﻋ  
4. Student \ ﺐﻟﺎط      5. Military officer \ يﺮﻜﺴﻋ         6. Unemployed \ ﻒظﻮﻣ ﺮﯿﻏ 
7. Retired \ ﺪﻋﺎﻘﺘﻣ      8. Other \ ىﺮﺧأ:_________              
 
 
 
101. Date \  ﺦﯾرﺎﺘﻟا:  
102. Interviewee \ 
كرﺎﺸﻤﻟا: 
 Mother \ مﻷا  Other \ ﺮﺧآ:_______ 
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Mother \ مﻷا 
204. Age (yr)\ ﺮﻤﻌﻟا:       
 <21         21-25         26-30         31-35         36-40         41-45         46-50         >50 
205. Education- What is the highest level of schooling that you have 
completed: 
 ؟ﺎﮭﺘﻠﻤﻛأ ﺔﯿﺳارد ﺔﻠﺣﺮﻣ ﺮﺧآ ﻲھ ﺎﻣ :ﻲﻤﻠﻌﻟا ىﻮﺘﺴﻤﻟا 
 
1. None \ ﺪﺟﻮﯾ ﻻ                             2. Read & write\ ﺐﺘﻜﺗو أﺮﻘﺗ 
3. Primary School \ ﺔﯿﺋاﺪﺘﺑﻻا           4. Middle school \ ﺔﻄﺳﻮﺘﻤﻟا 
5. High School \ ﺔﯾﻮﻧﺎﺜﻟا                  6. Less than Univ. Dip.\ ﻲﻌﻣﺎﺠﻟﺎﻧوﺪﻣﻮﻠﺑد 
7. University \ ﺔﻌﻣﺎﺠﻟا                  8. Higher degree\ ﺎﯿﻠﻌﺗﺎﺳارد 
 
206. Occupation \ ﺔﻔﯿظﻮﻟا: ___________ 
 
1. Professional \ ﺔﯿﻨﮭﻣ           2. Technician \ ﺔﯿﻨﻓ                 3. Worker \ ﺔﻠﻣﺎﻋ  
4. Student \ ﺔﺒﻟﺎط         5. Unemployed \ ﺔﻔظﻮﻣ ﺮﯿﻏ     6. Retired \ ةﺪﻋﺎﻘﺘﻣ  
7. House-wife \    لﺰﻨﻣ ﺔﺑر     8. Other \ ىﺮﺧأ:_________              
 
207.Marital Status - Which of the following best describes you now: 
:ﺔﯿﻋﺎﻤﺘﺟﻻا ﺔﻟﺎﺤﻟا :نﻵا ﻚﯿﻠﻋ ﻖﺒﻄﻨﯾ ﻲﺗﻵا يأ  
 
1. Single\ﺔﺟوﺰﺘﻣ ﺮﯿﻏ                                     2. Married\ﺔﺟوﺰﺘﻣ      
3. Divorced/separated \ ﺔﻠﺼﻔﻨﻣ/ﺔﻘﻠﻄﻣ             4. Widowed\ رأﺔﻠﻣ  
 
 
Family information 
208.What is your family’s approximate monthly spending \  
ا ﻮھ ﺎﻣﺎﻤﺟ :ﺎﺒﯾﺮﻘﺗ ﺮﮭﺸﻟا لﻼﺧ ةﺮﺳﻷا قﺎﻔﻧإ ﻲﻟ  
1. <1000         2. 1000-2999         3. 3000-4999        4. 5000-6999        5. 7000-8999        
6. 9000-10999          7. 11000-14999          8. >15000          9. Don't know \ ﻢﻠﻋأ ﻻ 
209. Family Type \ ﺔﻠﺋﺎﻌﻟا عﻮﻧ:       1. Nuclear\ ﺔﯾوﻮﻧ        2. Extended\  ةﺪﺘﻤﻣ  
210. Number of people living in the household \ لﺰﻨﻤﻟا ﻲﻓ ﻦﯿﻤﯿﻘﻤﻟا داﺮﻓﻷا دﺪﻋ: 
 
210.1  Number of adults \ ﻦﯿﻐﻟﺎﺒﻟا دﺪﻋ:  0  1  2  3  4  5  6  7  8  9  ≥10 
 
210.2  Number of children \ لﺎﻔطﻷا دﺪﻋ:  0  1  2  3  4  5  6  7  8  9  ≥10  
211.Number of children born to mother \ مﻸﻟ ﻦﯾدﻮﻟﻮﻤﻟا لﺎﻔطﻷا دﺪﻋ: 
0  1  2  3  4  5  6  7  8  9   ≥10  
212. Number of children alive \ ءﺎﯿﺣﻷا لﺎﻔطﻷا دﺪﻋ:  
0  1  2  3  4  5  6  7  8  9   ≥10 
213. Birth order of affected child \ ةدﻻﻮﻟا ﺐﺴﺣ بﺎﺼﻤﻟا ﻞﻔﻄﻟا ﺐﯿﺗﺮﺗ:  
0  1  2  3  4  5  6  7  8  9   ≥10 
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214. Number of children with disorder \  لﺎﻔطﻷا دﺪﻋﻦﯿﺑﺎﺼﻤﻟا : 
 0  1  2  3  4  5  6  7  8  9   ≥10 
215. Who is the primary care giver \ ﻞﻔﻄﻠﻟ ﺔﯾﺎﻋﺮﻟا ﻢﯾﺪﻘﺗ ﻦﻋ لوﻷا لﻮﺌﺴﻤﻟا ﻮھ ﻦﻣ?  
 
1. Mother\مﻷا                        2. Father\بﻷا                                       3. Sister\ﺖﺧﻷا 
4. Grandmother\ ﺪﺠﻟاة             5. Domestic helper\  ﺔﯿﻟﺰﻨﻤﻟا ﺔﻣدﺎﺨﻟا             
6. Other\ىﺮﺧأ:_____ 
216. Who is the secondary care giver \ ﻞﻔﻄﻠﻟ ﺔﯾﺎﻋﺮﻟا ﻢﯾﺪﻘﺗ ﻦﻋ ﻲﻧﺎﺜﻟا لﻮﺌﺴﻤﻟا ﻮھ ﻦﻣ? 
 
1. Mother\مﻷا                        2. Father\بﻷا                                     3. Sister\ﺖﺧﻷا 
4. Grandmother\ةﺪﺠﻟا            5. Domestic helper\  ﺔﯿﻟﺰﻨﻤﻟا ﺔﻣدﺎﺨﻟا           
6. Other\  ىﺮﺧأ :_____ 
 
 
 
3. Health related questions 
 
301. What was your child’s age at diagnosis \  ﺪﻨﻋ ﻚﻠﻔط ﺮﻤﻋ نﺎﻛ ﻢﻛﺺﯿﺨﺸﺘﻟا ? 
 
1. ___ days\مﺎﯾأ        2.___ weeks\ﻊﯿﺑﺎﺳأ        3. ___ months\ﺮﮭﺷأ        4. ___ 
years\تاﻮﻨﺳ 
 
302. How many times have you attended appointments at KFSH&RC in the 
past year? 
ﺎﺤﺑﻷا ﺰﻛﺮﻣ و ﻲﺼﺼﺨﺘﻟا ﻞﺼﯿﻓ ﻚﻠﻤﻟا ﻰﻔﺸﺘﺴﻣ ﻲﻓ ﺪﯿﻋاﻮﻤﻠﻟ كرﻮﻀﺣ تاﺮﻣ دﺪﻋ ﻢﻛ ﺔﻨﺴﻟا لﻼﺧ ث
؟ﺔﯿﺿﺎﻤﻟا 
 
0   1   2   3   4   5   6   7   8   9   10   11   ≥12   
303. How often do you visit a health care facility with your child other than 
KFSH? 
؟ﻚﻠﻔط ﻊﻣ ﺮﺧآ ًﺎﯿﺒط ًاﺰﻛﺮﻣ ﺎﮭﯿﻓ ﻦﯾروﺰﺗ ﻲﺘﻟا تاﺮﻤﻟا دﺪﻋ ﻢﻛ 
 
1. Once a month \ ﺮﮭﺸﻟﺎﺑ ةﺮﻣ              
2. Every 3months \ ﺮﮭﺷأ ﺔﺛﻼﺛ ﻞﻛ       
3. Every 6months \ ﺮﮭﺷأ ﺔﺘﺳ ﻞﻛ           
4. Never (only go to KFSH) \   ﻲﺼﺼﺨﺘﻟا ﻞﺼﯿﻓ ﻚﻠﻤﻟا ﻰﻔﺸﺘﺴﻣ ﺮﯿﻐﻟ ﺐھذأ ﻻ ،ﺎﻘﻠﻄﻣ                
5. Other \ ىﺮﺧأ:________ 
304. How often do you send blood samples for your child/children? 
؟ﻚﻟﺎﻔطأ/ﻚﻠﻔﻄﻟ مد تﺎﻨﯿﻋ ﻦﯿﻠﺳﺮﺗ ةﺮﻣ ﻢﻛ 
 
1. Once a month \ ﺮﮭﺸﻟﺎﺑ ةﺮﻣ                 2. Every 3months \ ﺮﮭﺷأ ﺔﺛﻼﺛ ﻞﻛ       
3. Every 6months \ ﺮﮭﺷأ ﺔﺘﺳ ﻞﻛ             4. Other \ ىﺮﺧأ:________ 
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305. What do you expect the dietitian to do if your child’s blood phenylalanine 
level was high? 
 ؟ﻚﻠﻔط مد ﻲﻓ (ﺔﺿﻮﻤﺤﻟا)ﻦﯿﻨﻟأ ﻞﻨﯿﻔﻟا ﺾﻤﺤٮﻮﺘﺴﻣ عﺎﻔﺗرا لﺎﺣ ﻲﻓ ﺔﯾﺬﻐﺘﻟا ﺔﯿﺋﺎﺼﺧأ ﻞﻌﻔﺗ نأ ﻦﯿﻌﻗﻮﺘﺗ اذﺎﻣ 
 Increase the formula \ ﺐﯿﻠﺤﻟا ﺔﻄﻠﺧ ةدﺎﯾز 
 Reduce the formula \ ﺐﯿﻠﺤﻟا ﺔﻄﻠﺧ ﻞﯿﻠﻘﺗ 
 Increase protein from food \ ءاﺬﻐﻟا ﻲﻓ ﻦﯿﺗوﺮﺒﻟا ةدﺎﯾز 
 Reduce protein from food \ ءاﺬﻐﻟا ﻦﻣ ﻦﯿﺗوﺮﺒﻟا ﻞﯿﻠﻘﺗ 
 Ask if the child was ill \  ًﺎﻀﯾﺮﻣ ﻚﻠﻔط نﺎﻛ نإ لﺄﺴﺗ 
 Don’t know \ ﻢﻠﻋأ ﻻ 
 Other \ ىﺮﺧأ: ________ 
306. What do you think is the risk for your child if his/her blood phenylalanine 
level was constantly high? 
؟راﺮﻤﺘﺳﺎﺑ ﻊﻔﺗﺮﻣ مﺪﻟﺎﺑ ﻦﯿﻨﻟأ ﻞﻨﯿﻔﻟا ﺾﻤﺣ ىﻮﺘﺴﻣ نﻮﻜﯾ ﺎﻣﺪﻨﻋ كﺮﻈﻨﺑ ﻚﻠﻔط ﮫﻟ ضﺮﻌﻤﻟا ﺮﻄﺨﻟا ﺎﻣ 
 No effect \ ﺮﺛﺆﯾ ﻻ 
 Irritability \ حﺎﯿﺗرا مﺪﻌﺑ رﻮﻌﺸﻟا 
 Illness \ ضﺮﻤﻟا 
 Hyperactivity \  طﺎﺸﻨﻟا ةدﺎﯾزﺔﻛﺮﺤﻟاو  
 Permanent learning difficulties \ ﺔﻤﺋاد ﻢﻠﻌﺗ تﺎﺑﻮﻌﺻ 
 Paralysis \ ﻞﻠﺷ 
 Don’t know \ ﻢﻠﻋأ ﻻ 
 Other \ ىﺮﺧأ: ________ 
307. How would you describe your child’s health in general\  ﻚﻠﻔط ﺔﺤﺻ ﻦﯿﻔﺼﺗ ﻒﯿﻛ
 ًﺎﻣﻮﻤﻋ?  
 
1. Excellent \ ةزﺎﺘﻤﻣ          2. Good \ ةﺪﯿﺟ          3. Fair \ ﻂﺳو          4. Poor \ ﺔﺌﯿﺳ 
308.1 Is there any other problem your child suffers from \  ﻞﻛﺎﺸﻣ ﻦﻣ ﻚﻠﻔط ﻲﻧﺎﻌﯾ ﻞھ
ىﺮﺧأ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
308.2 If yes, specify \ يدﺪﺣ ،ﻢﻌﻧ ﺔﺑﺎﺟﻹا ﺖﻧﺎﻛ اذإ: 
309.1 Has your child been ill in the past 2 weeks \  ﻦﯿﻋﻮﺒﺳﻹا لﻼﺧ ﻚﻠﻔط ضﺮﻣ ﻞھ
ﻦﯿﯿﺿﺎﻤﻟا? 
 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
309.2 If yes- What was the illness \ ﻲﻧﺎﻌﯾ نﺎﻛ ﻢﻣ ،ﻢﻌﻧ ﺔﺑﺎﺟﻹا ﺖﻧﺎﻛ اذإ?  
 
 Cold\مﺎﻛز           Fever\ةراﺮﺣ          Cough \  ﺔﺤﻛ          Diarrhea\لﺎﮭﺳإ 
 Vomiting\ﺆﯿﻘﺗ              Other\ىﺮﺧأ:_______ 
310. Did your child give a blood sample today \  مﻮﯿﻟا ﻚﻠﻔﻄﻟ مد ﺔﻨﯿﻋ تﺬﺧأ ﻞھ ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
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4. Development related questions 
 
401. Does your child go to school \ ﺔﺳرﺪﻤﻠﻟ ﻚﻠﻔط ﺐھﺬﯾ ﻞھ?   1. Yes \ ﻢﻌﻧ          2. No \ 
ﻻ 
If no, go to section 5 \ ٥ ةﺮﻘﻔﻟ ﻲﺒھذا ،ﻻ باﻮﺠﻟا نﺎﻛ اذإ 
 
If yes \ ﻢﻌﻧ باﻮﺠﻟا نﺎﻛ اذإ: 
402. Which year of school \ ﻚﻠﻔط ﺔﯿﺳارد ﺔﻨﺳ يﺄﺑ? 
Nursery\ﺔﻧﺎﻀﺣ    KG1\ﺔﺿور    KG2\يﺪﯿﮭﻤﺗ   1   2   3   4   5   6   7   8   9   10   11   12 
 
 
403. What is the school \ ﺔﺳرﺪﻤﻟا ﻲھ ﺎﻣ? ________________ 
 
1. Public school (regular)\ ﺔﯿﻣﻮﻜﺣ سراﺪﻣ 
2. Public school with special education classes\ صﺎﺧ ﻢﯿﻠﻌﺗ ﺎﮭﺑ ﺔﯿﻣﻮﻜﺣ سراﺪﻣ 
3. Private school (regular)\ ﺔﯿﻠھأ سراﺪﻣ 
4. Private school with special education classes\ صﺎﺧ ﻢﯿﻠﻌﺗ ﺎﮭﺑ ﺔﯿﻠھأ سراﺪﻣ 
5. Special education school\ صﺎﺧ ﻢﯿﻠﻌﺗ وأ ﻞﯿھﺄﺗ سراﺪﻣ 
6. Other \ ىﺮﺧأ: ________ 
404. Do you think your child needs special education \  ﻞھ ﺔﺟﺎﺤﺑ ﻚﻠﻔط نأ ﻦﯾﺪﻘﺘﻌﺗ
صﺎﺧ ﻢﯿﻠﻌﺘﻟ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
405. Does your child receive any special education at school\ ﻢﯿﻠﻌﺗ يأ ﻚﻠﻔط ﻰﻘﻠﺘﯾ ﻞھ
ﮫﺘﺳرﺪﻣ ﻲﻓ صﺎﺧ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
If no \ ﻻ باﻮﺠﻟا نﺎﻛ اذا: 
406. Why not \  ًﺎﻤﯿﻠﻌﺗ ﻰﻘﻠﺘﯾ ﻻ ﻢﻟ ًﺎﺻﺎﺧ ? 
 
 
 
5. Social activities questions 
 
501. How often do you as a family go out with your child \ ﻚﻠﻔط ﻊﻣ نﻮﺟﺮﺨﺗ ﻢﻛ ﻞﻛ
ةﺮﺳﺄﻛ? 
 
1. Daily \  ًﺎﯿﻣﻮﯾ          2. Weekly \  ًﺎﯿﻋﻮﺒﺳا          3. Monthly \  ًﺎﯾﺮﮭﺷ          4. Rarely \  ًاردﺎﻧ 
502. Where do you go/ نﻮﺒھﺬﺗ ﻦﯾأ ﻰﻟإ? 
 
 Family visits \ ﺔﻠﺋﺎﻌﻟا تارﺎﯾز 
 Outings \ ﺢﺴﻓ 
 Shopping \ قﻮﺴﺗ 
 Other \ ىﺮﺧأ: ________ 
503. Do you have limitations or difficulties when going out due to your child’s 
condition? 
 ﺔﻟﺎﺣ ﺐﺒﺴﺑ جوﺮﺨﻟا ﺪﻨﻋ تﺎﺑﻮﻌﺻ وأ ًاﺪﯿﯿﻘﺗ نﻮﮭﺟاﻮﺗ ﻞھ؟ﻚﻠﻔط  
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1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
504. If yes- is it due to \ ﺐﺒﺴﺑ ﻚﻟذ ﻞﮭﻓ ،ﻢﻌﻧ باﻮﺠﻟا اذإ: 
 
 Illness \ ضﺮﻤﻟا Diet \ ﺔﯿﻤﺤﻟا Formula \ ﺔﻄﻠﺨﻟا 
 Embarrassment \ جاﺮﺣﻹا 
 Influence of others \ ﻦﯾﺮﺧﻵا ﺮﯿﺛﺄﺗ 
 Disability of child \  ﻞﻔﻄﻟا ىﺪﻟ ﺔﻗﺎﻋﻹا 
 Difficulty with child \ ﻞﻔﻄﻟا ﻊﻣ ﻞﻣﺎﻌﺘﻟا ﺔﺑﻮﻌﺻ 
 General anxiety (worried about child) \  (ﻞﻔﻄﻟا ﻰﻠﻋ ﻖﻠﻗ) ﺔﻣﺎﻋ فوﺎﺨﻣ 
 Other \ ىﺮﺧأ: ________  
 
 
6. Attitudinal / practices questions 
 
601. How would you rate your knowledge about your child’s condition? 
؟ﻚﻠﻔط ﺔﻟﺎﺤﺑ ﻚﺘﻓﺮﻌﻣ ﻦﯿﻤﯿﻘﺗ ﻒﯿﻛ 
1. Excellent \ ةزﺎﺘﻤﻣ          2. Good \ ةﺪﯿﺟ          3. Fair \ ﻂﺳو       4. Poor \ ﺔﺌﯿﺳ 
602. How would you rate your knowledge about your child’s dietary needs?  
؟ﺔﯿﺋاﺬﻐﻟا ﻚﻠﻔط تﺎﺟﺎﯿﺘﺣﺎﺑ ﻚﺘﻓﺮﻌﻣ ﻦﯿﻤﯿﻘﺗ ﻒﯿﻛ 
1. Excellent \ ةزﺎﺘﻤﻣ          2. Good \ ةﺪﯿﺟ          3. Fair \ ﻂﺳو         4. Poor \ ﺔﺌﯿﺳ 
603. What do you think is the importance of your child drinking the special 
formula? 
؟ﺔﺻﺎﺨﻟا ﺔﻄﻠﺨﻠﻟ ﻚﻠﻔط بﺮﺷ ﺔﯿﻤھا ﺎﻣ ،كدﺎﻘﺘﻋﺎﺑ 
 
1.Very important\ ًاﺪﺟ ﻢﮭﻣ    2. Somewhat important\ﺎﻣ ًﺎﻋﻮﻧ ﻢﮭﻣ   3. Not important\ ﺮﯿﻏ
ﻢﮭﻣ 
604. What do you think is the importance of your child eating his/her specific 
diet? 
؟ﺔﺻﺎﺨﻟا ﮫﺋاﺬﻏ ﺔﯿﻤﺣ لوﺎﻨﺘﺑ ﻚﻠﻔط ماﺰﺘﻟا ﺔﯿﻤھأ ﺎﻣ ،ﻚﯾأﺮﺑ 
 
1.Very important\ ًاﺪﺟ ﻢﮭﻣ    2. Somewhat important\ﺎﻣ ًﺎﻋﻮﻧ ﻢﮭﻣ   3. Not important\ ﺮﯿﻏ
ﻢﮭﻣ 
605. How do you find adhering to the diet \ ﺔﯿﺋاﺬﻐﻟا ﺔﯿﻤﺤﻟﺎﺑ ماﺰﺘﻟﻻا ﻦﯾﺪﺠﺗ ﻒﯿﻛ? 
1. Very easy\ ًاﺪﺟ ﻞﮭﺳ     2. Easy\ﻞﮭﺳ     3. Difficult\ﺐﻌﺻ     4. Very difficult\ ًاﺪﺟ ﺐﻌﺻ 
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606.Which of the following you recognize as a barrier to following the diet for 
your child: 
:ﺔﯿﺋاﺬﻐﻟا ﺔﯿﻤﺤﻠﻟ ﻚﻠﻔط عﺎﺒﺗا ﻦﻣ ﻖﯿﻌﯾ ﺔﯿﺗﻵا رﻮﻣﻷا ﻦﻣ يأ 
 
 Family members; siblings, grandparents, aunts, or uncles \  ،داﺪﺟأ ،ناﻮﺧأ) ﺔﻠﺋﺎﻌﻟا داﺮﻓأ
(لاﻮﺧأ ، مﺎﻤﻋأ 
 Social visits \ ﺔﯿﻋﺎﻤﺘﺟﻻا تارﺎﯾﺰﻟا 
 School; teachers or pupils \ (بﻼطو ﻦﯿﺳرﺪﻣ) ﺔﺳرﺪﻤﻟا 
 Other children, friends of child \ ﻞﻔﻄﻟا ءﺎﻗﺪﺻأ ،ﻦﯾﺮﺧآ لﺎﻔطأ 
 Limited dietary choices \ ةدوﺪﺤﻤﻟا ﺔﯿﺋاﺬﻐﻟا تارﺎﯿﺘﺧﻻا 
 Child unattended around food \ مﺎﻌﻄﻟا لﻮﺣ ﻮھو ﻞﻔﻄﻟا ﺔﺒﻗاﺮﻣ مﺪﻋ 
 Child’s insistence on eating forbidden food \  ﺔﯾﺬﻏﻷا ﻦﻣ ﻞﻛﻷا ﻰﻠﻋ ﻞﻔﻄﻟا راﺮﺻإ
ﺔﻋﻮﻨﻤﻤﻟا 
 Limited knowledge of diet \ ﻲﺋاﺬﻐﻟا مﺎﻈﻨﻟﺎﺑ ةدوﺪﺤﻤﻟا ﺔﻓﺮﻌﻤﻟا 
 Other \ ىﺮﺧأ:________ 
 No barriers \ ﻖﺋاﻮﻋ ﺪﺟﻮﯾ ﻻ 
607. For how long do you think your child should follow this diet? 
؟ﺔﯿﺋاﺬﻐﻟا ﺔﯿﻤﺤﻟا هﺬھ ﻞﻔﻄﻟا ﻊﺒﺘﯾ نأ ﺐﺠﯾ كدﺎﻘﺘﻋﺎﺑ ﻰﺘﻣ ﻰﻟإ 
 
1. Few years \ تاﻮﻨﺳ ﻊﻀﺑ                        2.Until he/she grows up \ﺮﺒﻜﯾ ﻰﺘﺣ      
3. Until he/she is cured \ﻰﻔﺸﯾ ﻰﺘﺣ           4. All his/her life \ ﮫﺗﺎﯿﺣ لاﻮط     
5. Don’t know \ ﻢﻠﻋأ ﻻ                            6. Other \ ىﺮﺧأ:________ 
608. If you had a question regarding the diet, what would you do: 
؟ﺔﯿﺋاﺬﻐﻟا ﺔﯿﻤﺤﻟا ﻦﻋ لاﺆﺳ ﻚﯾﺪﻟ نﺎﻛ اذإ ﻦﯿﻠﻌﻔﺗ اذﺎﻣ 
 
 Wait till the next appointment. \ مدﺎﻘﻟا ﺪﻋﻮﻤﻠﻟ رﺎﻈﺘﻧﻻا 
 Call the dietitian to ask. \ لاﺆﺴﻠﻟ ﺔﯾﺬﻐﺘﻟا ﺔﯿﺋﺎﺼﺧﺄﺑ لﺎﺼﺗﻻا 
 Try to find some information to read. \ ةءوﺮﻘﻣ تﺎﻣﻮﻠﻌﻣ ﻦﻋ ﺚﺤﺒﻟا ﺔﻟوﺎﺤﻣ 
 Don’t know. \ ﻢﻠﻋأ ﻻ 
 Other \ ىﺮﺧأ:__________ 
 
 
7. Knowledge questions: 
 
Statement  True False Don’t 
know 
701. It is all right for a child with PKU to eat dates. 
.ﺮﻤﺘﻟا (ﻮﯾ ﻲﻛ ﻲﺑ) ـﺑ بﺎﺼﻤﻟا ﻞﻔﻄﻟا ﻞﻛﺄﯾ نأ سﺄﺑ ﻻ 1 2 3 
702. It is all right for a child with PKU to eat rice 
with meat stew. 
.ﻢﺤﻠﻟا ﺔﻗﺮﻣ ﻊﻣ زﺮﻟا ﻞﻔﻄﻟا ﻞﻛﺄﯾ نأ سﺄﺑ ﻻ 
1 2 3 
703. It is all right for a child with PKU to eat lintels. 
.سﺪﻌﻟا ﻞﻔﻄﻟا ﻞﻛﺄﯾ نأ سﺄﺑ ﻻ 1 2 3 
704. It is all right for a child with PKU to drink diet 
cola. 
.ﻻﻮﻛ ﺖﯾاد ﻞﻔﻄﻟا بﺮﺸﯾ نأ سﺄﺑ ﻻ 
1 2 3 
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8. Dietary habits 
 
801. Who usually buys the food for the family \  ﺔﯿﺋاﺬﻐﻟا داﻮﻤﻟا ءاﺮﺷ ﻦﻋ لوﺆﺴﻤﻟا ﻮھ ﻦﻣ
ﺔﻠﺋﺎﻌﻠﻟ? 
 
1. Father \ بﻷا            2. Mother \ مﻷا            3. Grandparent \ ةﺪﺠﻟا وأ ﺪﺠﻟا         
4. Both parents \ ﻦﯾﺪﻟاﻮﻟا ﻼﻛ           5. Driver \ ﻖﺋﺎﺴﻟا           6. Other \ ىﺮﺧأ:______ 
802. What is your food budget \ ءاﺬﻐﻠﻟ ﺔﺼﺼﺨﻤﻟا ﺔﯿﻧاﺰﯿﻤﻟا ﻲھ ﺎﻣ?  
 
1. < 500 per week \  ﻦﻣ ﻞﻗأ٥۰۰ عﻮﺒﺳﻷﺎﺑ ﷼     2. 500-1000 per week \ ٥۰۰ – ۱۰۰۰  ﷼
عﻮﺒﺳﻷﺎﺑ          3. > 1000 per week \  ﻦﻣ ﺮﺜﻛأ۱۰۰۰ عﻮﺒﺳﻷﺎﺑ ﷼         4. Don't know \  ﻢﻠﻋأ ﻻ 
803. Who usually prepares food for the family \  ًةدﺎﻋ ﺔﻠﺋﺎﻌﻠﻟ مﺎﻌﻄﻟا ﺮﻀﺤﯾ ﻦﻣ? 
 
1. Mother \ مﻷا          2. Father \ بﻷا        3. Grandparent \ ةﺪﺠﻟا وأ ﺪﺠﻟا        4. 
Domestic helper \ ﺔﻣدﺎﺨﻟا          5. Other \ ىﺮﺧأ: ________ 
804. Is the child’s food prepared separately \  مﺎﻌط ﻦﻋ ﻼﺼﻔﻨﻣ ﻞﻔﻄﻟا مﺎﻌط ﺮﯿﻀﺤﺗ ﻢﺘﯾ ﻞھ
ﺔﻠﺋﺎﻌﻟا? 
 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
805. Who usually prepares food for the child \  ًةدﺎﻋ ﻞﻔﻄﻠﻟ مﺎﻌﻄﻟا ﺮﻀﺤﯾ ﻦﻣ? 
 
1. Mother \ مﻷا          2. Father \ بﻷا        3. Grandparent \ ةﺪﺠﻟا وأ ﺪﺠﻟا        4. 
Domestic helper \ ﺔﻣدﺎﺨﻟا          5. Other \ ىﺮﺧأ: ________ 
806. Who prepares the formula for the child \ ﻞﻔﻄﻠﻟ ﺔﻄﻠﺨﻟا ﺮﻀﺤﯾ ﻦﻣ? 
 
1. Mother \ مﻷا             2. Father \ بﻷا           3. Grandparent \ ﺠﻟاةﺪﺠﻟا وأ ﺪ   
4. The child \ ﻞﻔﻄﻟا         5. Domestic helper \ ﺔﻣدﺎﺨﻟا          6. Other \ ىﺮﺧأ: ________ 
807. How long does it take to prepare the formula \  ﺮﯿﻀﺤﺗ قﺮﻐﺘﺴﯾ ﺖﻗﻮﻟا ﻦﻣ ﻢﻛ
ﺔﻄﻠﺨﻟا? 
 
1. <5min \  ﻦﻣ ﻞﻗأ٥ ﻖﺋﺎﻗد           2. 5-10min \ ٥ – ۱۰ ﻖﺋﺎﻗد       3. 10-15min \ ۱۰ – ۱٥ ﺔﻘﯿﻗد            
4. 15-20min \ ۱٥ – ۲۰ ﺔﻘﯿﻗد       5. >20min \  ﻦﻣ ﺮﺜﻛأ۲۰ ﺔﻘﯿﻗد  
808. How do you prepare the formula \ ﺔﻄﻠﺨﻟاﺮﯿﻀﺤﺗ ﻢﺘﯾ ﻒﯿﻛ? 
 
1. Prepare a batch for 2 days. \ ﻦﯿﻣﻮﯿﻟ ﻲﻔﻜﺗ ﺔﯿﻤﻛ ﺮﯿﻀﺤﺗ 
2. Prepare batch for one day. \ ﺪﺣاو مﻮﯿﻟ ﻲﻔﻜﺗ ﺔﯿﻤﻛ ﺮﯿﻀﺤﺗ 
3. Prepare batch for half a day. \  مﻮﯾ ﻒﺼﻨﻟ ﻲﻔﻜﺗ ﺔﯿﻤﻛ ﺮﯿﻀﺤﺗ 
4. Prepare an amount just before drinking. \ ﻞﯿﻠﻘﺑ ﺎﮭﻟوﺎﻨﺗ ﻞﺒﻗ ﺔﯿﻤﻛ ﺮﯿﻀﺤﺗ 
5. Other \ ىﺮﺧأ: ______ 
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809. What are the ingredients of your child’s formula \  تﺎﻧﻮﻜﻣ ﻲھ ﺎﻣﻚﻠﻔط ﺔﻄﻠﺧ ? 
 
1. _______ml water        2. ______scoops Phenex 1        3. ______ scoops Polycose 
 
4. _______scoops Pro-Phree           5. Other \ ىﺮﺧأ:______ 
810. Does your child drink all of his/her formula \ ﺔﻠﻣﺎﻛ ﺔﻄﻠﺨﻟا ﻚﻠﻔط بﺮﺸﯾ ﻞھ?  
 
1. Always \  ًﺎﻤﺋاد          2. Usually \  ًةدﺎﻋ         3. Occasionally \  ًﺎﻧﺎﯿﺣأ         4. Never \  ًاﺪﺑأ 
811. How many times per day does the child drink the formula \  مﻮﯿﻟﺎﺑ ةﺮﻣ ﻢﻛ
ﺔﻄﻠﺨﻟا ﻞﻔﻄﻟا بﺮﺸﯾ?  
 
812. How much formula does the child drink each time \ ﻤﻛ ﻲھﺎﻣ ﻲﻟا ﺔﻄﻠﺨﻟا ﺔﯿ
ةﺮﻣ ﻞﻛ ﻲﻓ ﻞﻔﻄﻟا ﺎﮭﺑﺮﺸﯾ? 
813. Total amount of formula the child drinks per day \  ﻲﺘﻟا ﺔﻄﻠﺨﻟا ﺔﯿﻤﻛ عﻮﻤﺠﻣ
مﻮﯿﻟﺎﺑ ﻞﻔﻄﻟا ﺎﮭﺑﺮﺸﯾ: 
 
814. Does your child have difficulty drinking the formula\ ﺔﺑﻮﻌﺻ ﻦﻣ ﻚﻠﻔط ﻲﻧﺎﻌﯾ ﻞھ
ﺔﻄﻠﺨﻟا بﺮﺷ ﻲﻓ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
815. If yes: Why \ اذﺎﻤﻟ ،ﻢﻌﻧ باﻮﺠﻟا نﺎﻛ اذإ?   
 
 Taste \ ﻢﻌﻄﻟا     Smell \ ﺔﺤﺋاﺮﻟا     Consistency \ ﺔﻓﺎﺜﻜﻟا     Other 
\ىﺮﺧأ:_______ 
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9. Diet history 
901. Twenty four hour food recall \  لا لﻼﺧ ﻞﻔﻄﻟا مﺎﻌط۲٤ ﺔﯿﺿﺎﻤﻟا ﺔﻋﺎﺳ  
 
Food item / Time of day  
مﻮﯿﻟا لﻼﺧ ﺖﻗﻮﻟا/ءاﺬﻐﻟا عﻮﻧ 
Quantity 
ﺔﯿﻤﻜﻟا 
First thing in the morning \  ءﻲﺷ لوأ
 ًﺎﺣﺎﺒﺻ: 
 
  
  
  
Breakfast \ رﺎﻄﻓﻹا:  
  
  
  
Morning snack \ حﺎﺒﺼﻟﺎﺑ ﺔﻔﯿﻔﺧ ﮫﺒﺟو:  
  
  
  
Lunch \ ءاﺪﻐﻟا:  
  
  
  
  
  
  
Afternoon snack \ ءﺎﺴﻤﻟﺎﺑ ﺔﻔﯿﻔﺧ ﺔﺒﺟو:  
  
  
  
Dinner \ ءﺎﺸﻌﻟا:  
  
  
  
  
Before bed time snack \  ﻞﺒﻗ ﺔﻔﯿﻔﺧ ﺔﺒﺟو
مﻮﻨﻟا: 
 
  
  
902. Do you cook with fat/oil \ مﺎﻌﻄﻟا ﻲﮭط ﻲﻓ ﻦھﺪﻟا وأ ﺖﯾﺰﻟا ماﺪﺨﺘﺳﺎﺑ ﻦﯿﻣﻮﻘﺗ ﻞھ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
If yes \  ﻢﻌﻧ باﻮﺠﻟا نﺎﻛ اذإ :   
903. What type of fat do you use \ نﻮﻣﺪﺨﺘﺴﺗ نﻮھﺪﻟا ﻦﻣ عﻮﻧ يأ? 
 
 Vegetable oil \ ﻲﺗﺎﺒﻧ ﺖﯾز     Butter \ ةﺪﺑز     Ghee \ ﻦﻤﺳ     Other \ىﺮﺧأ:____ 
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10. Personal concerns 
 
1001. What are your main concerns for this child (PKU) \  ﺎﻣ ﻲﺳﺎﺳﻷا ﻚﻠﻏﺎﺷ
بﺎﺼﻤﻟا ﻚﻠﻔط صﻮﺼﺨﺑ? 
 
1. ______________________ 
2. ______________________ 
3. ______________________ 
1002. Do you think caring for a child with PKU affects your health? 
 (ﻮﯾ ﻲﻛ ﻲﺑ) ـﺑ بﺎﺼﻣ ﻞﻔﻄﺑ مﺎﻤﺘھﻻا نأ ﻦﯾﺪﻘﺘﻌﺗ ﻞھ؟ﻚﺘﺤﺻ ﻰﻠﻋ ﺮﺛﺆﯾ 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
1003. Does it make you sad, depressed or stressed \  وأ ،ﺔﺑﺂﻜﻟا وأ ،نﺰﺤﻟﺎﺑ كﺮﻌﺸﯾ ﻚﻟذ ﻞھ
 ؟ﻂﻐﻀﻟا 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
1004. Do you have a family member(s) available to help you when you need 
help? (Probe: with care for this child or other responsibilities around the house) 
؟ ﻚﻟﺬﻟ ﻚﺘﺟﺎﺣ ﺪﻨﻋ ﻚﺘﻠﺋﺎﻋ داﺮﻓأ ﻦﻣ ﻚﻟ ةﺪﻋﺎﺴﻤﻟا ﻢﯾﺪﻘﺗ ﻊﯿﻄﺘﺴﯾ ﻦﻣ ﺪﺟﻮﯾ ﻞھ  ةﺪﻋﺎﺴﻤﻟا ءاﻮﺳ :ﺰﯿﻔﺤﺗ)
(ىﺮﺧﻷا ﺔﯿﻟﺰﻨﻤﻟا تﺎﯿﻟوﺆﺴﻤﻟا وأ ﻚﻠﻔط ﺔﯾﺎﻋﺮﺑ 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
1005.Rate the degree to which your child’s illness is understood by: 
:ﻞﺒﻗ ﻦﻣ ﻚﻠﻔط ضﺮﻣ ﻢﮭﻓ ﺔﺟرد ﻲﻟ ﻲﻤﯿﻗ 
  
Does not 
apply to 
me 
 ﻖﺒﻄﻨﯾ ﻻ
ﻲﻠﻋ 
Misunderstood 
مﻮﮭﻔﻣ ﺮﯿﻏ 
Understood 
مﻮﮭﻔﻣ 
Completely 
understood 
 ًﺎﻣﺎﻤﺗ مﻮﮭﻔﻣ 
1005.1 Your spouse ﻚﺟوز 0 1 2 3 
1005.2 Your children ﻚﻟﺎﻔطأ 0 1 2 3 
1005.3 
Other family 
members 
ﺔﻠﺋﺎﻌﻟا داﺮﻓأ ﻲﻗﺎﺑ 
0 1 2 3 
1005.4 Friends ءﺎﻗﺪﺻﻷا 0 1 2 3 
 
1006. Would you want a family member(s) to know more about your child’s 
illness? 
؟ﻚﻠﻔط ﺔﻟﺎﺣ ﻦﻋ ﺮﺜﻛأ ﻚﺘﻠﺋﺎﻋ داﺮﻓأ فﺮﻌﯾ نأ ﻦﯾدﻮﺗ ﻞھ 
 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
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11. Getting help 
 
1101. Where are you currently getting your information about PKU from? 
(ﻮﯾ ﻲﻛ ﻲﺑ) ﻦﻋ ﻚﺗﺎﻣﻮﻠﻌﻣ ﻰﻠﻋ ﻦﯿﻠﺼﺤﺗ ﻦﯾأ ﻦﻣ ً؟ﺎﯿﻟﺎﺣ 
 
1101.1 Doctor \ ﺐﯿﺒﻄﻟا 
1101.2 Nurse \ ﺔﺿﺮﻤﻤﻟا 
1101.3 Dietitian \ ﺔﯾﺬﻐﺘﻟا ﺔﯿﺋﺎﺼﺧأ 
1101.4 Another person with the same diagnosis \  ﺺﺨﺷضﺮﻤﻟا ﺲﻔﻧ ﻦﻣ ﻲﻧﺎﻌﯾ ﺮﺧآ  
1101.5 Books \ ﺐﺘﻛ 
1101.6 Internet \ ﺖﻧﺮﺘﻧا 
1101.7 Other \ ىﺮﺧأ: __________   
 
1102. Would you be interested in joining a family support group? 
؟ﻞﺋاﻮﻌﻟا ﻢﻋد ﺔﻋﻮﻤﺠﻣ ﻰﻟا مﺎﻤﻀﻧﻻﺎﺑ مﺎﻤﺘھﻻا ﻚﯾﺪﻟ ﻞھ 
 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
1103.List the topics you wish to learn more about: 
:ﺎﮭﻨﻋ ﺪﯾﺰﻤﻟا ﺔﻓﺮﻌﻣ ﻲﻓ ﻦﯿﺒﻏﺮﺗ ﻲﺘﻟا ﻊﯿﺿاﻮﻤﻟا يدﺪﺣ 
 
1. ______________________________________________________________ 
 
2. ______________________________________________________________ 
 
3. ______________________________________________________________ 
 
4. ______________________________________________________________ 
    
1104. How would you prefer to obtain this information? 
    ؟تﺎﻣﻮﻠﻌﻤﻟا ﻚﻠﺗ ﻰﻠﻋ لﻮﺼﺤﻟا ﺎﮭﺑ ﻦﯿﺒﻏﺮﺗ ﻲﺘﻟا ﺔﻘﯾﺮﻄﻟا ﻲھ ﺎﻣ 
1104 Form of information provision 
تﺎﻣﻮﻠﻌﻤﻟا ﻢﯾﺪﻘﺗ ﺔﻠﯿﺳو 
Yes 
ﻢﻌﻧ 
No 
ﻻ 
Don’t 
 
يردأ ﻻ 
1104.1 Formal group lectures 
ﺔﯿﻤﺳر ﺔﯿﻋﺎﻤﺟ تاﺮﺿﺎﺤﻣ  1 2 3 
1104.2 
Informal sessions during clinic visits from a 
member of your health care team 
 ﺪﺣأ ﻦﻣ ةدﺎﯿﻌﻟا ةرﺎﯾز لﻼﺧ ﺔﯿﻤﺳر ﺮﯿﻏ تﺎﺴﻠﺟ ﻖﯾﺮﻔﻟا ءﺎﻀﻋأ
ﻲﺒﻄﻟا 
1 2 3 
1104.3 Cassettes to listen to at home 
لﺰﻨﻤﻟا ﻲﻓ ﻞﯿﺠﺴﺗ ﻂﯾﺮﺷ ﻰﻟا عﺎﻤﺘﺳﻻا 1 2 3 
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1104.4 Videotapes to view at home  
لﺰﻨﻤﻟا ﻲﻓ ﻮﯾﺪﯿﻓ ﻂﯾﺮﺷ ةﺪھﺎﺸﻣ  1 2 3 
1104.5 Written material (e.g. pamphlets)  
(تارﻮﺸﻨﻣ :لﺎﺜﻣ) ﺔﺑﻮﺘﻜﻣ داﻮﻣ    1 2 3 
1104.6 
A designated time period during which you 
could phone a health professional to answer 
specific questions 
 ﺔﻠﺌﺳا ﻦﻋ ﺔﺑﺎﺟﻺﻟ دﺪﺤﻣ ﺖﻗو لﻼﺧ ﻦﯿﺼﺘﺨﻤﻟا ﺪﺣﺄﺑ لﺎﺼﺗﻻا
ةدﺪﺤﻣ 
1 2 3 
1104.7 Other:  ىﺮﺧأ 
 
 
1105. Please list suggestions on how we could improve your health care: 
 :ﻢﻜﻟ ﺔﻣﺪﻘﻤﻟا ﺔﯿﺤﺼﻟا تﺎﻣﺪﺨﻟا ﺮﯾﻮﻄﺗ ﺔﯿﻔﯿﻜﻟ ﻢﻜﺗﺎﺣاﺮﺘﻗا دﺮﺳ ءﺎﺟﺮﻟا 
 
1.________________________________________________________  
 
2.________________________________________________________ 
 
3.________________________________________________________ 
 
1106. Do you have any questions?  
؟ﺔﻠﺌﺳأ ﺔﯾأ ﻚﯾﺪﻟ ﻞھ 
 
 
 
1107. May I contact you within the next couple of weeks to ask you few 
questions? 
   ؟ﺔﻠﺌﺳﻷا ﺾﻌﺑ ﻚﻟﺄﺳﻷ ﻦﯿﻣدﺎﻘﻟا ﻦﯿﻋﻮﺒﺳﻷا لﻼﺧ ﻚﯿﻠﻋ ﻞﺼﺗا نأ ﻲﻨﻨﻜﻤﯾ ﻞھ 
 
1. Yes \،ﻢﻌﻧ ﻊﻧﺎﻣ ﻻ     2. No \  ﻻ 
 
 
 
 
Thank you very much for you time… 
ﻚﺘﻗو ﻰﻠﻋ ًاﺮﯿﺜﻛ كﺮﻜﺷأ
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Date: 
 
2. Socio-economic Status 
 
213. Birth order of affected child \ ةدﻻﻮﻟا ﺐﺴﺣ بﺎﺼﻤﻟا ﻞﻔﻄﻟا ﺐﯿﺗﺮﺗ:  
0  1  2  3  4  5  6  7  8  9   ≥10 
 
 
3. Health related questions 
 
301. What was your child’s age at diagnosis \ ﺺﯿﺨﺸﺘﻟا ﺪﻨﻋ ﻚﻠﻔط ﺮﻤﻋ نﺎﻛ ﻢﻛ? 
 
1. ____ days\مﺎﯾأ      2.____ weeks\ﻊﯿﺑﺎﺳأ     3. ____ months\ﺮﮭﺷأ    4. ____ 
years\تاﻮﻨﺳ 
 
303. How often do you visit a health care facility with your child? 
ﺗ ﻲﺘﻟا تاﺮﻤﻟا دﺪﻋ ﻢﻛ؟ﻚﻠﻔط ﻊﻣ ﺮﺧآ ﻲﺒط ﺰﻛﺮﻣ ﺎﮭﯿﻓ ﻦﯾروﺰ  
 
1. Once a month \ ﺮﮭﺸﻟﺎﺑ ةﺮﻣ            
2. Every 3months \ ﺮﮭﺷأ ﺔﺛﻼﺛ ﻞﻛ       
3. Every 6months \ ﺮﮭﺷأ ﺔﺘﺳ ﻞﻛ     
4. Never (only go to KFSH) \    ﻲﺼﺼﺨﺘﻟا ﻞﺼﯿﻓ ﻚﻠﻤﻟا ﻰﻔﺸﺘﺴﻣ ﺮﯿﻐﻟ ﺐھذأ ﻻ ﺎﻘﻠﻄﻣ 
5. Other \ ىﺮﺧأ:_______ 
 
307. How would you describe your child’s health in general\  ﻚﻠﻔط ﺔﺤﺻ ﻦﯿﻔﺼﺗ ﻒﯿﻛ
 ًﺎﻣﻮﻤﻋ?  
 
1. Excellent \ ةزﺎﺘﻤﻣ           2. Good \ ةﺪﯿﺟ           3. Fair \ ﻂﺳو           4. Poor \ ﺔﺌﯿﺳ 
308.1 Is there any other problem your child suffers from \ ﻔط ﻲﻧﺎﻌﯾ ﻞھ ﻞﻛﺎﺸﻣ ﻦﻣ ﻚﻠ
ىﺮﺧأ? 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
308.2 If yes, specify \ يدﺪﺣ ،ﻢﻌﻧ ﺔﺑﺎﺟﻹا ﺖﻧﺎﻛ اذإ: 
309.1 Has your child been ill in the past 2 weeks \  ﻦﯿﻋﻮﺒﺳﻹا لﻼﺧ ﻚﻠﻔط ضﺮﻣ ﻞھ
ﻦﯿﯿﺿﺎﻤﻟا? 
 
1. Yes \ ﻢﻌﻧ     2. No \ ﻻ 
309.2 If yes- What was the illness \ ﻲﻧﺎﻌﯾ نﺎﻛ ﻢﻣ ،ﻢﻌﻧ ﺔﺑﺎﺟﻹا ﺖﻧﺎﻛ اذإ?  
 
Cold\مﺎﻛز    Fever\ةراﺮﺣ   Cough \ ﺔﺤﻛ   Diarrhea\لﺎﮭﺳإ   Vomiting\ﺆﯿﻘﺗ 
 Other\ىﺮﺧأ:_______ 
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4. Development related questions 
 
401. Does your child go to school \ ﺔﺳرﺪﻤﻠﻟ ﻚﻠﻔط ﺐھﺬﯾ ﻞھ? 1. Yes \ ﻢﻌﻧ          2. No \ ﻻ 
If no, go to section 8 \ 8 ةﺮﻘﻔﻟ ﻲﺒھذا ،ﻻ باﻮﺠﻟا نﺎﻛ اذإ 
If yes \ ﻢﻌﻧ باﻮﺠﻟا نﺎﻛ اذإ: 
402. Which year of school \ ﻚﻠﻔط ﺔﯿﺳارد ﺔﻨﺳ يﺄﺑ? 
   Nursery \ ﺔﻧﺎﻀﺣ     KG1 \ ﺔﺿور    KG2 \ يﺪﯿﮭﻤﺗ      1    2    3    4    5    6    7    8    9    
10    11    12 
403. What is the school \ ﺔﺳرﺪﻤﻟا ﻲھ ﺎﻣ? ________________ 
 
1. Public school (regular)\ ﺔﯿﻣﻮﻜﺣ سراﺪﻣ 
2. Public school with special education classes\ صﺎﺧ ﻢﯿﻠﻌﺗ ﺎﮭﺑ ﺔﯿﻣﻮﻜﺣ سراﺪﻣ 
3. Private school (regular)\ ﺔﯿﻠھأ سراﺪﻣ 
4. Private school with special education classes\ صﺎﺧ ﻢﯿﻠﻌﺗ ﺎﮭﺑ ﺔﯿﻠھأ سراﺪﻣ 
5. Special education school\ صﺎﺧ ﻢﯿﻠﻌﺗ وأ ﻞﯿھﺄﺗ سراﺪﻣ 
6. Other \ ىﺮﺧأ: ________ 
404. Do you think your child needs special education \  ﻞھ ﺔﺟﺎﺤﺑ ﻚﻠﻔط نأ ﻦﯾﺪﻘﺘﻌﺗ
صﺎﺧ ﻢﯿﻠﻌﺘﻟ? 
1. Yes \ ﻢﻌﻧ        2. No \ ﻻ 
405. Does the child receive any special education at the school\ يأ ﻚﻠﻔط ﻰﻘﻠﺘﯾ ﻞھ
ﮫﺘﺳرﺪﻣ ﻲﻓ صﺎﺧ ﻢﯿﻠﻌﺗ? 
1. Yes \ ﻢﻌﻧ        2. No \ ﻻ 
If no \ ﻻ باﻮﺠﻟا نﺎﻛ اذا: 
406. Why not \ ﻌﺗ ﻰﻘﻠﺘﯾ ﻻ ﻢﻟصﺎﺧ ﻢﯿﻠ ? 
 
 
8. Dietary habits 
 
809. What are the ingredients of your child’s formula \ ﻚﻠﻔط ﺔﻄﻠﺧ تﺎﻧﻮﻜﻣ ﻲھ ﺎﻣ? 
 
1. _______ml water        2. ______scoops Phenex 1        3. ______ scoops Polycose 
 
4. _______scoops Pro-Phree           5. Other \ ىﺮﺧأ:______ 
810. Does your child drink all of his/her formula \ ﺔﻠﻣﺎﻛ ﺔﻄﻠﺨﻟا ﻚﻠﻔط بﺮﺸﯾ ﻞھ?  
 
1. Always \  ًﺎﻤﺋاد         2. Usually \  ًةدﺎﻋ         3. Occasionally \  ًﺎﻧﺎﯿﺣأ         4. Never \  ًاﺪﺑأ 
811. How many times per day does your child drink the formula \ ﻢﻛ  مﻮﯿﻟﺎﺑ ةﺮﻣ
ﺔﻄﻠﺨﻟا ﻞﻔﻄﻟا بﺮﺸﯾ?  
 
812. How much formula does your child drink each time \  ﻲﻟا ﺔﻄﻠﺨﻟا ﺔﯿﻤﻛ ﻲھﺎﻣ
ةﺮﻣ ﻞﻛ ﻲﻓ ﻞﻔﻄﻟا ﺎﮭﺑﺮﺸﯾ? 
813. Total amount of formula the child drinks per day \  ﻲﺘﻟا ﺔﻄﻠﺨﻟا ﺔﯿﻤﻛ عﻮﻤﺠﻣ
مﻮﯿﻟﺎﺑ ﻞﻔﻄﻟا ﺎﮭﺑﺮﺸﯾ: 
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814. Does your child have difficulty drinking the formula\ ﺔﺑﻮﻌﺻ ﻦﻣ ﻚﻠﻔط ﻲﻧﺎﻌﯾ ﻞھ
ﺔﻄﻠﺨﻟا بﺮﺷ ﻲﻓ? 
1. Yes \ ﻢﻌﻧ       2. No \ ﻻ 
815. If yes: Why \ اذﺎﻤﻟ ،ﻢﻌﻧ باﻮﺠﻟا نﺎﻛ اذإ?   
 
 Taste \ ﻢﻌﻄﻟا Smell \ ﺔﺤﺋاﺮﻟا Consistency \ ﺔﻓﺎﺜﻜﻟا Other \ىﺮﺧأ:___________ 
 
 
9. Diet history 
901. Twenty four hour food recall \  لا لﻼﺧ ﻞﻔﻄﻟا مﺎﻌط۲٤  ﺔﯿﺿﺎﻤﻟا ﺔﻋﺎﺳ  
 
Food item / Time of day  
مﻮﯿﻟا لﻼﺧ ﺖﻗﻮﻟا/ءاﺬﻐﻟا عﻮﻧ 
Quantity 
ﺔﯿﻤﻜﻟا 
First thing in the morning \  ءﻲﺷ لوأ
 ًﺎﺣﺎﺒﺻ: 
 
  
  
  
Breakfast \ رﺎﻄﻓﻹا:  
  
  
  
  
Morning snack \ حﺎﺒﺼﻟﺎﺑ ﺔﻔﯿﻔﺧ ﮫﺒﺟو:  
  
  
  
Lunch \ ءاﺪﻐﻟا:  
  
  
  
  
  
  
Afternoon snack \ ءﺎﺴﻤﻟﺎﺑ ﺔﻔﯿﻔﺧ ﺔﺒﺟو:  
  
  
  
Dinner \ ءﺎﺸﻌﻟا:  
  
  
  
  
Before bed time snack \  ﻞﺒﻗ ﺔﻔﯿﻔﺧ ﺔﺒﺟو
مﻮﻨﻟا: 
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Date:  
Twenty four hour food recall \  لا لﻼﺧ ﻞﻔﻄﻟا مﺎﻌط۲٤ ﺔﯿﺿﺎﻤﻟا ﺔﻋﺎﺳ  
 
Food item / Time of day  
مﻮﯿﻟا لﻼﺧ ﺖﻗﻮﻟا/ءاﺬﻐﻟا عﻮﻧ 
Quantity 
ﺔﯿﻤﻜﻟا 
First thing in the morning \  ًﺎﺣﺎﺒﺻ ءﻲﺷ لوأ:  
  
  
  
  
Breakfast \ رﺎﻄﻓﻹا:  
  
  
  
  
Morning snack \ حﺎﺒﺼﻟﺎﺑ ﺔﻔﯿﻔﺧ ﮫﺒﺟو:  
  
  
  
  
Lunch \ ءاﺪﻐﻟا:  
  
  
  
  
  
  
Afternoon snack \  ﺔﻔﯿﻔﺧ ﺔﺒﺟوءﺎﺴﻤﻟﺎﺑ :  
  
  
  
  
Dinner \ ءﺎﺸﻌﻟا:  
  
  
  
  
  
Before bed time snack \ مﻮﻨﻟا ﻞﺒﻗ ﺔﻔﯿﻔﺧ ﺔﺒﺟو:  
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C. Child Questionnaire 
       لﺎﻔطﻻا ﺔﻧﺎﺒﺘﺳا 
 
Date: 
 
General questions 
ﺔﻣﺎﻋ ﺔﻠﺌﺳأ 
 
Yes 
ﻢﻌﻧ 
No 
ﻻ 
C1. Do you go out shopping with your family? 
             ؟ﻞھﻷا ﻊﻣ قﻮﺴﺘﻠﻟ ﺐھﺬﺗ ﻞھ  
1 
 
2 
 
C2. Do you go out with your family to visit others? 
          ؟ﻦﯾﺮﺧﻵا ةرﺎﯾﺰﻟ ﻞھﻷا ﻊﻣ ﺐھﺬﺗ ﻞھ  
1 
 
2 
 
C3. Do you choose your food? 
           ؟ﻚﻣﺎﻌط رﺎﯿﺘﺧﺎﺑ مﻮﻘﺗ ﻞھ     
1 
 
2 
 
C4. What do you like to eat? 
         ؟ﻞﻛﺄﺗ نأ ﺐﺤﺗ اذﺎﻣ 
1. 
2. 
3. 
4. 
  
C5. When you are playing with other children do you feel you 
are different from them?  
؟ﻢﮭﻨﻋ ﺎﻔﻠﺘﺨﻣ ﻚﻧأ ﺲﺤﺗ ﻞھ ﻦﯾﺮﺧﻵا لﺎﻔطﻷا ﻊﻣ ﺐﻌﻠﺗ ﺎﻣﺪﻨﻋ 
1 
 
2 
 
C6. Is it difficult that you have to eat differently from others? 
؟ﻦﯾﺮﺧﻵا ﻦﻋ ﻒﻠﺘﺨﻣ مﺎﻌﻄﻠﻛأ ةروﺮﺿ ﻲﻓ ﺔﺑﻮﻌﺻ ﺪﺠﺗ ﻞھ  
1 
 
2 
 
C7. What do you think is the importance of drinking your formula? 
 ؟ﺐﯿﻠﺤﻟا ﺔﻄﻠﺧ لوﺎﻨﺗ ﺔﯿﻤھأ ىﺪﻣ ﺎﻣ كدﺎﻘﺘﻋا ﻲﻓ 
 
1. Very important \   ﺔﯾﺎﻐﻠﻟ ﻢﮭﻣ          2. Somewhat important \  ﺶﻟا ﺾﻌﺑ ﻢﮭﻣ    
3. Not important \  ﻢﮭﻣ ﺮﯿﻏ  
C8. What do you think is the importance of eating your specific diet? 
؟ﻚﻟ ﺔﺼﺼﺨﻤﻟا ﺔﯿﺋاﺬﻐﻟا ﺔﯿﻤﺤﻟﺎﺑ ماﺰﺘﻟﻻا ﺔﯿﻤھأ ىﺪﻣ ﺎﻣ كدﺎﻘﺘﻋا ﻲﻓ 
 
1. Very important \   ﺔﯾﺎﻐﻠﻟ ﻢﮭﻣ          2. Somewhat important \  ﺊﺸﻟا ﺾﻌﺑ ﻢﮭﻣ      
3. Not important \      ﻢﮭﻣ ﺮﯿﻏ  
C9. It is okay to drink only some of your formula? 
حﻮﻤﺴﻣ ﻞھ    ؟ﻚﻟ ﺔﺼﺼﺨﻤﻟا ﺐﯿﻠﺤﻟا ﺔﻄﻠﺧ ﻦﻣ اءﺰﺟ  ﻂﻘﻓ لوﺎﻨﺘﺗ نأ (ﻊﻧﺎﻣ ﻻ) ۱ ۲ 
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C10. Knowledge questions: 
    تﺎﻣﻮﻠﻌﻤﻟا ﺔﻠﺌﺳأ 
 
I’ll list some food items and you tell me if the food is a free food (you can eat as much 
as you like from it), if it is a low protein food (you can eat measured amounts from it), 
or if it is a forbidden food: 
 ﺎﻤﻛ ﮫﻨﻣ ﻞﻛﺄﺗ نأ ﻊﯿﻄﺘﺴﺗ يأ) ﺎﺣﻮﻤﺴﻣ ﺎﻣﺎﻌط ﺮﺒﺘﻌﯾ ﺎﮭﻨﻣ ﺎﯾأ دﺪﺤﺗ نأ كﺪﯾرأو ﺔﻤﻌطﻷا عاﻮﻧأ ﺾﻌﺑ دﺮﺴﺑ مﻮﻗﺄﺳ
 ﻻ) ﺎﻋﻮﻨﻤﻣ ﺎﻣﺎﻌط وأ ،(ةدوﺪﺤﻣ ﺔﯿﻤﻛ ﮫﻨﻣ ﻞﻛﺄﺗ نأ ﻊﯿﻄﺘﺴﺗ) ﻦﯿﺗوﺮﺒﻟا ﻦﻣ ﺔﻠﯿﻠﻗ ﺔﺒﺴﻧ ﻰﻠﻋ يﻮﺘﺤﯾ ﺎﻣﺎﻌط وأ ،(ءﺎﺸﺗ
:(اﺪﺑأ ﮫﻨﻣ ﻞﻛﺄﺗ 
 
 Food item 
ﺔﻤﻌطﻷا 
Free food 
ﻤﺴﻣ مﺎﻌطحﻮ  
Low 
protein 
 ﻞﯿﻠﻗ مﺎﻌط
ﻦﯿﺗوﺮﺒﻟا 
Forbidden 
food 
عﻮﻨﻤﻣ مﺎﻌط 
Don’t 
know 
ﻢﻠﻋأ ﻻ 
C10.1 Apples  حﺎﻔﺘﻟا 1 2 3 4 
C10.2 Carrots  رﺰﺠﻟا 1 2 3 4 
C10.3 Chick peas 
ﺺﻤﺤﻟا 1 2 3 4 
C10.4 Cheese  ﻦﺒﺠﻟا 1 2 3 4 
C10.5 Chicken جﺎﺟﺪﻟا 1 2 3 4 
C10.6 Chocolate 
ﮫﺗﻻﻮﻜﺸﻟا 1 2 3 4 
C10.7 Dates ﺮﻤﺘﻟا 1 2 3 ٤ 
C10.8 Diet Pepsi   ﺖﯾاد
ﻲﺴﺒﯿﺑ 1 2 3 4 
C10.9 
Lollypops 
 ﺮﻜﺳ ىﻮﻠﺣ
(ﺔﺻﺎﺼﻣ) 
1 2 3 4 
C10.10 Seven-up  ﻦﻔﺳ
با 1 2 ۳ ٤ 
C10.11 French fries 
ﺔﯿﻠﻘﻤﻟا ﺲطﺎﻄﺒﻟا 1 2 3 4 
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Appendix 11: The items adapted for the Arabic Vineland-II, the adaptations and adjustments, and the reasons for 
the adaptations 
Page No. Item No. Item in English Vineland-II Adaptation Reason 
5 
7 Points to at least three major body parts when asked (for example, nose, mouth, hands, feet, etc.). 
Replaced the word “hands” with “head” Cultural: a more common example is to ask 
children about their heads 
11 Points to at least three five minor body parts when asked (for example, fingers, elbows, teeth, toes, etc.). 
Replaced the word “toes” with “thumb” Language: translation of toes is “feet 
fingers”, and fingers were included already  
12 
Follows instructions with two actions or 
an action and two objects (for example, 
“Bring me the crayons and paper”. “Sit 
down and eat your lunch”; etc.). 
Replaced the word “crayons” 
with “pens” 
Language: no clear translation for crayons, 
pens in Arabic imply pens, pencils and 
colouring pens or crayons   
18 
Understands sayings that are not meant to be taken 
word for word (for example, “Button your lip”; “Hit 
the road”; etc.). 
Added explanation for sayings; “button 
your lip” meaning shut your mouth 
Language 
6 
12 Names at least three objects (for example, bottle, dog, favourite toy, etc.). 
Replaced “Dog” with “Cat” Cultural: cats are more common as pets 
17 States own first name or nickname (for example Latisha, Little Sister, etc.) when asked. 
Replaced “little sister” with a more 
common nick name 
Cultural 
18 Uses phrases with a noun and a verb (for example, “Katie Stay”; “Go home”; etc.). 
Replaced “go home” example with a more 
common one 
Language: used clearer example in Arabic 
22 Asks questions beginning with what or where (for example, “What’s that”; “Where doggie go?; etc.).  
Replaced “doggie” with “father” Cultural  
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Page No. Item No. Item in English Vineland-II Adaptation Reason 
7 
36 
Uses regular past tense verbs (for example, walked, 
baked, etc.); may use irregular past tense verbs 
ungrammatically (for example, “I runned away”; etc.).  
Only one type of past tense available in 
Arabic 
Language 
38 
Pronounces words clearly without sound substitutions 
(for example, does not say “wabbit” for “rabbit”, 
“Thally” for “Sally,” etc.). 
Replaced examples using the word “chair”. 
Chair in Arabic is pronounced as “kursi” 
the substitution could be “tursi” 
Language: this example can illustrate the 
point of letter substitution better in Arabic  
8 
50 Uses irregular plurals correctly (for example, children, 
geese, mice, women, etc.). 
Replaced examples with common ones 
relevant to plural type in Arabic  
Language 
52 
Describes a short-term goal and what he or she needs 
to do to reach it (for example, says, “I want to get an A 
on my test, so I’m going to study hard”; etc.). 
Replaced “A” with “high grades” Cultural: different grading system 
54 
Describes a realistic long-range goal that can be done 
in 6 months or more (for example, says, “I want to buy 
a bike, so I’ll babysit and run errands to earn enough 
money to buy it”; etc.). 
Replaced “babysit and run errands” with 
“work” 
Cultural: babysitting is not common. The 
word “work” in Arabic implies any uptake 
of work in general 
9 
4 
Points or writes using correct orientation (for example, 
in English from left to right; in some languages from 
right to left or top to bottom). 
Mentioned Arabic language writing 
direction as example 
Language 
6 
Identifies all printed letters of the alphabet, upper-and 
lowercase. 
Replaced “upper- and lower case” with 
“different forms”  
Language: Arabic does not have upper or 
lower cases but letters change forms 
according to their place in words 
7 Prints at least three simple words from example (for 
example, cat, see, bee, etc.). 
Replaced examples with more commonly 
used ones in Arabic 
Language 
10 Prints at least 10 simple words from memory (for 
example, hat, ball, the, etc.).  
Replaced examples with more common 
ones 
Language 
10 19 Wipes or blows nose using tissues or handkerchief. Replaced “handkerchief” with etc. Language: tissue and handkerchief are 
translated to the same word in Arabic 
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Page No. Item No. Item in English Vineland-II Adaptation Reason 
11 
25 Brushes teeth. Added  “with toothbrush” Language 
32 Bathes or showers and dries self. Used one word for “Bathes or showers” Language 
12 
8 
Helps prepare foods that require mixing and cooking 
(for example, cake or cookie mixes, macaroni and 
cheese, etc.). 
Replaced “macaroni and cheese” with 
“macaroni and tomato sauce”  
Cultural: this is a more common dish 
9 Uses simple appliances (for example, a toaster, can opener, bottle opener, etc.). 
Deleted the example “Bottle opener” Language: the previous example of can 
opener translates the same as bottle opener 
10 
Uses microwave oven for heating, baking, or cooking 
(that is, sets time and power setting, etc.). 
You may mark “N/O” for No Opportunity if there is no 
microwave in the home. 
Deleted “baking” Language: in Arabic cooking also implies 
baking 
12 Use tools (for example, a hammer to drive nails, a screwdriver to screw and unscrew screws, etc.).  
Replaced “screw, unscrew” with one word Language 
13 
4 Counts at least 10 objects, one by one. Deleted the phrase “one by one” Language 
12 
Identifies penny, nickel, dime, and quarter by name 
when asked; does not need to know the value of coins. 
Changed wording to be “Recognizes metal 
coin categories and refers to its names when 
asked, does not need to know value of coin” 
Cultural: coins do not have the US names. 
Kept it generic, different areas may have 
different names for coins. 
18 
States value of penny (1 cent), nickel (5 cents), dime 
(10 cents), and quarter (25 cent) 
Changed wording to be “defines value of 
coin when asked (for example: half a Riyal 
= 50 halala)” Riyal is the Saudi currency.  
Cultural 
14 
26 Carries or stores money safely (for example, in wallet, purse, money belt, etc.). 
Deleted the word “purse” Language 
28 
Obeys curfew parent or caregiver sets. Changed to “obeys orders of parent or 
caretaker on returning home on the 
specified  time” 
Language 
41 
Manages own money (for example, pays most or all 
own expenses, uses checks or money orders for 
purchases as needed, etc.). 
Deleted “money orders” Cultural: rarely used 
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Page No. Item No. Item in English Vineland-II Adaptation Reason 
16 
22 
Uses words to express happiness or concern for others 
(for example, says, “Yeah! You won”; “Are you all 
right/”; etc.). 
Replaced “yeah!” with “great” Language 
24 
Recognizes the likes and dislikes of others (for 
example, says, “Chow likes soccer”; “Susie doesn’t eat 
pizza”; etc.). 
Replaced names to “my brother” and “my 
sister” 
Language 
30 Chooses not to say embarrassing or mean things or ask rude questions in public. 
Added “inappropriate” Language 
31 
Places reasonable demands on friendship (for example, 
does not expect to be a person’s only friend or to have 
the friend always available, etc.). 
Rephrased to be “understands reasonable 
friendship parameters” 
Language 
37 Goes on group dates. Replaced “dates” with “gatherings or meetings” 
Cultural: No dating in Saudi, but meetings 
with friends without parents is acceptable 
38 Goes on single dates. Replaced “dates” with “gatherings or meetings” 
Cultural  
17 
16 Plays informal, outdoor group games (for example, tag, jump rope, catch, etc.). 
Deleted “informal” Language: “informal” is implied within the 
Arabic sentence 
18 Follows rules in simple games (relay races, spelling bees, electronic games, etc.). 
Replaced examples of games with more 
common ones in the area 
Cultural  
20 Plays simple card or board game based only on chance (for example, Go Fish, Crazy Eights, Sorry™, etc.). 
Replaced examples of games with more 
common ones in the area 
Cultural  
18 
24 Plays simple games that require keeping score (for example, kickball, pickup basketball, etc.). 
Replaced examples of games with more 
common ones 
Cultural 
26 
Plays more than one board, card, or electronic game 
requiring skill and decision making (for example, 
Monopoly™ , Cribbage, etc.). 
Deleted “cribbage” Cultural: cribbage is not played in the 
region 
27 
Goes places with friends in evening with adult 
supervision (for example, to a concert, lecture, sporting 
event, movie, etc.). 
Deleted “concert” and “movie” and used 
more common examples 
Cultural: no opportunity to go to concerts or 
movies 
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Page No. Item No. Item in English Vineland-II Adaptation Reason 
18 
28 Follows rules in complex games or sports (for 
example, football, soccer, volleyball, etc.). 
Deleted “football” (American football) Cultural: not played 
30 
Plans fun activities with more than two things to be 
arranged (for example, a trip to a beach or park that 
requires planning transportation, food, recreational 
items, etc.) 
Replaced example Cultural 
31 
Goes places with friends in evening without adult 
supervision (for example, to a concert, lecture, sporting 
event, movie, etc.). 
Deleted “concert” and “movie” and used 
more common examples 
Cultural 
19 
12 Changes voice level depending on location or situation 
(for example, in a library, during a movie or play, etc.).  
Replaced example with “in library or when 
close to someone sleeping” 
Cultural 
29 
Is aware of potential danger and uses caution when 
encountering risky social situations (for example, 
binge during parties, Internet chat rooms, personal ads, 
etc.). 
Replaced example “binge drinking parties” 
with “late night parties” 
Cultural 
20 
13 Climbs on and off low objects (for example, chair, step 
stool, slide, etc.).  
Replaced “step stool” with “step” Language 
27 Catches on beach ball-sized ball with both hands from 
a distance of 2 or 3 feet. 
Explained “beach ball” as an air filled ball 
with a size of 45 cm 
Clarification 
21 4 Squeezes squeaky toy or object.  Added explanation for “squeaky” Language 
22 32 Unlocks dead-bolt, key, or combination locks that 
require twisting.  
Deleted “dead-bolt” Language 
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